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Abstract 
Abstract 
I 
Abstract 
Following a review of the relevant literature a Cognitive Behavioural 
treatment protocol for the prevention of relapse in schizophrenia is presented. 
This treatment protocol is investigated in a 12-month non-blind randomised 
controlled trial comparing Cognitive Behavioural Therapy and Treatment as 
Usual (CBT + TAU) versus Treatment as Usual (TAU) alone. Three studies of 
treatment outcome are described: relapse and admission, remission and social 
functioning, and psychological distress. 144 participants with a DSM-IV 
Schizophrenia spectrum disorder were randomised to receive either CBT + 
TAU (n = 72) or TAU alone (n = 72). 11 participants dropped out (6 from 
CBT + TAU, 5 from TAU alone) leaving a completers sample of 133. 
Participants were assessed at entry, 12-weeks, 26-weeks, and 52 weeks. CBT 
was delivered over two stages: a 5-session engagement phase which was 
provided between entry and 12-weeks, and a targeted CBT phase which was 
delivered on the appearance of early signs of relapse. Over 12-months CBT + 
TAU was associated with significant reductions in relapse and admission rate. 
The clinical significance of the reduced relapse and admission rate amongst 
the CBT + TAU group was investigated. First, receipt of CBT + TAU was 
associated with improved rates of remission over 12-months. Second, 
clinically significant improvements in social functioning were investigated. 
Again, receipt of CBT + TAU was associated with clinically significant 
improvements in prosocial activities. However, receipt of CBT + TAU was 
not associated with improvements in psychological distress over 12-months. 
The theory underpinning the cognitive behavioural treatment protocol 
predicted that negative appraisals of self and psychosis represent a cognitive 
vulnerability to relapse. This hypothesis was investigated during the present 
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Abstract 
study. After controlling for clinical, treatment and demographic variables, 
negative appraisals of self and entrapment in psychosis were associated with 
increased vulnerability to relapse, whilst negative appraisals of self were 
associated with reduced duration to relapse. Finally, an explorative study of 
changes in negative appraisals of psychosis and self over time, which were 
associated with relapsers versus non-relapsers from the TAU alone group, was 
conducted. This study found a strong association between the experience of 
relapse, increasing negative appraisals of psychosis and self, and the 
development of psychological co-morbidity in schizophrenia. Results of 
treatment outcome and theoretical analyses are discussed in terms of their 
relevance to the further development of psychological models and treatments 
for psychosis. 
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Chapter 1 
Schizophrenia: Diagnosis, course and outcome 
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Schizophrenia: Diagnosis, course and outcome 
1.1 A First Person Account of Schizophrenia 
Schizophrenia "is to experience personal and social life as a 
maelstrom, to find one's world and oneself in perceptual disintegration 
and renewal, trouble and anguish, ambiguity and contradiction: to be 
part of a universe in which all that is solid melts into air. The chaos 
and trauma is intense. My perception of everything around me 
becomes much more heightened. My relations with other people, while 
they seem to be normal and usual to those who interact with me are 
problematic. I have no control. My mind becomes bombarded with 
thoughts, I have beliefs about myself, which are totally unfounded, the 
paranoia is intense. I worry about the slightest thing from did I say the 
right thing, did I frighten or harm that person, or do they think I'm 
mad. I think that my psychosis is inherently evil; a manifestation of the 
devil. It attacked and nearly destroyed me, and that's why I believed 
that the devil had taken my sour' 
This personal testimony, written by an individual who participated in the 
research described in this thesis encapsulates the major theme, which 
permeates this work. That is, this account illustrates the personal significance 
and meaning attached to the subjective experience of acute psychosis. Indeed, 
it is my proposal that understanding the personal meanings and appraisals 
attached to the experience of psychosis are critical to the development of 
psychological approaches to the conceptualisation and prevention of relapse in 
psychosis. 
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1.2 Historical Perspectives 
In 1896, Emil Kraepelin distinguished between two forms of insanity: Manic- 
Depressive insanity and Dementia Praecox. The term Dementia Praecox was 
taken from the work of Morel (1856) but also included Kahlbaum's concept of 
catatonia, Hecker's (1871) concept of hebephrenia, and what Kraepelin 
described as `Dementia Paranoides'. This split between affective disorder and 
Dementia Praecox rested on his observation of the long-term outcome of these 
disorders. Kraepelin proposed that Dementia Praecox was a progressive 
disease of early onset, which either pursued a steady deteriorating course to 
chronic invalidism or, if improvement did occur, there was only partial 
recovery. Kraepelin proposed that Dementia Praecox was a disease of the 
brain, and speculated that the aetiology was endocrinological. Kraepelin's 
proposals were in the context of advances in other areas of medicine, for 
example Broca in 1861 discovered that a lesion in the fronto-temporal cortex 
produced a type of aphasia; Parkinson in 1871 had described paralysis agitans; 
Duchene in 1847 described motor neurone disease, and Korsakoff in 1890 
gave a description of a diencephalic amnesic syndrome. 
Bleuler (1911) confirmed Kraepelin's concept of Dementia Praecox, however 
he also changed it fundamentally. Bleuler proposed that Dementia Praecox 
was not necessarily either a dementia or a disorder of early onset, rather he 
saw Dementia Praecox as a splitting of psychic functions. Bleuler, influenced 
by the writings of Sigmund Freud at the time, thought of schizophrenia in 
psychological rather than neuropathological terms. Bleuler coined the term 
schizophrenia, meaning `split mind', because he believed that the disorder was 
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due to the separation or splitting of normally integrated functions that co- 
ordinate thought, affect and behaviour. He described four fundamental 
symptoms: ambivalence, disturbance of association, disturbance of affect, and 
preference for fantasy over reality. Indeed, Bleuler saw deficits in affect as the 
core feature of the disorder. It is noteworthy that two psychotic features 
emphasised in current diagnostic criteria, hallucinations and delusions, were 
not crucial for Bleuler's diagnosis of schizophrenia. Rather, symptoms such as 
hallucinations and delusions were seen as psychological reactions to an 
underlying process. 
Bleuler also differed from Kraepelin with respect to prognosis. He saw 
prognosis in Schizophrenia as a complex and interwoven concept that could be 
determined by subgroups of schizophrenias or indeed individually. In sharp 
contrast to Kraepelin, Bleuler emphasised theory as a means of determining 
the diagnostic relevance of signs and symptoms. In addition, the relevance of 
his reformulation of Dementia Praecox as a group of schizophrenias 
foreshadowed contemporary views discussed in this chapter that schizophrenia 
is a heterogeneous condition. 
Kraepelian and Bleulerian perspectives and their hypotheses regarding the 
biological and psychological nature of schizophrenia have permeated the 
research literature throughout the 20th Century. Indeed, key to both Kraepelian 
and Bleulerian views of schizophrenia is the concept of prognosis and 
outcome. Indeed, research findings concerning the nature of onset, prognosis 
7 
Schizophrenia: Diagnosis, course and outcome 
and outcome are intimately linked to the classification systems for 
schizophrenia, which have evolved since the work of Kraepelin and Bleuler. 
1.3 Classification 
Bleuler's and Kraepelin's observations evolved into current classification 
systems, in particular the World Health Organisation's International 
Classification of Diseases (ICD) and the American Psychiatric Association's 
(APA) Diagnostic and Statistical Manual of Mental Disorders (DSM). Early 
diagnostic systems, for example the first DSM (APA, 1952) defined all 
psychiatric disorders as reactions to environmental causes or events. 
Definitions were vague and did not include specific operational criteria. Such 
imprecise definitions allowed clinicians much discretion in making diagnoses. 
The second edition of DSM (APA, 1968) dropped the term "reaction" and 
gave some consideration to differential diagnosis, however clear operational 
criteria continued to be lacking. Both the first and second editions of DSM 
gave priority to the presence of psychosis as the key feature of the disorder. 
However, DSM-II contained a category of "Schizophrenia- latent type" to 
describe those individuals with clear symptoms of schizophrenia but with no 
history of psychotic symptoms. Whilst the presence of this category did not 
detract from the primacy of psychotic symptoms, the term latent implied the 
presence of, but as yet an unexpressed psychosis. However, it did reflect an 
important attempt to clarify the role of psychosis in schizophrenia. 
Dissatisfaction with diagnostic criteria grew out of a number of factors 
including problems with reliability, the growing view that mental illness was a 
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myth, and that diagnostic labels resulted in harm to individuals through 
stigmatisation and marginalisation. The development of classification systems 
has therefore focused on the refinement of diagnoses, the development of 
reliability through clear operational criteria, and the adoption of empirical 
methods (e. g. Schneider, 1959; Langfeldt, 1960; Robins & Guze, 1970; 
Feighner et al., 1972). For example, Feighner et al (1972) offered diagnostic 
criteria, which continued to emphasise the necessary presence of psychotic 
symptoms such as hallucinations, thought disorder, or delusions. However, 
Bleuler's emphasis on the disturbance of affect was minimised, whilst other 
factors which emphasised chronicity were highlighted. These necessary 
criteria were the "presence of a chronic illness of at least six months duration 
prior to initial evaluation", and at least two of the following for definite 
schizophrenia; being single, poor premorbid history, family history of 
schizophrenia, absence of alcoholism or drug abuse in the preceding year, and 
onset of illness prior to 40 years of age. On the other hand, Schneiderian 
criteria (Schneider, 1959) did not emphasise the pattern and nature of onset, 
but rather attempted to offer clear operational criteria for the classification of 
psychotic symptoms. Schneiderian criteria have heavily influenced the 
development of Research Diagnostic Criteria (RDC; Spitzer & Endicott, 
1978), which in turn formed the basis of the third edition of the DSM (APA, 
1980). DSM-III contained several innovations including field tests of 
diagnostic reliability, specific inclusion and exclusion criteria, multiaxial 
diagnoses, and a focus on the description of syndromes and course of 
disorders rather than inferences regarding aetiology. Both DSM-III and DSM- 
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III-R (APA, 1987) criteria did however continue to emphasise the presence of 
psychotic symptoms. 
1.4 Current Diagnostic Criteria 
The Diagnostic and Statistical Manual of Mental Disorders- 4th Edition (DSM- 
IV; APA, 1994) defines the essential features of Schizophrenia as a mixture of 
positive and negative symptoms that have been present for a significant 
proportion of time during a one month period (or a shorter time if successfully 
treated), but with signs of the disorder persisting for at least six months 
(Criterion A and Q. DSM-N emphasises that these characteristic symptoms 
must be present in the context of significant impairment in social and 
occupational dysfunction in one or more areas such as work, interpersonal 
relationships, or self care (Criterion B). The diagnostic criteria for 
Schizophrenia are described in Table 1.1 below. 
Various subtypes are specified by DSM-IV including Paranoid, Disorganised, 
Catatonic, Undifferentiated and Residual. In addition, DSM-IV allows for the 
inclusion of specifiers to indicate the characteristic course over time including, 
Episodic (with inter-episode residual symptoms, with prominent negative 
symptoms, or with no inter-episode residual symptoms), Continuous (with 
prominent negative symptoms), Single Episode (with partial remission, full 
remission) or Other, Unspecified Pattern. 
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Table 1.1 Diagnostic Criteria for Schizophrenia 
A. Characteristic symptoms: Two (or more) of the following, each present for a 
significant portion of time during a 1-month period (or less if successfully treated). 
(1) delusions 
(2) hallucinations 
(3) disorganised speech (e. g. frequent derailment or incoherence) 
(4) grossly disorganised or catatonic behaviour 
(5) negative symptoms, i. e., affective flattening, alogia, or avolition. 
Note: Only one Criterion A symptom is required if delusions are bizarre or 
hallucinations consist of a voice keeping up a running commentary on the person's 
behaviour or thoughts, or two or more voices conversing with each other. 
B. Social/ occupational dysfunction: For a significant portion of time since the onset 
of disturbance, one or more major areas of functioning such as work, interpersonal 
relations, or self care are markedly below the level achieved prior to onset (or when 
the onset is in childhood or adolescence, failure to achieve expected level of 
interpersonal, academic, or occupational achievement). 
C. Duration: Continuous signs of the disturbance persist for at least 6-months. 
This 6-month period must include at least 1-month of symptoms (or less if 
successfully treated) that meet Criterion A (i. e. active phase symptoms) and may 
include prodromal or residual symptoms. During these prodromal or residual periods, 
the signs of the disturbance may be manifested by only negative symptoms or two or 
more symptoms listed in Criterion A present in an attenuated form (e. g. odd beliefs, 
unusual perceptual experiences). 
D. Schizoaffective and Mood Disorder Exclusion: Schizoaffective disorder and 
Mood Disorder with Psychotic Features have been ruled out because either (1) no 
Major Depressive, Manic or Mixed Episodes have occurred concurrently with the 
active phase symptoms; or (2) if mood episodes have occurred during active phase 
symptoms, their total duration has been brief relative to the duration of the active and 
residual periods. 
E. Substancel general medical condition exclusion: The disturbance is not due to 
the direct physiological effects of a substance (e. g. a drug of abuse, a medication) or 
a general medical condition. 
F. Relationship to a Pervasive Developmental Disorder: If there is a history of Autistic 
Disorder or another Pervasive Developmental Disorder, the additional diagnosis of 
Schizophrenia is made only if prominent hallucinations or delusions are also present 
for at least a month (or less if successfully treated). 
1.4.1 Criterion A 
Positive symptoms (Criterion Al-A4) include distortions or exaggerations of 
inferential thinking (delusions), perception (hallucinations), language and 
communication (disorganised speech), and behavioural monitoring (grossly 
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disorganised or catatonic behaviour). Definitions of positive symptoms in 
DSM-IV draw heavily on Schneider's list of first rank symptoms. 
1.4.1.1 Delusions (Criterion Al) 
Delusions are defined within DSM-IV as "erroneous beliefs that 
usually involve a misinterpretation of perceptions or experiences. Their 
content may reflect a variety of themes; for example persecutory, 
grandiose, referential, bizarre and religious. Persecutory delusions 
involve the belief that the individual is being made subject to being 
followed, tormented, spied on or ridiculed. Referential delusions 
involve the person believing that certain gestures, comments, passages 
from books, newspapers, television or radio are specifically directed at 
them. Despite being a characteristic feature of Schizophrenia, bizarre 
delusions are difficult to judge as the criteria on which to judge 
"bizarreness" will vary across cultures. An example of a bizarre 
delusion may be the belief that one's internal organs have been 
replaced with those of another person. Delusions, which express a loss 
of control over mind and body, are also considered by DSM-IV as 
bizarre. These include the belief that one's thoughts are being removed 
by some outside force ("thought withdrawal"), that thoughts are being 
placed in one's head by an outside force ("thought insertion") or that 
one's thoughts and actions are under external control ("passivity" or 
"delusions of control"). If delusions are judged to be bizarre within 
DSM-IV, this single symptom satisfies Criterion A for Schizophrenia. 
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1.4.1.2 Hallucinations (Criterion A2) 
Hallucinations can occur in any sensory modality (auditory, visual, 
tactile, olfactory or gustatory), although auditory hallucinations are 
judged to be the most common characteristic of schizophrenia. DSM- 
IV defines auditory hallucinations as the experience of familiar or 
unfamiliar voices, which are perceived as distinct from one's own 
thoughts. DSM-IV distinguishes between different types of auditory 
hallucinations, for example third person or second person 
hallucinations. If third person auditory hallucinations are present, then 
this single symptom satisfies Criterion A. Hallucination must occur in 
clear sensorium. Those which occur whilst falling asleep (Hypnagogic) 
or on waking (hypnapompic) are considered to lie within the range of 
normal experience. Other hallucinatory types of experiences are 
excluded from the diagnostic criteria, for example humming insides 
one's head, or voices which occur in the context of culturally 
appropriate religious experiences. 
1.4.1.3 Disorganised thinking (Criterion A3) 
The assessment of disorganised thinking, for example formal thought 
disorder, loosening of associations is primarily inferred by the 
individual's speech. The individual may slip off track from one topic to 
another ("derailment"), answers to questions may only be obliquely 
related or unrelated ("tangentially") or more rarely speech may be 
incomprehensible ("incoherence"). Mildly disorganised speech does 
not satisfy this criterion, as this is common and non-specific. The 
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symptoms must be severe enough to substantially impair 
communication. 
1.4.1.4 Grossly disorganised or catatonic behaviours (Criterion A4) 
This is defined as the presence of a variety of behaviours such as 
childlike silliness, unpredictable, or loss of goal directed behaviour. 
For example, the individual may be dishevelled, dress unusually, or 
behave inappropriately. On the other hand, catatonic behaviour is 
characterised by a marked decrease in reactivity to the environment 
and in extreme cases may be associated with complete loss of 
awareness ("catatonic stupor"), active resistance to instruction or 
movement ("catatonic negativism"), inappropriate or bizarre postures 
("catatonic posturing"), or purposeless and unstimulated motor 
behaviour ("catatonic excitement"). Differential classification of 
catatonic behaviours is important as they can occur as part of a mood 
disorder, as part of a general medical condition, or as a consequence of 
a medication-induced movement disorder. 
1.4.1.5 Negative Symptoms (Criterion A5) 
Three negative symptoms are considered for the definition of 
Schizophrenia: affective flattening, alogia, and avolition. Features such 
as anhedonia are not included in the Criterion A definition of 
Schizophrenia but considered alongside other associated features such 
as inappropriate affect, dysphoric mood, or suicide. 
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Criterion A for Schizophrenia requires the presence of two out of five items 
(Al to 5) to be present for at least one-month. Where delusions are judged to 
be bizarre, or if voices are "commenting" or "conversing", then the presence 
of only one item is required. Where these symptoms are successfully treated 
within one month, if the clinician judges that they would have continued 
without treatment for that period, Criterion A is fulfilled. In addition, unlike 
earlier versions of the DSM, psychotic symptoms have been de-emphasised. A 
diagnosis of schizophrenia may be made without the individual experiencing 
delusions or hallucinations. In that case gross disorganisation of speech or 
behaviour are still required for Criterion A. 
1.4.2 Criterion B 
The diagnosis of Schizophrenia requires the presence of significant problems 
in major areas of functioning (e. g. work, interpersonal relations, education or 
self-care). Functioning must be clearly below that which was achieved prior to 
the onset of the disturbance, or if onset is in childhood or adolescence, there is 
clear evidence of failure to achieve what would have been expected for the 
individual. For example, comparisons can be made with unaffected siblings, or 
educational progress and expectations can be examined. 
1.4.3 Criterion C 
Some signs of the disturbance must persist for a continuous period of at least 
six months, during which there will have been at least one month of active 
phase symptoms as defined in Criterion A. For example prodromal symptoms 
are often present prior to the active phase, which can occur in the form of mild 
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or subthreshold form of positive symptoms (e. g. digressive speech, ideas of 
reference, magical thinking, sensing the presence of an unseen person in the 
absence of auditory hallucinations). Furthermore, negative features can be 
considered, for example, increasing social withdrawal, disengagement from 
pleasurable activities. 
1.5 Differential Diagnosis 
Criteria D, E, and F are exclusion rules governing the diagnosis of 
schizophrenia, and require exclusion of Schizoaffective and Mood disorder 
(Criterion D), Substance/ general medical condition (Criterion E) and presence 
of a Pervasive Developmental Disorder (Criterion F). 
1.5.1 Criterion D 
The exclusion of Mood Disorders with psychotic features, and Schizoaffective 
Disorder are problematic due to the presence of mood disturbance during the 
prodromal, active and residual phases of Schizophrenia. If psychotic 
symptoms occur exclusively during the presence of mood disturbance, the 
diagnosis is Mood Disorder with psychotic features. In Schizoaffective 
Disorder (Table 1.2), there must be a mood episode, which is concurrent with 
active phase symptoms of Schizophrenia, and mood symptoms must be 
present for a substantial proportion of the total duration of the disturbance. 
However, active phase symptoms (delusions and hallucinations) must be 
present for a period of at least two weeks in the absence of prominent mood 
disturbance. By contrast, DSM-1V states that for the diagnosis of 
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schizophrenia mood symptoms have a brief duration relative to the total period 
of active phase disturbance in Schizophrenia. 
Table 1.2 Diagnostic Criteria for Schizoaffective Disorder 
A. An uninterrupted period of illness during which, at some time, there is either a Major 
Depressive Episode, a Manic Episode, or a Mixed Episode concurrent with 
symptoms which meet Criterion A for Schizophrenia. 
Note: The Major Depressive Episode must include Criterion Al: depressed mood. 
B. During the same period of illness, there must have been delusions or hallucinations 
for at least two weeks in the absence of prominent mood symptoms. 
C. Symptoms that meet criteria for a mood episode are present for a substantial period 
of the total duration of the active and residual periods of the illness. 
D. The disturbance is not due to the direct physiological effects of a substance (e. g. a 
drug of abuse, a medication) or a general medical condition. 
Specify Type: 
Bipolar Type: if the disturbance includes a Manic or Mixed Episode (or Manic, or 
a Mixed Episode with a Major Depressive Episode). 
Depressive Type: if the disturbance only includes Major Depressive 
Episodes. 
Schizophrenia differs from Schizophreniform Disorder on the basis of 
duration, where Schizophrenia requires the presence of symptomatology for at 
least six months, the total duration required for Schizophreniform Disorder 
must be at least one month but less than six months. In addition 
Schizophreniform Disorder does not require a decline in functioning (Table 
1.3). Brief Psychotic Disorder is defined by the presence of delusions, 
hallucinations, disorganised speech, or grossly disorganised or catatonic 
behaviour lasting for at least one day but less than one month. 
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Table 1.3 Diagnostic Criteria for Schizophreniform Disorder 
A. Criterion A, D, and E of Schizophrenia are met. 
B. An episode of the disorder (including prodromal, active, and residual phases) lasts at 
least one month but less than six months. (When the diagnosis is made without 
awaiting recovery, it should be qualified as provisional) 
Specify i£ 
Without Good Prognostic Features 
With Good Prognostic Features: as evidenced by two (or more) of the following: 
(1) onset of prominent psychotic symptoms within 4 weeks of the first 
noticeable change in usual behaviour or functioning. 
(2) Confusion or perplexity at the height of the psychotic episode. 
(3) Good premorbid social and occupational functioning. 
(4) Absence of blunted or flat affect. 
Schizophrenia is distinguished from Delusional Disorder on the basis of the 
nature of the delusion itself and the absence of other characteristic symptoms 
of Schizophrenia (e. g. hallucinations, disorganised speech and behaviour, or 
prominent negative symptoms). Delusional Disorder is difficult to distinguish 
from Schizophrenia (Paranoid Type), as this subtype does not include 
prominent disorganised speech or behaviour, flat or inappropriate affect, and is 
often associated with less decline in functioning compared to other types. 
When poor functioning is present in Delusional Disorder, it arises directly 
from the delusional beliefs (Table 1.4). 
1.5.2 Criterion E 
Psychotic symptoms occur in a wide variety of general medical conditions or 
in response to the use of substances and therefore must be excluded for 
diagnosis of Schizophrenia. For example sustained use of amphetamines and 
cocaine can cause delusions and hallucinations, or Ketamine can produce a 
mixture of positive and negative symptoms. 
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1.5.3 Criterion F 
Schizophrenia and Pervasive Developmental Disorders such as Autism, share 
disturbances in language, affect and interpersonal relations. An additional 
diagnosis of Schizophrenia in the context of a Pervasive Developmental 
Disorder is only warranted if prominent delusions and hallucinations have 
been present for at least one month. Schizophrenia also shares features with a 
number of Axis II disorders; Schizotypal, Schizoid and Paranoid. An 
additional diagnosis of Schizophrenia is appropriate when symptoms are 
severe enough to satisfy criteria for Schizophrenia. 
Table 1.4 Diagnostic Criteria for Delusional Disorder 
A. Nonbizarre delusions (i. e. involving situations that occur in real life such as being 
followed, poisoned, infected, loved at a distance, or deceived by spouse or lover, or 
having a disease) of at least one month's duration. 
B. Criterion A for Schizophrenia has never been met. Note: Tactile and olfactory 
hallucinations may be present in delusional disorder if they are related to the 
delusional theme. 
C. Apart from the impact of the delusion(s) or its ramifications, functioning is not 
markedly impaired and behaviour is not obviously odd or bizarre. 
D. If mood episodes have occurred concurrently with delusions, their total duration has 
been brief relative to the duration of delusional periods. 
E. The disturbance is not due to the direct physiological effects of a substance (e. g. a 
drug of abuse, a medication) or a general medical condition. 
Specify type (the following types are assigned based on the prominent delusional theme) 
Erotomanic Type: delusions that the other person, usually of a higher status, is in love 
with the individual. 
Grandiose Type: delusions of inflated worth, power, knowledge, identity, or special 
relationship to a deity or famous person. 
Jealous Type: delusions that the individual's sexual partner is unfaithful. 
Persecutory Type: delusions that the person (or someone to whom the person is close) 
is being malevolently treated in some way. 
Somatic Type: delusions that the person has some physical defect or general 
medical condition. 
Mixed Type: delusions characteristic of more than one of the above types but no 
one theme predominates. 
Unspecified Type 
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1.6 Criticisms of DSM-IV 
Tsuang et al., (2000) have criticised the DSM-IV diagnostic formulation of 
schizophrenia on the basis of (1) the APA's view of schizophrenia as a 
discrete category, (2) their emphasis on psychosis, and (3) their use of 
descriptive attributes and the neglect of information on the aetiology of the 
disorder. Tsuang and colleagues propose that whilst current operational 
criteria enable reliability in diagnosis, the current formulation lacks validity. 
1.6.1 Schizophrenia as a discrete category 
DSM-IV's classification of schizophrenia as a discrete category implies that 
schizophrenia differs qualitatively from states of health and normality. 
Second, the use of discrete categories may result in artificial boundaries 
between conditions leading to elevated rates of co-morbidity. In contrast, 
dimensional models of schizophrenia which emphasise the nature and patterns 
of symptomatology (e. g. positive, negative and disorganisation symptoms) 
may provide a better account of the nature and role of combinations of 
biological and environmental risk factors which may be causal to 
schizophrenia (Gottesman, 1991; Peralta et al., 1997; Bell et al., 1998; Crow, 
1998a; Toomey et al., 1998; Tsuang et al., 1999). 
1.6.2 The role of psychosis in the definition of schizophrenia 
The presence of psychotic symptoms including delusions, hallucinations, and 
conceptual disorganisation are essential criteria for the diagnosis of 
schizophrenia (DSM-IV, APA, 1994). However, this position can be criticised 
on a number of grounds. Bell and colleagues (1998) showed that the duration 
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of illness and the absence of affective symptoms correctly classified 97% of 
individuals with first episode psychosis as having DSM-III-R schizophrenia, 
and also correctly identified 97% of those who did not have schizophrenia. 
Inclusion of DSM-III-R's psychosis criteria did not improve prediction. 
Serretti et al (1996) obtained a four-factor solution for items on the 
Operational Criteria Checklist for Psychotic Illness (OPCRIT) with a large 
group of individuals with DSM-III-R schizophrenia or DSM-III-R mood 
disorder. Psychopathology of participants with schizophrenia and bipolar 
disorder overlapped on the disorganisation factor. Furthermore, Crow (1990, 
1991,1998b) has proposed that schizophrenia, schizoaffective disorder, and 
affective illness exist along the same continuum, rejecting the concept of 
distinct disease entities. Indeed a variety of evidence demonstrates that 
psychosis is not specific to schizophrenia, that Schneiderian symptoms occur 
in other disorders (Peralta & Cuesta, 1998), and indeed measures of psychosis 
do not differentiate schizophrenia from other disorders. 
1.6.3 Aetiology 
Key to the development of DSM-III, a characteristic retained by its subsequent 
editions, was the explicit separation of diagnostic criteria from speculation 
about aetiology. This results in a risk of disconnecting treatment of the 
disorder from its aetiology. Indeed this is particularly relevant to the current 
developments in the psychological conceptualisation and treatment of 
psychotic symptoms reviewed in Chapter 3. Knowledge about the aetiology of 
schizophrenia and its associated symptoms would potentially facilitate the 
development of more targeted treatment strategies. Indeed, the use of 
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operationalised diagnostic criteria without recourse to knowledge regarding 
the genesis of the disorder may result in a biased view of prognostic factors in 
longitudinal research (reviewed below), because those who do not meet strict 
criteria for schizophrenia are excluded from those studies. There is evidence 
that the pathophysiology and phenomenology of schizophrenia is in place long 
before the first psychotic episode (Kendler et al. 1995). Neurodevelopmental 
models of schizophrenia have emphasised that some combination of hereditary 
predisposition in combination with environmental events leads to disrupted 
neuronal development as early as the second trimester of life (e. g. Goldman- 
Rakic, 1995) and in line with neurodevelopmental theories, altered cell 
migration in glutamate mediated pathways in the hippocampus have been 
implicated in stress hyper-responsivity in dopamine which is not apparent until 
adolescence (Jentsch & Roth, 1999). Indeed this neurodevelopmental account 
has important ramifications for explaining the early subjective experience of 
schizophrenia, which is central to psychological accounts of the development 
of psychosis. In this sense the concept of biological or environmental 
vulnerability to schizophrenia is poorly understood, as indeed is the nature and 
pattern of transition to schizophrenia. Notwithstanding these limitations 
surrounding the diagnosis of schizophrenia, there has been considerable 
research into the course and outcome of the disorder, which is reviewed 
below. 
1.7 Course and Outcome 
Prognosis has been integral to the definition of Schizophrenia since Kraepelin 
combined seemingly disparate disease entities under the term "Dementia 
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Praecox". In early studies, clinical and methodological issues relevant to 
prognosis in schizophrenia were examined by a number of investigators 
(Vaillant, 1962,1978; Stephens et al., 1966; Garmezy, 1968; Tsuang et al., 
1979; Ciompi, 1980a, 1980b; Huber et al., 1980; McGlashan, 1984; Harding et 
al., 1987; Pietzcker and Gaebel, 1987; Robinson et al., 1999). Despite 
methodological variations, some consistent findings about predictors of 
favourable and unfavourable outcome have been noted. Poor prognosis was 
indicated by insidious onset, schizoid personality, withdrawal, restricted 
affective expression, never being married, and a family history of 
schizophrenia, whilst good prognosis was associated with acute onset, good 
pre-morbid development, prominent symptoms of anxiety and depression, the 
presence of precipitating factors, living in a family environment characterised 
by an absence of expressed emotion (EE), and being married. From the 
perspective of epidemiology Ram et al., (1992) note that most longitudinal 
studies have serious methodological limitations in sampling, diagnosis, and 
data collection procedures. For example, Carpenter and Strauss (1979) and 
Strauss and Carpenter (1978,1979) note that the issue of prognosis and 
outcome in schizophrenia is influenced by the diagnostic criteria employed by 
investigators. When criteria for diagnosis include prolonged illness and 
presence of deterioration (e. g. Feighner Criteria, DSM-III Schizophrenia), 
outcomes are naturally skewed toward chronicity. When diagnosis is defined 
by cross-sectional positive symptoms (e. g. Schneiderian or Langfeldt 
schizophrenia), outcome is heterogeneous, and positive symptoms have only 
modest to negligible prognostic value. For example, in a naturalistic one-year 
prospective study, Pietzcker & Gaebel (1987) investigated the course of 
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schizophrenia with that of other psychiatric disorders including affective 
psychosis and neuroses. A total of 161 individuals (Schizophrenia, n= 86; 
Neuroses, n= 34; Affective Psychoses, n= 17; Other, n= 24) discharged from 
hospital were recruited and diagnoses were made according to the 
International Classification of Diseases (ICD-9th Edition, World Health 
Organisation (WHO), 1978b). Diagnosis of schizophrenia was based on the 
criteria of Bleuler (1911) and Schneider (1950). Pietzcker (1983) has shown 
high concordance between these criteria and Research Diagnostic Criteria 
(RDC; Spitzer & Endicott, 1978) and DSM-III criteria (APA, 1980). A total of 
108 patients were followed up at one year, with an additional 14 reached via 
telephone interview and questionnaires. There were no significant differences 
between the initial and follow-up sample. At one year, all four diagnostic 
groups showed no significant differences in the areas of re-hospitalisation, 
employment, social contacts and symptomatology (on the whole a moderate to 
poor outcome) according to the Strauss-Carpenter (1972) outcome scale. 
Pietzcker & Gaebel (1987) hypothesised that the similarity of outcome across 
all diagnostic groups might be due to all four groups having a relatively long 
duration of illness thereby reflecting a predominantly chronic patient group. 
With specific respect to the schizophrenia group the mean duration of illness 
of this sample was 5.0 years, with a relapse rate of 48% in the follow-up 
period. Gaebel and Pietzcker (1987) further investigated predictors of outcome 
amongst this schizophrenia sub-sample at 1 year. Of the original schizophrenia 
sub-sample (n = 86), 57 were directly interviewed at 1 year, and a further 17 
by means of telephone interview, giving a total follow-up sample of 74 (86%). 
There were no significant differences between this follow-up group and the 
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individuals who dropped out. This prognostic study is of interest because the 
authors employed four established prognostic scales for schizophrenia: (1) The 
Phillips Prognostic Scale (Phillips, 1953), (2) The Vaillant Prognostic Scale 
(Vaillant, 1964), (3) The Stephens Prognostic Scale (Stephens et al., 1966) and 
(4) The Strauss Carpenter Prognostic Scale (Kokes et al., 1977). None of these 
scales were able to predict either relapse or duration of re-hospitalisation. 
However using multiple regression analysis, a combination of items on the 
Strauss Carpenter Scale was able to predict 25% of the variance in the 
outcome in terms of duration of re-hospitalisation. Unemployment, poor 
quality of social contacts, the presence of behavioural abnormalities, and the 
absence of self-support predicted longer re-hospitalisation. 
Perhaps the most striking methodological flaw in longitudinal studies has been 
the frequent failure to identify a homogeneous cohort with respect to illness 
stage. For prognostic research, cohort patients should be at the onset of their 
illness in order to test hypotheses about predictors of course and outcome. The 
majority of follow-up studies of individuals with schizophrenia have focused 
on consecutive admissions. These prevalence samples tend to over represent 
chronic cases remaining or returning to the treatment system (Cohen and 
Cohen, 1984). The specific proportion of first versus subsequent admission 
patients in any particular cohort will influence the findings on course and 
outcome. To illustrate, Shepherd and colleagues (1989) reported the 5-year 
status of 107 individuals with schizophrenia, 49 of whom having their first 
lifetime admission and 58, having a subsequent admission. Among the first 
episode individuals, 22% experienced no relapse at follow-up, 35% had one or 
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more, and 43% remained impaired throughout. In contrast, those with previous 
admissions, 10% had no impairment, and no further admissions at follow-up, 
29% had multiple episodes, and 60% remained impaired with no return to 
normality (Mantel-Haenszel x2 = 4.194; df = 1; p=0.041). Even more striking 
was the time spent in hospital during the 5-year follow-up was 26.2 weeks for 
the first admission subgroup compared to 76.2 weeks for those with previous 
admissions. Ram et al. (1992) conducted a review of first admission studies, 
which had examined the natural course of schizophrenia. Three types of 
studies were included in this review: statistical reports dating from the pre- 
neuroleptic era, long term retrospective studies, and prospectively designed 
cohort studies. 
1.7.1 Pre-neuroleptic period 
Ram et al. (1992) located fifteen studies carried out in North America and 
Europe that described the follow-up status of individuals diagnosed with 
schizophrenia prior to the introduction of neuroleptic medication (see Table 
1.5). The analyses contained in these studies were based on routinely collected 
hospital data concerning first admission, re-admission, discharge and death. 
Comparison of discharge rates is complicated by differing definitions of 
discharge. For example, in the New York State system, patients were not 
counted as discharged if they were transferred to a private inpatient facility, or 
to a state operated outpatient facility. However if they were transferred to a 
private outpatient facility they were counted as discharged. Therefore, the data 
on discharge from these early papers should be viewed as an estimate rather 
than a true picture. However a striking feature of these findings is the increase 
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in discharge rates beginning in the 1940's, which is at least one decade before 
the introduction of neuroleptics, illustrated by comparing Rosanoff (1914) and 
Fuller (1930). In addition, Israel and Johnson (1956) reported an incremental 
increase in the 10-year incremental discharge rate between 1913 and 1952. 
Three studies (McWalter et al., 1961; Achte & Apo, 1967; and Hurley & 
Conwell, 1967) investigated the effect of neuroleptic introduction on discharge 
patterns during the 1950's. McWalter et al., (1961) and Achte and Apo (1967) 
found no significant differences in discharge rates. Hurley and Conwell (1967) 
did find a significant increase in discharge rates after the introduction of 
neuroleptics. All these findings are, however, difficult to interpret because 
many treatment changes occurred simultaneously. Before the 1940's problems 
such as overcrowding, and improvements in treatment philosophy affected 
discharge rates. Furthermore, some of those included, as samples after the 
introduction of neuroleptics were not offered these drugs. One further obvious 
limitation is the reliability and criteria used by clinicians to make diagnosis, 
although Fuller (1930) noted that increases in discharge rates applied to 
individuals with a range of psychotic conditions. Despite these limitations, 
there are some consistent findings on prognosis and outcome. Rupp and 
Fletcher (1940) noted that good outcome was associated with shorter duration 
of illness prior to treatment, and longer initial admission was related to poorer 
outcome. Lehrman (1960) reanalysed the data of Malzberg (1952a, b) and 
found younger age and shorter duration of past illness predicted a better 
outcome. Locke (1962) found being married, prior education and employment 
predicted discharge from hospital. 
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Table 1.5 Pre-neuroleptic era follow-up studies (From Ram et al., 1992) 
Study Duration Findings (%) 
(n) (years) Dead Discharged In-patient 
Rosanoff(1914) 5 
169 
Fuller (1930) 15 
1,200 
58.6 
38.4 
Rupp & Fletcher (1930) 4.5 to 10 13.9 27.5 53.5 
641 
Malzberg (1952a, b) 5-6 5.6 61.9 43.9 
2,940 
Harris & Lubin (1952) 18 n/a 43.5 n/a 
289 
Isreal & Johnson (1956) 1913-22 n/a 54.9 n/a 
4,254 1923-32 54.4 
1933-42 61.2 
1943-52 72.5 
13.6 23.1 
25 35.3 
Marlzberg (1953) 34 59.3 n/a 
3,180 
Shepherd (1957) 
79 
58 
5 6.3 46.8 n/a 
1.7 56.8 
McWalter et al (1961)* 
129 
93 
5 
3 
3 
Locke(1962) 5 
5,781 
n/a 21 
16 
1.6 70 
n/a 
22 
Peterson & Olson (1964) 5 n/a 76 24 
177 
Achte (1967) 3 to 51 57 39 
275 
Achte & Apo (1967)* 3 to 5 >1 49 47 
285 
Hurley & Conwell (1967)* 
Two groups 1954 1 
1960 1 
61.3 to 91.7 
74.3 to 91.8 
Beck (1968) 25 to 35 n/a 35.7 64.3 
84 
NOTE- n/a = not available 
" These studies specifically examined the question of improvement in outcome of schizophrenia after the 
introduction of neuroleptics 
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1.7.2 Retrospective studies 
Ram et al. (1992) presented data on seven retrospective studies. These are 
summarised in Table 1.6 below. These studies employ case record strategies 
in order to understand short and long-term outcome patterns and their 
predictors. One advantage of this kind of study is that the selection factors, 
which apply in drug trials, which potentially limit the generalisability of 
findings, are avoided. However, this research suffers from sampling and 
reliability limitations that affect the inferences that can be drawn. For 
example, Ciompi (1980a, b) identified consecutive admissions with 
schizophrenia between 1900 and 1962. The subsequent variability in intake, 
treatment experiences, and length of follow-up (median = 37 years), means 
that the sample does not fit the usual criteria for a cohort. In the same study 
attrition was a problem, with only 289 (18%) of the original 1,682 identified 
individuals were reassessed. Furthermore, although information from medical 
records and key informants was used in these studies, in many cases the 
reconstruction was based on the retrospective interview with the individual 
(for example Bleuler, 1978). Despite these problems retrospective studies do 
reveal that there is heterogeneity in the outcome of schizophrenia, and a 
number of prognostic indicators associated with better or worse outcome. 
Better pre-morbid social, familial, and occupational adaptation, acute onset, 
and shorter duration of first hospitalisation all predicted better post treatment 
functioning. These findings suggest that a high-risk group of individuals at 
first admission will have persistent psychosocial difficulties predating the 
onset of illness. 
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Table 1.6 Long-term follow-back studies (From Ram et al., 1992) 
Study Subjects Follow-up Outcome 
(n) (years) (%) 
Bland & Om (1978) 43 14 Mortality =7 
Psychiatric Condition: 
Recovered = 21 
Other = 79 
Social Adjustment: 
Good = 37 
Fair = 28 
Poor & other = 35 
Bland et al. (1976,1978) 88 10 Mortality = 13.6 
Psychiatric Condition: 
Recovered = 58 
Other = 42 
Social Adjustment: 
Good = 35.2 
Salokangas (1983) 161 7.5/ 8.5 No symptoms = 26 
Neurotic symptoms = 21 
Mild psychotic symptoms = 29 
Continuous symptoms = 24 
Stephens (1978) 206 <10 Recovered = 22 
Improved = 51 
Unimproved = 26 
143 >10 Recovered = 24 
Improved = 45 
Unimproved = 30 
Bleuler (1911,1950) 68 20 Recovered = 23 
Mild = 20 
Moderate = 19 
Severe = 15 
Ciompi (1980a, b) 289 36.9 Global Outcome: 
Remission = 27 
Minor residual = 22 
Unfavourable = 42 
Social Outcome: 
In hospital = 44 
Community residence = 17 
Alone/ family = 39 
Wing (1966) 111 5 Relapse = 48 
Moderate symptoms = 28 
Disturbed in 15` year only = 35 
Favourable functioning = 49 
Employment: 
Male = 63 
Female = 69 
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Ciompi (1980a) classified 228 cases according to type of onset (acute versus 
insidious), interim course (undulating versus non-undulating), and end-state 
(recovery/ mild versus moderate/ severe). Log linear analysis of this three-way 
classification revealed a statistically significant bivariate association for each 
pair of variables. However, type of onset had no impact on end-state beyond 
its effect on interim course. In addition, the interaction between type of onset 
and interim course on end-state was not significant, implying that the 
significant relationship between interim course and end-state was not 
moderated by type of onset. 
1.7.3 Prospective studies 
Prospective studies have attempted to provide a solution to the methodological 
problems apparent in early studies of the course and outcome of 
schizophrenia. The studies reviewed here have sought to identify participants 
at first admission, and include them according to strict diagnostic criteria 
obtained through a combination of structured clinical interview and 
information from medical records and key informants. However, despite the 
advantages of prospective studies, these investigations also have limitations. 
Follow-up periods have often been variable making comparison difficult. 
Participant numbers have often been small, thereby limiting the power of the 
study to predict course and outcome from pre-morbid and initial clinical 
findings. In addition, as prospective studies identify participants at first 
hospitalisation, sample composition may be compromised. First, such a cohort 
may not be representative of all first episodes of psychosis. Second, co- 
morbidity with alcohol and drug use is often a reason for exclusion. Meuser et 
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al, (1990) suggest that first episode schizophrenia is associated with 
significant problems of substance and alcohol use. Third, potential participants 
who do not meet diagnostic criteria for schizophrenia at first admission are 
excluded, with the exception of Beiser et al. (1988). Individuals who are given 
other diagnoses may subsequently develop a clinical picture consistent with 
schizophrenia. Conversely, individuals meeting criteria for schizophrenia at 
study entry, whose later clinical picture is consistent with affective disorder, 
are included. For example, Schubart et al. (1986) found 8 of their initial cohort 
of 70 first episode participants were subsequently found to have affective 
disorder. 
The Scottish Schizophrenia Research Group (1989a, b) found that compared to 
the Research Diagnostic Criteria (RDC; Spitzer, Endicott & Robins, 1977, 
1978) and the International Classification of Diseases (ICD-9; WHO, 1978b), 
Feighner Criteria (Feighner et al., 1972) tended to predict poorer outcome. 
This is because Feighner criteria for Schizophrenia require a 6-month duration 
of illness. Furthermore, Beiser et al. (1988,1989) examined a cohort of 175 
individuals experiencing a first episode of functional psychosis. Participants 
were assigned diagnoses according to DSM-III (APA, 1980), ICD-9 (WHO, 
1978b), RDC (Spitzer, Endicott, & Robins, 1977,1978), and Feighner (1972) 
diagnoses. Participants were followed up at 9 and 18-months. Attrition was 
high, with 120 seen at 9-months and 129 at 18-months. Diagnostic stability 
according to DSM-III, ICD-9, RDC and Feighner criteria was examined at 
both 9 and 18-months, and outcome assessed at 18-months. ICD-9 had the 
broadest definition of schizophrenia, generating twice as many diagnoses of 
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schizophrenia as DSM-III, and almost three times as many as the Feighner 
criteria. The diagnostic criteria employed to classify schizophrenia were 
strongly associated with recovery status at 9-months. Those diagnosed to ICD- 
9 criteria (broad definition) were more likely to recover and no longer require 
a diagnosis, than those meeting either DSM-IH or Feighner criteria (narrow 
definition). Shepherd et al. (1989) identified a cohort of 121 individuals with 
schizophrenia (Schneiderian Criteria; Schneider, 1959), of whom 49 were first 
admissions. The clinical outcome of first admissions were assessed in terms of 
mortality and attrition, readmissions to hospital, psychotic symptoms present 
during the interim and at follow-up at five-years, and depressive symptoms 
present during the interim and follow-up. There was no attrition in the first 
episode group, and one had died at follow-up. A total of 55% of patients were 
readmitted during the follow-up period. The mean duration of hospital 
admission was 26-weeks, compared with 53-weeks for the whole cohort. 
Females did better than males; 19% of males spent more than a year in 
hospital compared to 4% of females. In terms of course of illness, four groups 
were identified; 22% were found to have had no further episodes and no 
impairment at follow-up, 35% had several episodes with minimal impairment 
between episodes, 8% were impaired after their first episode, and had 
subsequent exacerbations, whilst 35% had increasing impairment with each 
episode. Very clear differences exist between Shepherd et als' (1989) and 
Beiser et als' (1988) studies underlining the effects of diagnostic criteria used 
by investigators to include participants. This becomes an extremely important 
consideration when interpreting the findings on prognosis in schizophrenia 
reported by prospective studies. These are summarised in Table 1.7 below. 
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Three prospective studies, have included a long-term placebo-controlled trial 
of neuroleptic medication (May et al., 1976a, b; Kane et al., 1982; Scottish 
Schizophrenia Research Group, 1989a, b). These studies are considered in 
Chapter 2. 
With regards to clinical features at admission, longer duration of illness prior 
to admission, poor pre-morbid adjustment, insidious onset was found to 
predict poorer outcome (Rabiner et al. 1986; Wiersma et al. 1998; Robinson et 
al. 1999). Two studies (Salokangas & Stengard, 1990; Thara et al, 1994) found 
being male was associated with poorer outcome. Affective symptoms at entry 
were not found to have a bearing on outcome in two studies (Gift et al., 1980; 
House, 1987). Lieberman et al. (1989) found that abnormal brain morphology 
on MRI was predictive of poorer course, however this finding was not 
replicated in Robinson et als' (1999) study. 
The World Health Organisation (1978a) reported on follow-up information 
from the International Pilot Study of Schizophrenia on predictors of course 
and outcome amongst 906 participants across nine centres over two-years. 
This study examined the relationship of sociodemographic characteristics, past 
history characteristics and characteristics of the initial episode of illness in 
relation to outcome. In terms of sociodemographic data, male sex, social 
isolation and study centre predicted poorer outcome. 
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Table 1.7 Prospective follow-up studies of the course and outcome of 
schizophrenia. 
Study Subjects Follow-up Results 
Gift et al. 227 151 2-years 
(1980) Admissions 
Schneiderian 
Initial psychotic symptoms 
correlated with most outcome 
measures. 
Schubart et al. 70 ICD-9 5-years 
(1986), Biehl Schizophrenia 
et al. (1986) 
Rabiner et al. 36 RDC 1-year 
(1986) schizophrenia 
House (1987) 56 CATEGO 1-year 
Schizophrenia 
Beiser et al. 63 ICD-9,18-months 
(1988,1989) DSM-III, RDC 
& Feighner 
schizophrenia 
Lieberman et at. 45 RDC 3-years 
(1989) schizophrenia & 
schizoaffective 
Shepherd et al. 49 5-years 
(1989) 
Salokangas 227 DSM-III 2-years 
& Stengard schizophrenia 
(1990) 
Carpenter and 53 ICD-9 11-years 
Strauss (1991) schizophrenia 
Thara et al. 81 Feighner 10-years 
(1994) Schizophrenia 
Wiersma et al. 82 ICD-9 15-years 
(1998) Schizophrenia 
Robinson et at 104 RDC 5-years 
(1999) schizophrenia 
Level of disability at entry predicted 
level of disability at outcome. 
Longer duration of illness and 
pre-morbid asociality before admission 
predicted poorer outcome. 
Depression not associated with 
neuroleptic drugs. 
ICD-9 and RDC recognised relapsing 
schizophrenia. Few friends and negative 
symptoms predicted poorer outcome. 
Abnormal brain morphology 
on MRI predicted slower and less 
complete response to treatment. 
Duration of admission at entry, younger 
age of onset predicted poorer outcome 
in terms of duration of readmissions. 
Males did more poorly on all 
psychosis dimensions. 
More social contact, more stable 
relationships, and greater distress at 
Entry predicted better outcome. 
Being male, having negative symptoms 
and religious/ grandiose delusions 
predicted poorer outcome. 
Insidious onset/ longer duration of 
untreated illness predicted poorer 
course 
Early adolescent poor pre-morbid 
adjustment predicted poor outcome. 
The Aarhus and Washington centres were predictive of longer episodes of 
illness, whilst Ibadan was associated with shorter duration. In terms of past 
history, the presence of a precipitating stressor (physical, psychological or 
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environmental) to the first episode was predictive of better response to 
treatment and more favourable outcome. This finding appears consistent with 
those of Wiersma et als' (1998) Aarhus cohort of the same study at 15-years 
who found that insidious onset was associated with poorer outcome. In terms 
of characteristics at the episode of inclusion, the duration of illness prior to 
admission was the strongest predictor of poorer outcome. Secondary to this 
finding, social isolation, the presence of derealisation, history of past 
psychiatric treatment and history of behavioural symptoms were also 
predictive of poorer outcome. Carpenter and Strauss (1991) describe data from 
the Washington cohort of the International Pilot Study of Schizophrenia, 
which followed up individuals at two, five then eleven years, after the episode 
of inclusion. The original sample included a cohort of 131 individuals who 
were included if they had been admitted to hospital, were aged between 15 and 
44 years old, and had at least one psychotic symptom. Subjects were excluded 
if there was evidence of an organic, drug related or alcohol disorder, and if 
there was evidence of continuous psychosis for 3-years or more. Of this 
original sample 53 patients were interviewed at 11 years, 40 (75%) of whom 
met diagnostic criteria for Schizophrenia. The representativeness of the 11- 
year follow-up sample was evaluated across 29 demographic, clinical, 
familial, and prognostic variables. Statistically significant differences 
(uncorrected for multiple comparisons) were found for only four variables; the 
group was more likely to be male, from a lower socio-economic status, have a 
longer duration of illness prior to initial research evaluation, and be rated as 
having adequate relationships prior to illness. Outcome was evaluated across 
four dimensions including duration of hospitalisation in the previous year, 
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frequency of social contacts, time spent employed during the last year, and 
symptom severity during the last month. 
Prognostic factors were examined using correlations. Individuals with more 
frequent social contacts and more stable intimate relationships prior to study 
entry, showed a more favourable outcome with respect to frequency of social 
contacts, employment status and symptom severity. In addition the greater the 
severity of subjective distress at entry, the better the 11 year outcome with 
respect to social contacts and symptom severity. It was apparent from this 
study that the early deterioration among many of the cohort stabilised by two 
years and 75% of individuals showed no change in relapse, social contacts, 
occupational functioning, and residual symptoms between two and eleven 
years. The similarity in outcome at 2,5 and 11 years of this cohort show no 
evidence of a disorder of progressive deterioration. Indeed, amongst those 
individuals struggling at two years, one third showed improvement at eleven 
years. 
The findings of Carpenter and Strauss (1991) have been supported by two 
prospective studies; the Madras first episode schizophrenia study (Thara et al., 
1994; Eaton et al., 1995) and the Nottingham Centre cohort (Harrison et al., 
1996) of the first episode schizophrenic cohort of the Determinants of 
Outcome Study of Mental Disorders (DOSMD; Jablensky et al., 1992, Mason 
et al., 1996). Jablensky et al. (1992) reported an average of 39% of individuals 
with one psychotic episode and only mild or no impairment after two years in 
developed countries. In the UK centre, Mason et al. (1996) reported that 82% 
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had relapsed within thirteen years and the majority (75%) by four years. Thara 
et al. (1994) followed up 90 consecutive patients meeting Feighner criteria for 
schizophrenia. Seventy-six of the 81 patients who were alive at the end of 10- 
years were followed up, resulting in a follow-up rate of 94% (84% of the 
original sample). During the follow-up period, 4 patients had committed 
suicide, 5 had died due to physical illness, 4 were untraceable, and 1 refused 
consent. Outcome data were obtained through annual administrations of the 
Present State Examination (PSE; Wing et al., 1974). Five patterns of outcome 
were defined (see Table 1.8 below). It was striking that the pattern of illness 
course was good in 67% of cases, that is those who either made a complete 
recovery, those who did not relapse but had some residual symptoms or those 
who did relapse but made complete recoveries between episodes. Indeed, 
nearly 60% of the cohort had been able to retain employment at the end of 10- 
years. 
Table 1.8 Patterns of Course: The Madras Longitudinal Study 
Pattern Frequency Time spent in Psychosis 
(months) 
Complete recovery 11 10 
without relapse 
No relapses, but with 2 9 
residual symptoms 
One or more relapses 37 16 
with complete remissions 
One or more relapses but 21 37 
with residual symptoms 
Continuously psychotic 5 89 
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Linear regression analysis was used to examine predictors of duration of time 
spent in psychosis. Being female and having an earlier age of onset was more 
predictive of spending fewer months in psychosis. Four syndrome scores on 
the PSE at entry to the study predicted a statistically significant increase in the 
percentage of time spent in psychosis: flat affect, self-neglect, religious or 
grandiose delusions, and sub-cultural delusions and hallucinations. The 
presence of hypomania and non-specific psychosis at intake predicted a lower 
percentage of months in psychosis during follow-up. The R for the model was 
0.45, indicating that more than 20% of the variance in the percentage of 
months in psychosis is predicted by variables at intake. The finding that older 
age of onset was predictive of a greater proportion of time spent in psychosis 
is an interesting one, which has not been reported elsewhere. Thara et al. 
(1994) speculated that this factor might reflect the influence of social and 
cultural factors present in Indian settings, specifically the older individual is 
more likely to be married, having to support a family and hold a job and 
consequently may be exposed to more life stressors than a younger individual. 
1.8 Summary and Conclusions 
Whilst psychosis has long been recognised as a potentially devastating human 
experience, debate has continued as to the role of organic, psychological, and 
environmental factors in its development, expression, and course. Early 
precursors to modem conceptualisations (e. g. Kraepelin, 1896; Bleuler, 1911) 
differed markedly in their views regarding course and outcome. On the one 
hand, Kraepelin saw the disorder as having a progressively deteriorating 
course, whilst Bleuler saw course and outcome as heterogeneous. Furthermore 
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whilst Kraepelin brought a descriptive approach to psychopathology and 
speculated on the organic basis of schizophrenia, Bleuler emphasised theory as 
a means of describing and defining schizophrenia. 
The development of classification systems of schizophrenia has become 
relevant to this ongoing debate concerning aetiology, course and prognosis. 
For example, early classification systems saw all mental disorders as reactions 
to environmental causes. Later diagnostic systems aimed to strengthen 
operational criteria for differential diagnosis emphasising particular factors 
such as presence and nature of psychotic symptoms (e. g. Schneider, 1959; 
Spitzer & Endicott, 1978; DSM-HI-R, 1987), impact on functioning (e. g. 
DSM-IV, 1994), the duration of illness (e. g. Feighner et al., 1972) and the role 
of affect (e. g. Feighner et al., 1972; DSM-IV, 1994). Attempts to develop 
reliable criteria for diagnosing schizophrenia and differentiating it from other 
disorders involving psychotic symptoms have lead to the development of 
diagnostic systems (e. g. DSM-IV, ICD-10), which emphasise the description 
of psychopathology but neglect theoretical conceptualisations of aetiology. 
Therefore, whilst the evolution of diagnostic systems since Bleuler's (1911) 
description and classification of schizophrenia have improved the reliability of 
diagnosis (Tsuang et al., 2000). As was pointed out, diagnostic systems such 
as DSM and ICD have become divorced from conceptualisations of the 
aetiology of schizophrenia. At the same time they emphasise the presence of 
positive psychotic symptoms and impact on day to day functioning. However, 
Bell and colleagues (1998) showed that the duration of illness and the absence 
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of affective symptoms correctly classified 97% of individuals with first 
episode psychosis as having DSM-III-R schizophrenia, and also correctly 
identified 97% of those who did not have schizophrenia. Inclusion of DSM- 
III-R's psychosis criteria did not improve prediction. Serretti et al (1996) 
found that the psychopathology of participants with schizophrenia and bipolar 
disorder overlapped on the disorganisation factor. Crow (1990,1991,1998b) 
proposed that schizophrenia, schizoaffective disorder, and affective illnesses 
exist along the same continuum, rejecting the concept of distinct disease 
entities. Indeed a variety of evidence demonstrates that psychosis is not 
specific to schizophrenia, that Schneiderian symptoms occur in other disorders 
(Peralta & Cuesta, 1998), and indeed measures of psychosis do not 
differentiate schizophrenia from other disorders. 
These diagnostic debates are also relevant to sampling processes involved in 
studies of course and outcome. Adopting diagnostic systems which emphasise 
illness chronicity result in findings that indicate schizophrenia has a negative 
deteriorating course, whilst diagnoses made on the cross-sectional presence of 
psychotic symptoms, course and outcome is heterogeneous. Studies examining 
the course and outcome of schizophrenia were reviewed. These studies 
included those conducted prior to the introduction to neuroleptics, 
retrospective studies and prospective studies. All of these studies suffer from 
the methodological problems arising from the sampling procedures associated 
with diagnostic procedures. Prospective studies, reviewed in Section 1.7.3 
have compensated for sampling biases inherent in retrospective studies, 
reviewed in Section 1.7.2, by selecting participants at their first episode. 
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Despite this, prospective studies do have limitations including small sample 
sizes, exclusion of first admissions who later develop schizophrenia, and 
exclusion of participants due to drug and alcohol co-morbidity. 
Notwithstanding the methodological shortcomings and variations in diagnostic 
criteria employed, the outcome of schizophrenia is heterogeneous and the 
disorder does not appear to be a unitary one (e. g. Carpenter and Strauss, 1991; 
Thara et al., 1994; Eaton et al., 1995; Harrison et al., 1996; Mason et al., 
1996). Poor outcome is however associated with a longer duration of untreated 
illness, poor pre-morbid adjustment, and higher levels of social isolation. 
Indeed longer duration of untreated illness is associated with poorer outcome 
and increased risk of relapse for pharmacological treatments (e. g. Crow et al., 
1986; Robinson et al., 1999). In Chapter 2 will now turn to the examination of 
the course of schizophrenia, with particular reference to relapse and it's 
prevention. 
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Chapter 2 
Relapse and relapse prevention in schizophrenia 
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2.1 Relapse 
Little is known about the process of natural relapse in schizophrenia because 
most of the data has come from either treatment outcome trials, or studies 
which have included some treatment (Zubin et al., 1992). In general, the term 
relapse is used to refer to a deterioration or recurrence of positive rather than 
negative features of illness. However the boundaries of relapse in 
schizophrenia are not entirely clear. In fact, relapse is a relative term and must 
take into account the following factors: the individual's condition before the 
original onset of their condition, their level of functioning before the present 
episode, the severity of relapse in terms of symptom severity, duration and 
interference with personal functioning, and the appearance of new symptoms 
and behaviour patterns. Relapses may also be defined as the reappearance of 
psychotic symptoms in an individual who had been free of active phase or 
residual symptoms, and the exacerbation of persisting positive symptoms. 
Therefore operational definitions of remission and relapse vary across studies. 
For example, Shepherd et al. (1989) defined remission as a full clinical 
recovery and relapse as readmission. They found that 22% of their sample 
were relapse free at five years, 35% relapsed but recovered with no 
impairment. In contrast Crow et al. (1986) defined relapse as either the 
development of psychotic features or a deterioration of mental state described 
by a relative or clinician, death, or an "uncharacteristic non co-operation". 
Using these criteria 35% of the sample remained relapse free at two years. 
Thara et al (1994) and Eaton et al. (1998) reported on the rates of remission 
and relapse from the Madras Longitudinal Study. A total of 90 patients were 
followed up at monthly intervals using the Interim Follow-up Schedule (IFS), 
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which recorded symptoms of delusions, hallucinations, thought disorder, 
psychomotor disorder, flat affect, apathy, social withdrawal, odd behaviour, 
self neglect, anxiety, manic symptoms and depressive symptoms. A psychotic 
episode was defined as the presence during the month of any of the following 
IFS symptoms: hallucinations, thought disorder, delusions, or a combination 
of extreme psychomotor disorder combined with at least one other IFS 
symptom. A remission was defined as a period of at least three consecutive 
months without psychotic symptoms. Thara et al (1994) found 64% (n=58) 
of their sample relapsed over the 10-year follow-up. Of these 37 (41%) had 
one or more relapses, with complete remission between acute phases, and 21 
(23%) had incomplete remissions between phases. Logistic Regression 
analysis revealed that age of onset, and duration of psychosis prior to 
treatment were variables, which were both, associated with a greater odds of 
having a poorer course of illness (relapsing or continuous psychosis). 
Specifically poorer course was associated with an age of onset above 25-years 
old, and a longer period of illness prior to initiation of treatment. In a further 
analysis of this data using Proportional Hazard Regression Analyses, Eaton et 
al. (1998) found that the prescription of neuroleptic medication accelerated the 
time to remission at the first episode, but not for the second episode. In 
addition, withdrawal of, or non-adherence with neuroleptics was predictive of 
relapse. 
Wiersma and colleagues (1998) identified a cohort of 82 individuals in two 
geographically circumscribed areas of the Netherlands. This cohort was 
entered to the study meeting criteria for first episode functional non-affective 
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psychoses (International Classification of Diseases- 9`h Edition). Participants 
were followed up for a period of 15-years. Outcome was examined in terms of 
relapse, non-psychotic episodes, and full or partial remission. A relapse was 
defined as a discrete period of symptomatology characterised by overt 
psychotic signs and symptoms of hallucinations, delusions, cognitive 
disorganisation, marked psychomotor disturbance, or grossly inappropriate 
behaviour. Such an episode must have been preceded by at least 30-days 
during which the individual had no psychotic symptoms. Non-psychotic 
episodes refer to periods without psychotic signs, but with neurotic or negative 
symptoms. Complete remission was defined as being symptom free, combined 
with return of pre-morbid personality. A remission or partial remission could 
not be rated as present unless it had lasted more than 30-days. A total of 68% 
of participants experienced one relapse during the follow-up period, 58% 
experienced two, 49% three, and 47% experienced four relapses. Most 
relapses occurred between one or two years following remission from the 
previous episode, although there was a trend for the duration of remission to 
increase between episodes. Taking into account both affective and non- 
affective relapses, 43% of participants relapsed within 1-year, a further 12% 
by 2-years, and 8,7, and 2% in the subsequent 3-years. It is clear from these 
findings that a relapsing course of illness is apparent in the first 5-years 
following the first episode. Wiersma et al. (1998) did not analyse predictors of 
relapse itself. However, using Cox Regression, duration of first and 
subsequent psychotic episodes was predicted by two variables: type of onset 
and mental health treatment. Those with a longer duration of psychosis of first 
and subsequent episodes, were almost twice as likely to have a disorder 
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characterised by insidious onset (Hazard ratio = 1.88, p=0.07), and were 
more than twice as likely to experience delay before initiation of active 
treatment (Hazard Ratio = 2.33, p<0.01). 
2.2 Prevention of Relapse and Neuroleptic Medication 
Ohmori et al. (1999) conducted a retrospective study of psychotic relapse and 
maintenance neuroleptic therapy. These investigators identified fifty 
outpatients with ICD-9 paranoid schizophrenia who had been on maintenance 
neuroleptic therapy for a period of at least 15-years since their first episode. 
Relapse rates during follow-up were as follows; 52% at two years, 76% at five 
years, 86% at ten years, and 90% at fifteen years. A total of 207 relapses were 
recorded for the 50 participants over the follow-up period. Of this total 74 
(35.7%) occurred when participants were off medication, and in 25 of these 
relapses the participant had been without medication for more than twelve 
months. Relapses without medication were more likely to occur in the first 
five years of follow-up, however the incidence of relapse whilst off 
medication significantly reduced during the subsequent two 5-year epochs. On 
the other hand the incidence of relapse whilst on medication did not change 
over time. Ohmori et al. (1999) also found significant positive correlations 
between Haloperidol Equivalent Dosage and relapse rate. 
The Northwick Park First Episode Study (Johnstone et al., 1986) examined 
120 individuals with a first episode of schizophrenia in a study of maintenance 
neuroleptic treatment. Of a total of 462 referrals, 253 were suitable for 
inclusion, 116 did not consent to enter the trial and 17 were never well enough 
47 
Relapse and relapse prevention in schizophrenia 
to be discharged from hospital. All participants were discharged on one of five 
active antipsychotic medications: Fluphenthixol (IM, 40mg/month), 
Chlorpromazine (Oral, 200mg/ day), Haloperidol (Oral, 3mg/day), Pimozide 
(Oral, 4mg/day) and Trifluoperazine (Oral, 5mg/day). Attending psychiatrists 
were instructed to prescribe only one of these medications at or above the 
stated minimum dose. No upper limit on dosage was prescribed; this was at 
the discretion of the attending psychiatrist. Other psychotropic medication 
could be prescribed in addition to the antipsychotic medication once this 
medication had been initiated. For the first month following discharge all 
participants remained on their active antipsychotic medication. Any 
readmissions during this period were considered a continuation of the index 
psychotic episode. Thereafter participants who completed this one-month 
phase without readmission were then randomly assigned to receive either 
placebo or active medication. Participants were tailed into placebo, receiving 
half-strength matched medication in the second month and matched placebo 
thereafter. Again the participants' dosages could be changed at any point by 
the attending psychiatrist, but they were not allowed to fall below the stated 
minimum dosage. Relapse was determined by the responsible clinician and 
confirmed by one of the study team. Relapse was defined as readmission to 
psychiatric care for any reason; readmission considered necessary but not 
possible; and active antipsychotic medication considered by the attending 
psychiatrist to become essential due to features of imminent relapse. Crow et 
al., (1986) found that of those on maintenance neuroleptic treatment, 25 out of 
54 (46%) relapsed, and of those on placebo, 41 out of 66 (62%) relapsed by 24 
months. These results are illustrated in Table 2.1 below. It was not possible, 
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on the basis of length of hospital stay or demographic features to predict those 
who remained well on placebo. The authors concluded that it was, therefore, 
not possible to predict which individuals respond to placebo. However, 
caution is required in interpreting these results. Key to the design of the 
Northwick Park First Episode Study is the objective to define those clinical 
features, which predict response to antipsychotic medication. The logic of 
using of broad demographic and psychiatric treatment variables to predict a 
group of patients who respond to a placebo treatment seems flawed. It would, 
however, seem reasonable to suggest that those who remain well without 
active medication may have access to internal or external resources, which 
facilitate recovery and promote relapse prevention. No attempt was made in 
this study to examine such variables in relation to outcome. In addition, there 
was a remarkable stabilisation in relapse rate after one year amongst the group 
receiving placebo medication; 37% remained relapse free at one year 
compared to 30% at two years compared to the active group of whom 62% 
remained well at one year, and 42% at two years. According to the figures 
presented by Crow et al., (1986) 33 participants remained well at 12 months 
on active medication, versus 24 participants on placebo. A total of 10 (30%) of 
participants on active medication relapsed between 12 and 24 months 
compared to 4 (17%) participants maintained on placebo. 
Johnstone et al., (1990) followed up this study sample and those with a first 
episode of schizophrenia who were excluded from the original placebo 
controlled trial (Crow et al., 1986). A total of 252 individuals were assessed in 
terms of occupational outcome and the number of days spent as an in-patient 
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at two years or at the conclusion of the study. Occupational outcome was 
classified as (a) higher, (b) the same, (c) lower, and (d) no occupation. The 
number of days spent as an in-patient was dichotomised at 100 days: those 
spending less than 100 days were classified as a "good" outcome, and those 
spending greater than 100 days a "poor" outcome. 
Table 2.1 Northwick Park Study of First Episodes of Schizophrenia 
Relapse outcome at 6,12,18, and 24 months 
Group Entered 
N 
Relapsed 
N(%) 
Relapse free 
N(%) 
6 12 18 24 
DUP <1 year 
Active 31 10(32) 25 (80) 25 (80) 22 (71) 18 (59) 
Placebo 51 26 (51) 39 (66) 23 (45) 21(42) 21(42) 
Total 82 36 (44) 64 (72) 48 (59) 43 (54) 39 (48) 
DUP >1 year 
Active 22 15 (75) 17 (76) 7 (33) 6(26) 4 (18) 
Placebo 13 13 (100) 3 (23) 1 (8) - - 
Total 35 28 (80) 20 (55) 8 (23) 6 (14) 4 (10) 
Not known 
Active 1 0 - - - - 
Placebo 2 2 - - - - 
Total 3 2 - - - - 
Whole Group 
Active 54 25 (46) 43 (79) 33 (62) 29 (54) 23 (42) 
Placebo 66 41(62) 38 (57) 24 (37) 22 (33) 20 (30) 
Total 120 66 (55) 81(67) 57 (48) 51(42) 43 (35) 
Predictors of outcome were sought from a number of measures; the Past 
History and Socio-demographic Schedule (PHSD), Disability Assessment 
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Schedule (DAS), Psychological Impairments Rating Schedule (PIRS; 
Jablensky et al., 1980), and the Disturbed Behaviour Rating (DBR; Johnstone 
et al., 1986), and Neurological Soft Signs and Neuropsychological tests. 
Johnstone et al., (1990) found a variety of variables were predictive of 
occupational and treatment outcome. There was a strong association between 
poor outcome and relapse/ readmission, greater duration of illness prior to 
treatment, social withdrawal/ inactivity, and with more neurological soft signs. 
Active antipsychotic treatment was associated with reduced relapse/ 
readmission. Despite this association, placebo medication was associated with 
improved occupational outcome. Other predictors of good outcome were 
relatively short duration of pre-treatment illness, and the presence of `special 
assets' as measured by the PIRS. "Special assets" refers to factors such as 
`social charm and presence'. The use of x2 statistics to measure the 
associations between baseline and outcome variables as predictors makes 
interpretation of these results difficult. However, the findings strongly suggest 
that pre-treatment duration of illness was a particularly strong predictor of 
outcome. In addition, it was apparent that the benefits associated with active 
antipsychotic medication, that is reduced relapse and readmission, exact a cost 
in terms of occupational outcome. 
The Scottish first episode schizophrenia study (Scottish Schizophrenia 
Research Group, 1989a, b) examined 49 individuals with a first episode of 
schizophrenia, and described their outcome at 2-years. During their acute 
episode, participants had responded either pimozide or oral fluphenthixol. At 
remission participants were randomised in a double blind study of once 
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weekly pimozide versus intramuscular fluphenthixol decanoate maintenance 
therapy. Those who had remained relapse free at one year were then 
randomised to a double blind study of either active medication (pimozide or 
fluphenthixol decanoate) or placebo medication. A total of fifteen participants 
successfully completed the first year double blind study and proceeded to the 
second year. Eight participants received active medication and none were 
readmitted; seven received placebo and four (57%) were readmitted. Outcome 
at two years was categorised as good or poor. Good outcome was defined as 
no readmissions and no positive or negative symptoms at 24-months. Poor 
outcome was defined as having a readmission or by the presence of positive or 
negative symptoms. Information was obtained for 38 participants: 14 (37%) 
had a good outcome, and 24 (63%) had a poor outcome. Of the good outcome 
group 36% had received continuous medication over the two years were rated 
as having a good outcome, whilst 32% of the group who were rated as having 
a poor outcome had received continuous medication. Poor outcome was 
associated with being male and having negative symptoms at entry. Whilst the 
nature of the study's design and the small numbers included make these results 
difficult to interpret, being on continuous medication throughout the first two 
years following an initial episode of schizophrenia did not confer more a 
positive outcome in terms of remission and stabilisation in the community. 
The Northwick Park Functional Psychosis Study (Johnstone et al, 1988) 
selected 120 patients from the consecutive admissions of 326 individuals with 
a definite or possible psychotic illness. These patients were entered into a 
four-week trial, which compared the treatment efficacy of 1) lithium + placebo 
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pimozide; 2) pimozide + placebo lithium; 3) lithium + pimozide and 4) 
placebo lithium + placebo pimozide in acute functional psychotic episodes to 
which no diagnostic classification had been applied. At the end of the trial 
period a total of 56 patients met criteria for recovery and were therefore 
eligible for the continuation phase of the study. Of the 56 patients achieving 
criteria for recovery, 30 were entered into the maintenance phase of the trial, 
which involved continuation of one of the four trial phase treatments. Results 
were calculated in terms of survival to first relapse. Patients on placebo 
pimozide survived for significantly less time than patients on active pimozide. 
Whilst this is in line with previous research, it is interesting to note that those 
patients who were maintained on placebo neuroleptic, had achieved defined 
recovery during the acute phase of the trial whilst on placebo. 
Robinson et al (1999) conducted a long-term study of first episode 
schizophrenia and schizoaffective disorder. The sample included 104 
participants who were followed up for a period of five years following their 
initial response to treatment of their first episode. At entry to the study, 
participants were diagnosed according to Research Diagnostic Criteria (Spitzer 
et al., 1977) using the Schedule for Affective Disorders and Schizophrenia 
(Endicott & Spitzer, 1978). Participants had been ill for an extended period 
before study entry: the first psychotic symptoms began 16 months prior to 
study entry. Participants were treated openly according to a standard 
algorithm, progressing from one phase of the algorithm to the next until they 
met criteria for treatment response. At the end of the 5-year follow-up, the 
cumulative rate of relapse for the 104 participants was 81.9%. Of those 
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participants, 63 recovered after the first relapse. The cumulative rate for 
second relapse was 78.0%. Of this group, 20 made a recovery after a second 
relapse. Amongst this group, 86.2% relapsed for a third time. A survival 
analysis of relapse using medication status as a time dependent covariate 
indicated that the risk for a first and second relapse was almost 5 times greater 
when not taking medication than when taking medication. Survival analysis 
for third relapse produced high but unstable estimates because of the small 
number of participants. Thirteen stable participants not on medication dropped 
out of the study. When these participants were included in the survival 
analysis, the effect of antipsychotic medication on relapse remained 
significant, with a risk of first relapse 3 times greater for those not taking 
medication. This relationship between discontinuation of medication and 
relapse may have been an artefact of discontinuation as a result of the relapse 
process itself (e. g. loss of insight). This was examined in subsequent analyses 
by varying the time lag between stopping medication and relapse. The effect 
for this relationship remained significant using 14,28 and 56-day time lags, 
thus indicating that discontinuation was unlikely to be a manifestation of 
relapse itself. In a further analysis of predictors of relapse, medication status 
was entered as a control variable. Robinson et al., (1999) examined a range of 
predictor variables including pre-morbid adjustment, baseline positive and 
negative symptomatology, obstetric complications, baseline depression, 
neuropsychological performance, and brain abnormalities identified using 
Magnetic Resonance Imaging. Early adolescent pre-morbid adjustment was 
the only variable significantly related to first relapse independent of 
medication status. Early pre-morbid social isolation and poor adaptation to 
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school were particular characteristics of this measure. Thus specific 
behaviours present long before the expression of overt psychotic symptoms 
predict some aspects of the course of the disorder once it develops. This 
finding replicates that of Kane and colleagues (1982) who also examined a 
remitted first episode cohort with schizophrenia treated with either 
Fluphenazine or placebo. Unlike Crow et al., (1986), Robinson and colleagues 
did not find that duration of untreated illness was predictive of outcome. 
However the mean duration of untreated illness was 2.8 months in Crow et 
als. ' (1986) study versus 16.0 months in Robinson et als. ' cohort. This would 
indicate that (1) the two groups are not the same, and (2) Robinson et als' 
cohort are likely to be similar to Crow et als. ' poor prognosis subgroup. 
Therefore there is some limitation to the generalisability of the Robinson et al., 
(1999) findings to the wider population of individuals with a first episode of 
schizophrenia. 
Examination of the outcome of prospective first episode studies, which have 
included a placebo controlled trial of neuroleptics have produced a number of 
contradictory findings. First, neuroleptic maintenance is associated with 
reduced relapse rates (May et al., 1976a, b; Kane et al., 1982; Crow et al., 
1986, Johnson et al., 1988; Scottish Schizophrenia Research Group, 1989a, b; 
Johnson et al., 1990; Robinson et al., 1999). However, there are individuals 
who successfully recover and maintain recovery without neuroleptics (Scottish 
Schizophrenia Research Group, 1989a, b; Johnson et al., 1990) although it is 
not yet possible to classify this group prospectively. Furthermore, maintenance 
neuroleptic therapy in itself does not predict good or poor outcome, indeed 
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there is evidence that neuroleptic medication exacts a social cost on 
individuals functioning (Johnson et al., 1990). In addition, there appears to be 
desynchrony between relapse and functioning. For example, whilst Johnson et 
al., (1990) reported an increased relapse rate for those maintained on placebo, 
this group showed improved levels of social functioning in comparison to 
those maintained on active antipsychotic medication. Therefore whilst studies 
have demonstrated that neuroleptics reduced relapse rate, this reduced liability 
to relapse does not necessarily confer advantages to functioning and 
potentially to individuals' quality of life. 
2.3 Low Dosage Neuroleptics and Relapse 
Although the balance of evidence shows that neuroleptic treatment is more 
effective than placebo in preventing relapse in schizophrenia (Davis, 1975; 
Crow et al., 1986; Robinson et al., 1999), antipsychotics exert a social cost, 
and a number of serious complications occur after prolonged use (Morgenstern 
et al., 1987). Indeed the occurrence of extra pyramidal side effects, such as 
tardive dyskinesia, akathisia and akinesia are major problems, which 
compromise both long-term use and acceptability. There is little consensus on 
what is the optimal dosage. Dose- response studies have not demonstrated a 
correlation between neuroleptic serum levels and clinical efficacy 
(Baldessarini & Davis, 1980). To improve the benefits-to-risk ratio, low dose 
strategies have been developed, with the aim of establishing the minimum 
dosage needed to prevent relapse. Such an approach to treatment is based on 
the proposal that neuroleptic dosages can be prescribed at dosages less than 
the ones required in the acute phase (Marder, 1999), and that the dosage can 
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be increased to treat relapse. In a meta-analysis of randomised controlled 
trials, Bollini et al., (1994) found that a chlorpromazine equivalent daily 
dosage of more than 375-mg gave no therapeutic advantage. 
Barbui et al., (1996) conducted a meta-analysis of randomised controlled 
studies, which had compared low dosage neuroleptic therapy with a 
conventional dosage. Studies were included if they were double blind and had 
a follow-up of at least 12-months. A computerised search yielded a total of 
100 potential studies from which only six met inclusion criteria (Kane et al., 
1983; Marder et al., 1984; Marder et al., 1987; Hogarty et al., 1988; Johnson et 
al., 1987; Inderbitzin et al., 1994). This gave a total of 415 participants (214 in 
low dosage, and 201 in the conventional dosage group). In all the studies 
selected, relapse was defined as either an increase in two or more points on the 
Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962) or a 
worsening of symptomatology requiring hospital admission. Furthermore, all 
studies used a depot preparation: Fluphenazine decanoate in five trials, and 
Fluphenthixol decanoate in one. Low dosage was defined in three of the trials 
as 20% of the conventional dosage (Marder et al., 1984; Marder et al., 1987; 
Hogarty et al., 1988); 10% in one trial (Kane et al., 1983) and 50% in two 
trials (Johnson et al., 1987; Inderbitzin et al., 1994). All studies employed a 
12-month follow-up, except two which followed participants to 24-months 
(Marder et al., 1987; Hogarty et al., 1988). Results according to Intention to 
Treat Analysis are illustrated in Table 2.2 below. 
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Relative risk refers to the risk of relapse in the low dosage group compared to 
the risk of relapse in the conventional group. A relative risk ratio of 2.00 
means that the risk of an event occurring in an experimental group is two 
times greater than that of a control group. Relative risk reduction (RRR) is the 
complement of relative risk, expressed as percent. The results demonstrate that 
there is a significant increase in relapse rate associated with low-dosage 
neuroleptic therapy over 12-months. However over 24 months, relapse rates 
do not significantly differ. 
There are three implications of these findings. First, over 12-months at least, it 
is not possible to make substantial reductions in neuroleptic dosage without 
increasing the risk of relapse. There is a fine balance between maximising the 
protection against risk of relapse, and minimising the social costs exerted by 
neuroleptic treatment. Second, it is significant that no significant differences 
were found for relapse rate over 24-months. These findings are reminiscent of 
those found by Crow et al., (1986). As discussed above, relapse rates between 
12 and 24-months for participants on placebo were lower than those on active 
medication. Third, whilst low-dosage appears to be associated with increase 
risk in the short term, one solution may to provide increased medication 
during periods where there is evidence of imminent relapse. This approach to 
relapse prevention is discussed below. 
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Table 2.2 Low dosage studies of antipsychotic medication and relapse 
Intention to Treat Analysis at 12 and 24-months (From 
Barbui et al., 1996) 
Study Relapse Relative Risk RRR* (%) P 
Convent ional Low Dosage (95% Cl** RR) (95% Cl RRR) 
Kane, 1983 48 77 1.60 <. 001 
(1.20-2.13) 
Marder, 1984 36 29 0.79 NS 
(0.35-1.76) 
Johnson, 1987 10 34 3.56 <. 005 
(1.09-11.67) 
Hogarty, 1988 24 35 1.45 NS 
(0.69-3.05) 
Inderbitzin, 1994 35 35 0.99 NS 
(0.44-2.25) 
12-months overall -47 <. 005 
(-15 to -88) 
Hogarty, 1988 42 43 1.02 NS 
(0.59-1.75) 
Marder, 1987 45 49 1.08 NS 
(0.64-1.80) 
24-months overall -5 NS 
(28 to -52) 
*RRR: relative risk reduction **Cl: Confidence Interval 
2.4 Early Intervention for Relapse 
Docherty et al., (1978) proposed that prior to the development of full relapse 
there were identifiable and sequential phases, which they saw as an unfolding 
of a series of psychological states. These phases were conceptualised as being 
characterised by overextension, restricted consciousness, disinhibition, 
psychotic disorganisation and resolution. During the first phase of 
overextension, the individual begins to experience a sense of being 
overwhelmed by demands and conflicts. This phase is accompanied by 
increased symptoms of anxiety and nervousness. This is followed by the 
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appearance of a variety of mental phenomena, which limit the individual's 
ability to concentrate and think. Associated with this phase are increased 
symptoms of hopelessness, dissatisfaction, and loneliness. During 
disinhibition, the capacity of the individual to modulate impulses becomes 
impaired. The signs and symptoms of this phase are rage, panic and 
hypomania. This phase precedes increasing perceptual and cognitive 
disorganisation, loss of self-identity and fragmentation of control during the 
active phase of psychosis. This sequence suggests very clearly the hypothesis 
that relapse is characterised by the progression of increasing non-psychotic 
symptoms, through increased distress and psychological fragmentation and 
loss of control, into frank psychosis itself. 
Retrospective studies of individuals and their families (Herz & Melville, 1980; 
McCandless-Glincher et al., 1986; Birchwood et al., 1989) show that both 
groups are able to recognise reduced well being. The most commonly reported 
early signs are sleeplessness, irritability, tension, depression, and social 
withdrawal. In their seminal study, Herz and Melville (1980) provided the first 
attempt to systematically identify the characteristics of relapse. They 
examined 145 individuals with schizophrenia and 80 of their relatives. In 
response to the question "Could you tell if there were any changes in your 
thoughts, feelings, and behaviours that might have led you to believe that you 
were becoming sick and might have to go to the hospital? " approximately 70% 
of participants noticed changes. Families were more likely than the patients 
themselves to identify changes, and in about 66% of cases both families and 
individuals were in agreement. For most individuals and their families the time 
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interval before relapse was more than one week. Between 50 and 60% of 
individuals and families sought professional help, however less than 4% had 
been advised by a professional to do so. Creer and Wing (1974) also reported 
a survey of 80 relatives virtually none had been given advice about the nature 
of early signs of relapse. The symptoms reported were ranked in terms of their 
frequency of being reported. The most common were tension and nervousness, 
sleeplessness, trouble concentrating, and loss of appetite and pleasure. This is 
consistent with Docherty et als. ' (1978) proposal that the earliest stage of 
relapse is characterised by increased anxiety and tension. Herz and Melville's 
findings have been confirmed by three further retrospective studies (Kumar et 
al., 1989; Thurm & Haefner, 1987; and Hamera et al., 1992). However the 
results of these studies have suggested that across individuals there is 
considerable variation in the nature of specific prodromes. The consistency 
with which early signs themselves have been reported has led to the 
development of prospective investigations of early signs. In essence, these 
investigations have sought to identify the sensitivity and specificity of these 
early signs as an indicator of emerging relapse. Clearly if these early signs are 
sensitive and specific to relapse, the monitoring of such signs would enable 
early intervention potentially leading to the prevention and/ or amelioration of 
relapse. 
2.4.1 Sensitivity and Specificity 
In investigations of the predictive power of prodromes, researchers have 
adopted the concepts of sensitivity and specificity. Sensitivity refers to the 
ability of prodromes to correctly identify a forthcoming relapse. It is 
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essentially the proportion of individuals who experience a prodrome prior to 
relapse. Specificity refers to the power of such symptoms to correctly identify 
those individuals or times when a relapse will not occur. If prodromes are 
treated like a clinical test (Table 2.3 below), then sensitivity is inversely 
related to the number of false negatives (the proportion of those who relapse 
and do not experience a prodrome), and specificity is inversely related to the 
number of false positives (the proportion of individuals who experience a 
prodrome and do not relapse). 
Table 2.3: Sensitivity and Specificity 
High Low 
Sensitivity Low false positives High false positives 
Specificity Low false negatives High false negatives 
2.4.2 Prospective Studies 
Malla and Norman (1995) in their systematic review of the early signs 
literature found very few studies that directly assessed the relationship 
between putative prodromal symptoms or early signs, and the exacerbation of 
relapse (Subotnik & Neuchterlein, 1988; Birchwood et al., 1989; Gaebel et al., 
1993; Jolley et al., 1990; Jorgensen, 1998; Marder et al., 1991; Marder et al., 
1994; Tarrier et al. 1991). Table 2.4 below provides a summary of the studies 
that have examined the sensitivity and/ or specificity of putative prodromes. 
One study (Jorgensen, 1998) was not included in Malla & Norman's (1995) 
study. Three studies (Jolley et al., 1990; Gaebel et al., 1993; Marder et al., 
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1994) were conducted in the context of a concurrent intervention trial. These 
studies are considered under Section 2.4.3 below. 
Table 2.4 Sensitivity and Specificity of Early Signs 
Author(s) Relapses Sensitivity Specificity 
Subotnik & Neuchterlein (1988) 17 59 NR 
Birchwood et al (1989) 8 50 100 
63 82 
Jolley et al. (1990) 10 73 NR 
Tarrier et al (1991) 16 50 81 
62.5 87.5 
Gaebel et al (1993) 162 8 90 
14 70 
10 93 
Marder et al (1994) 42 37 NR 
48 
Malla & Norman (1994) 24 20 NR 
<50 90 
Jorgensen (1998) 11 73 89 
16 88 64 
Subotnik and Neuchterlein (1988) reported a prospective study of prodromes 
in relation to relapse amongst 50 individuals with schizophrenia or 
schizoaffective disorder. Participants were assessed fortnightly using the 18- 
item Brief Psychiatric Rating Scale (Overall & Gorham, 1962). Relapse was 
defined by a rating of severe or extremely severe on 3 of the items; Unusual 
Thought Content, Conceptual Disorganization, and Hallucinations. Using 
Discriminant Analysis, BPRS subscales Hostile-Suspicious and Thought 
Disturbance correctly classified 10 out of the 17 relapses giving a sensitivity 
of 59%. Birchwood and colleagues recruited 17 individuals with 
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Schizophrenia. Participants were assessed fortnightly using the self-rated or 
informant-rated Early Signs Scale over a nine-month period. Relapse was 
defined as any hospital admission or a clinician's judgement of imminent 
relapse or probable admission. Eight relapses were identified (6 readmissions 
and 2 incipient relapses). Increases in early signs yielded a sensitivity to 
relapse of 50% and specificity of 100%. Using an increase above a cut-off 
score of 30 on the scale yielded a sensitivity of 62% and specificity of 82%. 
Tarrier et al., (1991) examined 56 individuals with schizophrenia at monthly 
intervals over 9-months using the Psychiatric Assessment Scale (Krawiecka et 
al., 1977). Relapse was defined as the reappearance of positive psychotic 
symptoms or the worsening of persistent or residual positive symptoms, and a 
duration of at least one-week. Twenty-three participants relapsed during the 
course of the study. Of these participants, 7 were excluded from analysis; 3 
relapsed within the first three-months, and four had incomplete data. 
Discriminant analysis was used to predict relapse from symptom increases in 
the month prior to relapse. Depression alone yielded a sensitivity of 50% and 
specificity of 81%. When depression was combined with hallucinations, 
sensitivity was 62.5% and specificity 87.5%. Malla and Norman (1994) 
examined 55 individuals with schizophrenia monthly over a period of at least 
12 months (range: 12-29 months). Variance in psychotic symptomatology was 
rated using the Scale for Assessment of Positive Symptoms (SAPS; 
Andreasen, 1984). Participants' non-psychotic symptomatology was rated 
using Beck Depression Inventory (BDI; Beck, 1978), and the State-Trait 
Anxiety Inventory (STAI; Speilberger et al., 1968). Data were analysed using 
a longitudinal correlational design. Since many participants showed little or no 
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variation in psychotic symptoms, many were excluded from analysis. Less 
than half of the sample showed adequate variance; 24 demonstrated a range of 
scores on the Reality Distortion Subscale of the SAPS (delusions and 
hallucinatory phenomena), and 23 for Disorganization Subscale. Using a 1- 
month time lag, the percentage of significant positive correlations between 
non-psychotic and psychotic symptoms were low, the most significant being 
20% for depression and reality distortion. In order to account for the 
possibility that these correlations may be a reflection of level of psychosis 
rather than a predictor of psychosis itself, partial correlations were carried out. 
The percentage of significant correlations reduced, for example, only 4% of 
correlations between depression and reality distortion remained significant. 
This finding reflects the possibility that much of the predictive usefulness of 
non-psychotic symptoms may be because they themselves are related to early 
and subtle signs of psychosis. Malla and Norman (1994) proposed that whilst 
in their sample, psychotic symptoms were not frequently preceded by 
prodromal symptoms, when increases in non-psychotic symptoms occurred 
they would be invariably followed by increases in psychotic symptoms. In 
order to investigate this hypothesis increases in both psychotic and non- 
psychotic symptoms were treated as discrete events. Significant increases in 
symptomatology were defined by an increase over the mean of one standard 
deviation for each participant. In line with their hypothesis, specificity was 
high (90% for reality distortion and 83% for disorganization), meaning that it 
was relatively rare that a substantial increase in non-psychotic symptoms was 
not followed by a substantial increase in psychotic symptoms. On the other 
hand, sensitivity for both reality distortion and disorganization was low (less 
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than 50% for 83% of subjects), meaning that many increases in psychotic 
symptoms were not preceded by increases in non-psychotic symptoms. 
Jorgensen (1998) examined 60 individuals with schizophrenia, 30 of whom 
had residual positive psychotic symptoms (symptomatic), and 30 who were 
fully remitted (asymptomatic). Participants were interviewed every fortnight 
over six months or to relapse. Each interview assessed the participants mental 
state for the previous 72 hours according to the Positive and Negative 
Syndrome Scale (PANSS; Kay et al., 1987). Participants were also monitored 
every second week using the self -report Early Signs Scale (ESS; Birchwood 
et al., 1989). Relapse was defined as a rating of `moderate' or greater, 
representing an increase of at least two scale points on any one of the positive 
scale items of the PANSS. In total 27 (45%) participants relapsed, 16 (27%) of 
whom were readmitted. For symptomatic participants sensitivity was 88% and 
specificity 64%, and for asymptomatic participants sensitivity was 73% and 
specificity 89%. 
Across the eight studies reporting sensitivity and specificity for prodromal 
signs to relapse, findings on sensitivity range from 8 to 88%, and specificity 
from 64 to 93%. Strict comparison across these studies is problematic given 
the nature of differences in methodology and design. However it is clear that 
when studies include positive symptoms or incipient psychosis in definitions 
of prodromes (Subotnik & Nuechterlein, 1988; Birchwood et al., 1989; Tarrier 
et al., 1991; Jorgensen, 1998), this exaggerates the sensitivity of prodromes to 
relapse. This questions the basis of the concept of prodrome itself. Prodromes 
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have been viewed as dichotomous phenomena; that is events, which occur 
before a relapse. The inclusion of low level positive psychotic symptoms, such 
as ideas of reference or thought control, changes the concept of relapse 
radically to a continuous model, where the appearance of increased dysphoric 
symptoms represent an individual's response to the reemergence of psychotic 
symptoms. Such a continuous model of relapse therefore sees apparent 
prodromal signs, as evidence of early stages of relapse. The consistency of the 
findings on specificity, which are reported across these studies (64 to 93%), is 
supportive of this proposal. That is, when non-psychotic symptoms increase 
they are almost always, but not inevitably followed by a relapse in positive 
psychotic symptoms. 
2.4.3 Neuroleptic early intervention. 
A number of studies have sought to include the assessment of early signs to 
facilitate early pharmacological intervention. These studies are reviewed 
below. Carpenter and Heinrichs (1983) conducted a randomised-controlled 
trial comparing continuous and intermittent medication. In the intermittent 
condition participants were maintained drug free until symptoms suggestive of 
relapse appeared. When such symptoms appeared, drug treatment was 
reinitiated at therapeutic dosages. This protocol was also applied to those 
receiving continuous medication, where the appearance of early signs resulted 
in an increase in medication dosage to a discretionary level that was 
considered therapeutic for that episode. In addition to receipt of medication, 
participants received ongoing case management which included individual and 
family based education regarding the early signs of relapse, coping skills 
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enhancement for dealing with stressors and improving functioning. 
Participants who entered the trial entered a four to eight-week stabilisation 
phase prior to randomisation to intermittent or continuous medication 
conditions. A total of 4lparticipants (Intermittent n= 14, Continuous n= 27) 
were followed up at 24-months. At 24-months there were no significant 
differences in positive symptoms, social and work performance, negative 
symptoms or hospital admissions. 
Herz et al., (1989,1991) compared intermittent medication with continuous 
medication amongst a group of stable outpatients with schizophrenia on the 
basis of a nine-month pilot study (Herz et al., 1982) which found a relapse rate 
of 11% for 19 individuals without medication. In the 1989 study 140 
participants were entered into the study for gradual drug withdrawal. Of this 
group 101 were able to proceed to a double-blind placebo controlled study 
evaluating the relative efficacy of active medication (n = 51) or intermittent 
medication (n = 50). Participants were dropped from the study if they had 
three prodromal episodes in one-year or if an episode lasted longer than nine- 
weeks. Fourteen percent of participants were dropped from maintenance 
treatment, compared to 46% of intermittent. Seventy three percent (37/51) of 
the maintenance group and 38% (19/50) of the intermittent group completed 
the study at two-years. Time to first prodromal episode and 12- and 24-month 
survival rates were higher for the maintenance group (56% and 43%) than for 
the intermittent group (20% and 16%); the overall difference was statistically 
significant (Log,  k= 10.92, p=0.001). For relapse the 12- and 24-month 
survival rates were higher for the maintenance group (90% and 83%) 
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compared to the intermittent group (71% and 64%); the overall difference was 
statistically significant (Logrank = 4.14, p=0.042). 
Jolley et al., (1989) randomized 54 individuals who had been clinically stable 
for at least six months, without active phase or residual positive psychotic 
symptoms to two groups. The control group (n = 27) received fluphenthixol 
decanoate at pre-trial doses, whereas the intermittent group (n = 27) received 
equivalent doses of placebo injections. Treatments were administered under 
double blind conditions. Early symptoms were defined on the basis of the 
appearance of neurotic or dysphoric symptoms persisting for two days or 
more. Relapse was defined as the re-emergence of florid psychotic symptoms 
or by a re-admission to hospital. All participants and their closest relative or 
co-habitee received a one-hour educational session concerning schizophrenia 
and early signs of relapse. In the event of prodromal identification, additional 
oral haloperidol, 5-10 mg daily, was provided. Treatment in the early relapse 
period continued for two weeks unless a relapse occurred. Treatment of 
relapse continued for four weeks after remission. At one-year, relapse was 
significantly more frequent in the intermittent group compared to the control 
group (x2 = 3.0682, df = 1, p=0.04). There was no difference between the 
rates of admission between the two groups; indeed rates of admission were 
low, suggesting that the additional relapses in the intermittent group were of 
milder severity. Significantly more early signs were identified in the 
intermittent group (x2 = 9.7862, df = 1, p=0.002). Jolley et al. (1990) 
reported on two-year outcome for this cohort. By two years, 50% of the 
intermittent group, and 12% of the control group had relapsed (x2 = 6.36, df = 
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1, p=0.005). 
Marder et al., (1994) studied the effectiveness of treating individuals with low 
doses of Fluphenazine decanoate and supplementing them with oral 
Fluphenazine when there was evidence of early signs of relapse. They 
recruited 80 individuals with a diagnosis of schizophrenia (DSM-III-R). All 
participants were stabilised on 5 to 10mg Fluphenazine decanoate fortnightly 
over two-months. All participants were monitored fortnightly using the 
Idiosyncratic Prodromal Scale, which was a three-item scale derived from 
items endorsed by participants using the Early Signs Questionnaire (Herz et 
al., 1991). On the appearance of an increase in early signs, participants were 
randomized to either Fluphenazine or placebo supplementation. Participants 
were followed up for two-years. During this period a total of 88 relapses 
occurred across 42 participants (52.5%). Of those in receipt of active 
supplementation, 29% had early signs identified prior to relapse, versus 50% 
in the placebo supplementation group. In terms of the efficacy of active versus 
placebo supplementation there were no significant differences in the first year. 
However, among the patients who entered the second year of the study, 58% 
(n=14) of the participants treated with Fluphenazine survived without an 
exacerbation, versus 16% (n=15) of the placebo treated group (likelihood 
ratio: x2 = 4.61, p=0.032). The authors noted that in the active 
supplementation group, participants and clinicians improved in their ability to 
detect early signs, with the positive predictive value increasing from 29% in 
the first 6-months to 63% in the last 18-months. The change in the 
effectiveness of the active strategy over time suggests a limitation to early 
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intervention in the context of low or intermittent dosage approaches. There 
may be a trade-off between increased risk in the shorter term, and increased 
knowledge and skill in the longer term. Indeed the acquisition of knowledge is 
a continuous and collaborative process, which as evidenced by the results of 
Jolley et al (1989,1990), cannot be achieved in simple didactic and one-off 
educational sessions. 
Gaebel et al., (1993) and Doering et al., (1998) reported on 364 individuals 
with a diagnosis of Schizophrenia (ICD-9) or Schizoaffective Disorder (RDC) 
who were randomised to one of three neuroleptic treatment groups following a 
3-month stabilisation phase; maintenance therapy (122), early intervention 
(127), and crisis intervention (115). Individuals in maintenance therapy 
received a continuous standard neuroleptic treatment, where neuroleptic 
dosage was individually determined according to clinical requirements. Those 
who were randomised to early intervention had their neuroleptics discontinued 
according to a 50% reduction every two weeks. Neuroleptic treatment was 
reinitiated on the appearance of early signs of relapse. The crisis intervention 
group also had their neuroleptic treatment discontinued according to the same 
strategy as the early intervention group, but only had their neuroleptic 
treatment reinitiated in the event of a crisis; that is a full relapse. Participants 
were followed up for 2-years. A total of 205 (56.3%) participants dropped out 
during the study; 42.6% of maintenance treatment, 59.8% of early 
intervention, and 67% of crisis intervention. Of those who dropped out only 10 
could not be followed up. Maintenance treatment was associated with reduced 
relapse (23%) and re-hospitalisation (24.6%) compared to early intervention 
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(50.4%, 38.6%), and crisis intervention (62.6%, 44.4%) and participants who 
dropped out (41.3%, 33.0%). In terms of predictors of outcome, crisis 
intervention, a diagnosis of schizoaffective disorder, and having a strong 
religious faith were associated with increased risk of relapse, whilst 
maintenance treatment, and having a diagnosis of schizophrenia (residual 
type) were associated with reduced relapse risk. In terms of predictors of 
hospitalisation, being male, being aged under 40, having a history of a suicide 
attempt, and having had no hospitalisation in the previous year were 
associated with an increased risk of hospital admission. 
Whilst results show that maintenance medication is superior to intermittent 
medication for relapse prevention for most individuals, there is some evidence 
that early intervention is effective in reducing relapse rates when participants 
are without medication. Relapse rates for individuals on placebo in 
intermittent drug studies average 50% over two years compared to a relapse 
rate of 75% for individuals on placebo in conventional drug trials. 
Furthermore, Marder et al., (1994), in their study of low-dose neuroleptic 
medication, found a significant advantage for supplementary oral fluphenazine 
over placebo at the appearance of early signs. This was particularly true in the 
second year of the study after professionals and participants had learned to 
recognise early signs. Herz et al., (2000) have reported the only controlled 
study to date which has examined targeting increases in neuroleptic 
medication on the appearance of early signs of relapse, and used a comparison 
group of participants who were maintained on standard doses of neuroleptic 
medication. Eighty-two participants with a diagnosis of schizophrenia or 
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schizoaffective disorder (DSM-III-R; APA, 1987) entered the trial. 
Participants were randomised to either Treatment as Usual (n = 41) or an 
experimental group called the "Program for Relapse Prevention" (PRP; n= 
41). All participants, except two, received standard doses of antipsychotic 
medication (300-1000-mg Chlorpromazine daily equivalents). PRP consisted 
of (1) education for the participants and their families about the process of 
relapse; (2) active monitoring of early signs by the treatment team, 
participants, families, and others in frequent contact with the participant; (3) 
clinical interventions within 24 to 48 hours of identification of a `prodromal' 
episode; (4) one hour weekly supportive group therapy emphasising coping 
skills or 30- 45 minute supportive individual therapy sessions; and (5) 90 
minute multifamily psychoeducation groups, which were bi-weekly for six 
months and monthly thereafter. Clinical interventions during early signs 
consisted of crisis problem solving, supportive therapy, and increased 
medication as required. Treatment as Usual (control) consisted of individual 
supportive therapy and medication management bi-weekly for 15- 30 minutes. 
The operational definition of relapse was based on the Positive and Negative 
Syndrome Scale (PANSS; Kay et al., 1987) and the Global Assessment Scale 
(GAS; Endicott et al., 1976). Relapse was defined as an increase in any 
PANSS positive psychotic symptom score to moderately severe of higher 
(>=5) together with a GAS score of 30 or less. Participant outcomes at 18- 
months were coded as "Stable, no episodes", "Prodrome with no relapse" and 
"Relapsed". Outcome rates over 18-months were impressive. Of the PRP 
group there were 7 (17%) relapses compared to 14 (34%) in Treatment as 
Usual (x2 = 6.43, p=0.011). In addition, PRP teams were more effective at 
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detecting the early stages of relapse. There was some evidence that the PRP 
teams were declaring prodromal episodes too frequently, resulting in false 
positive interventions. PRP was associated with increased rates of "Prodrome 
with no relapse" at the expense of "stable" outcomes, compared to controls. 
However, balancing this finding there was a significant reduction in 
medication dosage between entry and 18-months in the PRP group compared 
to controls (t = 2.01, df = 70, p=0.05). 
Whilst this study shows convincing evidence of the value of early intervention 
for relapse, the case for the value of increasing neuroleptics during prodromal 
episodes is less convincing. First, there were significant reductions in overall 
neuroleptic dosage during the course of the study. Second, there was a 
sophisticated psychosocial intervention protocol combining psychoeducation, 
supportive therapy and coping skills enhancement. Amongst those families 
who attended the multifamily groups (29% of sample), only one participant 
relapsed, even though 50% of these participants experienced a prodromal 
episode. Uptake of supportive therapy in the experimental group was 100%, 
with 59% attending groups, and 41% selecting individual supportive therapy. 
Individual supportive therapy emphasised coping skills enhancement, whilst 
the control group received medication management. It is therefore reasonable 
to suggest that many of the active ingredients of PRP included non- 
pharmacological factors; active monitoring, assertive outreach within 48 
hours, coping skills enhancement and family psychoeducation. The design of 
the study does not allow close analysis of the influence of how participation in 
psychosocial interventions impact on reduced relapse. 
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2.5 Psychosocial Factors in Trials of Neuroleptic Medication 
May et al., (1976a, b) conducted a randomised controlled trial of five 
treatments in a cohort of individuals with a first admission of Schizophrenia. 
A total of 228 participants were randomised to either: (1) individual 
psychotherapy, (2) Stelazine, (3) Stelazine and Individual Psychotherapy (4) 
Electroconvulsive Therapy (ECT), and (5) Milieu. Milieu was a comparison 
group whose treatment was unspecified by the investigators other than to say 
that Milieu did not receive any of the treatments detailed in I to 4. Treatments 
were delivered on an inpatient basis until discharge, or for a period of 6 to 12 
months until agreement by therapist and supervisor that treatment had failed. 
Treatment "success" or "failure" was broadly defined by whether or not 
participants were discharged from hospital. In terms of initial response to 
treatment, 65% (n = 30) of the individual psychotherapy, 96% (n = 46) of 
Stelazine, 95% (n = 42) of Stelazine and individual psychotherapy, 79% (n = 
37) of ECT, and 58% of Milieu treatments were categorised as "successes". 
Participants were followed up for between two to five years. Experimental 
treatments were not continued, and intervening psychosocial or 
pharmacological treatment is not reported except hospital stay: the main 
outcome variable. Participants treated with Stelazine (alone and in 
combination) and those treated with ECT experienced fewer and shorter 
hospital stays than those treated with milieu or psychotherapy alone. The 
results of the trial are difficult to interpret given the presence of intervening 
treatments and high rates of attrition over the interim follow-up period. May et 
al. (1976b) speculated that the positive outcomes for ECT in comparison to 
75 
Relapse and relapse prevention in schizophrenia 
Stelazine might have been due to the shorter duration of index admission 
associated with these treatments, and thereby the minimisation of social 
exclusion and institutionalisation. However, this factor was not examined in 
relation to outcome across the five treatment groups. 
Hogarty et al., (1974) conducted a two-year maintenance study which 
controlled for antipsychotic medication (APM) and psychosocial treatment 
(Major Role Therapy, MRT, an atheoretical treatment, which included an 
emphasis on problem solving skills). A total of 374 Participants were 
randomised to either APM + MRT or placebo APM + MRT, placebo APM 
alone, APM alone. At two-years MRT gave no additional benefit, to placebo 
medication alone, with over 80% of participants experiencing a relapse within 
two-years. However, analysis of predictors of outcome, indicated that better 
remitted participants survived longer on the combination of active 
antipsychotic and psychosocial intervention, whilst the poorly remitted group 
were more likely to relapse if they received psychosocial treatment. 
In a further study by Hogarty et al., (1979) recently discharged individuals 
with schizophrenia were randomised to either fluphenazine decanoate (FD) or 
fluphenazine hydrochloride (FLZ). All participants received either a 
combination of FD and an oral placebo, or active FLZ and depot placebo. 
Therefore if relapse was due to covert non-compliance, greater survivorship 
would follow upon receipt of the active depot FD. This study produced 
provocative results. At one year 29% of those participants receiving FD in 
combination with the same psychosocial treatment delivered in the Hogarty et 
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al. (1974) study, had relapsed compared to 41% of FD alone, 34% of FLZ 
alone, and 46% of FLZ in combination with psychosocial intervention. By the 
second year there were no further relapses in the FD and psychosocial group. 
However by two years 53% of FD alone, 68% of FLZ and psychosocial 
treatment, and 65% of FLZ had relapsed. The difference in relapse rates for 
FD and psychosocial treatment in combination compared to FD alone did not 
achieve statistical significance at two years (29% versus 53%; x2 = 3.35, df = 
1, p=0.07). In a further study by Hogarty et al. (1986), the atheoretical nature 
of the psychosocial intervention was abandoned in light of emerging evidence 
concerning the role of family stress acting on relapse vulnerability. Hogarty 
and colleagues compared Family Psychoeducation (FT), with Social Skills 
Training (SST), and the two treatments in combination (FT + SST). They 
found relapse rates of 19% for FT, 20% for SST, 0% for FT + SST, and 38% 
for medication controls at one year. At two-year follow-up (Hogarty et al., 
1991) the effects of SST had reduced, but a significant effect for FT persisted 
over medication controls (27% versus 66%). There was evidence that those in 
receipt of FT were more compliant than their medication only controls (21% 
versus 40%), however the effect of treatment remained statistically significant 
after controlling for compliance. However, the question of how psychosocial 
treatment may confer reduced vulnerability to relapse remains open. In 
particular, are the benefits of psychosocial intervention limited to those who 
are living with their family, thereby excluding a potentially large proportion of 
individuals living independently of their families in the community? 
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In an attempt to develop a more disorder and context relevant approach to 
psychosocial interventions, Hogarty et al., (1997a, b) reported on the three year 
outcome of 151 individuals with schizophrenia or schizoaffective disorder 
(RDC) who were examined in one of two trials over 36 months. In Trial 1,97 
participants who resided with their family were randomly allocated to one of 
four conditions: Personal Therapy (PT), Family Psychosocial Management 
(FT) a combination of FT and PT, or to a Supportive Therapy (ST) control. In 
Trial 2,54 participants who either lived alone or in shared accommodation 
were randomised to either PT or ST. Personal Therapy involved three phases; 
(1) psychoeducation and the identification of affective, cognitive, and 
physiological experience of stress. The appraisal of stress and the effect of its 
expression on the behaviour of others was also facilitated; (2) Participants 
were also taught stress management techniques, and social skills training was 
offered if required. In addition, (3) further skills training in managing criticism 
and resolving conflict was offered. PT was offered for the first 18-months of 
the study. Supportive Therapy (ST) involved the provision of psychoeducation 
alongside ingredients included in other treatment modalities (i. e. active 
listening, correct empathy, appropriate reassurance, reinforcement of health 
promoting behaviours, and use of the therapist as advocate and problem solver 
in times of crisis). 
Relapse was defined by the reoccurrence of psychotic symptoms or the 
exacerbation of residual symptoms in combination with a decrease in the 
Global Assessment Scale score of 10-points or more. Over three years, 44 
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(29%) of participants across both trials experienced a total of 66 psychotic 
relapses. All but two psychotic relapses required hospital admission. 
Overall, for participants in Trial 1 (those living with family), of those who 
received PT either alone or in combination with FT (n = 49), 12 (24.5%) 
participants relapsed compared to 35.4% (17 / 48) of those who received either 
ST or FT. This difference was not statistically significant (x2 = 2.87, df = 1, p 
= 0.09). Of the PT alone group, 3 out of 23 (13.0%) participants experienced 
a relapse compared to 7 out of 24 (29.2%) of the ST alone group. Again this 
difference was not statistically significant (x2 = 2.74, df = 1, p=0.098). PT 
was associated with a statistically significant reduction in relapse rate in 
comparison with FT alone (10 / 24; 41.7%, x2 = 5.33, df = 1, p=0.021). In 
contrast, in Trial 2 (participants without family) participants receiving PT 
experienced significantly more relapses (11 / 25; 44%) than those receiving 
ST (4 / 29; 13.8%), (x2 = 5.63, df = 1, p=0.018). 
This was a complex study with multiple treatment groups, which attempted to 
control for the context of the individuals' living circumstances. Compounding 
this, there were a number of additional problems, which limit the 
interpretation of the study's findings. Whilst all participants in both trials were 
prescribed antipsychotic medication, which was adjusted to the Minimum 
Effective Dose, i. e., the dosage below which prodromes of a new episode are 
likely to emerge but above which more than mild hypokinetic rigidity was 
observed (Hogarty et al., 1988). Assurances were made for balance of depot 
versus oral preparations of antipsychotic medication, and non-compliance was 
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infrequent. There were, however, important antipsychotic medication 
differences within trials. Neuroleptic doses were higher amongst participants 
in trial 2, and by year 3,27% of participants in trial 2 were receiving 
clozapine, compared to 14% of participants in Trial 1. In addition those 
participants in Trial 2 were older (F = 4.03, df = 1,145, p=0.002), were ill for 
a longer period of time (F = 2.75, df = 1,145, p=0.020), and had a greater 
history of prior hospitalisations (F = 2.55, df = 1,145, p=0.030). 
Furthermore, not all participants received the same "dosage" of psychosocial 
interventions. In terms of phase of treatments in the PT and FT conditions, 8% 
of participants and families failed to move beyond the basic phase of therapy 
(engagement, psychoeducation, and identification of stress responses). Thirty 
eight percent of participants and 40% of families entered intermediate phases 
of PT or FT but did not complete this stage. Therefore, approximately one half 
of participants and their families were able to move into more advanced stages 
of treatment. In conclusion, a significant proportion of participants did not 
receive the full treatment protocols. 
Kemp et al., (1998) conducted a randomised-controlled trial of Compliance 
Therapy, a brief pragmatic intervention targeting medication adherence, 
amongst 74 participants with psychosis. A substantial proportion of these 
individuals (58%) had a diagnosis of Schizophrenia (DSM-III-R, APA, 1987). 
Compliance Therapy consisted of 4 to 6-sessions divided into three phases. 
Phase 1 consisted of review of illness history in order to ascertain participants' 
view of their illness and their stance towards treatment. In Phase 2, where 
ambivalence towards treatment was identified, this was explored further by 
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helping the individual weigh up costs and benefits of treatment. Therapist 
emphasised benefits of medication compliance. Phase 3 focused on the role of 
medication as an `insurance policy' against relapse. Psychosis itself was 
normalised, and parallels drawn with the role of medication in physical 
illnesses. Booster sessions were offered at 3,6 and 12 months. Participants 
were followed up to 18-months. Compliance therapy had a significant 
advantage in terms of survival in the community over the 18-month follow-up 
period, but not for relapse. Indeed relapse was high in both groups. Using 
Cox's Regression analysis, the hazard function (risk of readmission) of a 
participant in the control group was 2.2 times that of Compliance Therapy. 
Compliance therapy was also associated with improved compliance, insight 
(Schedule for Assessment of Insight; David, 1990), drug attitudes (Drug 
Attitudes Inventory; Hogan et al., 1983) and global functioning (Global 
Assessment of Functioning Scale; GAF disability scale from DSM-III-R). 
However, overall 35% were lost to follow-up; or 28% (n = 11) from 
Compliance therapy and 43% (n = 15) from control. The authors noted that 
this sample was an inner city group, which was highly mobile and difficult to 
follow-up. In addition, inspection of baseline assessments revealed that both 
groups were receiving very high chlorpromazine equivalent dosages (869 mg 
in Compliance Therapy and 776 mg in control). In addition 59% of 
participants were detained under the Mental Health Act at index admission, 
had an average of about 9 years of illness, a mean of about 4 previous 
admissions. This data would indicate that the participants in this study were a 
severely ill group with high chronicity; indeed a group who are likely to have 
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had both negative illness experiences and negative beliefs concerning 
neuroleptic treatment. 
2.6 Family studies of Expressed Emotion and relapse in Schizophrenia 
The relationship between expressed emotion and relapse is a strong one, with 
High Expressed Emotion being a robust predictor of relapse in Schizophrenia. 
This is so much so, that some investigators have called for a moratorium on 
further Expressed Emotion research (Butzlaff & Hooley, 1997). Expressed 
Emotion (EE) refers to the construct representing some key aspects of 
interpersonal relationships and includes measurements of criticism, hostility, 
warmth, positive comments, and emotional overinvolvement (EOI). Kavanagh 
(1992) reviewed 23 studies of the relationship between EE and relapse. These 
studies had followed 1707 participants and their families over a 9- to 12- 
month period, and only three of these studies failed to find a relationship 
between EE and relapse. A median relapse rate of 21% was found for low EE 
families compared to 48% of high EE families. Twenty studies found that 
relapse was greater in the high EE group, and 16 of these studies found this to 
be statistically significant. Four studies reported relapse rate at two-years. The 
median relapse rate for low EE families was 27% compared to 61% for high 
EE families. 
In terms of specific constructs of EE, Criticism and Hostility are strongly 
correlated, and Hostility is rarely present in the absence of Criticism. Indeed, 
Hostility has been found to independently predict relapse (Leff et al., 1987), 
whilst on the other hand, the association between EOI and relapse is less clear. 
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Warmth is negatively correlated with criticism to a moderate degree, and 
positively correlated with EOI. Brown et al., (1972) found that warmth in the 
absence of EOI, was associated with a positive outcome. 
Leff and Vaughn (1985) proposed that high and low EE are trait-like 
measures: a characteristic response manner, where low EE relatives are seen 
as tolerant, non-intrusive and sensitive to their family members, whilst their 
high EE counterparts are prone to intolerance, intrusiveness, and the use of 
inappropriate and inflexible coping strategies. However, Brewin et al., (1991) 
found that relatives who had communication patterns characterised by hostility 
and criticism made more attributions to factors personal to and controllable by 
the individual with schizophrenia (e. g., " he doesn't get up because he's 
lazy"), than did relatives with marked EOI. These relatives made non-personal 
and uncontrollable attributions about the individual's behaviour. This has been 
investigated by Barrowclough et al., (1994) who examined the role of 
relatives' attributions for illness as a predictor of relapse in schizophrenia. 
Barrowclough and her colleagues proposed that critical, and particularly 
hostile, relatives would make attributions, which were more internal, personal 
and controllable to the patient, compared to relatives who display marked EOI 
and low EE. They proposed that these latter relatives would make more 
external, universal, and uncontrollable attributions to the patient. Spontaneous 
causal attributions were drawn from audiotaped interviews with the family and 
coded according to the Leeds Attributional Coding System (LACS). 
Attributions were coded along the following causal dimensions: internal- 
external; personal-universal, controllable-uncontrollable; stable-unstable. All 
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dimensions were assessed for the relative's perception of the patient's causal 
role in events. A total of 99lattributional statements (AS) were drawn from 
taped interviews with 60-relatives. Relatives with high levels of EE had a 
higher rate of making causal attributions than did relatives with low EE. 
Compared to high EOI relatives, high EE relatives made more internal, 
personal and controllable attributions to the patient. In addition high EE 
relatives invoked causal attributions attributing responsibility to the patient for 
outcome. This pattern was apparent for those relatives who were hostile or 
critical, whether or not they were considered to be high EE or high EOI. 
Relatives high on EOI, made more attributions of causality to external and 
uncontrollable causes, and indeed made most attributions to illness. The 
contribution of attributions to relapse prediction was investigated using 
discriminant function analysis. Controllability and internality were 
significantly contributed to relapse prediction, even after controlling for EE 
status and intervention. Univariate analysis showed that relatives made more 
controllable by patient attributions than relatives of non-relapsers. 
In a further analysis of this data, Barrowclough et al., (1996) investigated the 
relationship between expressed emotion, attributions and distress experienced 
by relatives. The association between relative attributions and distress was 
examined using Spearman's rank correlations. Distress was measures by 
relative scores on the four General Health Questionnaire (Goldberg & 
Williams, 1988) subscales (somatic symptoms, anxiety/ insomnia, social 
dysfunction, and depression). There was a general lack of association between 
distress and relatives' attributions, except for a relationship between the 
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tendency for relatives who blame themselves to have higher levels of distress 
across all subscales and total score on the GHQ. Further analysis of the 
relationship between EE and distress found a significant relationship between 
median scores for depression and high EE status. Furthermore there were 
significant correlations between depression and expressed criticism (r = 0.44, 
p<0.001) and depression and hostility (r = 0.35, p<0.01). Stepwise multiple 
regression was used to examine the contribution of illness chronicity, 
dimensions of EE, and self-blaming attributions to the variance in GHQ 
scores. Self-blaming attributions accounted for 18% of the variance in GHQ 
total (ß = 0.44, R2 = 0.18, F= 13.29, p <0.0006), 14% for depression (ß = 
0.27, R2 = 0.14). Other variables predicting depression were hostility (ß = 
0.30, adjusted R2 change = 0.06) and emotional overinvolvement (ß = 0.29, 
adjusted R2 change = 0.06). 
These studies demonstrate the importance of the role of attributions in the 
development of expressed emotion, the prediction of relapse in individuals 
with schizophrenia and the development of distress amongst relatives. Indeed 
this is consistent with the proposals of other investigators including Weiner 
(1985). Weiner proposed that causal beliefs held about other people's 
problems would be instrumental in the development of distressing emotions. 
Indeed attributional theories of depression propose that in depression negative 
events will be attributed to self, and will be perceived as enduring and stable. 
Given that causal attributions play a critical role in the development of 
patterns of expressed emotion and distress amongst relatives, which in 
themselves predict relapse, one could hypothesise that similarly, individuals 
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with schizophrenia will make attributions about their illness and illness 
experience which may predict the development of psychological distress 
associated with relapse and poor recovery. 
2.7 Family interventions for relapse 
Pitschel-Walz et al., (2001) describe a meta-analysis of 25 studies which has 
evaluated the efficacy of family interventions for relapse in schizophrenia. 
Previous meta-analyses (Mari & Streiner, 1994; Mari & Streiner, 1996, 
Pharoah et al., 1999) containing up to 13 studies, have demonstrated a 
moderate effectiveness of family interventions for schizophrenia in decreasing 
the frequency of relapse and rehospitalisation. Pitschel-Walz et al., were able 
to include more studies, which had not been published at the time of these 
earlier meta-analyses. Thirty-nine studies were identified, four were excluded 
because of lack of control group, nine studies did not use a randomised design, 
and in one study group comparisons were missing. Twelve studies compared 
family intervention with usual care (Goldstein et al., 1978; Leff et al., 1985; 
Speigel & Wissler, 1987; Spencer et al., 1988; Tarrier et al., 1989; Kelly & 
Scott, 1990; Hogarty et al., 1991, Posner et al., 1992, Vaughan et al., 1992; 
Randolf et al., 1994; Xiong et al., 1994; Zhang et al., 1994). Pitschel-Walz et 
al., found clear superiority for family interventions over usual care 6,9,12, 
18, and 24 months after treatment. Long-term interventions (between 9 to 24 
months) were more effective than short-term interventions (less than three 
months). Furthermore, analyses of five studies which combined family 
intervention with individual intervention (Cranach, 1981; Kelly & Scott, 1990; 
Hogarty et al., 1991; Buchkremer et al., 1997; Pitschel-Walz et al., 1998) 
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found clear superiority for this combination of treatments over routine care. 
However adding individual treatment to family intervention did not result in 
significant improvements over family intervention alone. Six studies 
compared family intervention with individual intervention (Ro-Trock et al., 
1977; Falloon et al., 1982,1985; Kelly & Scott, 1990; Hogarty et al., 1991; 
Teiles et al., 1995; Hogarty et al., 1997a, b). There were no significant 
differences between the two interventions during the first year. However at 
two years, there was a highly significant advantage for family intervention. 
2.8 Summary and Conclusions 
Definitions of relapse vary across studies from readmission (Shepherd et al., 
1989), the redevelopment of psychotic features or the deterioration of mental 
state as observed by others (Crow et al., 1986), or the return of exacerbation of 
positive psychotic symptoms such as hallucinations, delusions, and thought 
disorder (Eaton et al., 1998). Whilst little is known about the natural process 
of relapse in schizophrenia, numerous studies have examined the effectiveness 
of pharmacological and psychosocial treatments for relapse. 
Studies examining the prophylactic efficacy of pharmacotherapy, have found 
that antipsychotic medication is superior to placebo in preventing relapse 
(Kane et al., 1982; Johnstone et al., 1986; Crow et al., 1986; Johnstone et al., 
1988; Scottish Schizophrenia Research Group, 1989a, b; Robinson et al., 
1999). However, antipsychotic medication exerts a social cost on individuals 
(Crow et al., 1988), and there appears to be a trend for those with a longer 
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duration of untreated psychosis requiring antipsychotic maintenance (Crow et 
al., 1986; Robinson et al., 1999). 
Studies of low dosage (20 to 50% of conventional dosages) antipsychotic 
treatment reviewed by Barbui et al., (1996), have found an increased risk of 
relapse at 12-months, but not at 24-months. In addition, studies, which have 
examined maintenance versus intermittent prescriptions of antipsychotics, 
show superiority for maintenance treatment in the prevention of relapse (Jolley 
et al., 1989; Herz et al., 1991). However there is strong evidence that the 
efficacy of intermittent medication is influenced by the presence and dosage of 
a concurrent psychosocial intervention (Carpenter et al., 1987; Herz et al., 
1991). Furthermore, the only study to compare antipsychotic early 
intervention + maintenance treatment with maintenance treatment alone (Herz 
et al., 1999) found superiority for early intervention in the prevention of 
relapse. Again this study had a continuous concurrent psychosocial 
intervention. 
Psychosocial treatments in combination with antipsychotic treatment have 
been associated with reduced relapse (Hogarty et al., 1974; Hogarty et al., 
1979; Hogarty et al., 1994; Hogarty et al., 1997a, b; Kemp et al., 1998). There 
is tentative evidence that the efficacy of these interventions is improved by 
having a theoretical and conceptual basis (e. g. family interventions) as 
compared to those, which do not (May et al., 1976; Hogarty et al., 1979). 
There is some evidence that individuals living outside of a family do less well 
with psychosocial intervention (Hogarty et al., 1997a). In addition, given that 
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that the uptake of family interventions has been low (Tarrier et al., 1998) and 
that many individuals live outside families or other established support 
systems, there is a need to develop individually based interventions, which can 
reduce relapse. Individual Cognitive Behavioural Therapy (CBT) is one such 
possible intervention. Chapter 3 will examine the efficacy of CBT in relation 
to relapse and consider the conceptual basis for individualised relapse 
prevention interventions. 
89 
Psychological models of relapse 
Chapter 3 
Psychological models of relapse 
90 
Psychological models of relapse 
3.1 Introduction 
As was seen in Chapter 2, despite the advances in pharmacological 
management of schizophrenia, relapse still remains a major factor in the 
development of illness chronicity. Indeed for the individual themselves, 
relapse is critical in the development of secondary depression. Birchwood et 
at., (1993) found that perception of control over illness was the most powerful 
predictor of depression in schizophrenia. Recognition of the social, emotional 
and psychological costs of relapse has lead investigators to attempt to 
conceptualise psychological approaches to the detection and prevention of 
relapse. In this chapter I will propose that an individual's attempts to assimilate 
and accommodate the changes associated with psychosis are central to the 
development and maintenance of symptomatology, associated disability and 
distress. It will be argued that the process of relapse encapsulates this 
interaction between an individual and their experience of psychosis. Indeed, 
given that relapse sees the emergence of positive symptomatology, there is a 
need to develop an integrative model of psychotic relapse that can 
accommodate existing psychological conceptualisations of relapse and 
positive psychotic symptoms such as hallucinations and delusions. 
3.2 Cognitive Behavioural Therapy for Schizophrenia 
Five controlled trials of Cognitive Behavioural Therapy (CBT) for 
schizophrenia have been reported (Tarrier et al., 1993; Drury et al., 1996a, b; 
Kuipers et al., 1997; Tamer et al., 1998; Pinto et al., 1999; Sensky et al., 
2000). All these trials have involved providing CBT in conjunction with 
antipsychotic medication. Four of these trials have examined the efficacy of 
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CBT for drug resistant positive psychotic symptoms (Tarrier et al., 1993; 
Kuipers et al., 1997; Tarrier et al., 1998; Pinto et al., 1999; Sensky et al., 
2000). One trial examined the efficacy of CBT delivered during the acute 
psychotic phase (Drury et al., 1996a, b). CBT has been found to be superior to 
waiting list control (Tarrier et al., 1993), routine care (Kuipers et al., 1997), 
structured activity and informal support (Drury et al., 1996a, b), supportive 
counselling and routine care (Tarrier et al., 1998). Pinto et al., (1999) found 
that when combined with clozapine, CBT was superior to supportive therapy 
in combination with clozapine. Sensky et al. (2000) compared CBT to a 
befriending condition and found that at the end of treatment phase both had 
equal efficacy, however at 9-month follow-up the CBT group had continued to 
improve, while those in befriending did not. 
Three CBT trials provide follow-up data at 9-months post treatment (Kuipers 
et al., 1998; Sensky et al., 2000), at 12-months (Tarrier et al., 1999), and 24- 
months (Tarrier et al., 2000). Kuipers et al., (1998) found that at 9-month 
follow-up those who had received CBT continued to improve, evidenced by 
significant improvements in delusional distress and frequency of 
hallucinations. Relapse rates at follow-up were not reported, although there 
were no statistically significant differences between CBT and routine care 
participants for time spent as psychiatric in-patients during the study period 
(Mean = 14.5 days versus 26.1 days respectively). Sensky et al., (2000) also 
did not report relapse rates at 9-month follow-up although the CBT group 
continued to improve on measures of positive symptoms, depression and 
negative symptoms, compared to the befriending control group who had lost 
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most of the treatment gains made during the treatment phase. Tarrier et al. 
(1999) reported 12-month follow-up results for CBT compared to supportive 
counselling (SC) or routine care alone (RC). Participants in CBT continued to 
show significant treatment effects for both positive symptoms and negative 
symptoms. Pairwise comparisons showed a significant effect for CBT over RC 
for positive and negative symptoms, but not for SC. Unlike previous studies, 
Tarrier et al. did examine relapse rates pre-treatment and the 12-month post- 
treatment follow-up period (total duration = 15-months). A relapse was 
defined as a clinical deterioration or functional impairment, which resulted in 
a hospitalisation of five days or more, corroborated by casenote inspection. Of 
the original group of 87 participants, 70 were successfully followed up. 
Amongst this group there were the following relapse rates; CBT (6/23,26%), 
SC (4/21,19%) and RC (7/26,27%). These differences were not statistically 
significant. Tarrier et al. (2000) reported on the two-year follow-up of 61 
(70%) of participants randomised to treatment. At two years there were 
significant differences for both CBT and SC over RC for positive symptoms. 
There was no significant difference between CBT and SC groups. Again for 
negative symptoms both CBT and SC showed significant differences with RC, 
but there were no significant differences between CBT and SC. Time to 
relapse was examined using Kaplan-Meier survival curves for treatment 
groups. There were no significant differences between CBT and SC, and these 
groups were combined for comparison with RC. The number of relapses was 
greater in the RC group (11/28,39%) compared to the combined group (13/59, 
27%). The statistical significance of this difference in relapse rates was not 
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reported by the investigators. There was not a statistically significant 
difference between these groups on duration to relapse. 
Outcome in terms of co-morbid symptoms of anxiety and depression are not 
reported by a number of trials (Tamer et al., 1993; Pinto et al., 1999). Kuipers 
et al., (1997) found no effect for CBT on measures of self-rated depression. 
Tarrier et al., (2001) reported on the detailed outcome of their 1998 trial of 
CBT, which compared intensive CBT + Routine Care (RC), with Supportive 
Counselling (SC) + RC, and RC alone. Measures of anxiety and depression 
were examined to investigate whether affective symptoms improved over time 
and whether treatment groups differed at post treatment or in their relative 
change over time. There were no significant effects for time, group or time by 
group interaction on affective symptoms. 
Drury et al., (1996b) delivered CBT during the acute psychotic phase of illness 
and defined clinical recovery as personal recovery from psychotic symptoms, 
recovery of insight, and the resolution of non-specific symptoms including 
dysphoria and `low-level' psychotic thinking. Personal recovery from 
psychotic symptoms was defined as the lowest rating of hallucinations and 
delusions achieved over the follow-up period and maintained for at least three 
consecutive assessment points. Recovery of insight was defined as a score of 
>9 on the Insight Scale (Birchwood et al., 1994). Resolution of non-specific 
symptoms was defined as a score of <30 on the Early Signs Scale (Birchwood 
et al., 1989). Time to clinical recovery was defined as the time to resolution of 
all three components. Survival analysis using the clinical recovery definition 
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showed that the cumulative proportion failing to recover by 100-days was 
50% for CBT and 85% for controls (Wilcoxan Gehan 4.9, df = 1, p <0.05). 
Sensky et al. (2000) examined the outcome of CBT versus befriending (BF) in 
a group of individuals with chronic drug resistant positive psychotic 
symptoms. Outcome of treatment was examined in terms of positive 
symptoms, negative symptoms and depression. At the end of treatment both 
CBT and BF groups showed significant improvements in positive symptoms, 
negative symptoms and depression. However at 9-month follow-up, CBT 
resulted in significantly greater improvements in positive, negative and 
depression symptoms compared to BF. Using an outcome criterion of 50% or 
greater improvement in symptoms as a measure of clinical significance of 
outcome, 31 of the 46 (67%) participants in CBT achieved this criterion, 
compared to 22 out of 44 (50%) of the BF group; a non-significant difference. 
Evidence from recent randomised controlled trials of CBT for schizophrenia 
show that it is not yet possible to conclude on the basis of current results that 
CBT is effective in reducing relapse rate following treatment. Examination of 
treatment manuals adopted by trial investigators reveals that relapse 
prevention strategies are included within these protocols (Kingdon & 
Turkington, 1994; Fowler et al., 1995). These strategies focus on helping 
individuals recognise and respond to early signs of relapse by seeking help but 
do not specify particular cognitions or behaviours associated with the 
development of relapse acceleration, nor do these manuals specify 
psychological strategies to address cognition or behaviour during relapse. It 
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would seem reasonable to suggest that the results on relapse could, perhaps, be 
in part due to an inadequacy of existing CBT treatment protocols for relapse in 
psychosis. However, it should also be stated that the reduction of relapse was a 
secondary aim of these studies. 
Results regarding the effectiveness of CBT in the treatment of psychological 
co-morbidity are both surprising and disappointing. Only one study (Sensky et 
al., 2000) demonstrates efficacy in the treatment of co-morbid depression, 
although CBT was not uniquely effective. In addition, whilst the treatment 
manual adopted in the Sensky et al., study specifically targets anxiety and 
depression, other treatment manuals also detail techniques and strategies 
aimed at reducing psychological co-morbidity (e. g. Fowler et al., 1995). Again 
such a finding may be accounted for by the lack of a specialised psychological 
conceptualisation of psychological co-morbidity in schizophrenia. For 
example, Birchwood et al., (2000) found that in a sample of 105 individuals 
with schizophrenia, 36% developed post psychotic depression (PPD) without 
concomitant changes in positive and negative symptoms. Iqbal et al., (2000) 
have proposed that, in line with Gilbert (1992) certain life situations are likely 
to be depressogenic, particularly if they encapsulate feelings of loss, 
humiliation and entrapment. In line with their proposal, psychosis is seen as a 
life event whose appraisal may involve these elements. Participants who 
developed PPD were more likely than their non-PPD counterparts to attribute 
the cause of psychosis to themselves, perceive greater loss of autonomy and 
valued role, and perceive themselves to be entrapped and humiliated by their 
illness. Given this finding, it may be that strategies aimed at reducing 
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psychological co-morbidity in schizophrenia should target cognitions and 
appraisal surrounding the meaning and appraisal of psychosis itself. This may 
help partially explain the findings of Sensky and colleagues who emphasise a 
normalising rationale for psychosis early in treatment. 
However, empirically there is a strong link between the experience of relapse 
and the occurrence of psychological symptoms before relapse, and as a result 
of relapse itself via appraisals of entrapment. I propose that (1) there is a need 
to develop a psychological conceptualisation of relapse which can assist the 
targeting of relevant cognitive behavioural factors involved in the evolution of 
relapse and that such a model should (2) account for the relationship between 
relapse and psychological symptoms and distress. 
3.3 Psychological Models of Relapse 
Thurm & Haefner (1987) proposed a model of relapse in schizophrenia, which 
placed the individual as an active agent, using coping strategies to decelerate 
or forestall the process of relapse. Their model (see figure 3.1 below) 
emphasized how individuals with schizophrenia face numerous adaptational 
demands as a consequence of their illness, and that individuals' perception of 
vulnerability to relapse would be associated with anticipatory coping strategies 
aimed at reducing relapse risk and regulating cognitive and emotional 
experience. Thurm & Haefner's (1987) model draws heavily from models of 
coping developed by Lazarus and co-workers (Lazarus & Launier, 1978; 
Roskies & Lazarus, 1980) and Moos & Tsu (1977). Lazarus formulated a 
dynamic transactional model of coping, implying a bi-directional relationship 
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between the person and their environment. Central to this model is the 
hypothesis that an event is not stressful per se, but the significance of an event 
is determined by the meaning attributed to it by the process of cognitive 
appraisal. Primary appraisal can lead to the judging of an event as a threat of 
loss, harm or challenge. Secondary appraisal implies the judgement of 
available coping reactions. It is the interaction between primary and secondary 
appraisal, which determines the perception of threat from an event. In a model 
of physical illness, Moos and Tsu, enumerated the various adaptive tasks to be 
dealt with by the individual. They distinguished between three illness-related 
tasks and four general tasks. Illness-related tasks were dealing with pain and 
incapacitation, dealing with the treatment environment, and developing 
satisfactory relationships with professional staff. The general tasks were 
preserving emotional well being, preserving a satisfactory self-image, 
preserving relationships with family and friends, and preparing for an 
uncertain future. Other important variables in their model are the factors 
determining cognitive appraisal and the choice of specific coping responses. 
Moos and Tsu proposed that these fell into three categories: background and 
personal characteristics (age, intelligence, self-esteem, previous coping 
experiences), features of the physical and social environment (hospital setting, 
home milieu, social support), and illness related factors (type and location of 
symptoms, pain, impairment). 
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Figure 3.1 Model of coping with schizophrenia 
(from Thurm & Haefner, 1987) 
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Hultman et al. (1997) examined the role of life events, social support and 
coping-style in relation to relapse amongst 42 consecutive individuals 
admitted to an inpatient unit following a relapse of schizophrenia. In this study 
social support and coping were described and examined as moderating 
variables serving as protective factors which may mediate the relationship 
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between stress and relapse. Participants were followed up for 9-months 
following discharge from hospital. Of this group, 26 (62%) were living alone, 
the remainder with parents (12,29%), partner (2,5%) or friend (2,5%). 
During the 9-month follow-up 14 (36%) relapsed. Hultman et al., (1997) 
found close proximity between the occurrence of life events and relapse. 
Those participants with few social contacts and a withdrawal-orientated 
coping-style were more likely to relapse than those who had social contact and 
a socially orientated coping style. When coping style was considered alone, 
relapse rates were significantly higher for those participants who withdrew 
during early relapse (x2 = 10.19, df = 1, p<0.001). This study provides 
evidence that individuals coping response to early relapse may accelerate or 
forestall relapse itself. Indeed, Birchwood (1995) points out that the individual 
variations in the nature and timing of early signs may be due to individual 
variations in coping response. Such variation will therefore act to reduce their 
apparent amplitude in group studies. Group studies fail to capture the 
qualitative and quantitative differences between individuals in their early 
signs. Therefore it may be more appropriate to think of early signs as an 
individualised configuration of symptoms which Birchwood refers to as a 
`relapse signature'. 
Birchwood (1995) accounts for this variation in the nature and timing of early 
signs by integrating individual's own idiosyncratic response to emerging 
relapse. This cognitive explanation for the variation in early signs suggests 
that dysphoric symptoms such as anxiety, tension, withdrawal, depressed 
mood, suspiciousness, and sleeplessness arise from the way in which 
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individuals explain and interpret internal and external events. Birchwood 
(1995) offers a compelling cognitive analysis of early relapse which integrates 
Maher's (1988) model of delusional formation and Weiner's (1985,1986) 
attribution theory (see Figure 3.2 below). Maher (1988) had offered a 
cognitive account of delusions, which emphasised the experience of 
disturbances in perception. He proposed that in the experience of perceptual 
anomalies such as increased vividness of colours or difficulty in selectively 
attending to auditory stimuli against background noise, the individual seeks an 
explanation which is then developed through normal cognitive mechanisms. 
The explanation or delusion is maintained in the same way as any normal 
strongly held belief, and that the delusional belief is reinforced by the anxiety 
reduction, which accompanies the development of an explanation for 
disturbing and puzzling experiences. Evidence supporting this proposal is 
cited by Maher & Ross (1984) who noted that delusions occur in a large 
number of medical and psychological conditions. Second, Zimbardo et al., 
(1981) cited evidence that irrational beliefs can be provoked in the general 
population under anomalous environmental conditions such as hearing loss. 
Like Maher (1988), Birchwood proposes that the attributions made by 
individuals to account for and explain the emergence of disturbing symptoms 
can serve to either accelerate or retard the process of relapse. In this model, 
dysphoria is seen as a response to the fear of impending relapse (perhaps for 
those with previous experience of relapse) or a failure to explain symptoms 
and experiences (perhaps for those with less experience of relapse). This 
model might therefore predict that those individuals with extensive prior 
experience of relapse and its associated negative repercussions would respond 
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with high levels of fear and perhaps helplessness leading to depression and 
withdrawal. On the other hand, those with less experience may respond with 
puzzlement, confusion and perplexity. The model may also help explain the 
speed at which relapse proceeds by specifying the cognitive mechanisms and 
associated emotional consequences responsible for acceleration. 
Figure 3.2 Attributional model of relapse 
(from Birchwood, 1995) 
r----------------------- 
INTERNAL ATTRIBUTION 
Affect: fear, demoralisation 
COGNITIVE-PERCEPTUA L DYSPHORIA INCIPIENT 
CHANGES PSYCHOSIS 
Attentional dysfunction Low mood, fear Suspiciousness 
Derealisation Preoccupation with mental life Ideas of reference 
Racing thoughts Loss of interest, self care Voices 
ý----------------------- 
EXTERNAL ATTRIBUTION 
----------, 
----------ý Affect: anger 
To summarise, existing models of relapse in schizophrenia emphasise a 
number of factors. First, individuals can perceive subjective experience of 
internal changes in cognitive and attentional processes as indicating increased 
relapse risk and is accompanied by a search for meaning. Second, the 
experience of these changes is processed in terms of an evaluation of 
vulnerability to relapse in terms of available internal and external coping 
resources. Third, these appraisals are associated with the instigation of active 
strategies aimed at prevention of relapse and/ or the coping with relapse itself. 
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The phenomenological evidence for the presence, and indeed the role of these 
factors in initiating psychosis will now be examined. 
3.4 Subjective experience in schizophrenia 
The basis of Birchwood's (1995) model is that basic changes in cognitive 
perceptual processes account for the initiation of a psychological response 
involving attributions for the individual's experience. McGhie & Chapman 
(1961) proposed that the fundamental disorder in schizophrenia was a 
cognitive one, which was most clearly evident in the observation of attentional 
and perceptual processes. They argued that other aspects of the 
symptomatology of schizophrenia could be understood as the individual's 
psychological response to this basic disorder. They interviewed 26 individuals 
with schizophrenia early in their illness and obtained a vivid account of 
changes in attention, perception, awareness of movement, thinking and 
emotion. From these accounts they suggested that there was a loss of 
attentional focality. Attention was not directed in a determined manner by the 
individual's own volition, but by the diffuse pattern of stimuli existing in the 
total environment. The perceptual changes reported by these individuals were 
a heightening of sensory vividness in auditory and visual modalities, and a 
disturbance in the perception of speech patterns. McGhie & Chapman argued 
that disturbances in attention lead to a widening of the perceptual field, 
leading to the subjective experience of a changed sense of reality. In terms of 
the disturbance in the perception of speech patterns, McGhie and Chapman 
proposed that the disturbance in attention meant that information such as the 
syntax and form of speech, normally processed automatically, overloaded 
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normal information processing. Therefore individuals' were unable to 
appreciate the meaning of speech. Changes in bodily awareness were 
attributed to heightened awareness of bodily sensation and volitional 
responses causing overload in the ability of individuals' processing of 
information. The consequences of this overload were a loss of spontaneity of 
action, and `self consciousness' of the minutiae of behaviour. 
Freedman (1974) read 60 autobiographical accounts of the early experience of 
schizophrenia. She describes clear perceptual experiences including enhanced 
sensory awareness, muted sensory awareness, less acute vision, visual 
illusions, changes in depth perception, and changes in perception of one's own 
voice. She also found changes in more complex function including thinking 
being replaced by emotion, thinking in images, mistaking identities of other 
people, experiences of loss of meaning of objects, and physical sensations in 
the brain. Freedman & Chapman (1973) found that 8 subjective experiences 
distinguished patients with and without schizophrenia. These experiences 
included thought block, mental fatigue, inability to focus attention, visual 
illusions, hyperacute auditory perception, and misidentification of people and 
inability to comprehend others' language. Cutting (1985) interviewed 30 
individuals with schizophrenia (15 remitted, 15 acute) and 15 individuals with 
depression about their early subjective experience. The features, which 
characterised schizophrenia rather than depression, were visual and auditory 
perceptual distortions, impaired understanding of language, and distortions in 
memory. Such findings have also been replicated by Docherty et al (1978), 
Heinricks et al (1985), and indeed recall Bleuler's descriptions of mood and 
104 
Psychological models of relapse 
perceptual disturbance in prodromal schizophrenia (Bleuler, 1950). 
Such changes have also been associated with affective disturbance, which is 
common at the initial presentation of schizophrenia (Johnson, 1981; 
MacGlashan, 1982) and following the initial episodes (Steinberg et al, 1987; 
Roth, 1970; Rada & Donlon, 1975; MacGlashan & Carpenter, 1976; Singh et 
al, 1978; Siris et al, 1978; Prusoff et al, 1979; Johnson, 1981; Knights & 
Hirsch, 1981). Indeed affective disturbance accounts for more primary care 
consultations than psychotic episodes (Johnson, 1981; Prusoff et al, 1979; 
Roth, 1970). This is consistent with previous studies of co-morbidity, which 
have documented that psychiatric co-morbidity can lead to heavier use of 
psychiatric services via more frequent and prolonged hospital stays (Menezes 
et at., 1996; Stakowski & Tolien, 1993). In addition, Glazer et al., (1981) 
found that individuals with depression in the context of chronic schizophrenia 
were more impaired in their social functioning and adjustment. Cheadle et at. 
(1978) found that in a sample of 190 patients with Schizophrenia, neurotic 
symptoms were not only prevalent, but also seemed to cause most of the 
reported personal problems including social isolation and unemployment. It 
has been suggested that these affective disturbances are neuroleptic induced 
(Alarcon & Carney, 1969; Van Putten & May, 1978). However, Johnson 
(1981) notes that such complaints are found in individuals maintained or not 
maintained on neuroleptics, and indeed prior to any neuroleptic exposure. 
Chapman & McGhie (1963) suggested that individuals with schizophrenia 
become aware of abnormal experiences and that their reactions to these 
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experiences may play an important role in the development and maintenance 
of illness. They recommended that a psychotherapeutic understanding of the 
individuals perceptual and experiential difficulties would aid improved 
communication. In addition, they suggested that psychotherapy should aim to 
discover individuals' subjective experiences and cognitive disabilities, and 
reduce unhelpful or ineffective reactions to these experiences. Bowers (1968) 
argued that self-experienced changes in perception and awareness were critical 
to the transformation of normal experience to psychosis. In a composite 
experiential account drawn from interviews with fifteen patients, Bowers 
described changes in heightened awareness of internal and external stimuli. 
Associated with these perceptual changes he described individuals as having 
an increasing sense of urgency, reduced need for sleep, exaggerated affect, and 
a heightened sense of self. Alongside this heightened experience, internal and 
external events and stimuli normally outside awareness became meaningful 
and self-relevant. Individuals described becoming engaged, fascinated, 
perplexed or indeed scared by they're own experience. This state of 
heightened awareness of self gave way to what Bowers referred to as "a 
dissolution of self' or "loss of mental self-representation". This loss of 
meaning combined with a heightened awareness of internal and external 
stimuli gave way to the development and evolution of delusional beliefs 
constructed to make sense of "heightened and altered sensory influx and self 
experience, widened categories of relevance and a push for closure or 
meaning" (Page 352). Conrad (1958) had earlier referred to this stage as 
`apophany', which he regarded as the essence of the process of the evolution 
of schizophrenia. In the purest form of apophany, the world took on a new 
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meaning but the individual could not say what this was. The compulsion of 
significance overwhelmed the individual. 
In a review of the literature, Nuechterlein and Dawson (1984) found that 
several deficits on information processing and attentional tasks show great 
similarity across groups of individuals at heightened risk for schizophrenia, 
actively symptomatic individuals and relatively remitted individuals. 
Problems were identified in sustaining focused attention in high-processing- 
load vigilance tasks, in rapid read-out from sensory storage in the presence of 
patterned noise stimuli, and in short term recall involving rehearsal, especially 
in the presence of distraction. Similar deficits were found in reaction time, 
selective attention, and short-term recognition memory. Nuechterlein and 
Dawson (1984) proposed that these deficits represented enduring 
vulnerability-linked characteristics of individuals who are prone to 
schizophrenia. They also found evidence of deficits on certain tasks amongst 
individuals with active symptomatology, which were not present amongst 
those whose symptomatology was remitted or amongst those at risk of 
developing schizophrenia. These tasks involved vigilance with relatively low 
momentary processing loads or letter recognition tasks, which use very brief 
exposure times without a visual mask. This finding is consistent with McGhie 
& Chapman's (1961) original proposal that early in the course of the 
symptomatic emergence of schizophrenia, information processing becomes 
overloaded. They proposed that this was a primary problem in attentional 
processing of irrelevant stimuli, which initiated a changed sense of perception 
of the internal and external environment. 
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Healy (1990) developed the proposals of Chapman and his colleagues, by 
arguing that application of their basic proposal requires recognition of the 
multi-dimensionality of the positive and negative syndromes apparent in 
schizophrenia. Healy argues that the proposal by Chapman & McGhie (1963) 
is congruent with the evidence for the efficacy of cognitive therapy in the 
management of `biological' depression (Healy and Williams, 1988), and 
indeed the role of mediating processes in schizophrenia (Brenner & Boker, 
1989). Experimental evidence supporting Healy's (1990) proposal comes from 
two studies. First, consistent with Healy (1990), Van den Bosch and 
Rozendaal (1988) hypothesised that the self-report of cognitive difficulties in 
schizophrenia should be correlated with objective indicators of vulnerable 
information processing. In a study of 21 recently admitted psychotic 
individuals, repeated measures of psychotic symptoms, psycho-physiology, 
and subjective experience of cognitive dysfunction were taken 10 days after 
admission, and at 1 and 2 month follow-ups. The psycho-physiological 
measures included in this study were Smooth Pursuit Eye Movements 
(SPEM), Contingent Negative Variation (CNV) and Reaction Time (RT). All 
of these measures are known to be associated with psychosis and are assumed 
to reflect disorders of information processing (Nuechterlein, 1977; Levin, 
1983; Pritchard, 1986). Close relationships were found between the subjective 
experience of cognitive dysfunction and the psycho-physiological measures. 
In particular, high correlations were found between subjective experience and 
SPEM (r = 0.66, p<0.01), and RT (r = 0.58, p<0.01). No significant 
correlations were found between psychotic symptoms and SPEM (r = 0.35, p 
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= n. s. ) and RT (r = 0.31, p=n. s. ). Whilst, the correlational nature of this study 
weakens its power, the results support the view that subjective experience is 
more closely related to information processing difficulties than psychotic 
symptoms themselves. In this sense, subjective cognitive difficulties seem to 
have a mediating descriptive value, between, on the one hand neuro- 
physiological dysfunction, and on the other psychotic experiences. Second, 
Albers et al. (1998) examined individuals who showed definite evidence of the 
basic symptoms described by Chapman (1966) at an index examination and 
individuals who did not show any evidence of symptoms, in order to 
determine whether the presence and type of basic symptoms can predict the 
development of schizophrenia. Of the 78 patients who showed definite 
evidence of basic symptoms, 56 (72%) underwent transition to psychosis 
during the intervening 8-year follow-up period. None of the 18 patients 
without evidence of basic symptoms at index examination were found to have 
developed psychosis in the intervening period. The analysis was able to 
predict the presence or absence of transition to schizophrenia accurately in 
77% of individuals, whilst psychosis was falsely predicted in 23% of the 
sample. Therefore the development of schizophrenia was predicted with a 
specificity of 45% (the percentage of patients who had not shown basic 
symptoms and had not shown transition to schizophrenia) and a sensitivity of 
100% (the percentage of individuals with basic symptoms who had shown 
transition to schizophrenia). The basic symptoms which best discriminated 
between the groups at outcome were cognitive thought disturbances such as 
pressure of thought, interference of thought, tendency to delusion of reference, 
disturbance in thought initiative, and disturbance in receptive speech. These 
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disturbances in cognition were associated with disturbances in perception 
including the experience of being captivated by details of perception. 
Cognitive perceptual disturbance was also associated with problems in the 
perception of olfactory, gustatory and tactile stimuli. 
Thurm & Haefner (1988), Healy (1990), and Birchwood (1995) all emphasise 
the role of the individual's perception and experience of subtle changes in 
cognitive, perceptual and information processing as being critical to the 
development and evolution of psychosis itself. These proposals have been 
based on the phenomenological evidence attesting to subjective experiences in 
schizophrenia described by a number of authors (Bowers, 1968; Chapman & 
McGhie, 1963; Conrad, 1958; Cutting, 1985; Freedman & Chapman, 1973; 
Freedman, 1974; McGhie & Chapman, 1961). Indeed, as early as 1963, 
Chapman & McGhie recommended that individual psychotherapy should 
focus on eliciting the experience of cognitive dysfunction and assist the 
individual in labelling and understanding these experiences. Indeed, Boker et 
al. (1984) investigated naturally occurring coping strategies associated with 
the experience of these basic disorders. They examined 40 inpatient 
individuals with schizophrenia during their acute episode. Basic disorders 
were elicited using the Frankfurt Complaint Questionnaire (Sullwood, 1977), 
which gives four subscales (1) Disorders of normally automatic skills, (2) 
Perceptual disorders, (3) Depression, anhedonia, and (4) Stimulus Overload. 
Furthermore a semi-structured interview was undertaken to elicit consciously 
undertaken efforts at compensation for these disorders. Reporting of 
compensatory efforts were common (nearly 75%) amongst participants. 
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Indeed there was a highly significant relationship between awareness of 
subjectively experienced basic disorders and active problem solving orientated 
coping strategies, but not strategies such as avoidance or withdrawal. Most of 
the coping strategies reported by participants were active problem solving 
based ones, as opposed to more passive strategies such as avoidance or 
withdrawal. Such experiences were interpreted by many participants as 
"danger signals". In this sense the subjective experience of cognitive and 
perceptual dysregulation, is by no means a passive experience. Individuals 
actively attempted to make sense of their experience, and pursue coping 
strategies to ameliorate these experiences. 
3.5 Psychological Models of Psychotic Symptoms 
Fowler et al., (2000) propose a cognitive model of the development of acute 
psychosis, and indeed cite experimental evidence that difficulties in source 
monitoring may underlie the subjective experience of psychosis. Unlike 
Birchwood's (1995) model, Fowler and colleagues emphasise their model as 
one, which explains the evolution of psychosis itself. Psychosis is assumed to 
arise in the context of a vulnerable predisposition (of bio-psycho-social origin) 
and triggers to the onset of psychosis are assumed to include factors such as 
life events or drug misuse. There may be different types of vulnerability, 
triggers and stresses for different individuals. Their model emphasizes that 
individuals' routes into psychosis are idiosyncratic, and that complex 
psychotic symptoms can be regarded as thoughts, beliefs, emotional reactions 
and behaviours. The model implies that by careful assessment, it may be 
possible to trace the evolution of such cognitions from their formation as 
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premorbid beliefs. Subsequent beliefs about self, others and psychosis are then 
assumed to be shaped by the appraisal of stressful life events, anomalies of 
experience, early psychotic symptoms, and early and subsequent experiences 
of psychosis and its treatment. This model is illustrated in Figure 3.3 below. 
The model implies that there are two types of trigger into psychosis; anomalies 
of experience, and the experience of bio-psycho-social stress. Anomalous 
experiences are proposed to arise from source monitoring problems leading to 
inner/ outer confusion. The model assumes that this confusion is the common 
pathway that underpins the experience of psychotic experience (hallucinations, 
delusions and thought disorder). This pathway is described as confusion in 
distinguishing between experience, which is internally generated (e. g. 
thoughts, memories, hopes, and fears) and experience that is externally 
generated (sensations, perceptions of events in the world). Confusion of this 
type has been described by various researchers as a problem of reality 
monitoring (Bentall, 1990), self-monitoring (Hemsley, 1993,1998), 
metacognition (Frith, 1992), source monitoring (Morrison, 1999) and 
autonoetic agnosia (Keefe et al., 1999). First, Fowler et al (2000) propose that 
source-monitoring problems may be associated with impairments in automatic 
cognitive processes, which have been commonly observed amongst 
individuals with schizophrenia (Frith, 1992; Hemsley, 1998). Specific support 
for this proposal is described by Keefe et al., (1999) who found that 
individuals with schizophrenia had general rather than specific difficulties in 
distinguishing sources of information, and that this deficit was not associated 
with specific psychotic symptoms. Second, unlike cognitive deficits, cognitive 
biases arise from and are shaped by psychological processes such as beliefs 
112 
Psychological models of relapse 
and expectations. Bentall et al. (1991) and Morrison & Haddock (1997) have 
found experimental evidence for the role of cognitive bias and source 
monitoring in hallucinations. 
Fig 3.3 Maintenance of threatening reactions to Psychosis 
(From Fowler et al., 2000) 
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3.5.1 Hallucinations 
Attribution theory (Weiner, 1985) has been helpful in developing 
psychological models of hallucinations and delusions. Attributional models of 
hallucinations conceptualise an auditory hallucination as a mental event that is 
misattributed to an external source. This hypothesis has been supported by 
various studies which have shown that individuals with hallucinations 
demonstrate a bias toward assuming a voice had been presented when it had 
not (Bentall, 1996). Indeed, Slade & Bentall (1988) demonstrated that 
individuals with hallucinations are more inclined to judge a perceived event as 
real and make rapid and over-confident judgements about their perceptions. 
Bentall's (1990) cognitive model of hallucinations incorporates the concept of 
'metacognition': the process whereby individuals are able to reflect upon their 
own experience and mental processes. Bentall argues that in normal reality 
discrimination, individuals determine the source (internal or external) of a 
perceived event by non-consciously applying a set of criteria, such as the 
properties of the event, contextual cues, and expectations. Factors that may 
influence application of these criteria include environmental stimulation and 
style of information processing. Therefore, individuals will hallucinate when 
they wrongly infer that internally generated cognitive events such as thoughts 
are externally generated stimuli. This misattribution may be influenced by 
environmental factors (e. g. overstimulation) leading to high arousal and 
shallow information processing of stimuli caused by high stress. Furthermore, 
the misattribution of an aversive cognitive event to an external 'non-self 
source may be negatively reinforcing through arousal reduction. This process 
may be influenced by the individual's own schemata about self, world and 
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future. Such schemata will influence individuals' expectations, interpretation 
and emotional response to both internal and external events (Padesky & 
Greenberger, 1995) 
Morrison et al (1995) have elaborated a cognitive model of auditory 
hallucinations which proposes that auditory hallucinations arise from an 
attributional bias. Morrison et al. 's model draws on existing cognitive 
conceptualisations of intrusive thoughts (Rachman, 1978). Intrusions are 
defined as repetitive thoughts, images or impulses that are unacceptable or 
unwanted and are usually accompanied by subjective discomfort. Salkovskis 
(1985) hypothesizes that such thoughts are also ego-dystonic; i. e. they are 
incompatible with the individual's own belief system. Salkovskis & Kirk 
(1997) hypothesize that the occurrence and content of intrusive thoughts in 
obsessive compulsive disorder, are interpreted by individuals as meaning that 
they might be responsible for harm to themselves or others unless they take 
action to prevent it. It is the appraisal of responsibility, therefore, which is 
central to the development of distress. This results in attempts to suppress or 
neutralize the intrusive thought. Morrison et al., (1995) note that there is a 
similarity in the content of intrusions and auditory hallucinations. Thus it is 
argued that the occurrence of auditory hallucinations is accounted for by the 
result of an attributional process whereby individuals misattribute ego- 
dystonic, unwanted, and uncontrollable thoughts to an external source thereby 
leading to reduced distress. Cognitive dissonance theory (Festinger, 1957; 
Bouvois & Joule, 1996) states that dissonance results when two cognitions 
contradict each other. Therefore when positive thoughts are inconsistent with 
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the individual's own beliefs about self, dissonance will result. An attribution to 
an external source (resulting in an auditory hallucination) will reduce 
dissonance. This would account for the experience of pleasant auditory 
hallucinations in individuals with negative self-schemata. Morrison et al also 
hypothesize that their theory may also be useful in explaining thought 
insertion, thought withdrawal, and thought broadcasting, which may be related 
to misattributions in response to uncontrollable and/or unwanted cognitive 
events. 
Experimental support for this hypothesis is described by Morrison & Haddock 
(1997) who examined the cognitive processes underlying auditory 
hallucinations in an experiment which investigated delayed and immediate 
source monitoring for positive, negative and neutral verbal material. They 
found that individuals experiencing auditory hallucinations had an external 
attributional bias for their immediate thoughts, but not for their memories of 
those thoughts. This bias was not demonstrated in individuals with no 
auditory hallucinations but with other psychotic symptoms. This implies a bias 
in moment by moment source monitoring specific to auditory hallucinations. 
Morrison & Haddock also found that the emotional valence of verbal material 
was a significant factor, which influenced the bias in source monitoring. This 
is consistent with Bentall's (1990) and Morrison et al. 's (1995) theories which 
predict that emotional content of intrusions has a direct effect on their 
misattribution to an external source. Furthermore, Baker & Morrison (1998) 
found that negative metacognitive beliefs concerning the controllability of 
one's own thoughts was significantly related to the experience of auditory 
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hallucinations. Morrison (1999) proposed that negative metacognitive beliefs 
play a role in the maintenance of auditory hallucinations by increasing 
individual's internal attentional focus on unwanted cognitive events. Further 
evidence for this hypothesis was derived from an experiment examining a 
group of individuals predisposed to experience unusual visual and auditory 
perceptual aberrations (Morrison et al., 2000). Morrison and colleagues found 
that positive metacognitive beliefs were associated with these experiences, 
suggesting that an attentional focus based on an interest and fascination with 
one's own thoughts was associated with the reporting of these perceptual 
aberrations. 
Chadwick & Birchwood (1994) have studied individual's beliefs about voices 
in relation to their emotional and behavioural responses to voices. Using an 
ABC framework they formulated voices as activating events (A) and found 
that there was cognitive content specificity in that voices believed (B) to be 
malevolent were associated with negative affect and were always resisted (C), 
whereas voices believed to be benevolent were associated with positive affect 
and were engaged with. In a latter study of 59 voice hearers, Birchwood et al., 
(2000) examined the relationship between individuals' appraisal of power and 
social rank in relation to their voices, in addition to parallel measures of power 
and rank in wider social relationships. This study builds on ongoing research 
by Birchwood and colleagues who have examined models of social cognition 
and `ranking' theory in relation to post psychotic depression (Iqbal et al., 
2000). Ranking theory (Gilbert & Allen, 1998) predicts that stimuli perceived 
as powerful and threatening, activate defensive and self protective responses, 
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including submissive and escape behaviour; resistance to malevolent voices 
would be an example of this. According to social ranking theory, 
subordination to another arises from a process of social comparison serving 
the formation of social rank. Social rank not only involves a comparison of 
relative strength and power, but also social attractiveness and talent, and 
perceived belonging with a social group. Birchwood and colleagues found that 
the difference in rank between the voice and voice hearer is mirrored in social 
rank differences between self and others. This effect was maintained after 
controlling for depressed mood. Therefore measures of rank and power were 
not an artefact of mood linked appraisal. It was not possible to determine 
whether the appraisal of rank determined individuals' beliefs about voices and 
their level of depression, or if perceived social rank was an outcome of the 
experience of psychosis itself. Fowler et al., (2000) have proposed that 
psychological vulnerability arising from pre-morbid negative beliefs about 
self, and world shape the evolution of negative cognitions and beliefs 
associated with psychosis itself, and indeed becoming "stuck in psychosis" 
may be due to the way in which individuals' appraise and then develop 
attributions or beliefs about psychotic experience. 
3.5.2 Delusions 
Attributional models have also been utilized to explain the development of 
delusions. Maher (1988) hypothesizes that delusions are formed by the same 
cognitive processes as normal theories and beliefs, and evolve as an 
explanation of puzzling anomalous experiences. Like Morrison et al. 's (1995) 
formulation of hallucinations, Maher's theory incorporates the concept of 
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cognitive dissonance. When a discrepancy occurs between an expected 
sequence of events and an observed sequence of events, this leads to a sense of 
puzzlement and perplexity. The adoption of a delusional explanation which 
accounts for personally significant and/or anomalous experiences is 
accompanied by a reduction in tension and uncertainty (Maher, 1988). 
However this model can be criticized on the grounds that abnormal cognitive 
processes have been demonstrated in individuals with delusions (Garety, & 
Hemsley, 1994). Garety and Hemsley proposed a multifactorial account in 
which past experience, affect, self esteem, and motivation can play a role in 
the development of some delusions, while other delusions may arise from 
biases in judgement and attention. Garety (1991,1992) proposed one factor, 
which may account for delusional development is a tendency to `jump to 
conclusions'. Garety et al., (1991) found evidence of jumping to conclusions 
in individuals with delusions where these individuals are excessively 
influenced by current information, and make less use of past learned 
regularities in making inferences. This finding has been replicated by a 
number of investigators (Huq et al., 1988; Mortimer et al., 1996; Dudley et al., 
1997a, b; Peters et al., 1997; Fear & Healy, 1997), reviewed by Garety & 
Freeman (1999). However when participants are asked to make probability 
estimates, individuals perform more like controls and the jumping to 
conclusions bias disappears. Garety & Freeman (1999) propose that these 
findings indicate that there appears to be a bias towards early acceptance of 
conclusions or hypotheses, as opposed to a deficit in probabilistic reasoning 
and hypothesis testing. Garety (1991) also found an apparently contradictory 
bias in other individuals with paranoid delusions, which was a tendency to rely 
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excessively on prior expectations when processing new information. These 
contradictory biases are accommodated in her model of delusional formation 
(Garety & Hemsley, 1994). Garety proposes that these two judgmental styles 
may reflect two stages of response to an information processing abnormality. 
In this model the initial process of delusional formation arises from the 
excessive reliance on current perception. The resulting delusional belief will 
then generate strong expectations, which influence affective state and attention 
to 'belief congruent information. 
Attributional processes associated with delusional beliefs have also been the 
focus of recent experimental investigation. Individuals with persecutory 
delusions seem to be more likely to attribute blame for negative events to 
external causes and positive events to internal causes (Kaney & Bentall, 1989; 
1992; Fear et al. 1996). They also preferentially attend to (Bentall & Kaney, 
1989) and recall (Bentall et al, 1995) threatening information. Kinderman 
(1994) found that individuals with persecutory delusions have a specific 
attentional bias for information of relevance to self-concept. It has been 
suggested that these experimental findings are consistent with the proposition 
that deluded individuals have negative self-schemata, which are experienced 
by the individual as a discrepancy between their actual and ideal selves. The 
model conceptualizes persecutory delusions as compensatory beliefs, which 
arise in response to this perceived discrepancy. This concept of delusional 
beliefs serving such a protective function has also been suggested for 
grandiose delusions. 
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Trower and Chadwick (1995) concur with the suggestions of Bentall and other 
investigators that persecutory delusions have a defensive function in that they 
are associated with low self esteem which is outside the individual's 
awareness. They have expanded this theory to encompass an interpersonal 
focus. They suggest that sources of threat are a solely interpersonal negative 
evaluation and that the defence, too, has this interpersonal focus in that it is an 
interpersonal evaluation of the other person which characterizes the paranoid 
'defence'. They also suggest that paranoia can be divided into two types- 
persecution paranoia (the type researched by Bentall and others) and 
punishment paranoia. These two types of paranoia are held to be characterized 
by differing attributional styles which relate to how information is processed 
with reference to self. Punishment paranoia is hypothesized to be 
characterized by an attributional style where the individual attributes negative 
events to self and positive events to external causes. With punishment 
paranoia the individual believes that they are bad and blameworthy and that 
others are justifiably punishing them. The defensive function of punishment 
paranoia is less clear than in persecutory paranoia. 
Most of the work on cognitive theory and therapy has emphasized the 
importance of conceptualising delusions with regard to core self-schemata. A 
number of psychological factors may play a role in the initiation, acceleration 
and maintenance of delusional beliefs. The initiation of delusions arises from 
the evolution of explanations for anomalous events, which are experienced as 
puzzling, confusing and discrepant with expectations. Central to the process of 
acceleration of these explanations is the appraisal of threat and the 
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reinforcement contingencies inherent in the adoption of delusional 
explanations. Individuals' core beliefs form a central reference point for the 
appraisal of threat. Gilbert (1997) argues that attacks on, and/or losses of 
social attractiveness are associated with shame and humiliation. Gilbert's 
model proposes that both shame and humiliation are associated with 
sensitivity to criticism, a desire to protect oneself, increased arousal, and 
complex affects. However shame and humiliation differ on a number of 
dimensions including attributional style, view of self, attentional focus, 
emotion, and behaviour. One could argue that the experience of shame or 
humiliation associated with attacks on or loss of social attractiveness is 
ontogenic in the development and acceleration of delusions. Humiliation, like 
persecutory paranoia, is characterized by an external attributional bias, where 
others are seen as bad and are blamed for negative events. In both humiliation 
and persecutory paranoia there is a strong sense of injustice and the individual 
is more likely to react to negative events with anger and hostility. On the other 
hand, both shame and punishment paranoia are characterized an internalising 
or self blaming attributional style, where self is seen as bad and blameworthy 
of negative events. Shame and punishment paranoia are both associated with 
heightened self-consciousness, and no obvious sense of injustice. Individuals 
are more likely to react with depression, submissiveness and withdrawal. Both 
shame and humiliation are associated with differing evolutionary strategies 
aimed at the maintenance of private social attractiveness (humiliation) or 
public social attractiveness (shame). The maintenance of private and public 
social attractiveness may be implicit in the defensive functions of persecutory 
and punishment paranoia. This is not currently addressed within current 
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psychological conceptualisations of psychosis. 
3.6 Theoretical Conceptualisation of Relapse 
Gumley et al., (1999) proposed a conceptualisation of relapse (see Figure 3.4 
below), which like Fowler et al., (2000) emphasised the personal significance 
of the experience of psychosis. According to this model, the occurrence of a 
pattern or configuration of internal and/ or external events which have a strong 
similarity with previous relapses will access negative beliefs concerning self 
and self in relation to psychosis more rapidly than if the configuration has a 
lower similarity. The activation of negative appraisals of psychosis derived 
from previous experiences of psychosis will initiate the process of relapse. A 
primary source of information for a relapse configuration is internal 
information on body state and arousal (Tarrier & Turpin, 1992), and cognitive- 
perceptual change (Neuchterlein & Dawson, 1984; Frith, 1992). Indeed, 
feelings of lack of control over cognitive and perceptual processes during 
relapse have been reported by a number of authors (Bowers, 1968; Freedman 
& Chapman, 1973; Donlan & Blacker, 1975). There are three implications of 
this analysis. 
First, definitions that are currently used to capture sensitivity of early signs 
could well benefit from definitions more closely allied to how individuals 
appraise their experience of psychosis rather than relying on a more closely 
delineated set of individual signs and symptoms alone. For example, for an 
individual a combination of signs and symptoms such as increased sleep 
disturbance, reduced attention and concentration and increased agitation may 
trigger negative beliefs concerning the control of (e. g. "I can't control my 
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illness"), or consequences of relapse (e. g. "I'll let everyone down", "I'm a 
failure"). If the clinician pays sole attention to the occurrence of specific signs 
and symptoms, they risk failing to capture the central meanings experienced 
by the individual. Therefore, configurations of early signs which are more 
closely allied to the schematic meanings activated during early relapse may 
increase sensitivity, and reduce the apparent variance in the nature and timing 
of experiences signaling future relapse. Second, the activation of negative 
beliefs concerning illness results in a range of negative automatic thoughts, 
distressing emotions, and safety behaviours, which may lead to the 
acceleration of relapse. Therefore the activation of negative beliefs about self, 
and self in relation to illness constitute the central engine responsible for 
relapse acceleration. Interventions targeted on these beliefs during the early 
relapse phase may therefore be effective in preventing or ameliorating relapse. 
This model attempts to illustrate the process of initiation, acceleration and 
maintenance of relapse. Box 1 to 2 illustrates the relationship between early 
symptomatic changes in body-state and information processing and how these 
changes activate schematic meanings. Within Box 2, the activation of these 
negative beliefs form the central engine of relapse leading to a range of 
negative automatic thoughts and distressing emotions. The development of 
psychotic symptoms (Box 3) serves to reduce some of the emotional and 
affective experiences produced by this engine. For example, externalising 
attributions for negative external events (leading to paranoia) or negative 
internal events (leading to voices) serve significant defensive functions, such 
as the preservation of an already vulnerable self-concept. The process of 
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maintenance is hypothesised to be accounted for through the continuing 
regeneration of schematic meanings illustrated in the direct relationship 
between psychotic symptoms (Box 3) and negative beliefs (Box 2). 
Figure 3.4 Model of Relapse (from Gumley et al., 1999) 
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Persistent reactivation of negative beliefs about self and illness will present as 
increased chronicity and resistance to treatment, whereas intermittent 
reactivation will present as a relapsing course with periods of remission. A 
range of factors may be responsible for this process of reactivation including a 
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range of internal or external experiences, which have special and specific 
psychological significance for individuals. This model may provide a useful 
means of identifying and preventing early treatment resistance by guiding 
clinicians in their conceptualisation of the interaction between the individual 
and their beliefs, their experience of psychosis, and the subsequent 
development of secondary beliefs about self, illness, environment and future. 
These beliefs are likely to have their basis in the early episodes of psychosis. 
Indeed, Jackson and Birchwood (1996) refer to the first few years of psychosis 
as the critical period. It is this period, which sees the emergence of secondary 
co-morbidity and treatment resistance. This period can be characterized by 
high levels of traumatisation (McGorry et al., 1991) and negative 
consequences associated with reduced social attractiveness, status and rank. 
3.7 Cognitive Behavioural Therapy for Relapse 
Gumley et als. ' (1999) model predicts that there are long term and short term 
vulnerabilities to relapse in psychosis. First, negative underlying beliefs about 
self will increase an individual's vulnerability to responding to the early stages 
of relapse with increased fear, depression, shame, and helplessness. Second, 
specific and covert early symptoms such as changes in perception, attention 
and cognition which have psychological significance, will activate 
implicational models of self in relation to illness, for example beliefs 
concerning entrapment, shame, humiliation, loss and blame will have a state 
mediated role in the acceleration of relapse. 
Consequentially, CBT could work to reduce relapse by the systematic 
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identification and transformation of negative beliefs concerning self, and self 
in relation to illness. In addition, the model outlined above predicts that short- 
term vulnerability to relapse is mediated by the activation of implicational 
models of illness. Therefore delivering CBT during the early stages of relapse 
would provide an opportunity to transform such beliefs "in vivo". This would 
be much akin to the way in which CBT is delivered for other problems, for 
example, Panic Disorder. 
3.8 Summary and Conclusions 
There is growing evidence that CBT in combination with antipsychotic 
medication is effective in the treatment for individuals with schizophrenia. In 
particular its efficacy in the reduction of positive symptoms has been 
demonstrated (Tamer et al., 1993; Drury et al., 1996a, b; Kuipers et al., 1997; 
Tarrier et al., 1998; Pinto et al., 1999; Sensky et al., 2000). However, the 
evidence for CBT in the treatment of affective symptoms and in the prevention 
of relapse is less certain (Tarrier et al. 2000; Tarrier et al., 2001). Empirically 
there is strong evidence for a link between affective symptoms and relapse 
reviewed in Chapter 2. In light of this, psychological models of co-morbidity 
and of relapse were considered. In relation to co-morbidity, there is strong 
evidence that post-psychotic depression is related to negative beliefs about 
blame, entrapment, humiliation, shame and loss associated with illness (Iqbal 
et al., 2000). 
Psychological models of relapse (Thurm & Haefner, 1987, Birchwood, 1995; 
Gumley et al., 1999) emphasise that individuals' prior experience and current 
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attributions or beliefs about psychosis are potentially key factors in the 
development and acceleration of relapse. In addition, Fowler et al., (2000) 
propose that vulnerability to developing threatening reactions to psychosis 
arises from an interaction between premorbid beliefs, assumptions and 
experiences, and the subjective experience of psychosis. In this analysis, 
individuals with a history of trauma, low self-esteem etc, will be 
psychologically vulnerable to negative illness course. Furthermore, 
psychological models of psychotic symptoms emphasise attributions (e. g. 
Bentall, 1990; Morrison et al., 1995), negative beliefs (Chadwick and 
Birchwood, 1994; Birchwood et al., 2000), biases in reasoning and judgement 
(Garety & Hemsley, 1994), and attentional biases (Kinderman, 1994). 
Given that there is considerable evidence to suggest that psychological factors 
play an important role in the initiation, acceleration, and maintenance of 
psychosis, CBT could be employed as an individually tailored strategy, with 
the aim of preventing or ameliorating relapse. Chapter 4 will now outline a 
treatment protocol for CBT for relapse based on the review contained within 
this chapter. 
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Chapter 4 
Targeting Cognitive Behaviour Therapy for relapse: A treatment protocol 
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4.1 Cognitive Behavioural Therapy (CBT) for Psychosis 
Existing treatment manuals of CBT for psychosis emphasise the psychological 
treatment of positive symptoms, negative symptoms and co-existing anxiety 
and depression (Kingdon & Turkington, 1994; Fowler et al., 1995). These 
manuals detail specific relapse prevention strategies delivered towards the end 
of treatment. Kingdon & Turkington emphasise the identification of stressors, 
which may trigger relapse, the development of a relapse profile which include 
signs and symptoms indicative of relapse, and the development of a range of 
response options, for example medication adherence, seeking help, and coping 
skills developed during treatment. Fowler et al., provide specific strategies, 
introduced at the end of therapy, aimed at addressing social disability and risk 
of relapse. These strategies are embedded in the development of a normalising 
rationale and a personal formulation of the individual's illness experience. The 
aim of this phase is to establish hope, develop medium term and long term 
goals, and address any continuing misconceptions regarding diagnosis. 
Reattribution strategies are specified to reduce self-blame associated with 
social disabilities. For example, individuals may blame themselves, or feel 
blamed for negative symptoms. Provision of education regarding negative 
symptoms is utilised to correct any misconceptions. In addition, individuals 
are encouraged to actively participate in the management of their illness. The 
importance of using medication, and the use of strategic avoidance during 
times of increased stress or symptoms are highlighted. 
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4.2 Theoretical background to CBT for relapse 
Given that relapse in schizophrenia is often associated with adverse events, 
individuals will frequently recall their experiences of relapse as being 
traumatic and distressing. For example, McGorry et al., (1991) found that 35% 
of their participants displayed symptoms consistent with Post Traumatic Stress 
Disorder 11-months following their first episode. Many cited their hospital 
admission as a major cause of their traumatic experience. Meyer et al., (1999) 
found that the symptoms of acute psychosis were stronger predictors of 
traumatic reactions, than the use of coercive measures to implement and 
provide treatment (e. g. compulsory hospital admission). Indeed the first and 
subsequent episodes will be associated with substantial feelings of loss 
(Erikson et al., 1999), disappointment, fear, shame and humiliation (Jackson & 
Iqbal, 2000). Furthermore experiences of hospital admission and subsequent 
treatment can be confirmatory of these feelings. For example, previous 
attempts at help seeking may have resulted in adverse consequences for the 
individual such as increased side effects due to increased medication or 
emergency admission to hospital. 
MacGlashan (1987) has proposed that individuals' coping, as part of their 
recovery from psychosis, can be characterised on a continuum between 
"sealing over" and "integration". Sealing over is characterised by a coping 
style where individuals isolate their experience of psychosis. The experience 
tends to be viewed as alien and incompatible with their life experience and 
goals. Individuals who seal over tend not to explore their experiences but 
maintain awareness of the negative aspects of psychosis. On the other hand, 
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integration is characterised by an awareness of continuity between life 
experience and psychosis. Individuals who integrate tend to be explore their 
psychotic experience, and are more likely to take responsibility for their 
thinking during psychosis. Jackson et al., (1998) found that those individual's 
who sealed over and refused psychological intervention were less likely to be 
aware of, or accept their disorder, but were also less likely to be depressed. 
Sealing over may therefore represent an attempt to deny and avoid reminders 
of illness, and given the advantage for reduced depression, has adaptive 
qualities. Jackson & Igbal (2000) suggest that the impact of psychosis can be 
understood with reference to trauma theory (e. g. Janoff-Bulman, 1992) and 
propose that psychosis can act to undermine or indeed "shatter" pre-existing 
assumptions about self, world and future, or indeed, for those who have 
experienced early adversity, psychosis may confirm premorbid beliefs 
concerning personal vulnerability and negative evaluation. Drayton et al., 
(1998) found that those individuals who seal over or deny significant aspects 
of their illness were more likely to view their early experience of parenting as 
less caring, than those who were categorised as integrators. In this sense, 
sealing over may represent a marker of psychological vulnerability arising 
from the interaction between early experience and psychosis, as proposed by 
Fowler et al., (2000). 
An alternative conceptualisation of integration and sealing over which may 
explain the interaction between the individual and their psychosis, and the 
behavioural, cognitive and emotional consequences of psychosis are the 
processes of "assimilation" and "accommodation". Assimilation refers to the 
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process whereby information is altered and distorted to fit into pre-existing 
beliefs. Accomodation on the other hand involves changing existing beliefs to 
accept new information. Hollon and Garber (1988) propose that 
accommodation is necessary for successful integration of a traumatic event. 
Resick and Schnicke (1993) has also proposed that trauma interacts with 
individuals' pre-existing beliefs concerning self, world and future, and that in 
response to a trauma individuals may reject their pre-existing beliefs 
(overaccomodation), or distort the trauma to fit with their pre-existing beliefs 
(assimilation). Overaccomodation involves a radical change in underlying 
beliefs and assumptions, for example an individual who viewed themselves as 
competent and safe prior to psychosis, may view their illness as highly 
dangerous, and as meaning they have no control. This would therefore give 
rise to high levels of fear concerning relapse. Assimilation, on the other hand, 
represents an individual's attempt to preserve their pre-existing beliefs, despite 
their experience of psychosis. For example the same individual, may use 
cognitive strategies aimed at minimisation (e. g. "It didn't happen", "It 
happened because I wasn't eating properly") or behavioural strategies aimed at 
avoidance. Whilst this strategy may lead to reduced depression in the short 
run, the cost may be a corresponding reduced awareness of relapse risk, 
excessive and unnecessary avoidance, and reduced control of illness in the 
longer run. 
The processes of assimilation and overaccomodation can also explain the 
development of shame and humiliation attributions following psychosis and 
the development of secondary depression. For example, an individual who 
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believes "good things happen to good people, bad things happen to bad 
people" may respond to the experience of their psychosis with 
overaccomodation (e. g. "It doesn't matter what I do, bad things will happen to 
me") leading to increased helplessness and hopelessness, or assimilation (e. g. I 
must have done something wrong to have deserved this") leading to increased 
self blame and shame. According to this formulation, what is critical is the 
interaction between the individuals' pre-existing beliefs concerning 
themselves, the world and future, the occurrence of psychosis as a critical 
incident, and the individuals' attempt to assimilate or accommodate their 
experience. 
4.3 Overview of CBT for relapse 
A description of a treatment protocol for the use of CBT in relapse prevention 
has been detailed in Gumley and Power (2000) and is summarised below. CBT 
for relapse is divided into two phases. An engagement phase is delivered over 
5-sessions. A targeted phase is delivered at the appearance of early signs of 
relapse. 
Phase one of CBT for relapse focuses on engagement and formulation of the 
key psychological factors and early signs that might be associated with 
initiation or acceleration of early relapse. Phase one begins with an 
explanation of the cognitive model of relapse, which emphasises the 
occurrence of early signs of relapse, and the triggering of negative beliefs 
concerning relapse. An explanation of the potential role of these beliefs in 
accelerating relapse is given. Individuals are encouraged to test this model of 
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relapse through the exploration of previous experiences of relapse. During the 
examination of previous relapse experiences, individuals and therapist 
collaboratively identify negative beliefs concerning self and illness experience 
and the historical antecedents of these beliefs. This procedure enables the 
development of an individualised case formulation of the cognitive factors and 
their associated early signs involved in relapse acceleration. At the end of this 
intervention phase, both individual and therapist construct an idiosyncratic 
early signs monitoring questionnaire, and it was agreed to monitor these early 
signs on a fortnightly basis. A detailed description of the individualised early 
signs monitoring procedure is available in Tait et al., (2002). Every two weeks 
individuals' questionnaires are dispatched by post. Individuals are instructed 
to complete and return their questionnaires using a stamped addressed 
envelope enclosed for their use. 
There were two main routes to the initiation of Targeted CBT. First, an 
assessment for targeted CBT was initiated if there were increases in 
individuals' self-reported early signs. Prior to the initiation of this assessment, 
the therapist liases with the individuals keyworker in order to, where 
appropriate, discuss and co-ordinate any possible interventions. Second, if 
individuals' keyworkers report symptom changes or circumstances/ stressors, 
which are suggestive of an increase in relapse risk, an assessment for 
Targeting is initiated. 
Session one of Targeted CBT involves a detailed assessment of the evidence 
of and against emerging relapse. The purpose of this assessment is twofold (1) 
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to identify potential false alarms, and (2) to provide a test of the case 
formulation developed during the engagement phase. The therapist 
collaboratively elicits negative beliefs concerning relapse, and these beliefs are 
prioritised according to their importance and associated distress rated by the 
participant. In order to reduce individuals' fear or helplessness associated with 
early relapse, early signs are reframed as an opportunity to develop mastery 
over an apparently uncontrollable and inevitable process. 
Where early relapse is associated with non-adherence with prescribed 
medication, positive and negative beliefs about adherence and non-adherence 
are elicited and summarised. Where individuals wish to continue to avoid 
medication, they are encouraged to treat their non-adherence as an opportunity 
to conduct an experiment with not taking medication. Anticipated benefits and 
problems are considered. Where problems are anticipated, the implementation 
of existing or potential coping skills is discussed, and assistance is given to 
individuals in rehearsing and implementing these. In addition, as part of this 
experimental approach to treatment thresholds for reinitiating medication are 
agreed. 
In other circumstances, the negative beliefs associated with relapse are 
examined. Alternative beliefs of relapse as a controllable process are 
developed in collaboration with the individual. These alternative beliefs are 
tested using within and between session behavioural experiments. Behavioural 
experiments involve strengthening existing coping skills or developing novel 
coping strategies. The outcomes of experiments are then used as evidence for 
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and against alternative beliefs concerning relapse. Emphasis is given to 
developing strategies to counter ruminative withdrawal, avoidance, criticism 
from others, and the use of alcohol and illicit drugs. In addition, cognitive and 
behavioural strategies are employed to reduce intrusive cognitive phenomena 
such as flashbacks to previous episodes. 
Targeted CBT is terminated when early signs have reduced to baseline levels. 
Targeted CBT is concluded by a review of strategies employed during 
treatment, and an examination of the evidence for and against participants' 
negative beliefs and their alternative beliefs concerning relapse. 
4.4 Therapist Style 
A key assumption of CBT for relapse is that the development of beliefs 
concerning relapse have arisen from traumatic or distressing illness 
experiences, and individuals' beliefs about their illness are adaptive to that 
experience. This has immediate consequences for the therapist and therapeutic 
alliance. The therapist may encounter hostility or suspiciousness regarding the 
focus on relapse, depending on the individual's previous treatment experience. 
The therapist therefore adopts a supportive, empathic, and validating 
approach. The therapist makes frequent summaries to check for accuracy of 
understanding. Careful assessment of negative treatment experiences is made; 
in particular negative experiences concerning relapse, emergency or 
compulsory admissions to hospital are elicited. The therapist adopts a non- 
judgemental role, balancing validation of the individual's experience without 
making evaluative statements regarding other service providers. 
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4.5 Assessment and engagement 
Assessment and engagement is conducted over 5-sessions. The aim of the 
assessment and engagement phase is the development of a therapeutic 
alliance, the identification of barriers to early intervention, the development of 
an early signs hypothesis informed by cognitive behavioural formulation, and 
the engagement in early signs monitoring. The initial interview is crucial to 
the identification of individuals' principal concerns and problems related to 
relapse, and potential barriers to engagement as described below. The therapist 
makes a careful assessment of the individual's view of their experience, their 
attitude to their illness, and their readiness to discuss their experience and 
symptoms. 
4.6 Identification of Barriers to Engagement 
Early in the process of engagement, the therapist should consider a number of 
specific potential barriers to engagement. These possible barriers include the 
individual's style of coping (for example, minimising or denying significant 
aspects of illness experience), the presence of traumatic reactions to psychosis, 
and the development of shame and self blaming attributions concerning 
illness. Clearly, whilst these factors might act as barriers to engagement, they 
are also relevant to the development of an individualised formulation of 
relapse, including the identification of factors which may act against early and 
prompt intervention. 
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4.7 Formulation 
Formulation is of central importance within CBT. It provides the individual 
and therapist with a guide to the key cognitive behavioural factors involved in 
relapse, and attempts to make sense of the pattern of early signs experienced 
during the early stages of relapse. The experience of acute psychosis as a 
critical incident lies at the centre of the case formulation approach for targeted 
CBT. It is proposed that the beliefs and assumptions, which arise from this 
experience, represent the individual's attempts to accommodate and assimilate 
their experience, and that these beliefs may represent an enduring cognitive 
vulnerability to relapse. The Cognitive Interview for Early Signs (Figure 4.2) 
provides a prototypic guide and summary to the processes involved in the 
development of the formulation. During this process the therapist's skills in 
pacing and being alert to subtle changes in mood, eye contact and behaviour 
are most important. This is because the individual is being asked to recollect 
previous episodes of acute psychosis and hospitalisation. This interview 
utilises cognitive techniques to facilitate the development of an early signs 
hypothesis. Gumley et al's., (1999) model of relapse predicts that the 
activation of negative beliefs about self and illness serve to accelerate the 
transition into acute psychosis. Therefore this interview aims to elicit 
important beliefs and assumptions which may be relevant to relapse by 
identifying specific memories associated with previous episodes. The 
individual and therapist may choose to focus on the last episode of psychosis 
or another which may have more personal significance to the individual, for 
example the first or second episode. 
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Figure 4.1 Interview procedure for eliciting early signs 
Cognitive Interview for Early Signs 
ESTABLISH DATE OF LAST RELAPSE 
ESTABLISH ONSET OF EARLY SIGNS 
CHOOSE EVENT DURING PERIOD BETWEEN ONSET OF EARLY SIGNS AND 
RELAPSE 
Prototypic questions: 
When talking about your last relapse is there a particular memory that comes to mind? 
At what point did this occur? 
Are their other events, which come to mind? 
ESTABLISH TIME LINE FOR EVENTS IN RELATION TO ONSET OF EARLY SIGNS 
AND RELAPSE 
ESTABLISH EVENT ASSOCIATED WITH `HOT' COGNITIONS 
Prototypic questions: 
Which of these events distresses you most? 
If only one of these events occurred which would have been the most upsetting? 
Why is that? 
ELICIT MEMORIES AND IMAGES ASSOCIATED WITH THE EVENT? 
Prototypic questions: 
What was so upsetting about that? 
Are there thoughts and images, which come to mind? 
Can you describe these? 
GUIDED DISCOVERY TO ESTABLISH MEANING 
What does that event mean to you? 
What was the worst thing about that? 
ELICIT COGNITIONS RELATED TO SELF, AND SELF IN RELATION TO ILLNESS 
What does it say about your illness? 
Do you still think that? 
How does it make you feel about your illness? 
LINK EVENT AND MEANING THROUGH COGNITIVE, PERCEPTUAL, AND 
PHYSIOLOGICAL EXPERIENCE 
When you think about that now how do you feel? (Probe cognitive, perceptual and physical 
experience? 
What do / did you notice about your thoughts? 
What do/ did you notice about your body? 
FORMULATE AND SUMMARIZE BY LINKING EVENT, INTERNAL EXPERIENCES, 
BELIEFS AND EMOTIONAL/ BEHAVIOURAL SEQUELAE 
TEST CONFIGURATION OF SYMPTOMS AGAINST PREVIOUS EPISODES AND 
ADJUST AS NECESSARY. 
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The therapist and individual construct a time line between the onset of early 
signs and the initiation of acute psychosis on which relevant and personally 
significant events are "pegged" to the process of relapse. Birchwood et al., 
(2000) have described similar methodology. However, extending this 
methodology, the therapist collaboratively elicits and prioritises, in terms of 
personal significance, events that the individual considers critical in the 
development and evolution of relapse. That is those events, which define the 
meanings that they attach to becoming unwell. Guided discovery is used to 
uncover the significance that the individual attaches to these memories, for 
example, "I have lost control" or "I've let others down". These beliefs are then 
linked to their associated cognitive, emotional, behavioural and physiological 
sequelae, for example fearfulness, shame, avoidance, increased tension and 
sleeplessness. The configuration of symptoms elicited associated with 
personal meanings is the used as a basis for the early signs hypothesis. This 
hypothesis can then be tested and evaluated by comparing the configuration 
and timing of symptoms in relation to previous episodes of relapse. The 
information gathered by the therapist and individual is then used to develop an 
idiosyncratic early signs questionnaire. Relevant beliefs and assumptions are 
included in this scale in order to help "bind" the apparent variance in 
symptoms. 
4.8 Explaining beliefs 
Beliefs are regarded as arising from the individual's attempts to either 
assimilate or accommodate their experience of psychosis with their pre- 
existing beliefs and assumptions. These beliefs act like rules, which contain 
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predictions about the significance and consequences of internal or external 
events. Accordingly, the occurrence of experiences reminiscent of previous 
episodes of psychosis will have implicational meaning for the personal 
relevance of these beliefs. For example, during the early stages of relapse 
physiological changes including increased tension in the head, neck and 
shoulders might be experienced as if their head is growing out of proportion to 
their body. Their beliefs about this experience, for example, "I'm loosing 
control", "people will start staring at me", "I'm vulnerable", "People attack 
folk who look vulnerable" are elicited. The impact of these beliefs on relapse 
can be explained with reference to systematically identifying their 
disadvantages or consequences. 
Th: You told me when you feel your body changing, you begin to think 
that you are loosing control, that your vulnerable, and that people will 
harm you. When you think that how does that make you feel? 
P: I get frightened. I can't think properly and I can't go out. 
Th: What frightens you most? 
P: It's the thought of not having control. I need to have control or I'll 
become unwell and end up in hospital. 
Th: Is there anything else that frightens you? 
P: It's the thought of looking like a freak. People will see and will attack 
me. I won't go out, unless it's really late at night. 
Th: Is there anything else you do when you feel like that? 
P: I can't sleep at night. I clean all the time to keep my mind off things 
but I keep thinking about it. I have to check myself in the mirror. It's 
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got really bad before. I remember feeling this pain in my stomach. I 
thought there was an animal inside me, and it was going to eat itself 
out. 
The trauma associated with the experience of psychosis, in this example, is 
self-evident. This individual describes the implicational meaning of changes in 
her body. These changes are associated with strong beliefs concerning control 
and vulnerability to harm by others. Indeed these core themes are continued 
and contained in the evolution of delusional beliefs associated with their acute 
psychosis. The formulation of this example is contained in Figure 4.2 below. 
The formulation is the key means of communicating the relevance of beliefs in 
relation to personal experience and the acceleration of relapse. This 
formulation also contains the key early physiological, emotional, behavioural 
and cognitive signs of relapse, described diagrammatically to assist the 
individual in making sense of the process of relapse. 
4.9 Early Signs Monitoring 
The formulation of an early signs hypothesis informs the development of an 
individualised early signs questionnaire, which integrates the cognitive, 
emotional, behavioural and physiological factors which characterise the 
evolution of relapse. Individuals are asked to complete their early signs 
questionnaire on a fortnightly basis. Early signs questionnaires are dispatched 
by post with a stamped addressed envelope for use by individuals. Targeted 
CBT for relapse is initiated following an increase in early signs suggestive of 
relapse. 
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Figure 4.2 Case Formulation for Targeted CBT 
Experience of Psychosis 
Beliefs 
I have no control over my illness 
If I appear vulnerable, then people will harm me 
1 Activating events 
Feeling my body changing 
Thoughts Emotions Behaviour Physical 
I've no control Fear Avoidance Sleeplessness 
I'm vulnerable Suspiciousness Cleaning Poor concentration 
People will harm me Helplessness Checking 
I'm relapsing 
4.10 Targeted Cognitive Behaviour Therapy 
Targeted CBT is a brief intervention delivered during the early phase of 
relapse. Given the nature of relapse, the opportunity for intervention is limited. 
Therefore the strategies employed during treatment are designed to (a) 
minimise risk, (b) reduce the speed of the relapse process, thereby (c) 
increasing the window of opportunity to prevent the occurrence of a relapse. 
Targeted CBT is initiated when there has been an increase in early signs of 
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relapse or if there is evidence of psychosocial stressors which are likely to 
confer increased relapse risk, for example, the loss of a loved one or being 
assaulted. 
4.10.1 Order of treatment tasks 
Treatment tasks are prioritised at the beginning of targeted CBT according to 
the careful assessment and identification of evidence of risk of harm to self 
and / or harm to others. Once these priorities have been addressed treatment 
can move to addressing other treatment priorities. The general order of 
treatment is illustrated in Figure 4.3 below. 
Figure 4.3 Order of treatment tasks 
1 
Identify and target behaviours which increase risk to self or others 
2 
Identify and target beliefs and behaviours accelerating relapse 
1 
3 
Identify alternative beliefs and reinforce through behaviour 
change 
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4.10.2 The Initial Interview for targeted CBT 
The initial interview begins with a brief review of the individual's early signs, 
and the identification of any other problems or symptoms, including checks 
for risk of harm to self or others. The therapist and individual prioritise 
problems identified in the review for the session's agenda. Problems and 
symptoms identified in the review are examined in relation to concerns 
regarding relapse. The evidence for and against relapse is considered in 
relation to the formulation developed during the assessment and engagement 
phase. In addition, given that relapse is likely to be associated with heightened 
arousal, high levels of fear and anxiety, and catastrophic thoughts, the 
therapist takes particular care in pacing the initial and subsequent targeted 
sessions. The pace of the session is deliberately slowed in order to identify 
salient beliefs, and indeed to provide a model of a non-catastrophic reaction to 
emerging relapse. 
4.10.3 Testing the formulation 
A critically important therapist task at the beginning of targeting is the 
identification of evidence for and against emerging relapse. This procedure 
has three functions including (a) the careful assessment of relapse risk, (b) 
assisting the individual in taking perspective on their experience, and (c) 
clarification of the relapse hypothesis. This procedure also provides an 
opportunity for the therapist and individual to critically evaluate the accuracy 
of their formulation. This test can be undertaken using a number of strategies. 
First the accuracy of the formulation can be evaluated by comparing the nature 
and pattern of current early signs, with those predicted by the formulation 
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itself. Second, variations between expected and current experience are 
examined in terms of the individual's appraisal of their early signs in terms of 
their current beliefs about relapse, and their recollections of previous relapses. 
Third similarities between current and prior experience can also be evaluated. 
4.10.4 Decatastrophising Relapse 
During the initial session the therapist prioritises any catastrophic beliefs 
concerning relapse. This is an important clinical priority, as catastrophic 
beliefs will increase physiological arousal and fear, thereby accelerating the 
speed at which a potential relapse progresses. A number of techniques can be 
useful in decatastrophising relapse. First, relapse can be reframed as an 
opportunity for new learning. In particular, historical evidence concerning 
delayed intervention for relapse can be employed to underline the current 
opportunities, which may arise from early intervention. On the other hand, 
previous experiences of failed early intervention can be examined in terms of 
identifying additional procedures, which may have been helpful. Second, the 
therapist can further work with the individual to highlight the advantages and 
disadvantages of early intervention. The results of this can be compared to 
previous experience. Third, the therapist can elicit experiences where 
individuals have sought help and / or employed coping skills, which have 
prevented or reduced the severity of relapse. Evidence of this can be 
discovered, by asking the individual to recall previous experiences where early 
signs have been experienced without a subsequent relapse. Whilst this 
procedure allows the therapist to evaluate the probability of the current 
episode being a false positive, it also enables the identification of particular 
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coping skills employed by the individual, which have been helpful. Fourth, the 
therapist remains vigilant throughout for evidence of increased affect. 
Evidence of increased affect within session is explored by the therapist in 
order to elicit other negative beliefs concerning self, illness, others and future 
which may be relevant to relapse, or acting as barriers to reframing relapse 
itself. 
4.10.5 Contracting intervention 
At the end of the initial session, targeted CBT is contracted on the basis of the 
evidence collected concerning relapse probability. The rationale for CBT is 
made on the basis of the accuracy of the original or adapted formulation, 
which provides a focus for targeting key beliefs and behaviours, which seem 
to be relevant to the relapse process. For example, in explaining the rationale, 
it can be useful to feedback the relationship between the catastrophic thoughts 
which have arisen from negative experiences, and the acceleration of 
increased fear, arousal, and sleeplessness. The use of metaphor can be helpful, 
where the relapse process is compared to an engine that becomes engaged by 
frightening thoughts, memories, and beliefs, which increase the speed of 
unpleasant emotions and feelings. By learning new or strengthening existing 
coping strategies, this engine can be slowed down, or disengaged. The purpose 
of the metaphor also enables the introduction of realistic hope of increased 
control over relapse. 
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4.11 Subsequent sessions 
4.11.1 Identifying the most emotionally salient beliefs 
As described, the therapist remains vigilant for any changes in affect, and 
follows changes in emotion as signals that a particular belief is active. 
Changes in emotion provide an opportunity to gently enquire about any 
thought and / or images that the individual is experiencing. Ascertaining the 
meaning of events is a crucial procedure. Whilst increased emotion and 
distress is an obvious consequence of early relapse, the meaning of the event 
needs to be established. An example of this process is illustrated below. 
Th: You look distressed just now. What is the worst thing about what you 
are experiencing? 
P: I don't know. I'm so confused, I can't think properly; it's all too much 
for me. 
Th: You feel confused, you can't think properly, and it feels too much. 
(Summarise to slow pace) Which one of those things upset you most? 
P: It's not being able to think. It's like there's nothing I can do. 
Everything feels out of control. I'm scared that I'll get unwell. 
Th: I can see why you feel so distressed (therapist provides validation). 
When you feel confused and unable to think properly, this means that 
you feel you can't do anything, that you have no control, and that you 
will become unwell. Have I got that right? (Check for accuracy) 
P: Yes, (tearful) I have no control over what's happening. That's what it's 
like (relapse). It's like something just takes over me, everything speeds 
up, and I can't do anything about it. 
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Making specific enquiries about the nature and presence of imagery can be 
helpful in ascertaining the meaning and psychological significance of early 
relapse. Given that relapse experience can be traumatic, the therapist needs to 
be aware of evidence of intrusive imagery in relation to previous events, and 
that individuals' may describe images in an over general manner (cognitive 
avoidance). An example of this process is given below. 
Th: You say that you've been thinking about the last time you were unwell. 
Is there a particular aspect of that memory that sticks in your mind? 
P: I remember my Mum shouting at me. She was screaming; it didn't 
make any sense. I could hear the voices. They were mad too. The noise 
wouldn't stop. 
Th: Can you see that in your mind as your speaking? 
P: (Looks away) I could hear the voices. They were telling me how bad I 
am. My Mum's face was red. I can see her eyes. She looked really 
angry. She was shouting, but I don't know what she was saying. 
Th: What does that image mean to you? 
P: I've let her down again. I'm a disappointment to her. I'm no good. 
Th: In this image you can see your Mum shouting, you remember the 
voices, but you don't know what your Mum was saying. This image 
means something to you which is distressing, that is that you've let her 
down, that you're no good, and that you're a disappointment. Is this 
how you think about yourself when you're worried about relapse? 
P: Yes, its like if I get unwell, then I've let her down again. 
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The therapist is careful and supportive in eliciting key thoughts, beliefs and 
images, which occur during relapse. It is important for the therapist to ensure 
that they have a reasonable sample of cognitions in order not to miss any 
salient concerns. However, the vast number of thoughts and images, which 
occur during early relapse can, understandably, be overwhelming to both 
individual and therapist. This difficulty can be addressed by identifying the 
most salient cognition. Most simply this can be achieved by asking which 
thought or image is most upsetting. On the other hand careful documentation 
of thoughts, beliefs and images can then enable the therapist to invite the 
individual to systematically rate the distress associated with each. By this 
means the most salient cognition or cognitions can be identified. Furthermore, 
the therapist can undertake reliability checks by verifying the relationship 
between specific thoughts and the principal emotions, physiological reactions, 
and behaviours associated with the relapse process. 
4.11.2 Introducing flexibility into beliefs 
Beliefs during early relapse can be absolute, acting like unconditional core 
beliefs, for example, "I have no control", and "I am bad". Critical to the 
process of decelerating the speed of relapse is the introduction of flexibility 
into such beliefs through identifying situations where that belief is true or 
untrue. However, if the individual states that it is true in all situations, then the 
eliciting evidence for the belief can be used as a means of introducing 
flexibility. This evidence is then utilised to create conditions where the belief 
is true for the individual, thereby creating a conditional belief. An example of 
this process is given below. 
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Th: You say that you have no control. Can you tell me what makes that 
true for you? 
P: My thoughts are going too fast, I can't think. I can't talk to people 
properly. There's nothing I can do. 
Th: Are there other things that make you feel that you've no control? 
P: Yes. Thoughts keep coming into my head (looks away), they're awful. 
It's like I've harmed someone. I can see my sister lying dead. 
Th: How does that make you feel? 
P: I'm doing something wrong, something bad is going to happen if I 
don't stop it. 
Th: Let me see if I've got this right. Because your thoughts are going too 
fast, you can't think right, and awful thoughts keep coming into your 
mind this makes you feel that you have no control. Is that right? 
P: Yes I can't stop what is happening in my head. 
Th: So "If you can't stop what is happening in your head, then you have no 
control". Does that feel right to you? 
P: Yes, that's it, it's what's going on inside my head that is so bad. 
Here the therapist balances validation of the belief, with an enquiry into the 
conditions at activate the belief and make it "feel" true. Creating conditions 
attached to the belief facilitates the implementation of strategies to transform 
the belief. Some examples of conditional beliefs that are associated with 
relapse acceleration are given in Table 4.1 below. These beliefs bind the 
personal experiences of relapse (e. g. changes in thought, emotion, physiology, 
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cognition and behaviour) to consequences for self (e. g. loss of control, failure), 
world/ others (e. g. anger, punishment), and future (e. g. hospital admission). 
Table 4.1 Conditional beliefs during relapse 
If I relapse, then others will be disappointed in me. 
If I loose control of my thoughts, then I'll relapse. 
If I don't cope, then I will relapse 
If I relapse, then I'll end up in hospital 
If I tell someone I'm not well, then they'll be angry with me 
If I get unwell, then I'll be punished 
If I relapse, then I am a failure 
4.11.3 Transforming beliefs 
Given that a key assumption of targeted CBT is that the beliefs developed 
concerning relapse emerge as a result of negative experiences, these beliefs are 
seen as contextually adaptive. During this process the therapist may identify a 
number of conditional beliefs. This is dealt with by identifying which belief is 
associated with the strongest emotion, for example by rating each belief for 
the amount of distress associated with it. In addition, the therapist does not 
necessarily take a challenging approach to these beliefs. Rather, the therapist 
examines the evidence supporting these beliefs in order to establish their 
function for the individual. For example, the belief "If I do not control my 
thoughts, then I will become unwell" will result in a number of safety 
behaviours such as avoidance of situations that trigger intrusive thoughts, 
vigilance for changes in thinking, cognitive avoidance, or other thought 
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control strategies. The function of these safety behaviours is the control of 
thinking. Transforming beliefs involves establishing alternative assumptions 
that achieve the function (in this case control), without the costs associated 
with the former conditional belief. The therapist establishes the meaning of 
"control" and the parameters which determine control, for example whether 
perceived control governed by the individuals cognitive experience alone, 
whether there are other factors which influence perceived control, and 
importantly, whether there are alternative behaviours that can enhance the 
individual's sense of control. By identifying an alternative, or existing 
behaviour that enhances sense of control, this behaviour can be used to bind a 
new belief. The importance of using behaviour to transform and develop 
alternative beliefs is related to the subsequent use of behavioural experiments 
to test transformed beliefs. In this way the therapist does not challenge the 
logic or truth of the former belief, but works with the individual to develop 
alternative beliefs. An example of this process is given below. 
Th: You say, "If I do not control my thoughts, then I will become unwell". 
Could you tell me how that belief is helpful to you? 
P: It means I won't get unwell. 
Th: Are there other ways this belief is helpful to you? 
P: Well... I suppose it means that I feel better, I feel more in control of 
my head. 
Th: OK, so this way of looking at your thoughts means that you're less 
likely to get unwell, you feel better and feel more in control. Is there 
anything else that is helpful about this belief? 
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P: I don't think so, but I never seem to feel better, and I get unwell 
anyway. 
Th: OK whilst this belief can be helpful for you, it doesn't work all the 
time. Are there disadvantages to having to control your thoughts? 
P: It's really hard, the harder I try the harder it gets. I worry about what 
I'm thinking, and I can't go outside because I might start getting 
upsetting thoughts, other people might notice. I get really depressed 
about it. 
Th: So this is really hard for you, it leads you to worry about what you're 
thinking, worry of other people will notice, so you don't go outside, 
and you get really depressed. So rather than avoiding upsetting 
thoughts altogether, what if you felt as if you could cope better with 
upsetting thoughts? How would that be? 
P: I'm not sure. I don't like getting these thoughts. 
Th: (therapist checks parameters of control) All right so when you say that 
you would like to control these thoughts what do you mean by that? 
P: Well I mean not get them at all, I should be able to control my thoughts 
all of the time. 
In this example the therapist decides to address the belief that all thoughts 
should be controlled and provides some explanation of the difference between 
voluntary (e. g. planning a shopping list) and involuntary thoughts (e. g. 
negative automatic thoughts or intrusive thoughts in reaction to stress). 
Information is provided and discussed on the frequency of intrusive thoughts 
in the general population, and the role of thought suppression in producing 
155 
Targeting Cognitive Behaviour Therapy for relapse: A treatment protocol 
rebound (Wells, 1997). A behavioural experiment investigating the effects of 
thought suppression is conducted within the session by asking the individual 
construct an image of a banana in their imagination and then to avoid thinking 
about bananas. Once the belief that all thoughts should be controllable is 
addressed, the belief that "If I do not control my thoughts, then I will become 
unwell" can be addressed. 
Th: So what kind of things help you feel more in control? 
P: Talking to my friend helps, when I'm not upset I feel more in control, 
having a drink helps me as well. 
Th: OK so what is it about these situations that make you feel more in 
control? 
P: I feel more relaxed. I still get upsetting thoughts but they don't bother 
me so much. 
Th: So what do you do in these situations when you get an upsetting 
thought? 
P: I think about something else or I distract myself by doing something. 
Th: So as a first step, rather than trying to abolish these thoughts altogether 
if you were able to ignore these thoughts what would that mean? 
P: I suppose I wouldn't get so upset. 
Th: And if you were less upset by them, what would that mean to you? 
P: I'd feel better. 
Th: So "If I can ignore unwanted thoughts, I will feel better"? Does that 
sound right? 
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At this point the therapist produces an alternative transformed belief, and as 
with the former belief (If I do not control my thoughts, I will become unwell), 
the therapist works with the individual to identify the advantages and 
disadvantages of this belief with respect to self and relapse. 
4.11.4 Testing transformed beliefs 
During the process of relapse individuals adopt a range of behavioural 
strategies aimed at increasing safety, preventing relapse or increasing control. 
For example common signs associated with early relapse include 
suspiciousness and vigilance, withdrawal and avoidance, use of alcohol and 
drugs. However, these "safety behaviours" may result in the acceleration of 
relapse, thus confirming individuals' beliefs concerning their helplessness, or 
the inevitability of relapse. 
Behavioural experiments provide an ideal methodology of intervention during 
this process. Behavioural experiments enable the individual to achieve a 
behavioural change (e. g. implementing a coping skill), which results in a 
cognitive change (beliefs concerning self or illness). Behavioural experiments 
can be conducted within session and between session. Furthermore 
behavioural experiments can be also graded according to difficulty. During 
CBT for relapse behavioural experiments are targeted on the development of 
alternative behaviours practised across a number of situations beginning with 
coaching within session to applying between session and in-vivo. The example 
given below continues from the example described in Section 4.9.3 above. In 
this example the therapist had begun with the belief that "If I do not control 
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my thoughts, then I will become unwell" and with the individual had 
transformed this to "If I can ignore unwanted thoughts, I will feel better". 
Th: Is there a way to test this belief out? 
P: I'm not sure, what do you mean? 
Th: Well, how could you find out if this belief is helpful to you or not? 
P: I suppose that I could try it out and see what happens. 
Th: OK that seems like a good idea. How could you do that? 
P: Well the next time I get an unwanted thought, I could try to ignore it 
and do something else. 
Th: What kind of problems might happen if you did that? 
P: Well other people might see that there's something going on, and they 
might get upset or angry. 
Th: OK, could anything else go wrong? 
P: I could get upset anyway, and then it wouldn't work. 
Th: All right then. There are two problems, first other people might notice 
and get upset or angry and you might get upset anyway. Why don't we 
try and address each of these in turn. Why don't you try this 
experiment without any other people around first, before trying it out 
in other situations. Maybe we could try it out just now? 
As behavioural interventions are implemented and practised, these changes are 
consolidated through the review and examination of individuals' beliefs 
concerning the control, stigma, shame, and / or fear associated with illness. 
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The therapist aims to assist the individual in accommodating new information 
gained during intervention into pre-existing assumptions concerning illness, in 
comparison with the beliefs tested during treatment. 
4.12 Summary and conclusions 
This chapter has described a treatment protocol for the prevention of relapse in 
schizophrenia. This treatment protocol is based on the review of the literature 
developed in Chapter 3 of this thesis. At the centre of this treatment protocol is 
the targeting of negative illness appraisals arising during early relapse phase. It 
is proposed that these appraisals represent key cognitive factors, which 
accelerate the speed at which relapse, evolves. These appraisals have their 
origins in the initial episodes of psychosis and have been associated with the 
development of post psychotic depression occurring following the first episode 
(Iqbal et al., 2000). 
It is hypothesised that delivering CBT using this protocol will result in 
reduced relapse, increased duration of survival without relapse, reduced 
severity of relapse, and reduced rates of admission to hospital. Chapter 5 
provides a description of the methodology and results of a randomised- 
controlled trial evaluating the effectiveness of delivering this treatment 
protocol with treatment as usual compared to treatment as usual alone. Given 
that the treatment protocol targets negative appraisals of psychosis and the 
behaviours associated with their maintenance, it is also hypothesised that the 
prevention of relapse will result in increased rates of remission and improved 
social functioning. Chapter 6 provides a description of the outcome of this trial 
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in terms of these outcome variables. Furthermore, I have proposed that 
negative appraisals of entrapment, shame, humiliation and loss associated with 
having psychosis are activated by internal or external events at the initiation of 
relapse. Given that these appraisals are associated with the development of 
psychological morbidity (Birchwood et al., 1993, Iqbal et al., 2000), the 
impact of CBT for relapse on psychological distress is investigated in Chapter 
7. Lastly, given my proposal that these appraisals play a role in the 
acceleration of relapse itself, Chapter 8 is an investigation of this hypothesis. 
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Chapter 5 
A non-blind randomised-controlled trial of targeting cognitive 
behavioural therapy on relapse in schizophrenia: I. relapse outcome at 12- 
months 
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5.1 Introduction 
Relapse in schizophrenia is a major factor associated with the development of 
residual symptoms, illness chronicity and social disability. Pharmacological 
studies demonstrate that maintenance antipsychotic medication is associated 
with reduced relapse rate when compared to placebo (e. g. Crow et al., 1986). 
In addition, maintenance medication is superior to intermittent medication in 
relapse prevention (Jolley et al., 1989; Carpenter et al., 1990; Herz et al., 
1989). In addition, maintenance medication plus early signs monitoring 
supplemented increased antipsychotic medication on the appearance of early 
signs superior to maintenance medication without early signs monitoring. 
(Herz et al., 2000). It has also been proposed that psychosocial interventions, 
when combined with antipsychotic medication, could reduce the risk of 
relapse in schizophrenia (Linzen et al., 1998; De Haan et al., 1998). 
Cognitive Behavioural Therapy (CBT) is one such intervention. CBT is a 
structured psychological therapy, which focuses on the identification and 
modification of problematic beliefs and behaviours that maintain and 
exacerbate specific difficulties. There is growing evidence that Cognitive 
Behavioural Therapy (CBT) is an effective treatment for individuals with 
schizophrenia. Five controlled trials of CBT for schizophrenia have been 
reported (Tamer et al., 1993; Drury et al., 1996a, b; Kuipers et al., 1997; 
Tarrier et al., 1998; Pinto et al., 1999; Sensky et al., 2000). All these trials 
have involved providing CBT in conjunction with antipsychotic medication. 
Four of these trials have examined the efficacy of CBT for drug resistant 
positive psychotic symptoms (Tarrier et al., 1993; Kuipers et al., 1997; Tamer 
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et al., 1998; Pinto et al., 1999; Sensky et al., 2000). One trial examined the 
efficacy of CBT delivered during the acute psychotic phase (Drury et al., 
1996a, b). CBT has been found to be superior to waiting list control (Tarrier et 
al., 1993), routine care (Kuipers et al., 1997), structured activity and informal 
support (Drury et al., 1996a, b), supportive counselling and routine care 
(Tarrier et al., 1998). Pinto et al., (1999) found that when combined with 
clozapine, CBT was superior to supportive therapy in combination with 
clozapine. Sensky et al. (2000) compared CBT to a befriending condition and 
found that at the end of treatment phase both had equal efficacy, however at 9- 
month follow-up the CBT group had continued to improve, while those in 
befriending did not. Three CBT trials provide follow-up data at 9-months post 
treatment (Kuipers et al., 1998; Sensky et al., 2000), at 12-months (Tamer et 
al., 1999), and 24-months (Tarrier et al., 2000). Kuipers et al., (1998) found 
that at 9-month follow-up those who had received CBT continued to improve, 
evidenced by significant improvements in delusional distress and frequency of 
hallucinations. Relapse rates at follow-up were not reported, although there 
was a non-statistically significant trend for CBT participants to have spent less 
time as psychiatric in-patients (Mean = 14.5 days versus 26. ldays). Sensky et 
al., (2000) also did not report relapse rates at 9-month follow-up although the 
CBT group continued to improve on measures of positive symptoms, 
depression and negative symptoms, compared to the befriending control group 
who had lost most of the treatment gains made during the treatment phase. 
Tamer et al. (1999) reported 12-month follow-up results for CBT compared to 
supportive counselling (SC) or routine care alone (RC). Participants in CBT 
continued to show significant treatment effects for both positive symptoms 
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and negative symptoms. Pairwise comparisons showed a significant effect for 
CBT over RC for positive and negative symptoms. There were non- 
statistically significant trends for positive and negative symptoms favouring 
CBT over SC. Unlike previous studies, Tarrier et al. did examine relapse rates 
pre-treatment and the 12-month post-treatment follow-up period (total 
duration = 15-months). A relapse was defined as a clinical deterioration or 
functional impairment, which resulted in a hospitalisation of five days or 
more, corroborated by casenote inspection. Of the original group of 87 
participants, 70 were successfully followed up. Amongst this group there were 
the following relapse rates; CBT (6/23,26%), SC (4/21,19%) and RC (7/26, 
27%). These differences were not statistically significant. Tamer et al. (2000) 
reported on the two-year follow-up of 61 (70%) of participants randomised to 
treatment. At two years there were significant differences for both CBT and 
SC over RC for positive symptoms. There was no significant difference 
between CBT and SC groups. Again for negative symptoms both CBT and SC 
showed significant differences with RC, but there were no significant 
differences between CBT and SC. Time to relapse was examined using 
Kaplan-Meier survival curves for treatment groups. There were no significant 
differences between CBT and SC, and these groups were combined for 
comparison with RC. The number of relapses was greater in the RC group 
(11/28,39%) compared to the combined group (13/59,27%). There was not a 
statistically significant difference between these groups on duration to relapse. 
Based on these findings there is strong evidence that CBT is effective in 
reducing the severity of psychotic symptoms resistant to medication (Tarrier et 
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al. 1993; Kuipers et al., 1997; Tarrier et al., 1998). When delivered during the 
acute phase, CBT is associated with improved rates of remission and increased 
speed of recovery (Drury et al., 1996a, b). Treatment gains associated with 
CBT are maintained at 9-months post-treatment (Kuipers et al., 1998; Sensky 
et al., 2000) and 12-months post-treatment (Tarrier et al., 1999). However, the 
differential effects of CBT on relapse rate are less clear, either because relapse 
rates are not reported by investigators (Sensky et al., 2000) or because broad 
definitions of relapse which rely on hospital admission statistics are described 
(Tarrier et al., 1999, Kemp et al., 1998; Tamer et al., 2000). In addition, these 
CBT studies have symptom reduction as their main clinical outcome and not 
the prevention of relapse, which was a secondary objective of these studies. 
Therefore there is a need to examine the efficacy of CBT in the prevention of 
relapse. The author knows of no other study, which has examined the 
feasibility or effectiveness of targeting CBT on the early signs of relapse. 
Therefore, the present study is an investigation of the feasibility and 
effectiveness of targeting CBT during the appearance of early signs of relapse 
in schizophrenia. The treatment protocol is based on the proposal that relapse 
is accelerated by a number of psychological factors including individuals' 
attributions for their psychotic experience (Birchwood, 1995) and their 
negative beliefs about self, relapse and psychosis (Gumley et al., 1999). Two 
hypotheses were tested. First, it was hypothesised that, over 12-months, CBT 
plus treatment as usual (CBT + TAU) would be associated with reduced 
relapse rate, increased time to first relapse, and reduced severity of relapse in 
comparison to treatment as usual alone (TAU). Second, predictors of relapse 
and duration to relapse were examined. It was hypothesised that, controlling 
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for treatment received, that participants' with stronger negative beliefs about 
themselves and their illness would be more likely to experience a relapse 
during the 12-months, and experience a shorter duration to relapse. 
5.2 Method 
5.2.1 Design 
This was a pragmatic clinical trial with random allocation and prospective 
follow-up over 12-months. The study compared treatment as usual alone 
(TAU alone) with Cognitive Behavioural Therapy plus TAU (CBT + TAU). 
The study was conducted between 1997 and 2000. The patients from the 
caseloads of 8 Community Mental Health Teams in the west of Scotland (6 in 
Ayrshire and 2 in Glasgow) were recruited into the study. The locality area for 
these teams includes a population of approximately 460,000 encompassing 
rural, suburban, and metropolitan areas. Inclusion required that patients 
fulfilled DSM-N (American Psychiatric Association, 1994) criteria for 
schizophrenia or a related disorder confirmed by the Structured Clinical 
Interview for DSM-IV (First et al., 1994), were receiving antipsychotic 
medication and were considered as relapse prone. Diagnostic interviews were 
carried out by a Consultant Psychiatrist (MO'G). Patients were considered 
relapse prone if they had one or more of the following characteristics, (1) a 
history of relapse in the last two years, (2) living in a stressful environment 
(e. g. a home environment characterised by high levels of expressed emotion), 
(3) living alone or socially isolated, (4) non-adherence with antipsychotic 
medication (where this is viewed as problematic by the participant's 
keyworker and/ or prescribing psychiatrist), and (5) being on a neuroleptic 
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dosage reduction programme. Patients were excluded if they were a non- 
English speaker, had organic brain disorder, presence of significant learning 
disability, severe persisting positive psychotic symptoms (rating of 5 or more 
on the positive scale of the Positive and Negative Syndrome Scale; Kay et al., 
1987), a primary drug or alcohol dependence disorder, or being in receipt of a 
concurrent psychotherapy outside the study. The sample size was calculated 
on the basis that a sample of 150 participants (75 per group), would have 80% 
power to detect at p<0.05 a reduction in relapse/ exacerbation rates from 50% 
in the TAU alone group to 25% in the CBT + TAU group (Pocock, 1975). 
Figure 5.1 shows that from the entire patient caseload of the 8 Community 
Mental Health Teams, 742 potential participants with a possible diagnosis of 
schizophrenia were identified. The casenotes of all these individuals were 
screened. A total of 505 individuals were deemed to be ineligible for the 
following reasons: 6 were deceased, 3 were outside the age range, 5 were not 
maintained on antipsychotics, 21 had moved out of area, 86 did not meet 
diagnostic criteria, 45 were deemed to be drug/ alcohol dependent, 135 were 
deemed to have severe drug resistant positive psychotic symptoms, and 204 
did not meet criteria for being relapse prone. From the remaining 237 potential 
participants, 24 were not approached by their keyworker to discuss the 
research, 15 were excluded by the Responsible Medical Officer because of 
severe instability of the individual's condition, and 38 refused consent, and 16 
failed to meet diagnostic criteria at formal entry assessment. The remaining 
144 were randomised to the TAU alone and CBT + TAU treatment groups. 
All participants provided written informed consent. 
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Figure 5.1 Recruitment and allocation of participants 
742 Casenotes Screened 
i 505 Failed to meet initial criteria 3 Outside age range 
5 No antipsychotic medication 
86 Incorrect diagnosis 
204 Not relapse prone 
6 Deceased 
21 Moved out of area 
45 Drug / Alcohol dependence 
135 Severe positive symptoms 
i 237 Fulfilled initial criteria 
93 Failed entry criteria at 
pretreatment assessment 
24 Not approached by keyworker 
15 Excluded by RMO 
38 Refused 
16 Diagnosis incorrect 
144 Allocated to treatment 
CBT + TAU (n = 72) 
TAU alone (n = 72) 
i CBT + TAU Withdrawn (n = 6) Followed up (n = 66) 
Entry (n = 70) 
12-weeks (n = 66) 
26-weeks (n = 66) 
52-weeks (n = 66) 
Completed Trial (n = 66) 
TAU alone 
Withdrawn (n = 5) 
Followed up (n = 67) 
Entry (n = 67) 
12-weeks (n = 65) 
26-weeks (n = 66) 
52-weeks (n = 67) 
Completed Trial (n = 67) 
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5.2.2 Withdrawals 
The 144 participants were randomised to TAU alone or CBT + TAU treatment 
groups. Randomisation was by means of a predetermined schedule, 
unbeknown to the assessors, therapist or participants. Following the diagnostic 
entry assessment a member of the research tern opened an envelope that 
informed as to which group individual participants were to be allocated. 
Another member of the team witnessed this procedure, and the envelope was 
placed in the participant's casefile. From the 144 participants, who originally 
entered the study, 11 dropped out within 12-weeks after entry (6 from the CBT 
+ TAU and 5 from the TAU alone). The final sample consisted of 133 (66 in 
the CBT + TAU and 67 in the TAU alone). Although the small numbers of 
withdrawals make comparison with completers difficult, the only significant 
difference between these two groups was that withdrawals had significantly 
higher levels of positive symptoms (t = -3.4, df = 135, p=0.001). 
Within the CBT + TAU group, three of the participants refused treatment, one 
participant relapsed and withdrew consent following the relapse, and two 
dropped out for uncertain reasons. In TAU two participants refused 
assessments and three dropped out for uncertain reasons. Therefore in order to 
err on the side of caution all `drop-outs' were treated as relapsed, for the 
purposes of the intention to treat analysis for relapse outcome at 12-months. 
5.2.3 Assessments 
Assessments were carried out at entry, 12-weeks, 26-weeks and 52-weeks 
using a battery of measures. Repeated measures were the responsibility of two 
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assessors who were trained Community Psychiatric Nurses (LM & JR). These 
assessors were independent but not blind to treatment. Additional cover for 
these assessments was provided by a Consultant Psychiatrist (MO'G) 
5.2.3.1 Positive and Negative Symptoms 
The Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987, 
Appendix A) was chosen as the main outcome measure. The PANSS is a 30- 
item observer rated scale. Each item is rated on a severity scale ranging from 1 
(absence of psychopathology) to 7 (extremely severe). The sum of the first 
seven items constitutes the positive scale score: delusions, conceptual 
disorganisation, hallucinatory behaviour, excitement, grandiosity, 
suspiciousness/ persecution and hostility. The sum of items 8 to 14 constitutes 
the negative scale score (e. g. blunted affect, emotional withdrawal). The sum 
of items 15 ' to 30 constitute the global psychopathology scale score (e. g. 
somatic concern, anxiety). The raters were trained using interviews with 
patients, either face to face or on video. Interclass correlations for the positive, 
negative and global subscales were 0.91,0.87,0.72 respectively and for the 
total score 0.80. 
5.2.3.2 Medication 
Given that both groups were being maintained on antipsychotic medication, it 
was important to exclude the possibility that differential improvement between 
CBT + TAU versus TAU alone groups was attributable to antipsychotic 
treatment. Therefore, data concerning maintenance antipsychotic medication 
were extracted from clinical records for the duration of the investigation. Total 
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dose of antipsychotic medication at each assessment was calculated as 
chlorpromazine equivalents in milligrams per day (Atkins et al., 1997). Type 
of antipsychotic medication was also noted. 
5.2.3.3 Psychological distress 
Psychological distress was measured using the Brief Symptom Inventory 
(BSI; Derogatis & Melisaratos, 1983, Appendix B). The BSI gives measures 
across nine symptom dimensions: somatisation, obsessive-compulsive 
symptoms, interpersonal sensitivity, depression, anxiety, hostility, phobic 
anxiety, paranoid ideation, and psychoticism. The BSI gives three global 
indices of distress: the Positive Symptom Total (PST), the Positive Symptom 
Distress Index (PSDI) and the Global Severity Index (GSI). The PST is simply 
a count of the symptoms which individuals report experiencing to any degree. 
The PSDI is an intensity of distress measure, corrected for the number of 
symptoms positively endorsed. According to Derogatis & Melisaratos (1983) 
PSDI functions as a measure of response style, communicating whether an 
individual is `augmenting' or `attenuating' distress in their manner of 
reporting. According to the authors, the GSI is the single best indicator of 
current distress levels. The GSI combines information on the numbers of 
symptoms reported, and the intensity of perceived distress associated with 
those symptoms. 
5.2.3.4 Negative appraisals of psychosis 
Negative appraisals of psychosis were assessed using the Personal Beliefs 
about Illness Questionnaire (PBIQ; Birchwood et al., 1993, Appendix C). The 
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PBIQ is comprised of 16-items rated on a four-point scale and assesses 
individuals' beliefs in five domains (Rooske & Birchwood, 1998): loss of 
autonomy and valued social role; humiliation and loss of rank arising from a 
belief in social segregation of those with mental illness; shame; attribution of 
behaviour during illness experience to self or to psychosis; and entrapment in 
or an inability to control psychotic experience. The scale has been 
demonstrated to have good reliability and validity with schizophrenia. 
5.2.3.5 Negative appraisals of self 
The Rosenberg Self-Esteem Scale (RSES; Rosenberg, 1965, Appendix D) was 
selected as a measure of negative appraisals of self. The RSES is a ten-item 
self-report measure of self-esteem. The scale was originally developed as a 
measure to assess self-esteem in adolescents but has been widely used in adult 
populations. Rosenberg (1965) proposed a complex scoring system, which 
was simplified by Corcoran & Fischer, (1987). Items are in statement form, 
and respondents are asked to rate their agreement on a four point Guttman 
Scale (strongly agree to strongly disagree). The RSES gives a score range of 4 
to 40, with higher scores indicating lower self-esteem. 
5.2.4 Relapse Definition 
Relapse data for all participants were collected prospectively with the 
exception of one relapse in the CBT + TAU group, which was identified 
retrospectively. Independent assessors confirmed relapses. Date of relapse was 
recorded as date of evaluation. Such data included, length of relapse (less than 
or greater than two weeks), hospital admission associated with relapse 
172 
A non-blind randomised-controlled trial of targeting cognitive behavioural therapy on relapse in 
schizophrenia: I. relapse outcome at 12-months 
(including compulsory admissions), the occurrence of adverse events (harm to 
others, harm to self, self-neglect) associated with relapse, and severity of 
relapse itself. Relapse severity was rated according to the criteria described in 
Table 5.1 below, and is similar to the methodology adopted by De Haan et al., 
(1998) to categorise relapse severity. 
Table 5.1 Relapse Severity Ratings 
Mild A sustained return of positive symptoms for less than two 
weeks without hospital admission. 
Moderate A sustained return of positive symptoms for more than two 
weeks without hospital admission, 
Or 
Less than two weeks with a hospital admission. 
Severe A sustained return of positive symptoms for more than 
two weeks with a hospital admission. 
Extreme A sustained return of positive symptoms with a compulsory 
hospital admission. 
In the present study the operational definition of relapse was based on 
participants' positive symptoms rated at entry on the positive scale of PANSS. 
Those who scored greater or equal to 3 on any one item of the positive scale of 
the PANSS classified as having residual symptoms; all other participants were 
classified as having minimal or no residual positive symptoms. Therefore, for 
those without residual symptoms, an increase in positive symptoms (rated 3 or 
more), sustained for at least one week, was defined as meeting criteria for a 
relapse. For those with residual symptoms, a 50% increase in the positive scale 
score, sustained for at least one week, was defined as meeting criteria for 
relapse. Tarrier et al., (1991) also used a 1-week time criterion as part of their 
definition of relapse. 
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5.2.5 Participants 
Table 5.2 illustrates the baseline demographic and diagnostic characteristics of 
the two groups. 
Table 5.2 Demographic, diagnostic and treatment characteristics by 
treatment group 
Variable CBT + TAU TAU alone 
n=66 n=67 
Age (Sd) 35.8 (9.8) 36.8 (10.3) 
Gender (%) 
Males 48 (72.7) 47 (70.1) 
Females 18 (27.3) 20 (29.9) 
Primary Diagnosis (%) 
Schizophrenia 53 (80.3) 56 (83.6) 
Schizoaffective Disorder 12 (18.2) 8(11.9) 
Delusional Disorder 0 (0.0) 1 (1.5) 
Schizophreniform Disorder 1(1.5) 1(1.5) 
Psychotic Disorder nos 0(0.0) 1 (1.5) 
Type of Medication (%) 
Typical 29 (43.9) 29 (43.3) 
Atypical 31 (46.9) 28 (41.8) 
Clozapine 6(9.2) 10 (14.9) 
Medication equivalent to Chlorpromazine 
in mg (Sd) 404 (251.1) 362 (226.1) 
Psychiatric contacts during 12-months 
(Sd) 
Medical 5.91 (3.08) 6.76 (4.10) 
Nursing 27.81(18.37) 27.54 (19.10) 
Others 2.02 (5.92) 4.38 (9.80) 
Table 5.3 summarises the baseline clinical and treatment characteristics for 
both groups. The overall sample comprised 133 participants, although on some 
of the measures there was a small proportion of missing data. No significant 
differences between the two groups were found, except that the CBT + TAU 
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had lower levels of self-esteem in comparison to TAU alone (t (126) = -2.1, p 
= . 034). 
Table 5.3 Clinical and history of illness characteristics by treatment 
group 
Variable CBT + TAU TAU alone 
n=66 n=67 
Positive and Negative Syndrome Scale 
(PANSS) 
Positive 10.6 (2.9) 10.5 (2.7) 
Negative 12.8 (4.5) 12.6 (5.3) 
Global 31.3 (7.5) 29.3 (6.6) 
Brief Symptom Inventory (BSI) 
Global Severity Index 1.3 (0.8) 1.0 (0.7) 
Personal Beliefs about Illness Questionnaire 
(PBIQ) 
Self versus illness 9.3 (2.7) 8.8 (2.9) 
Entrapment 10.1 (2.4) 10.1 (2.8) 
Shame 7.4 (2.1) 7.0 (1.8) 
Humiliation 4.4 (0.8) 4.6 (1.0) 
Loss 7.7 (2.0) 7.4(2.4) 
Rosenberg Self-esteem Scale (RSES) 
Duration of illness in months (sd) 
No of relapses at 12 months pre-treatment 
(%) 
25.0 (6.1) 22.8 (5.4) 
113.8 (79.9) 111.8 (85.7) 
No relapse 32 (45.7) 29 (43.3) 
One or more relapses 34 (54.3) 38 (56.7) 
Hospital admissions at 12 months pre- 
treatment (%) 
No admission 42 (65.6) 30 (46.9) 
One or more admissions 22 (34.4) 37 (53.1) 
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5.2.6 Treatments 
5.2.6.1 Treatment as Usual 
All participants continued to receive their ongoing usual treatment, which was 
overseen by the participants' own Responsible Medical Officer. The 
independent assessors (LM & JR) undertook regular monthly liaison with the 
participants' treatment team and monitored the progress of all participants. 
This enabled the prospective identification of relapse. This liaison included 
monthly attendance at team review meetings, attendance at participants' case 
management meetings, feedback on assessments, and feedback on progress of 
participants receiving CBT. 
The core components of TAU entailed ongoing medication, regular psychiatric 
review, and regular follow-up from a keyworker, usually a Community Mental 
Health Nurse. All participants had access to a wider multidisciplinary 
community mental health team in addition to their regular follow-up. Table 2 
illustrates that there were no significant differences between CBT + TAU and 
TAU alone in the number of community mental health service contacts 
participants had with medical staff, nursing staff and others (i. e. Occupational 
therapists, Mental Health Social Workers, and Clinical Psychology). 
5.2.6.2 Cognitive Behavioural Therapy 
A description of the treatment protocol has been detailed in Gumley & Power 
(2000), Chapter 4 (this volume), and is summarised below. A clinical 
psychologist (AG) provided all CBT sessions. CBT was divided into two 
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phases. An engagement phase was delivered between entry and 12-weeks. A 
targeted phase was delivered at the appearance of early signs of relapse. 
Phase one of CBT, which was delivered over five sessions, focused on 
engagement and formulation of the key psychological factors and early signs 
that might be associated with initiation or acceleration of early relapse. Phase 
one began with an explanation of the cognitive model of relapse, which 
emphasised the occurrence of early signs of relapse, and the triggering of 
negative beliefs concerning relapse. An explanation of the potential role of 
these beliefs in accelerating relapse was given. Participants were encouraged 
to test this model of relapse through the exploration of previous experiences of 
relapse. During the examination of previous relapse experiences, participants 
and therapist collaboratively identified negative beliefs concerning self and 
illness experience and the historical antecedents of these beliefs. This 
procedure enabled the development of an individualised case formulation of 
the cognitive factors and their associated early signs involved in relapse 
acceleration. At the end of this intervention phase, both individual and 
therapist constructed an idiosyncratic early signs monitoring questionnaire. A 
detailed description of the individualised early signs monitoring procedure is 
available in Tait et al., (2002). On a fortnightly basis, a member of the 
research team dispatched the questionnaires to participants. Participants were 
instructed to complete and return their questionnaires using a stamped 
addressed envelope enclosed for their use. Early signs monitoring continued 
for the duration of the trial. 
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There were two main routes to the initiation of Targeted CBT. First, an 
assessment for targeted CBT was initiated if there was an increase in a 
participant's self reported early signs. Prior to the initiation of this assessment, 
the therapist liased with the participants keyworker in order to, where 
appropriate, discuss and co-ordinate appointments and any possible 
interventions. Second, assessors undertook regular monthly liaison with 
participants' treatment teams. Therefore, when treatment teams reported 
symptom changes or circumstances/ stressors, which were suggestive of an 
increase in relapse risk, an assessment for Targeting was initiated. 
Session one of Targeted CBT involved a detailed assessment of the evidence 
of and against emerging relapse. The purpose of this assessment was twofold 
(1) to identify potential false alarms, and (2) to provide a test of the case 
formulation developed during the engagement phase. The therapist 
collaboratively elicited negative beliefs concerning relapse, and these beliefs 
were prioritised according to their importance and associated distress rated by 
the participant. In order to reduce participants' fear or helplessness associated 
with early relapse was reframed as an opportunity to develop mastery over an 
apparently uncontrollable and inevitable process. 
Where early relapse was associated with non-adherence with prescribed 
medication positive and negative beliefs about adherence and non-adherence 
were elicited and summarised. Where participants wished to continue to avoid 
medication, they were encouraged to treat their non-adherence as an 
opportunity to conduct an experiment with not taking medication. Anticipated 
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benefits and problems were considered. Where problems were anticipated, the 
implementation of existing or potential coping skills was discussed, and 
assistance was given to participants in rehearsing and implementing these. In 
addition, as part of this experimental approach to treatment thresholds for 
reinitiating medication were agreed. 
In other circumstances, the negative beliefs associated with relapse were 
examined. Alternative beliefs of relapse as a controllable process were 
developed in collaboration with the participant. These alternative beliefs were 
tested using within and between session behavioural experiments. Behavioural 
experiments involved strengthening existing coping skills or developing novel 
coping strategies. The outcomes of experiments were then used as evidence 
for and against alternative beliefs concerning relapse. Emphasis was given to 
developing strategies to counter ruminative withdrawal, avoidance, criticism 
from others, and the use of alcohol and illicit drugs. In addition cognitive and 
behavioural strategies were employed to reduce intrusive cognitive 
phenomena such as flashbacks to previous episodes. 
Targeted CBT was terminated when early signs had reduced to baseline levels. 
Targeted CBT was concluded by a review of strategies employed during 
treatment, and an examination of the evidence for and against participants' 
negative beliefs and their alternative beliefs concerning relapse. 
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5.2.7 Statistical Analysis 
All statistical analyses were carried out using SPSS for Windows (Version 
10.0). Treatment effectiveness in relation to relapse, length of relapse, hospital 
admission, compulsory admission, adverse events and relapse severity rating 
was assessed using x2 for differences between categorical variables and t tests 
for differences between continuous variables. Changes over time in 
chlorpromazine equivalent dosage were analysed using repeated measures 
analysis of variance (ANOVA). Post hoc comparisons were made using the 
Sheffe test (a = 0.05), or t tests where appropriate. The overall sample 
comprised of 133 participants, although on some of the measures there was a 
small proportion of missing data. To analyse differences in survival times 
between treatment groups, a Kaplan-Meier survival analysis was performed. 
Predictors of relapse were also examined. Prior to analysis, checks for 
normality, outliers, collinearity, and multicollinearity were made. Daily 
chlorpromazine equivalence presented with moderate positive skewness 
(skewness = 1.144). For this variable transformed data have been used {NewX 
= SQRT (X)}. Five sets of factors entered the Logistic regression analysis. 
The order in which predictors entered analysis both as individual factors and 
as sets was: Treatment factors (treatment group, type of medication, dosage 
equivalent to chlorpromazine), demographic factors (age, gender), history of 
illness factors (duration of illness, history of relapse and history of admission 
at 12 months pre - treatment), clinical factors (PANSS Positive, PANSS 
Negative, PANSS General Psychopathology, BSI Global Severity Index) and 
psychological factors (RSES, PBIQ Self versus Illness, PBIQ Entrapment, 
180 
A non-blind randomised-controlled trial of targeting cognitive behavioural therapy on relapse in 
schizophrenia: I. relapse outcome at 12-months 
PBIQ Shame, PBIQ Humiliation, PBIQ Loss). Results are reported for 
significant predictors of relapse status. 
Those variables found to be significant predictors using the logistic regression 
analysis were further examined using Cox Proportional Hazards Survival 
analysis (Cox, 1972). Time to relapse was coded in days from entry to the 
study. In addition to checks for normality, presence of outliers and 
multicollinearity, variables were also checked to ensure that the proportional 
hazards assumption of Cox regression was met. Cox regression assumes that 
the shape of the survival curve over time is the same for all cases, and as an 
extension, for all groups. Otherwise there is an interaction between groups and 
time in survival rates, or between other covariates (independent variables) and 
time. As this regression analysis involves a smaller sample of participants who 
relapsed the smaller set of covariate predictors derived from the logistic 
regression analysis were chosen for this analysis. Each covariate was 
transformed into a new variable (variable x the natural logarithm of the time 
variable). These log-transformed variables were entered to a Cox regression 
analysis, with the original variables. None of these log-transformed variables 
had a significant Wald value, indicating that the proportional hazards 
assumption was met. No further precautions were taken. 
5.3 Results 
5.3.1 Did CBT reduce relapse rate? 
Relapse rates over 12 months were 10 (14.9%) relapses from the CBT + TAU 
group and 24 (35.8%) relapses from the TAU alone group. Differences in the 
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relapse rates between the two groups were significant (x2 (1) = 7.5, p=0.006, 
Odds ratio = 2.36: 95% Cl, 1.23 to 4.55). The intent to treat analysis, which 
includes those who did not complete the study categorised as relapsed (CBT + 
TAU = 6, TAU alone = 5), continued to reveal that the advantage for CBT + 
TAU (n = 16,24.2%) over TAU alone (n = 29,40.3%), (x2 (1) = 5.5, p=0.02, 
Odds ratio = 1.81: 95% CI, 1.08 to 3.04). According to the intention to treat 
analysis, the Number Needed to Treat (NNT) to prevent one relapse in CBT + 
TAU is 8 participants. In terms of hospital admissions, there were 8 (11.8%) 
admissions in CBT + TAU versus 18 (26.9%) in TAU alone. This difference 
was also statistically significant (x2 (1) = 4.60, p=0.032, Odds ratio = 2.22: 
95% CI, 1.04 to 4.74, NNT = 10). Figure 5.2 illustrates the relapse-free 
survival curves for each group. Duration to first relapse was examined in the 
two treatment groups. Mean duration to first relapse for the CBT + TAU was 
216 days (sd = 104 days) versus 158 days (sd = 101 days) for the TAU alone 
group. This difference was not statistically significant (logrank (1) = 2.4, p= 
0.12). 
5.3.2 Did CBT reduce severity of relapse? 
Table 5.4 shows that there were no significant differences between CBT + 
TAU versus TAU alone groups in the proportion of mild, moderate, severe 
and extreme relapses. CBT + TAU was associated with a significant reduction 
in the duration of relapse itself (x2 (1) = 7.5, p=0.006, Odds ratio = 0.17: 
95% CI, 0.04 to 0.72). The length of relapse for half of the CBT + TAU group 
(n = 5,50.0%) was less than two weeks, whereas for the TAU alone group 
91.7% (n = 22) had a relapse lasting more than two weeks. 
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Figure 5.2 
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Table 5.4 Relapse Characteristics by treatment group 
Variable CBT + TAU TAU alone Significance 
n=10 (%) N=24(%) 
Length of relapse 
Less than two weeks 5 (50.0) 2 (8.3) 
More than two weeks 5 (50.0) 22 (91.7) 
Compulsory admissions 
Yes 3 (30.0) 8 (33.3) 
No 7 (70.0) 16 (66.7) 
Adverse events 
Yes 7 (70.0) 18 (75.0) 
No 3(30.0) 6(25.0) 
Relapse severity rating 
**p < . 01 
Mild 2 (20.0) 0 (0.0) 
Moderate 1 (10.0) 7 (29.2) 
Severe 4(40.0) 8(33.3) 
Extreme 3 (30.0) 9 (37.5) 
x2 (1) = 7.5, p=0.006* 
x2(1)=0.0, p=0.850 
x2(1)=0.1, p=0.763 
x2(3)=6.1, p=0.107 
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5.3.3 Was CBT associated with increased false positives? 
The question of whether CBT resulted in inflated rates of false positive relapse 
identification was examined. This is because overreacting to early signs might 
lead to increased false positive identifications to early relapse culminating in 
unnecessary intervention, and indeed the possibility of alerting participants to 
symptoms which do not herald relapse itself. The treatment received by 
participants who were randomised to CBT + TAU was examined. Of the 66 
participants in CBT + TAU all received 5 hours of phase one of the 
intervention. Following an increase in early signs, 28 (42%) participants 
received targeted CBT (mean hours = 7.0, s. d. = 3.72). A total of 5 (7.5%) 
participants relapsed without receiving targeted CBT. Of the 28 participants 
who received targeting, 5 (7.5%) experienced a relapse. 
Outcomes in CBT + TAU and TAU alone groups were coded according to 
those who relapsed ("Relapse"), those who did not relapse but received 
targeted CBT ("Targeted") and those who did not relapse and did not receive 
targeted CBT ("Stable"). There were no significant differences between rates 
of participants categorised as "Stable" (33 / 66) in the CBT + TAU group in 
comparison to TAU (43 / 67), (x2 (1) = 1.9, p=0.164). This analysis suggests 
that whilst CBT + TAU was associated with a significant reduction in relapse 
rate in comparison to TAU alone, this does not appear to be at the expense of a 
statistically significant reduction in participants in CBT + TAU remaining 
"stable". 
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5.3.4 What was the impact of CBT on antipsychotic treatment? 
Daily chlorpromazine equivalent dosages for participants in CBT + TAU and 
TAU alone are summarised in Table 5.5 below. There were no significant 
effects for time (F (3,390) = 0.3, p=0.88), or for treatment group (F (1,130) 
= 0.8, p=0.37), or for time by group interaction (F (3,390) = 0.4, p=0.73). A 
further analysis compared participants across the outcome categories defined 
above; that is "Stable", "Targeted" and "Relapse". The purpose of this 
analysis was to check for changes in antipsychotic dosage associated with the 
targeted treatment which may otherwise explain the differences in relapse and 
rehospitalisation rates observed during the 12-months. 
Table 5.5 Chlorpromazine dosage at entry, 12,26 and 52 weeks by 
Treatment Group and by Outcome Category 
Chlorpromazine Equivalent daily dosage in mg (sd) 
Group Entry 12-weeks 26-weeks 52-weeks 
Treatment Group 
CBT + TAU 404 397 399 395 
(n = 66) (251.1) (229.1) (230.9) (232.2) 
TAU alone 362 356 365 379 
(n = 67) (226.1) (200.8) (231.1) (246.6) 
Outcome category 
Stable 356 351 337 346 
(n = 76) (222) (222) (202) (215) 
Targeted 364 380 398 376 
(n = 23) (234) (235) (237) (226) 
Relapsers 455 429 469 485 
(n = 34) (269) (179) (265) (274) 
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Table 5.5 shows that there were no significant main effects for time (F (3,390) 
= 0.5, p=0.659). Significant group effects were observed (F (2,130) = 3.4, p 
= 0.037). There was no significant time by group interaction (F (6,390) = 1.1, 
p=0.334). Post hoc Sheffe tests revealed that relapsers were receiving 
significantly higher chlorpromazine equivalent daily dosages in comparison to 
participants categorised as stable (Mean difference = 112 m. g. daily, p= 
0.037,95% CI: 5 to 218 m. g. ) 
5.3.5 What were the predictors of relapse and duration to relapse? 
The overall model for all predictors was significant (Wald x2 (24) = 60.8, p< 
0.001) and manifested a high degree of overall accuracy (90.6%) and in the 
accuracy of predicting not relapsing (95.6%), and relapsing (73.1%). As 
shown in Table 5.6 below, the only variables that were found to significantly 
predict relapse were allocation to the TAU treatment group (Wald x2 (1) = 8.4, 
p=0.004, Exp 2.544), receipt of typical medication (Wald x2 (1) = 4.8, p 
= 0.028, Exp ß=1.731), receipt of atypical medication (Wald x2 (1) = 4.1, p= 
0.044, Exp ß=1.128), increased chlorpromazine equivalent medication 
dosage (Wald x2 (1) = 7.9, p=0.005, Exp 1.002), increased baseline 
positive symptoms (Wald x2 (1) = 4.2, p=0.041, Exp ß=1.016), and lower 
self-esteem (Wald x2 (1) = 5.2, p=0.023, Exp = 1.032). In addition, lower 
global psychopathology (Wald x2 (1) = 5.7, p=0.017, Exp ß=0.644) and 
reduced perceptions of entrapment in illness (Wald x2 (1) = 4.6, p=0.033, 
Exp ß=0.349) were associated with a reduced risk of having a relapse. 
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Table 5.6 Predictors of relapse (Logistic Regression Analysis) 
Variable B S. E. Wald Wald Wald Exp 
x2 df P= (ß) 
Treatment Condition 2.903 1.005 8.4 1 . 004** 2.544 
Typical Medication 5.168 2.357 4.8 1 . 028* 1.731 
Atypical Medication 4.436 2.202 4.1 1 . 044* 1.128 
Chlorpromazine 0.005 0.002 7.9 1 . 
005** 1.002 
dosage 
Positive Symptoms 0.383 0.187 4.2 1 . 041* 1.016 
(PANSS) 
Global -0.242 0.101 5.7 1 . 017* 
0.644 
Psychopathology 
(PANSS) 
Entrapment (PBIQ) -0.548 0.257 4.6 1 . 033* 0.349 
Rosenberg Self 0.230 0.101 5.2 1 . 023* 1.032 
Esteem Scale 
x2 df p= 
Model 60.8 24 . 000*** 
*p < 0.05, **p < 0.01, ***p < 0.001 
Using the Cox's Proportional Hazards Regression analysis, seven variables 
were entered as covariates; treatment condition, type of medication, daily 
Chlorpromazine equivalent dosage, positive symptoms, Global 
Psychopathology, Entrapment and the Rosenberg Self Esteem Scale. The 
overall model was significant (x2 (8) = 21.8, p=0.005). Table 5.7 shows that 
allocation to treatment condition (Wald x2 (1) = 10.8, p=0.001, Exp p= 
4.283), daily chlorpromazine equivalent dosage (Wald x2 (1) = 8.3, p=0.004, 
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Exp ß=1.002), and Rosenberg Self Esteem Scale (Wald x2 (1) = 6.2, p= 
0.013, Exp ß=1.103) were significant predictors of duration to relapse. 
Table 5.7 Duration to relapse (Cox Proportional Hazards Regression 
Analysis) 
Variable B S. E. Wald Wald Wald Exp 
x2 df P= (R) 
Treatment Condition 1.455 0.443 10.8 1 . 001** 
4.283 
Daily 0.002 0.001 8.3 1 . 004** 1.002 
Chlorpromazine 
equivalent 
Rosenberg Self 0.098 0.039 6.2 1 . 013* 1.103 
Esteem Scale 
x2 of p= 
Model 21.756 8 . 000*** 
*p < 0.05, **p < 0.01, ***p < 0.001 
5.4 Discussion 
5.4.1 Relapse Outcome 
The present study compared two treatment groups for prevention of relapse in 
schizophrenia, usual treatment (TAU alone) versus CBT plus treatment as 
usual (CBT + TAU). The study found that over a period of 12-months CBT + 
TAU was associated with a significant reductions in relapse rate, admission 
rate, and duration of relapse itself in comparison with TAU alone. There were 
no significant differences between CBT + TAU and TAU alone on time to 
relapse or the proportion of participants experiencing a mild, moderate, severe 
or extreme relapse. 
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The CBT itself also appeared to show a reasonable rate of accuracy in 
targeting those who relapsed or were assessed at being at risk of relapse 
("Targeting"). Only 5 relapses, that is 15% of the total relapses or potential 
relapses (n = 33) were missed. In addition, the reduction in relapse rate that 
was observed during the study period was not associated with reduced rates of 
"stable" outcomes in comparison with TAU alone. Reduced rates of stable 
outcomes in the CBT + TAU group would potentially reflect increased rates of 
false positive interventions for relapse. This is an important consideration 
because increased rates of false positive interventions would result in 
unnecessary treatment provision. Unnecessary treatment could inadvertently 
sensitise individuals to interpreting potentially benign symptoms as evidence 
early signs of relapse. 
Additional strengths in the design of the present study included systematic 
screening of patient populations, randomised allocation to groups, use of 
treatment protocol for the CBT group, and monitoring of medication 
psychiatric care contacts, and an explicit definition of relapse itself. The 
definition of relapse emphasised the sustained return of positive psychotic 
symptoms of over a one-week period. In addition, the definition of relapse 
enabled a rating of relapse severity. In this way, this study was able to 
overcome some of the limitations of other studies of CBT for schizophrenia, 
which have emphasised hospital admission as the criterion for relapse. 
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5.4.2 Limitations 
When considering the findings of the present study a number of limitations 
should be borne in mind. First, whilst assessors were blind at initial 
assessment prior to randomisation, following randomisation assessors were 
not blind to treatment received. The follow-up and the prospective 
identification of relapses amongst 133 participants over 12-months required 
close liaison with each participant's treatment team. Across the two centres a 
total of 8 community mental health teams were involved in the study. At the 
outset of the study, it was decided that blind assessment was not a realistic 
possibility given the amount of liaison required by assessors. Therefore the 
results of this trial should therefore be regarded, as preliminary and 
appropriate caution is required in generalising these findings. Notwithstanding 
this methodological limitation, Shapiro (1996) has commented that blind 
evaluation is virtually impossible with psychological treatment trials, 
particularly those who compare an experimental psychological treatment with 
a non-psychological treatment condition (Kuipers et al., 1998). Indeed, 
Shapiro (1996) comments that "personnel employed to interview patients to 
assess their progress are seldom able to avoid exposure to information 
(especially within patients' accounts of their experiences) that gives away the 
nature of the treatment they have undergone" (p. 204). 
Second, therapist time was not controlled for in the TAU alone group. No 
other study has examined either the feasibility or effectiveness of targeting 
CBT on the appearance of early signs of relapse. Therefore, in planning the 
study a pragmatic view was taken, that in the absence of any evidence 
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differences between the treatment groups in terms of the number of psychiatric 
contacts during the study period, which, if had occurred, would indicate 
increased monitoring or change in treatment delivery. 
Fourth, a single therapist carried out the CBT treatments and outcome results 
may reflect factors associated with the presentation of the treatments by this 
therapist rather than factors associated with the treatment itself. One possible 
advantage of using a single therapist in a treatment trial is that it avoids 
potentially introducing additional sources of variance into a study via variation 
in the quality of treatment provided by different therapists. For example, the 
Sensky et al., (2000) study of CBT for drug resistant psychosis, which 
employed two therapists, one at each of the treatment centres found that there 
was an overall significant difference between the two therapists on the 
Cognitive Therapy Rating Scale. However, in this preliminary study, the 
therapist did attempt to adhere to the treatment protocol although formal 
assessments of treatment quality and fidelity were not undertaken. Such issues 
should be rectified in future studies. 
Finally, it is possible that providers of treatment as usual adopted elements of 
the experimental treatment without the investigator's knowledge. Such 
problems are common to randomised controlled trials and are often referred to 
"contamination" or "leakage". However in a review of the dissemination of 
psychological treatments for schizophrenia, Tarrier et al., (1998) conclude that 
there is little evidence that these treatments are routinely available to 
individuals or their families. Indeed this fmding is supported by a recent 
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Scottish review of standards of treatment for schizophrenia (Clinical Standards 
Board for Scotland, 2002). 
5.4.3 Predictors of Outcome 
The study employed a cognitive behavioural treatment, which specifically 
targeted the negative beliefs and attributions thought to be associated with the 
initiation and acceleration of relapse (Birchwood, 1995; Gumley et al., 1999). 
Two regression analyses were employed, the first examined predictors of 
relapse itself, and the second examined predictors of duration to relapse. A 
number of predictors of relapse were identified; allocation to the TAU 
treatment group, receipt of typical medication, receipt of atypical medication, 
increased chlorpromazine equivalent medication dosage, increased baseline 
positive symptoms, and lower self-esteem. In addition, lower global 
psychopathology and reduced perceptions of entrapment in illness were 
associated with a reduced risk of having a relapse. Predictors of duration to 
relapse were; allocation to treatment condition, daily chlorpromazine 
equivalent dosage and Rosenberg Self Esteem Scale. 
The findings that higher daily chlorpromazine dosage and receipt of typical 
and atypical antipsychotic medication were associated with increased risk of 
relapse were unexpected findings. It may be that these findings reflect pre- 
existing differences in the severity of illness. The findings that increased 
positive symptoms and global psychopathology are also associated with 
relapse may be consistent with this interpretation. More contentiously, 
however, higher chlorpromazine dosage and receipt of typical medication may 
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also impair learning and implementation of coping strategies. In this study 
relapsers had a chlorpromazine daily dosage of 445 to 485-mg during the 12- 
months. In a meta-analysis of randomised controlled trials, Bollini et al. 
(1994) found that a chlorpromazine equivalent daily dosage of more than 375- 
mg gave no therapeutic advantage. 
Consistent with the proposals of the model of treatment, negative appraisals of 
self was associated with increased vulnerability to relapse and duration to 
relapse. Reduced appraisals of entrapment in illness were predictive of not 
having a relapse and therefore may represent a protective factor against having 
a relapse. Negative appraisals of self and illness have also been found to be 
associated with the development of Post Psychotic Depression (PDD; Iqbal et 
al., 2000). Iqbal et al., (2000) proposed that certain life situations are likely to 
be depressogenic, particularly if they encapsulate feelings of loss, humiliation 
and entrapment. In line with their proposal, psychosis is seen as a life event 
whose appraisal may involve these elements. Participants who developed PPD 
were more likely than their non-PPD counterparts to attribute the cause of 
psychosis to themselves, perceive greater loss of autonomy and valued role, 
and perceive themselves to be entrapped and humiliated by their illness. In a 
similar manner, for those with heightened negative appraisals of themselves, 
who perceive their illness experience as entrapping and uncontrollable, may 
respond to early signs of relapse with feelings of fear and helplessness, which 
in turn accelerate the process of relapse. Thus individuals' beliefs and 
attributions for their illness experience may play a pivotal role in the 
development of relapse. Further evidence concerning the role of attributions in 
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the development of relapse has been described by Barrowclough et al., (1994) 
who found that relatives' attributions for their family members' behaviour 
were predictive of relapse. Relatives with high expressed emotion (EE) 
invoked causal attributions attributing responsibility to the patient for 
outcome. Relatives high on emotional overinvolvement (EOI), made more 
attributions of causality to external and uncontrollable causes, and indeed 
made most attributions to illness. Controllability and internality were 
significantly contributed to relapse prediction, even after controlling for EE 
status and intervention. 
5.4.4 Clinical implications 
The study found that providing CBT specifically tailored to targeting the early 
stages of relapse was associated with reduced relapse, duration of relapse and 
admission rate over 12-months. Further studies of CBT for relapse, which 
address the methodological weaknesses of this study need to be undertaken. 
Furthermore consistent with the proposals of the treatment negative appraisals 
of self was predictive of relapse and duration to relapse, and increased 
appraisal of control over illness was associated with reduced relapse risk. 
These findings are suggestive that heightened negative self-appraisal and 
increased sense of entrapment in illness may represent cognitive 
vulnerabilities to relapse in schizophrenia. The clinical significance of 
preventing relapse in terms of impact of CBT on remission rates and social 
functioning have not been described, and these will now be considered in 
Chapter 6. 
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Chapter 6 
A non-blind randomised-controlled trial of targeting cognitive 
behavioural therapy on relapse in schizophrenia: II. Remission and social 
functioning at 12-months 
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6.1 Introduction 
Cognitive Behavioural Therapy (CBT) in conjunction with antipsychotic 
medication for schizophrenia has been shown to be effective in the reduction 
of chronic positive psychotic symptoms at the end of treatment (Tarrier et al., 
1993; Kuipers et al., 1997; Tarrier et al., 1998; Sensky et al., 2000). When 
delivered during the acute phase of illness, there is evidence that CBT is 
associated with improved rates of remission from positive psychotic 
symptoms (Drury et al., 1996). These treatment effects appear to maintained at 
six-months (Tamer et al., 1993), nine-months (Kuipers et al., 1998; Sensky et 
al., 2000), twelve-months (Tamer et al., 1999) and at twenty-four month 
follow-up (Tamer et al., 2000). 
Traditionally randomised controlled trials make comparisons between pre- and 
post treatment data to evaluate the impact of a treatment relative to a control or 
comparison group. Changes that are associated with an intervention, which are 
statistically significant provide evidence attesting to the reliability of change 
or group differences. However statistically significant changes associated with 
an intervention, may or may not be clinically significant. This distinction 
between statistical significance and clinical significance of improvement in the 
evaluation of psychotherapies has been increasingly emphasised by a number 
of investigators (e. g. Jacobson et al., 1984; Kazdin, 1999), including those 
evaluating CBT for schizophrenia (Tarrier et al., 1993; Kuipers et al., 1997; 
Tamer et al., 1998; Sensky et al., 2000). Clinically significant change can be 
defined as whether the magnitude of changes is large enough to be considered 
meaningful (e. g. Jacobson & Truax, 1991; Jacobson et al., 1999), or whether 
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treated individuals are distinguishable from normal individuals with respect to 
their principal complaints following treatment (e. g. Kendall & Grove, 1988; 
Kendall et al., 1999). In the latter approach, known as normative comparisons, 
clinical significance is defined as end-state functioning that falls within the 
normative range on important measures (Kendall et al., 1999). This latter 
definition of clinical significance may be too stringent, particularly for 
disorders, which are associated with a chronic course, or, as in CBT for 
schizophrenia, where the intervention has been delivered during the chronic 
phase of illness. Clinical significance however remains an important criterion 
for evaluating outcome. Jacobson and colleagues have proposed three methods 
for the assessment of clinically significant change, which emphasise the 
magnitude of change as a measure of clinical significance. The three proposed 
methods for clinically significant change are (a) if the level of functioning falls 
outside the range of the dysfunctional population, where the range is defined 
as 2 SDs above the mean for that population; (b) if the level of functioning 
falls within the range of the normal population, where the range is defined as 
beginning 2 SDs below the normal population mean; or (c) when the 
individual's level of functioning is statistically more likely to be in the 
functional rather than the dysfunctional population. Therefore, if an individual 
reliably improves with a treatment, but at the end of intervention remains 
somewhat dysfunctional compared to normative data then they are considered 
"improved but not recovered". On the other hand, if an individual reliably 
improves with treatment, and is within normal limits on the variable of 
interest, then they are considered "recovered". 
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Foster & Mash (1999) describe a further approach to the definition of clinical 
significance: social validity. Social validity refers to the social importance and 
acceptability of treatment goals, procedures and outcomes. In particular, the 
distinction is made between instrumental and ultimate goals. Ultimate goals 
are problems that lead an individual to seek help. Instrumental goals in 
contrast can be defined as desired outcomes that can lead to ultimate goals. In 
this case instrumental goals are defined by their causal and predictive 
relationship to ultimate goals. For example, a CBT therapist might propose 
that modifying negative beliefs about oneself and others (instrumental goals) 
will result in improved relationships with others (individual's ultimate goal). 
The measurement of the social validity of treatment goals can be made 
through the evaluation of normative comparisons as described by Kendall & 
Grove, (1988) and Kendall et al., (1999), subjective evaluation (Foster & 
Mash, 1999) or changes in functional impairment and adaptation (Hawkins, 
1991). Hawkins suggested that the importance of treatment goals could be 
examined in relation to their contribution to improvements in social 
functioning or indeed the reduced burden of care for family members. Gladis 
et al., (1999) point out that many disorders can be viewed as "lifetime" or 
chronic illnesses that have long-term effects despite periods of remission. 
Schizophrenia is an example of such a long-term disorder that has effects 
above and beyond the acute or persisting symptoms of psychosis. Strauss and 
Carpenter (1977), for example, have shown that clinical recovery from 
schizophrenia does not necessarily imply social recovery. Therefore, whilst it 
is important to know whether a clinically significant reduction in symptoms 
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has occurred, it is also of central clinical significance to determine if the 
individual's quality of life has also improved (e. g. Kazdin & Wilson, 1978). 
Randomised controlled trials of CBT for schizophrenia have sought to 
examine the clinical significance of reductions in persisting positive psychotic 
symptoms (Tarrier et al., 1993; Kuipers et al., 1997; Tarrier et al., 1998; 
Sensky et al., 2000). Tarrier et al., (1993) used a reduction of 50% of total 
symptom severity score accompanied by a1 SD improvement in social 
functioning as a definition of clinically significant change. No participants 
achieved this criterion. When the requirement for a1 SD improvement in 
social functioning was removed, 60% (9/15) of those receiving Coping Skills 
Enhancement (CSE) had a decrease in symptoms of 50% or greater compered 
to 25% (3/12) of the Problem Solving (PS) group (p = 0.065). Tamer et al., 
(1998) used this definition to examine "Clinically Important Improvement". 
CBT was associated with significantly increased rates of clinically important 
improvement compared to supportive counselling and routine care. Using 
logistical regression analysis clinically important improvement was predicted 
by allocation to CBT, shorter duration of illness, and less severe symptoms at 
entry. Sensky et al., (2000) adopted the same criterion of clinically significant 
change to measures of positive symptoms, negative symptoms and depression. 
Using this criterion CBT was associated with a significant advantage over 
controls in the clinically significant reduction of positive symptoms. Kuipers 
et al., (1997) defined reliable clinical change on the basis of the average 
variability in the scores of their main outcome measure (the root mean sum of 
the squared standard deviation of individual scores for each case in the control 
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group). This equated to a 5-point change or 20% improvement. Clinically 
significant improvement was taken as a 10-point change or more. Clinically 
significant improvement was achieved in 21% (6/28) of individuals receiving 
CBT versus 3% (1/32) of the routine care group. In terms of their criterion for 
reliable clinical improvement (5-points or more) 29% (8/28) of the CBT group 
and 28% (9/32) of the routine care group achieved this criterion. At nine- 
month follow-up after treatment, the CBT group had continued to improve 
with 65% (15/23) demonstrating a reliable clinical improvement, versus 17% 
(4/24) of the standard treatment group. Drury et al., (1996) examined the 
effectiveness of CBT delivered during the acute phase of psychosis. The 
clinical significance of outcomes was defined by a `clinical recovery' 
criterion. Clinical recovery was deemed to have taken place when (a) 
participants had recovered from their positive symptoms, (b) insight had 
returned, and (c) non-specific symptoms such as dysphoria and low level 
psychotic thinking had resolved. According to this criterion 50% of those 
treated with CBT achieved clinical recovery by 100 days versus 15% of 
controls. Two trials of CBT for schizophrenia have examined the impact of 
treatment on social functioning (Tarrier et al., 1993; Kuipers et al., 1997). 
Tamer et al., (1993) found that only 2 participants from the two treatments 
(CSE and PS) achieved any change of magnitude in their level of social 
functioning. Kuipers et al., (1997) did not find any effect for CBT relative to 
standard treatment in terms of changes in social functioning. 
The present study is a randomised-controlled trial of CBT targeted on the 
prevention of relapse in schizophrenia. As described in Chapter 5, over 12- 
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months CBT in combination with treatment as usual (TAU) was associated 
with a significant reduction in relapse rate (14%, 9/66) compared to TAU 
alone (36%, 24/67). This observed reduction in relapse rates was statistically 
significant, but was it clinically significant? Similar to Teasdale et al., (2000) 
who examined mindfulness based CBT for recurrent major depressive 
disorder; the principal key outcome of interest was the prevention of a future 
event (relapse/ recurrence) rather than the resolution of symptoms present at 
baseline. Teasdale et al., argued that the application of tests of clinical 
significance, such as those defined by Kendall et al., (1999) were not 
applicable to outcome trials of this nature. This was because the population of 
interest was largely remitted or recovered at entry. However, in the case of 
schizophrenia, even during periods of relative remission individuals continue 
to report some residual positive psychotic symptoms and continue to 
experience significant difficulties in their day to day social functioning (e. g. 
Thara et al., 1994). 
It was hypothesised that preventing relapse in schizophrenia would promote 
(a) recovery from any residual positive psychotic symptoms of schizophrenia, 
and (b) would enable some recovery of social functioning to occur. Therefore 
this study aims to evaluate the clinical significance of relapse prevention in 
schizophrenia in terms of observed remission rates and clinically significant 
improvements in social functioning at 12-months. 
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6.2 Method 
Methodology, case identification, assessment criteria and definitions of relapse 
are described in Chapter 5. The treatment procedures are summarised in 
Figure 6.1 below. 
Figure 6.1 Summary of treatment procedures 
Randomised (n = 144) 
Dropped Out TAU CBT + TAU 
(n = 11) (n = 67) (n = 66) 
Targeting 
Yes No 
(n = 28) (n = 38) 
II 
Relapsed Relapsed Relapsed 
(n = 24) (n = 5) (n = 5) 
6.2.1 Assessments 
Assessments were carried out at entry, 12-weeks, 26-weeks and 52-weeks 
using a battery of measures. Positive and negative symptoms were measured 
using the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987). 
Psychological distress was measured using the Brief Symptom Inventory 
(BSI; Derogatis & Melisaratos, 1983). Negative appraisals of psychosis were 
assessed using the Personal Beliefs about Illness Questionnaire (PBIQ; 
Birchwood et al., 1993). The Rosenberg Self-Esteem Scale (RSES; 
Rosenberg, 1965) was selected as a measure of negative appraisals of self. 
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6.2.1.1 Remission 
The proportion of remitted participants was assessed at entry, and 52 weeks. 
Remission of positive symptoms was defined as a score of less than 10 (scores 
of 7,8, and 9) on the positive scale of the PANSS. Larsen et al., (2000) 
defined remission as no score higher than 3 on any of the actual PANSS items. 
This clinical definition according to PANSS criteria is the similar to Larsen et 
al., (2000). However, in addition this definition also required that the 
individual had no relapses in the year preceding assessment. 
6.2.1.2 Social Functioning 
The Social Functioning Scale (SFS; Birchwood et al., 1990; Appendix E) was 
used to assess social role and behavioural functioning across seven basic areas 
of community functioning. The scale was first used in studies of family 
interventions of schizophrenia and was found to be sensitive to changes over 
time (Barrowclough & Tarrier, 1990). The scale has also been used in two 
previous studies of CBT for schizophrenia (Tarrier et al., 1993; Kuipers et al., 
1997). The scale assesses social functioning in the following areas, social 
engagement, interpersonal behaviour, prosocial activities, recreation, 
independence and employment. The scale also differentiates between lack of 
performance and lack of skills necessary for independent living. The scale has 
demonstrable reliability and validity for the assessment of social functioning 
in schizophrenia. For social functioning, a criterion of clinical significance 
was used to define whether of not a participant achieved clinically significant 
improvement in their social functioning defined as whether an individual's 
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outcome response fell outside the range of the population by 2 SDs from the 
pre-treatment mean (Jacobson & Truax, 1991). 
6.2.2 Baseline Characteristics 
As described in Chapter 5, the CBT + TAU and TAU alone groups did not 
significantly differ in relation to demographic characteristics, clinical 
characteristics and history of illness. Furthermore there were no differences 
between the two groups on rates of remission prior to study entry as defined in 
Section 6.2.1.1 above. Of the CBT + TAU group 52 (81.2%) were classified 
as not remitted, compared to 51 (79.7%) in TAU alone group (x2 (1) = 0.1, p= 
0.824). Table 6.1 shows the CBT + TAU and TAU alone groups did not differ 
significantly at pre-treatment in relation to social functioning (SFS). 
Table 6.1 Baseline Characteristics between treatment groups for Social 
Functioning Scale (SFS). 
Variable CBT + TAU TAU alone 
n=66 n=67 
Mean (Sd) Mean (Sd) 
Social Functioning Scale (SFS) 
Social Engagement 9.2 (2.5) 9.7 (2.4) 
Interpersonal Communication 6.5 (1.9) 6.6 (2.0) 
Independence Performance 26.0 (6.6) 27.0 (6.2) 
Independence Competence 34.9 (3.9) 36.0 (3.3) 
Recreation 14.6 (6.0) 13.7 (5.5) 
Prosocial 12.6 (8.3) 12.0 (6.3) 
Occupational 3.1 (3.0) 2.9 (3.1) 
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6.2.3 Statistical Analysis 
Associations between categorical variables at baseline were assessed by use of 
x2, whereas t-test analysis was used to test associations between continuous 
variables. Pre-treatment differences were examined using one-way ANOVA. 
A Repeated measures ANOVA was used to test time, group and interaction 
effects on the PANSS and Social Functioning Scale. Post hoc comparisons 
were made using t tests. The overall sample comprised of 133 participants, 
although on some of the measures there was a small proportion of missing 
data. The same methodology was adopted for the examination of predictors of 
remission and clinically significant improvements in social functioning as 
described in Chapter 5. To summarise, logistic regression was performed for 
the study of the predictors of remission and social functioning. Two 
dichotomous variables, one for remission outcome (remitted versus not 
remitted) and one for social functioning outcome (clinically significantly 
improved versus not clinically significantly improved), were created, in order 
to be used as dependent variables. Five sets of factors were created and 
entered the logistic regression analysis. The order in which predictors entered 
analysis both as individual factors and as sets was: treatment factors 
(treatment group, type of medication, dosage equivalent to chlorpromazine), 
demographic factors (age, gender), history of illness factors (duration of 
illness, history of relapse and history of admission at 12 months pre - 
treatment), clinical factors (PANSS Positive, PANSS Negative, PANSS 
General Psychopathology, BSI GSI) and psychological factors (RSES, PBIQ 
Self versus Illness, PBIQ Entrapment, PBIQ Shame, PBIQ Humiliation, PBIQ 
Loss). Predictor variables were retained in the model only if they showed a 
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significant Wald test (Wald p< . 05), indicating the significance of this 
predictor. Any predictor variable that failed to achieve this criterion was 
discarded from the analysis and a new logistic regression analysis was 
performed on significant factors only. Such methodology has enabled to 
reduce the number of factors entering the final model, in order to produce 
meaningful results. Results are reported for significant predictors only. 
6.3 Results 
6.3.1 Did CBT increase remission? 
Table 6.2 shows that on the Positive and Negative Syndrome Scale (PANSS) 
there were significant time effects for positive symptoms (F (3,387) = 9.7, p< 
0.001), negative symptoms (F (3,387) = 10.0, p<0.001), and general 
psychopathology (F (3,387) = 25.3, p <0.001). There were no significant 
group effects on positive, negative and general psychopathology scales. There 
were significant treatment time by group interaction effects for negative 
symptoms (F (3,387) = 3.1, p=0.027) and general psychopathology (F (3, 
387) = 5.5, p=0.001). Post hoc univariate analysis showed that CBT + TAU 
was associated with significantly lower positive symptoms (t (131) = 2.01, p= 
0.046, Mean difference = 1.03: 95% CI, 0.01 to 2.04) and lower negative 
symptoms (t (131) = 2.03, p=0.044, Mean difference = 1.68: 95% CI, 0.04 to 
3.31). This means that a linear change over time in positive and negative 
symptoms for the two groups showed a significant advantage for CBT + TAU 
at 52 weeks. 
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There were no significant differences in the proportion of participants who 
were remitted at entry (CBT + TAU = 18.8%, TAU = 20.3%, x2 (1) = 0.1, p= 
. 824). 
At 52-weeks the proportion of those receiving CBT + TAU who were 
remitted was 62.1% (41 / 66) compared to 38.8% (26 / 67) for TAU alone (x2 
(1) = 7.2, p= . 007, 
Odds Ratio = 2.58: 95% CI, 1.28 to 5.20). The intent to 
treat analysis, which includes those who did not complete the study 
categorised as not remitted (CBT + TAU = 6, TAU alone = 5), continued to 
reveal that the advantage for CBT + TAU (n = 41,56.9%) over TAU alone (n 
= 26,36.1%), (x2 (1) = 6.3, p=0.01, Odds ratio = 2.34: 95% CI, 1.20 to 4.57). 
According to the intention to treat analysis, the Number Needed to Treat 
(NNT) to achieve one remission in CBT + TAU is 7 participants. 
6.3.2 Did CBT improve social functioning? 
As described in Table 6.2, there were significant time effects for social 
engagement (F (3,127) = 4.6, p=0.003), interpersonal communication (F (3, 
127) = 6.2, p<0.001), performance of independent activities (F (3,127) = 
12.6, df = 3, p<0.001), competence in independent activities (F (3,127) = 
5.3, p=0.001), prosocial activities (F (3,127) = 10.9, p<0.001), and 
occupational functioning (F (3,127) = 8.3, p<0.001). There were significant 
group effects for Prosocial Activities (F (1,127) = 5.4, p=0.022). There were 
significant time by treatment group interaction effects for performance of 
independent activities (F (3,381) = 3.5, p= . 
016) and prosocial activities (F 
(3,381) = 6.6, p< . 001). Post hoc univariate comparisons revealed that 
CBT 
+ TAU was associated with significant improvements in Prosocial Activities 
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in comparison to TAU alone (t (129) = -3.37, p=0.001, Mean difference =- 
4.99: 95% Cl, -7.91 to -2.07). 
Table 6.2 Analysis of variance of time (pre - treatment, 12 - weeks, 26 - 
weeks, 52- weeks) x group (CBT + TAU, TAU alone) for PANSS, and 
SFS. 
Variable Time Time x Group Group Post Hoc 
(df = 3,387) (df = 3,387) (df = 1,129) Analysis 
FFP=F P= 52 weeks 
Positive and 
Negative Syndrome 
Scale (PANSS) 
Positive 9.7 . 000*** 2.0 . 
119 2.6 
. 111 1 >2* 
Negative 10.0 . 000*** 3.1 . 027* 1.7 . 187 1 >2* 
General 25.3 . 000*** 5.5 . 001*** 0.1 . 748 n. s. 
Time Time x Group Group Post Hoc 
(Df = 3,127) (Df = 3,381) (Df = Analysis 
1,127) 
Social Functioning 
Scale (SFS) 
Social Engagement 4.6 . 003** 1.5 . 212 0.2 . 631 n. s. 
Interpersonal 6.2 . 000*** 1.4 . 252 
0.6 
. 
448 n. s. 
Communication 
Independence 12.6 . 000*** 3.5 . 016* 0.5 . 464 n. s. 
Performance 
Independence 5.3 . 001*** 1.3 . 263 1.2 . 266 n. s. 
Competence 
Recreation 0.9 . 
431 2.2 . 083 3.2 . 075 n. s. 
Prosocial 10.9 . 000*** 6.6 . 
000*** 5.4 . 
022* 1> 2*** 
Occupational 8.3 
. 
000*** 0.4 . 730 0.7 . 410 n. s. 
*p < 0.05, **p < 0.01, ***p < 0.001,1 = CBT + TAU, 2= TAU alone 
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The clinical significance of changes in Prosocial Activities was examined 
according to the methodology developed by Jacobson and colleagues (1984). 
Clinically significant change is defined as a magnitude of change of 2 SDs 
towards functionality according to the population's distribution of scores at 
entry. The results of this analysis are illustrated in Table 6.3 below. The two 
treatment groups were found to differ only in Prosocial Sub-scale. At 12 
months, the proportion (n = 39,59.1%) of participants in CBT + TAU who 
had achieved clinically significant improvements in Prosocial Activities was 
significantly greater than those in TAU (n = 25,38.5%) (x2 (1) = 5.6, p= 
0.023, Odds Ratio = 2.31: 95% CI, 1.15 to 4.66). 
Table 6.3 Number and percentage of participants achieving clinically 
significant change in Prosocial activities. 
CBT TAU 
Variable (n = 66) (n =67) x2 p= 
(%) (%) df =1 
Social Functioning Yes No Yes No 
Scale (SFS) 
39 27 25 40 
Prosocial (59.1) (40.9) (38.5) (61.5) 5.6 . 023* 
*p < 0.05 
The intent to treat analysis, which includes those who did not complete the 
study categorised as not having achieved clinically significant changes in 
Prosocial Activities (CBT + TAU = 6, TAU alone = 5), continued to reveal 
that the advantage for CBT + TAU (n = 39,54.2%) over TAU alone (n = 25, 
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34.7%), (x2 (1) = 5.5, p=0.02, Odds ratio = 2.22: 95% CI, 1.13 to 4.35). 
According to the intention to treat analysis, the Number Needed to Treat 
(NNT) to achieve clinically significant change in one participant in CBT + 
TAU is 7 participants. 
6.3.3 What were the predictors of remission? 
The overall model for all predictors was significant (Wald x2 (24) = 59.0, p< 
0.001) and manifested a high degree of overall accuracy (80.3%) and in the 
accuracy of predicting not being remitted (76.4%), and being remitted 
(83.9%). As shown in Table 6.4 below, the only variables that were found to 
significantly predict remission were allocation to the CBT + TAU treatment 
group (Wald x2 (1) = 7.4, p=0.006, Exp ß=0.188), reduced baseline positive 
symptoms (Wald x2 (1) = 13.5, p<0.001, Exp ß=0.588), reduced daily 
chlorpromazine equivalent medication (Wald x2 (1) = 8.9, p=0.003, Exp 
0.996). 
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Table 6.4 Predicting remission outcome 
Variable B S. E. Wald Wald Wald Exp (ß) 
x2 df p= 
Treatment -1.673 . 
613 7.4 1 0.006** 0.188 
Group 
Clorpomazine -. 004 . 001 8.9 1 0.003** 0.996 
dosage 
PANSS -. 531 . 145 13.5 1 . 000*** 0.588 
Positive 
xý df P= 
Model 59.0 24 . 000*** 
*p < 0.05, **p < 0.01, ***p < 0.001 
6.3.4 What were the predictors of clinically significant improvements in 
social functioning? 
The overall model for all predictors was significant (Wald x2 (24) = 63.4, p< 
0.001) and manifested a high degree of overall accuracy (81.2%) and in the 
accuracy of predicting not being improved (80.3%), and being improved 
(82.1%). As shown in Table 6.5 below, the only variables that were found to 
significantly predict remission were allocation to the CBT + TAU treatment 
group (Wald x2 (1) = 8.1, p=0.004, Exp ß=0.167), lower baseline negative 
symptoms (Wald x2 (1) = 16.0, p<0.001, Exp ß=0.706), lower appraisals of 
humiliation associated with having psychosis (Wald x2 (1) = 6.7, p=0.010, 
Exp ß=0.403). 
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Table 6.5 Predicting prosocial outcome 
Variable B S. E. Wald Wald Wald Exp (ß) 
x2 df P= 
Treatment -1.791 . 627 8.2 1 0.004** 0.167 
Group 
PANSS -. 348 . 087 16.0 1 0.000*** 0.706 
Negative 
PBIQ -. 909 . 351 6.7 1 . 010* 0.403 
Humiliation 
x2 df 
Model 63.4 24 . 000*** 
*p < 0.05, **p < 0.01, ***p < 0.001 
6.4 Discussion 
6.4.1 Clinical Significance and CBT for Schizophrenia 
Randomised controlled trials of CBT for schizophrenia have sought to 
examine the clinical significance of reductions in persisting positive psychotic 
symptoms (Tarrier et al., 1993; Kuipers et al., 1997; Tarrier et al., 1998; 
Sensky et al., 2000). Tamer et al., (1993) used a reduction of 50% of total 
symptom severity score accompanied by a1 SD improvement in social 
functioning as a definition of clinically significant change. However in their 
study, no participants achieved this criterion. Consequently Tamer et al., 
removed the requirement for a1 SD improvement in social functioning and 
found that 60% (9/15) of those receiving Coping Skills Enhancement (CSE) 
had a decrease in symptoms of 50% or greater compered to 25% (3/12) of the 
Problem Solving (PS) group (p = 0.065). Tarrier et al., (1998) used this 
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definition to examine "Clinically Important Improvement". CBT was 
associated with significantly increased rates of clinically important 
improvement compared to supportive counselling and routine care. Sensky et 
al., (2000) adopted the same criterion of clinically significant change to 
measures of positive symptoms, negative symptoms and depression. Sensky et 
al., found that using this criterion CBT was associated with a significant 
advantage over controls in the clinically significant reduction of positive 
symptoms. Kuipers et al., (1997) defined reliable clinical change on the basis 
of the average variability in the scores of their main outcome measure (the root 
mean sum of the squared standard deviation of individual scores for each case 
in the control group). This equated to a 5-point change or 20% improvement. 
Clinically significant improvement was taken as a 10-point change or more. 
Kuipers et al., found that clinically significant improvement was achieved in 
21% (6/28) of individuals receiving CBT versus 3% (1/32) of the routine care 
group. In terms of their criterion for reliable clinical improvement (5-points or 
more) 29% (8/28) of the CBT group and 28% (9/32) of the routine care group 
achieved this criterion. At nine-month follow-up after treatment, the CBT 
group had continued to improve with 65% (15/23) demonstrating a reliable 
clinical improvement, versus 17% (4/24) of the standard treatment group. 
Drury et al., (1996) examined the effectiveness of CBT delivered during the 
acute phase of psychosis. The clinical significance of outcomes was defined 
by a `clinical recovery' criterion. Clinical recovery was deemed to have taken 
place when (a) participants had recovered from their positive symptoms, (b) 
insight had returned, and (c) non-specific symptoms such as dysphoria and 
low level psychotic thinking had resolved. Drury et al., found that according to 
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attesting to the effectiveness of targeting CBT, a control for therapist time was 
not regarded as essential. Participants receiving the targeted CBT had a mean 
of about 7 hours of treatment. This compares well to other studies of CBT, 
which have included 19 to 24-hours of therapy (Kuipers et al., 1997; Sensky et 
al., 2000). In addition, the results described in the present study were achieved 
in the context of a treatment as usual, which had a high level of routine follow- 
up from nursing and psychiatry. Participants were seen, on average, 
fortnightly by their Community Psychiatric Nurse, and bi-monthly by their 
psychiatrist. 
Third, the responsibility for prescribing antipsychotic medication remained 
with the participants' Responsible Medical Officer, and therefore it was not 
possible to control for concurrent antipsychotic medication prescribing. To 
compensate for this antipsychotic medication was monitored throughout the 
study, and no significant differences were found between the treatment groups 
(CBT + TAU versus TAU alone). However, those who relapsed during the 
study had significantly higher daily chlorpromazine equivalent dosages in 
comparison to those participants who remained stable during the trial. 
Furthermore, as there were no controls on medication and because assessors 
were not blind, communications to participants prescribing psychiatrists and 
treatment teams could well have sensitised staff to provide closer monitoring 
and better treatment for the CBT + TAU group. However, there was little 
evidence of any substantial increases in antipsychotic medication amongst 
participants who received Targeted CBT. In addition, there were no significant 
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this criterion 50% of those treated with CBT achieved clinical recovery by 100 
days versus 15% of controls. Two trials of CBT for schizophrenia have 
examined the impact of treatment on social functioning (Tamer et al., 1993; 
Kuipers et al., 1997). Tarrier et al., (1993) found that only 2 participants from 
the two treatments (CSE and PS) achieved any change of magnitude in their 
level of social functioning. Kuipers et al., (1997) did not find any effect for 
CBT relative to standard treatment in terms of changes in social functioning. 
6.4.2 Remission 
The present study found that CBT + TAU was associated with a significant 
advantage over TAU alone in the reduction of positive and negative symptoms 
over 12-months. In terms of the clinical significance of the reduction in 
positive symptoms, a criterion of remitted status was defined according to the 
absence of positive symptoms at 12-months, amongst those who did not 
relapse during the course of the study. CBT + TAU was associated with a 
significant advantage over TAU alone in the achievement of remitted status. 
These findings are similar to those of Drury et al., (1996b) who found that the 
delivery of CBT during the acute phase of psychosis was associated with 
increased rates of remission (55% versus 25%) at 100 days following entry to 
the study. Similar to the present study, Drury et al., defined remission as the 
full resolution of positive symptoms. However, unlike Drury et al's., study, the 
present trial examined CBT delivered in a group of stabilised outpatients 
without severe drug refractory positive psychotic symptoms. 
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Predictors of remitted status at 12-months were also analysed. Remission was 
associated with allocation to the CBT + TAU group, lower dosages of 
antipsychotic medication, and lower levels of positive symptoms at entry to 
the study. The finding that a combination of CBT and lower dosages of 
antipsychotic medication is an interesting one. Previous research has shown 
that whilst maintenance antipsychotic medication is associated with reduced 
relapse, it exerted a cost in terms of reduced social functioning (Johnstone et 
al., 1990). Low dosage (reviewed by Barbui et al., 1996) and intermittent 
medication (e. g. Jolley et al., 1989,1990) strategies are associated with 
reduced side effects but increased relapse rates at 12-months. However, the 
inclusion of adjunctive psychological interventions appear to offset the 
increased relapse risk associated with low dosage treatment (e. g. Goldstein et 
al, 1978) and intermittent treatment (e. g. Carpenter et al., 1987; Herz et al., 
1991). This finding that the combination of CBT and lower dosages of 
antipsychotic medication predicted remitted status is in line with these results. 
In terms of studies of CBT for schizophrenia, this is the first study to report 
such a finding that CBT augments a lower dosage strategy. Clearly such a 
finding may be a feature of the group of participants included in this study. 
They were different to those included in other studies of CBT as they were not 
experiencing severe drug resistant symptoms of psychosis (Tarrier et al., 1993, 
Kuipers et al., 1997; Tarrier et al., 1998; Sensky et al., 2000) and were not 
experiencing an acute psychotic episode (Drury et al., 1996a, b). 
6.4.3 Social Functioning 
Receipt of CBT + TAU was associated with statistically significant 
improvements at 12-months on all domains of social functioning measured 
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except recreation. This study also found that CBT + TAU was associated with 
an advantage over TAU alone for improvement in engagement in prosocial 
activities. The study examined the clinical significance of improvements in 
this domain of social functioning across the two treatment groups. The criteria 
used to define clinically significant change in social functioning was informed 
by wider developments in the evaluation of psychotherapies (e. g. Jacobson et 
al., 1984; Kazdin, 1999). The present study found that CBT + TAU was 
associated with a significant advantage over TAU for clinically significant 
improvements in engagement in prosocial activities. This is the first study of 
CBT to report significant improvements in social functioning compared to 
controls. There are three possible explanations for this finding. First, this 
finding may reflect the impact of CBT on a group of stabilised individuals 
with schizophrenia without severe drug resistant positive symptoms. Repeated 
measures analysis of variance showed that both treatment groups made 
improvements in their social functioning across the following domains: social 
engagement, interpersonal communication, independence performance and 
independence communication. It is an encouraging finding that many 
individuals who were stabilised at entry continued to make statistically 
significant improvements in their social functioning. Second, the 
improvements in social functioning observed in the CBT group might also 
reflect an outcome of treatments, which target relapse risk. A number of 
family intervention studies have shown improvements in social functioning 
(Cranach, 1981; Falloon, et al., 1987; Spiegel & Wissler, 1987; Barrowclough 
& Tamer, 1990; Hogarty et al., 1991; Vaughn et al., 1992; Xiang et al., 1994). 
Third, allocation to treatment group, and lower negative appraisals of illness as 
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humiliating were also predictive of improved engagement in prosocial 
activities. Iqbal et al., (2000) have already reported that negative appraisals of 
illness were predictive of the development of post psychotic depression. The 
treatment delivered in this study explicitly targeted negative appraisals of 
illness. The finding that treatment group was predictive of improved social 
functioning provides some evidence that CBT targeted on the negative 
appraisals of illness associated with relapse risk can lead to meaningful 
improvements in social functioning. 
6.4.4 Clinical Implications 
The study aimed to examine the clinical significance of preventing relapse 
using targeted CBT. The main findings were that CBT + TAU was associated 
with increased rates of remission and clinically significant changes in 
engagement in prosocial activities. Two logistic regression analyses were 
performed to examine predictors of outcome across these domains. Predictors 
of remission were allocation to CBT, lower antipsychotic medication, and 
lower positive symptoms. Predictors of improved engagement in prosocial 
activities were allocation to CBT, lower negative symptoms and lower 
perceived humiliation. Furthermore, the fording on the relationship between 
perceived humiliation and social functioning is a potentially important 
observation and indicates that cognitive factors may be intimately related to 
the deficits in social functioning observed in schizophrenia. Such a finding 
requires further investigation and opens up the possibility that cognitive 
treatments which target the perception of stigma and humiliation may result in 
improved social functioning for individuals with schizophrenia. 
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Chapter 7 
A non-blind randomised-controlled trial of targeting cognitive 
behavioural therapy on relapse in schizophrenia: III. Psychological distress at 
12-months 
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7.1 Introduction 
Despite the advances in pharmacological management of schizophrenia, 
relapse still remains a major factor in the development of illness chronicity. 
For example, the experience of relapse is critical to the development of 
secondary depression. Birchwood et al., (1993) found that perception of 
control over illness was the most powerful predictor of depression in 
schizophrenia. Recognition of the social, emotional and psychological costs of 
relapse has lead investigators (e. g. Birchwood, 1995) to attempt to 
conceptualise psychological approaches to the detection and prevention of 
relapse. In addition, evidence from recent randomised controlled trials of 
Cognitive Behavioural Therapy (CBT; Tamer et al., 1993; Kuipers et al., 
1997; Tarrier et al., 1998) for schizophrenia show favourable prospects that 
the effects of CBT to be maintained at follow-up (e. g. Sensky et al., 2000). 
However, it is not yet possible to conclude on the basis of current results that 
CBT is uniquely effective in reducing relapse rate following treatment (e. g. 
Tamer et al., 1998). 
Treatment manuals adopted by trial investigators (e. g. Kingdon & Turkington, 
1994; Fowler et al., 1996) include relapse prevention strategies. These 
strategies focus on helping individuals recognise and respond to early signs of 
relapse by seeking help. However, as discussed in Chapter 3, these manuals do 
not base their relapse prevention strategies on a specialised psychological 
conceptualisation of relapse itself. In addition, empirically there is a strong 
link between the experience of relapse and the occurrence of psychological 
symptoms before relapse, and as a result of relapse itself via appraisals of 
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entrapment (Birchwood et al., 1993). In Chapter 3, I proposed that there was a 
need to develop a psychological conceptualisation of relapse which can assist 
the targeting of relevant cognitive behavioural factors involved in the 
evolution of relapse and that such a model should account for the relationship 
between relapse and psychological symptoms and distress. Chapter 5 
described an exploratory randomised controlled trial of CBT as a targeted 
intervention in the prevention of relapse. CBT was delivered during the early 
signs of relapse and focused on the development of an individualised case 
formulation of psychological factors associated with relapse acceleration, the 
modification of negative beliefs concerning illness, and the development and 
implementation of cognitive or behavioural coping strategies within and 
between sessions. Receipt of CBT in addition to treatment as usual (TAU) was 
associated with reduced relapse rate and reduced admission rate. In addition, 
Chapter 6 reported on the clinical significance of preventing relapse in 
psychosis, and reported improved remission rates and improved social 
functioning in prosocial activities at 12-months. Given that this approach to 
relapse prevention focused on the targeting of negative beliefs concerning self 
and self in relation to psychosis, and that these beliefs appear to be intimately 
linked to the development of psychological co-morbidity (Birchwood et al., 
1993; Iqbal et al., 2000), it would be reasonable to hypothesise that receipt of 
CBT would result in reduced psychological distress and morbidity. 
The outcome in terms of co-morbid symptoms of anxiety and depression are 
not reported by a number of CBT trials (Tamer et al., 1993; Kuipers et al., 
1997; Pinto et al., 1999). Kuipers et al., (1997) found no effect for CBT on 
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measures of self-rated depression. Tamer et al., (2001) reported on the 
detailed outcome of their 1998 trial of intensive CBT. Measures of anxiety and 
depression were examined to investigate whether affective symptoms 
improved over treatment and whether treatment groups differed at post 
treatment or in their change. There were no significant effects for time, group 
or time by group interaction on affective symptoms. Drury et al., (1996b) 
delivered CBT during the acute psychotic phase of illness and defined clinical 
recovery as personal recovery from psychotic symptoms, recovery of insight, 
and the resolution of non-specific symptoms including dysphoria and `low- 
level' psychotic thinking. Personal recovery from psychotic symptoms was 
defined as the lowest rating of hallucinations and delusions achieved over the 
follow-up period and maintained for at least three consecutive assessment 
points. Recovery of insight was defined as a score of >9 on the Insight Scale 
(Birchwood et al., 1994). Resolution of non-specific symptoms was defined as 
a score of <30 on the Early Signs Scale (Birchwood et al., 1989). Time to 
clinical recovery was defined as the time to resolution of all three components. 
Survival analysis using the clinical recovery definition showed that the 
cumulative proportion failing to recover by 100-days was 50% for CBT and 
85% for controls (Wilcoxan Gehan 4.9, df = 1, p <0.05). Sensky et al. (2000) 
examined the outcome of CBT versus befriending (BF) in a group of 
individuals with chronic drug resistant positive psychotic symptoms. Outcome 
of treatment was examined in terms of positive symptoms, negative symptoms 
and depression. At the end of treatment both CBT and BF groups showed 
significant improvements in positive symptoms, negative symptoms and 
depression. However at 9-month follow-up, CBT resulted in significantly 
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greater improvements in positive, negative and depression symptoms 
compared to BF. Using an outcome criterion of 50% or greater improvement 
in symptoms as a measure of clinical significance of outcome, 31 of the 46 
(67%) participants in CBT achieved this criterion, compared to 22 out of 44 
(50%) of the BF group; a non-significant difference. 
The results regarding the effectiveness of CBT in the treatment of 
psychological co-morbidity is both surprising and disappointing. Only one 
study (Sensky et al., 2000) demonstrates efficacy in the treatment of co- 
morbid depression, although CBT was not uniquely effective. In addition, 
whilst the treatment manual adopted in the Sensky et al., study specifically 
targets anxiety and depression, other treatment manuals also detail techniques 
and strategies aimed at reducing psychological co-morbidity. Again such a 
finding may be accounted for by the lack of a specialised psychological 
conceptualisation of psychological co-morbidity in schizophrenia. For 
example, Birchwood et al., (2000) found that in a sample of 105 individuals 
with schizophrenia, 36% developed post psychotic depression (PPD) without 
concomitant changes in positive and negative symptoms. Iqbal et al., (2000) 
have proposed that, in line with Gilbert (1992) certain life situations are likely 
to be depressogenic, particularly if they encapsulate feelings of loss, 
humiliation and entrapment. In line with their proposal, psychosis is seen as a 
life event whose appraisal may involve these elements. Participants who 
developed PPD were more likely than their non-PPD counterparts to attribute 
the cause of psychosis to themselves, perceive greater loss of autonomy and 
valued role, and perceive themselves to be entrapped and humiliated by their 
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illness. Given this finding, it may be that strategies aimed at reducing 
psychological co-morbidity in schizophrenia should target cognitions and 
appraisal surrounding the meaning and appraisal of psychosis itself. This may 
help partially explain the findings of Sensky and colleagues who particularly 
emphasised a normalising rationale for psychosis early in treatment. 
This study therefore seeks to investigate whether CBT targeted on the 
prevention of relapse will result in the reduction of psychological distress. It is 
specifically hypothesised that given that negative appraisals of psychosis are 
associated with the development of secondary psychological morbidity and 
distress, receipt of CBT will be associated with reduced psychological distress 
at 12-months. Second, outcome in terms of negative appraisals of psychosis 
and negative appraisals of self are investigated. It is hypothesised that receipt 
of CBT will be associated with reduced negative appraisals of psychosis and 
self at 12-months. 
7.2 Method 
Methodology, case identification, relapse criteria and outcome are described in 
Chapter 5. To summarise, 144 participants with a diagnosis of schizophrenia 
spectrum disorder (DSM-IV; APA, 1994). All participants were in receipt of 
maintenance antipsychotic medication, were outpatients, and considered 
relapse prone at entry. Of the 144 participants randomised, 72 were allocated 
to treatment as usual alone (TAU alone) and 72 were allocated to Cognitive 
Behavioural Therapy plus TAU (CBT + TAU). Of this group a total of 11 
participants dropped out of the study, 5 from TAU alone and 6 from CBT + 
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TAU. All completers (TAU alone = 67, CBT + TAU = 66) were followed up 
over the 12 month treatment phase. Participants allocated to CBT + TAU 
received a 5-session intervention between entry and 3-month assessment. This 
intervention focused on engagement, assessment and formulation of the key 
cognitive and behavioural factors hypothesised to be involved in the initiation 
and acceleration of early relapse. Following this intervention participants in 
CBT + TAU monitored their own idiosyncratic early signs. Individualised 
early signs forms were dispatched by post on a fortnightly basis and returned 
by participants using a stamped addressed envelope. During the study period a 
total of 28 participants proceeded to the targeted CBT phase following an 
increase in early signs. Of this group who received the targeted intervention, 5 
participants relapsed. A further 5 participants from the CBT + TAU relapsed 
during the 12-months giving a total of 10 (14.9%) relapses in this group. Of 
those participants allocated to the TAU alone group, 24 (35.8%) relapsed 
during the 12-month phase. The differences in the relapse rates between the 
two groups were significant (x2 = 7.7, Df = 1, p=0.005, Odds ratio = 2.40: 
95% CI, 1.25 to 4.62). 
7.2.1 Measures 
7.2.1.1 Psychological Distress 
Psychological distress was measured using the Brief Symptom Inventory 
(BSI; Derogatis & Melisaratos, 1983; Appendix B). This self rated instrument 
gives measures across nine symptom dimensions: somatisation, obsessive 
compulsive symptoms, interpersonal sensitivity, depression, anxiety, hostility, 
phobic anxiety, paranoid ideation, and psychoticism. The BSI gives three 
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global indices of distress: the Positive Symptom Total (PST), the Positive 
Symptom Distress Index (PSDI) and the Global Severity Index (GSI). The 
PST is simply a count of the symptoms which individuals report experiencing 
to any degree. The PSDI is an intensity of distress measure, corrected for the 
number of symptoms positively endorsed. 
7.2.1.2 Negative appraisals of Psychosis 
Participants' appraisal of their psychosis was evaluated using the Personal 
Beliefs about Illness Questionnaire (PBIQ; Birchwood et al., 1993; Appendix 
C). The PBIQ is comprised of 16-items rated on a four-point scale and 
assesses individuals' beliefs in five domains: loss, humiliation, shame, 
attribution of behaviour to self or to illness, and entrapment in psychosis. The 
scale has been demonstrated to have good reliability and validity with 
schizophrenia. 
7.2.1.3 Negative appraisals of self 
Negative beliefs concerning participants' worth and value were assessed using 
the Rosenberg Self-Esteem Scale (RSES; Rosenberg, 1965; Appendix D). The 
RSES is a ten-item self-report measure of self-esteem. Lyon et al., (1994) 
describe this measure as a relatively pure measure of subjective self-worth 
which typically correlates well with other measures of self-esteem (Arnold, 
1988). 
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7.2.2 Data Analysis 
Associations between categorical variables at baseline were assessed by use of 
x2, whereas t-test analysis was used to test associations between continuous 
variables. Pre-treatment differences were examined using one-way ANOVA. 
The overall sample comprised of 133 participants, although on some of the 
measures there was a small proportion of missing data. 
Prior to analysis data were checked for abnormalities in distribution, presence 
of outliers, collinearity, and multicollinearity. All continuous variables used in 
the analysis were examined for skewness. The distributions for the 
Somatisation and Hostility subscales of the BSI were highly positively skewed 
(i. e. skew > 1.0, c. f. Ferguson & Cox, 1993), thus logarithmic transformations 
(log 10 (variable + 1)) were performed on these variables to correct skewness. 
Presence of outliers was checked by the use of boxplots. Very few outliers 
were present, and no variables were excluded on this basis. 
There were significant group differences between participants in CBT + TAU 
and participants in TAU alone at baseline. Those randomised to CBT had 
significantly higher levels of Depression (p = 0.015), Psychoticism (p = 
0.035), Positive Symptom Distress Index (p = 0.046), and lower levels of self- 
esteem (p = 0.034). 
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Table 7.1 Baseline clinical characteristics of treatment groups 
Variable CBT + TAU TAU alone 
N=66 n=67 
Mean (Sd) Mean (Sd) 
Brief Symptom Inventory 
Somatisation 0.9 (0.8) 0.8 (0.8) 
Obsessive Compulsive 1.6 (1.1) 1.3 (0.9) 
Interpersonal Sensitivity 1.6 (1.2) 1.2 (1.1) 
Depression 1.7 (1.2) 1.2 (1.0) 
Anxiety 1.3(l. 0) 1.2(l. 0) 
Hostility 0.6 (0.8) 0.6 (0.6) 
Phobic anxiety 1.5(l. 2) 1.2(l. 2) 
Paranoia 1.3(l. 0) 0.9 (0.9) 
Psychoticism 1.4 (1.0) 1.0 (0.8) 
Global severity Index 1.3 (0.8) 1.0 (0.7) 
Positive Symptom Index 29.5 (14.8) 27.0 (13.1) 
Positive Symptom Distress Index 2.1 (0.8) 1.8 (0.7) 
Personal Beliefs about Illness 
Questionnaire 
Self versus Illness 9.3 (2.7) 8.9 (2.9) 
Entrapment 10.2 (2.4) 10.1 (2.8) 
Shame 7.4 (2.1) 7.0 (1.8) 
Humiliation 4.5 (0.8) 4.6(l. 0) 
Loss 7.7 (2.0) 7.4(2.4) 
Rosenberg Self Esteem Scale 25.0 (6.1) 22.8 (5.4) 
The presence of statistically significant differences between the two treatment 
groups poses a significant statistical problem. Given that participants were 
randomised to their respective treatment groups it could be argued that there is 
therefore no need to statistically account for these baseline differences in the 
subsequent statistical analysis of treatment outcome. In this case the 
appropriate analysis for these data is repeated measures Analysis of Variance 
(ANOVA). On the other hand, the presence of statistically significant 
differences on these important variables at baseline suggests that those 
randomised to CBT + TAU had significantly higher levels of psychological 
distress and lower self esteem prior to the provision of the experimental 
treatment. Given that the level of psychological distress experienced at 
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baseline is likely to be one highly important factor associated with the level of 
psychological distress at 12-months it was decided to statistically control for 
these baseline differences during the analysis of treatment outcome. Therefore 
an analysis of covariance (ANCOVA) was carried out, with baseline ratings on 
the dependent variable entered as the covariate, and treatment condition as the 
independent variable (CBT + TAU versus TAU alone). 
7.3 Results 
7.3.1 Baseline Characteristics 
Baseline scores on the BSI, PBIQ and RSES between treatment groups are 
shown in Table 7.1. Participants in CBT + TAU had significantly higher levels 
of depression (t = -2.5, df = 123, p=0.015, Mean difference = -0.48: 95% CI, 
-0.86 to -0.05), psychoticism (t = -2.1, df = 123, p=0.035, Mean difference = 
-0.36: 95% CI, -0.68 to -0.02), and positive symptom distress index (t = -2.0, 
df = 123, p=0.046, Mean difference = -0.27: 95% Cl, -0.53 to -0.05) as 
measured by the Brief Symptom Inventory. In addition, CBT + TAU 
participants had significantly lower levels of self-esteem (t = 12.1, df = 126, p 
= 0.034, Mean difference = -2.19: 95% CI, -4.21 to -0.17) as measured by the 
Rosenberg Self Esteem Inventory. Given these significant differences at 
baseline, Repeated Measures Analysis of Covariance (ANCOVA) was 
selected to examine changes in psychological distress (BSI) negative beliefs 
about illness (PBIQ) and self-esteem (RSES) between CBT + TAU and TAU 
alone treatment groups over time. 
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7.3.2 Is CBT effective in reducing psychological distress? 
Table 7.2 shows BSI subscale means and standard deviations at pre-treatment, 
3-months, 6-months and 12-months. Repeated measures Analysis of 
Covariance (Tables 7.3 a and b) shows that both groups improved over time 
on all the BSI subscales and total scores except for Psychoticism (F (3,321) = 
2.3, p=0.077). There were also significant covariate and time by covariate 
effects for all subscales and total scores on the BSI. There was a significant 
time by group effect for Obsessive Compulsive symptoms (F (3,321) = 3.4, p 
= 0.018). A Post hoc t-test revealed that differences between CBT + TAU and 
TAU alone were not significant (t (123) = 0.1, p=0.929). There were no 
significant effects for group on the BSI. 
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Table 7.2 Means and standard deviations of BSI by CBT + TAU (n=66) and 
TAU alone (n = 67), at pre - treatment, 2- month, 6- month and 12 - month 
assessment points 
Variable Pre 
treatment 3- months 6- months 12 - months 
Mean (Sd)----- Mean_(Sd)---- Mean (Sd) Mean ýSdý 
Somatisation 
CBT + TAU 0.9 (0.8) 0.8 (0.7) 0.8 (0.7) 0.7 (0.6) 
TAU alone 0.8 (0.8) 0.8 (0.9) 0.6 (0.7) 0.8 (0.8) 
Obsessive Compulsive 
CBT + TAU 1.6(l. 1) 1.5(l. 0) 1.5(l. 2) 1.3 (0.9) 
TAU alone 1.3 (0.9) 1.2(l. 0) 1.0 (0.9) 1.3 (1.1) 
Interpersonal Sensitivity 
CBT+TAU 1.6(l. 2) 1.4(l. 2) 1.4(l. 2) 1.2(l. 1) 
TAU alone 1.2(l. 1) 1.3(l. 2) 1.0 (1.0) 1.2(l. 2) 
Depression 
CBT+ TAU 1.7(l. 2) 1.4(l. 1) 1.4(l. 2) 1.2(l. 0) 
TAU alone 1.2(l. 0) 1.2(l. 0) 0.9 (0.9) 1.0 (0.9) 
Anxiety 
CBT + TAU 1.2(l. 0) 1.3(l. 0) 1.2(l. 0) 1.0 (0.9) 
TAU alone 1.2(l. 0) 1.2(l. 0) 1.0 (0.9) 1.1 (1.0) 
Hostility 
CBT + TAU 0.6 (0.8) 0.6 (0.8) 0.6 (0.8) 0.5 (0.6) 
TAU alone 0.6 (0.6) 0.6 (0.7) 0.5 (0.7) 0.6 (0.8) 
Phobic anxiety 
CBT + TAU 1.5(l. 2) 1.4(l. 1) 1.4(l. 2) 1.2(l. 1) 
TAU alone 1.2 (1.2) 1.1 (1.1) 1.1 (1.1) 1.1 (1.1) 
Paranoid ideation 
CBT + TAU 1.3(l. 0) 1.2(l. 0) 1.1 (1.1) 1.0 (1.0) 
TAU alone 0.9 (0.9) 1.0 (1.0) 0.9 (0.8) 1.0 (1.1) 
Psychoticism 
CBT + TAU 1.4(l. 0) 1.3(l. 1) 1.2(l. 1) 1.0 (1.0) 
TAU alone 1.0 (0.8) 1.0 (0.9) 0.8 (0.9) 0.9 (1.0) 
Global severity index 
CBT + TAU 1.3 (0.8) 1.2 (0.8) 1.2 (0.9) 1.0 (0.7) 
TAU alone 1.0 (0.7) 1.0 (0.8) 0.8 (0.7) 1.0 (0.8) 
Positive symptom total 
CBT + TAU 29.5 (14.8) 29.3 (14.5) 28.8 (15.5) 26.3 (14.6) 
TAU alone 27.0 (13.1) 26.2 (14.3) 23.8 (14.5) 23.9 (15.1) 
Positive symptom distress 
index 
CBT + TAU 2.1 (0.8) 1.9 (0.7) 1.9 (0.8) 1.8 (0.7) 
TAU alone 1.8 (0.7) 1.8 (0.8) 1.6 (0.6) 1.8(0.8) 
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Table 7.3a Psychological distress at 12-months (CBT + TAU versus TAU alone) 
Adjusted 
Mean 
(Standard 
Error 
Brief Symptom 
Inventory 
Somatisation 
CBT + TAU 
TAU alone 
Obsessive Compulsive 
CBT + TAU 
TAU alone 
Interpersonal 
Sensitivity 
CBT + TAU 
TAU alone 
Depression 
CBT + TAU 
TAU alone 
Anxiety 
CBT + TAU 
TAU alone 
Hostility 
CBT + TAU 
TAU alone 
Phobic anxiety 
CBT + TAU 
TAU alone 
Paranoia 
CBT + TAU 
TAU alone 
F 
Error (dl) _ 
Time (3) = 5.3 
Time x Covariate (3) = 15.4 
0.77 (0.44) Time x Condition (3) = 1.7 
Covariate (1) = 295.3 
0.77 (0.47) Condition (1) = 0.0 
Time (3) = 3.9 
Time x Covariate (3) = 10.7 
1.40 (0.57) Time x Condition (3) = 3.4 
Covariate (1) = 386.6 
1.35 (0.61) Condition (1) = 0.4 
Time(3)=3.9 
Time x Covariate (3) = 11.7 
1.31 (0.72) Timex Condition (3) = 0.9 
Covariate (1) = 266.2 
1.34 (0.76) Condition (1) = 0.1 
Time (3) = 3.1 
Time x Covariate (3) = 15.8 
1.30 (0.65) Timex Condition (3) = 1.2 
Covariate (1) = 276.0 
1.28 (0.69) Condition (1) = 0.1 
Time (3) = 5.3 
Time x Covariate (3) = 15.5 
1.23 (0.61) Timex Condition (3) = 1.4 
Covariate (1) = 280.8 
1.11 (0.64) Condition (1) =1.7 
Time (3) = 3.8 
Time x Covariate (3) = 13.5 
0.62 (0.05) Timex Condition (3) =1.1 
Covariate (1) = 206.9 
0.55 (0.05) Condition (1) = 0.9 
Time (3) = 4.9 
Time x Covariate (3) =15.5 
1.29 (0.63) Timex Condition (3) = 0.1 
Covariate (1) = 387.7 
1.27 (0.66) Condition (1) = 0.1 
Time (3) = 4.5 
Time x Covariate (3) = 12.7 
1.08 (0.61) Time x Condition (3) = 0.3 
Covariate (1) = 274.6 
1.10 (0.64) Condition (1) = 0.1 
*p <. 05, **p <. 01, ***p <. 001 
Sig 
P= 
0.001** 
0.000*** 
0.169 
0.000*** 
0.941 
0.009** 
0.000*** 
0.018* 
0.000*** 
0.555 
0.009** 
0.000*** 
0.461 
0.000*** 
0.779 
0.027* 
0.000*** 
0.315 
0.000*** 
0.787 
0.001** 
0.000*** 
0.253 
0.000*** 
0.192 
0.011* 
0.000*** 
0.359 
0.000*** 
0.353 
0.002** 
0.000*** 
0.965 
0.000*** 
0.818 
0.004** 
0.000*** 
0.835 
0.000*** 
0.833 
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Table 7.3 b Psychological distress at 12-months (CBT + TAU versus TAU alone) 
Adjusted F Sig 
Mean Error (dt) =P= 
(Standard 
Error 
Brief Symptom 
Inventory 
Psychoticism 
CBT + TAU 
TAU alone 
Global severity Index 
CBT + TAU 
TAU alone 
Positive Symptom 
Index 
CBT + TAU 
TAU alone 
Positive Symptom 
Distress Index 
CBT + TAU 
TAU alone 
*p <. 05, **p <. 01, ***p <. 001 
Time (3) = 5.8 0.001** 
Time x Covariate (3) =13.5 0.000*** 
Time x Condition (3) = 2.4 0.069 
Covariate (1) = 212.0 0.000*** 
Condition (1) = 0.0 0.901 
7.3.3 Is CBT effective in reducing negative appraisals of psychosis? 
Table 7.4 shows PBIQ subscale means and standard deviations at pre- 
treatment, 3-months, 6-months and 12-months. Repeated measures analysis of 
covariance (ANCOVA) shows that there were significant time, covariate, and 
time by covariate effects on all PBIQ subscales. There were no significant 
group or time by group effects on any of the PBIQ subscales (Table 7.5). 
Time (3) = 2.3 0.077 
Time x Covariate (3) = 9.0 0.000*** 
1.15 (0.65) Timex Condition (3) = 0.5 0.677 
Covariate (1) = 229.5 0.000*** 
1.06 (0.68) Condition (1) = 0.8 0.363 
Time (3) = 2.7 0.047* 
Time x Covariate (3) = 9.0 0.000*** 
1.11 (0.46) Time x Condition (3) = 1.2 0.316 
Covariate (1) = 344.9 0.000*** 
1.08 (0.49) Condition (1) = 0.2 0.652 
Time (3) = 2.7 0.046* 
Time x Covariate (3) = 6.9 0.000*** 
28.06 (0.845) Time x Condition (3) = 1.1 0.343 
Covariate (1) = 349.8 0.000*** 
26.15 (0.892) Condition (1) = 2.4 0.112 
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Table 7.4 Means and standard deviations of PBIQ & RSES by CBT + TAU 
(n=66) and TAU alone (n = 67). at pre - treatment, 2- month, 6- month and 12 
- month assessment points 
Variable Pre - 
treatment 3- months 6- months 12 - months 
Mean Sd Mean Sd Mean Sd Mean Sd 
------- --- PBIQ 
Self versus Illness 
CBT + TAU 9.3 (2.7) 8.9 (2.4) 8.5 (2.3) 8.6 (2.4) 
TAU alone 8.8 (2.9) 8.8 (2.6) 8.7 (2.4) 8.7 (2.2) 
Entrapment 
CBT + TAU 10.1 (2.4) 10.0 (2.5) 9.4 (2.2) 9.4 (2.5) 
TAU alone 10.1 (2.8) 9.6 (2.8) 9.3 (2.7) 9.7 (2.5) 
Shame 
CBT + TAU 7.4 (2.1) 7.1 (1.7) 7.0 (1.8) 6.9(l. 8) 
TAU alone 7.0 (1.8) 7.0 (1.9) 6.9(l. 8) 7.1 (1.8) 
Humiliation 
CBT + TAU 4.4 (0.8) 4.5 (1.0) 4.6(l. 1) 4.5(l. 1) 
TAU alone 4.6(l. 0) 4.5(l. 0) 4.4(l. 2) 4.3(l. 2) 
Loss 
CBT + TAU 7.7 (2.0) 7.1 (2.1) 7.1 (2.1) 7.0 (2.1) 
TAU alone 7.4 (2.4) 7.3 (2.3) 7.0 (2.3) 7.5 (2.0) 
RSES 
CBT + TAU 25.0 (6.1) 23.9 (5.6) 23.8 (5.6) 22.7 (6.3) 
TAU alone 22.8 (5.4) 23.5 (5.6) 22.9 (4.7) 23.3 (5.1) 
7.3.4 Is CBT effective in negative appraisals of self? 
Table 7.4 summarises pre-treatment, 3-month, 6-month and 12-month means 
and standard deviations for self esteem by treatment group. Using repeated 
measures analysis of covariance (ANCOVA), there were significant time, 
covariate, and time by covariate effects for self-esteem. There was a 
significant group effect (F (1,113) = 4.6, p=0.034). However, a post hoc t-test 
showed that differences between CBT + TAU and TAU alone at 52-weeks 
were not significant (t (123) = 0.6, p=0.547). There was no significant time 
by group effect for self-esteem (Table 7.5). 
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Table 7.5 Negative appraisals of psychosis and self at 12-months (CBT + TAU 
versus TAU alone) 
Adjusted 
Mean 
(Standard 
Error 
F 
Error (dl) _ 
Sig 
P= 
Personal Beliefs about 
Illness Questionnaire 
Self versus Illness 
CBT + TAU 8.74 (0.153) 
TAU alone 8.85 (0.166) 
Entrapment 
CBT + TAU 9.80 (0.169) 
TAU alone 9.70 (0.183) 
Shame 
CBT + TAU 7.06 (0.114) 
TAU alone 7.09 (0.124) 
Humiliation 
CBT + TAU 4.55 (0.076) 
TAU alone 4.44 (0.082) 
Time (3) = 25.0 0.000*** 
Time x Covariate (3) = 34.1 0.000*** 
Time x Condition (3) = 0.6 0.643 
Covariate (1) = 230.3 0.000*** 
Condition (1) = 0.2 0.622 
Time (3) = 15.1 0.000*** 
Time x Covariate (3) = 21.2 0.000*** 
Time x Condition (3) = 1.2 0.309 
Covariate (1) =165.3 0.000*** 
Condition (1) = 0.2 0.675 
Time (3) = 20.7 0.000*** 
Time x Covariate (3) = 25.0 0.000*** 
Time x Condition (3) = 0.2 0.868 
Covariate (1) = 198.7 0.000*** 
Condition (1) = 0.0 0.840 
Time (3) = 14.6 0.000*** 
Time x Covariate (3) = 15.8 0.000*** 
Time x Condition (3) = 0.6 0.591 
Covariate (1) = 67.1 0.000*** 
Condition (1) =1.1 0.301 
LOSS 
CBT + TAU 7.12 (0.133) 
TAU alone 7.37 (0.143) 
Rosenberg Self Esteem 
Scale 
CBT + TAU 
TAU alone 
*p <. 05, ***p < . 001 
Time (3) = 11.4 0.000*** 
Time x Covariate (3) = 16.1 0.000*** 
Time x Condition (3) =1.4 0.237 
Covariate (1) = 256.7 0.000*** 
Condition (1) = 1.7 0.197 
Time (3) = 9.6 0.000*** 
Time x Covariate (3) = 11.7 0.000*** 
Time x Condition (3) = 2.4 0.064 
Covariate (1) = 460.5 0.000*** 
Condition (1) = 4.6 0.034* 
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7.4 Discussion 
The study examined the effect of CBT for relapse on measures of 
psychological distress, negative appraisals of psychosis, and negative 
appraisals of self. The study did not find any evidence that receipt of CBT in 
addition to TAU was associated with reduced psychological distress, negative 
appraisals of self and psychosis at 52-weeks. On the other hand, there were 
significant time effects on all these variables, showing that in general, and 
amongst this group of participants, levels of psychological distress, negative 
appraisals of psychosis, and negative appraisals of self improve over time. 
Therefore, given that the CBT examined in the present study was targeting 
negative appraisals of self and psychosis, and these appraisals are linked to the 
development of psychological distress (Birchwood et al., 1993; Iqbal et al., 
2000), then why did the treatment in this study not result in reduced 
psychological distress and negative appraisals of self and psychosis? 
The format of CBT examined in this study was specifically tailored to the 
detection and prevention of relapse. This treatment targeted negative 
appraisals of self and psychosis during the early stages of relapse. Whilst these 
beliefs are known to mediate the development of psychological distress, the 
format of treatment may not have permitted generalisation of context specific 
treatment effects concerning relapse to more generic self-representations 
related to psychological morbidity. Research suggests that the origins of the 
beliefs targeted during early signs of relapse probably lie in the early 
experience of the initial episodes of psychosis (e. g. Iqbal et al., 2000). Igbal et 
al., (2000) have proposed that, in line with Gilbert (1992) certain life situations 
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are likely to be depressogenic, particularly if they encapsulate feelings of loss, 
humiliation and entrapment. In line with their proposal, psychosis is seen as a 
life event whose appraisal may involve these elements. Furthermore, Jackson 
& Iqbal (2000) suggest that the impact of psychosis can be understood with 
reference to trauma theory (e. g. Janoff-Bulman, 1992) and propose that 
psychosis can act to undermine or indeed "shatter" pre-existing assumptions 
about self, world and future, or indeed, for those who have experienced early 
adversity, psychosis may confirm premorbid beliefs concerning personal 
vulnerability and negative evaluation. Drayton et al., (1998) found that those 
individuals who seal over or deny significant aspects of their illness were more 
likely to view their early experience of parenting as less caring, than those 
who were categorised as integrators. In this sense, sealing over may represent 
a marker of psychological vulnerability arising from the interaction between 
early experience and psychosis, as proposed by Fowler et al., (2000). 
Therefore it is likely that CBT designed specifically for the treatment of 
psychological distress may well require a more extended treatment protocol 
focused on the modification and transformation of negative beliefs concerning 
self and psychosis. If successful such a treatment could have a number of 
advantages over the treatment examined in this study. Obviously a more 
extended protocol designed for the treatment of psychological co-morbidity 
should result in reduced psychological distress. However, if successful such a 
treatment should result in improved negative appraisals of self and psychosis. 
Given that these self-representations are implicated in vulnerability to relapse 
(Chapter 5) and are associated with social functioning (Chapter 6), a more 
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extended treatment may also reduce medium to long-term vulnerability to 
relapse, and produce more widespread improvements in social functioning. In 
addition, such a treatment may reduce the necessity to rely on implementing 
targeted phases of treatment during periods of increased relapse risk. These 
hypotheses could be addressed in future treatment outcome research in CBT 
for psychosis. 
The finding that receipt of the CBT employed in this study resulted in reduced 
relapse and admission (Chapter 5) and improved remission and prosocial 
functioning (Chapter 6) but did not produce changes in psychological distress 
and negative appraisals of self and psychosis also begs important theoretical 
questions. The CBT targeted negative appraisals of self and psychosis in the 
specific context of early signs of relapse. It may therefore be possible that the 
beliefs targeted amongst those participants who received targeted CBT were 
specific to that context, and that any changes in those beliefs during that phase 
were not elaborated to corresponding or associated mental representations. If 
this is the case then future experimental research could investigate biases in 
cognitive processes amongst individuals who are at high risk of relapse versus 
those who are low risk of relapse, or amongst individuals during remission and 
during early relapse. For example, it is now well established that clinical 
anxiety patients commonly display an encoding advantage for threat-related 
information (Macleod, 1990,1991; Macleod & Mathews, 1991) which has 
been demonstrated through the use of the Stroop colour naming interference 
paradigm (Stroop, 1938). Anxiety patients have difficulty ignoring the content 
of threat-related words, revealed by disproportionately long colour naming 
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latencies for these words in comparison to non-threat words. In contrast 
anxiety patients typically do not show facilitated recall or recognition memory 
for threat-related stimuli (Macleod, 1990,1991; Macleod & Mathews, 1991). 
Such explicit memory tasks require subjects to consciously recollect 
previously presented stimulus items. In contrast, implicit memory tasks do not 
require conscious recollection of past experience but assess retention by 
assessing the degree to which previous exposure to stimulus items passively 
serves to facilitate subsequent processing of the same stimuli. A number of 
investigators (Mathews et al., 1989; Zeitlin & McNally, 1991; Richards & 
French, 1991; Macleod & McLaughlin, 1995) have found that anxiety patients 
have an implicit memory bias for threat-related words. According to Graf & 
Mandler (1984) integration of stimulus information is an automatic process 
that strengthens the internal structure of a stimulus representation, thus making 
that representation more accessible in the sense that activation of any part will 
serve to activate the whole. In consequence, stimuli corresponding to 
representations that are in a high state of integration will tend to `pop out' of 
the stimulus array, and hence will tend to be selectively encoded. In contrast, 
elaboration is a strategic process that serves to establish and strengthen 
associative connections between a mental representation and other existing 
representations in memory. A highly elaborated representation will be 
disproportionately easy to retrieve on intentional memory tasks, such as recall 
and recognition. Williams et al., (1988) hypothesise that elevated anxiety is 
characterised by emotionally congruent integrative processing but not 
emotionally congruent elaborative processing, which accounts for the finding 
that anxious patients show emotionally congruent encoding biases, implicit 
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memory biases, but not explicit memory biases. Such an account has an 
appealing application to relapse in psychosis and could be investigated in 
experimental research. If correct, then during relapse, individuals would show 
emotionally congruent encoding biases, and implicit memory biases, but not 
explicit memory biases in comparison with individuals who are stable and 
remitted. In addition those at high risk of relapse would show a similar pattern 
of results in comparison with those who are at low risk. In terms of the form of 
CBT employed in this study, the strategies employed may have addressed 
emotionally congruent integrative processing as opposed to emotionally 
congruent elaborative processing, which would account for the failure of CBT 
to result in improvements in psychological distress and negative appraisals of 
self and psychosis in comparison to TAU alone. Furthermore context specific 
changes in negative beliefs about self and psychosis could be investigated in 
longitudinal studies. As the present study examined these appraisals at entry, 
3-months, 6-months and 12-months it would be possible to examine changes 
in these appraisals amongst relapsers and non-relapsers over time. Chapter 8 
will now investigate this question. 
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Chapter 8 
Negative appraisals of self and psychosis and the development of psychological 
co-morbidity: an explorative analysis of relapsers and non-relapsers. 
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8.1 Introduction 
In Chapter 2, eight studies (Subotnik & Neuchterlein, 1988; Birchwood et al. 
1989; Gaebel et al. 1993; Jolley et al. 1990; Jorgensen, 1998; Marder et al. 
1991; Marder et al. 1994; Tarrier et al. 1991) which have reported the 
sensitivity and specificity of early "prodromal" signs to relapse were 
reviewed. The findings on sensitivity ranged from 8 to 88%, and specificity 
from 64 to 93%. Strict comparison across these studies was problematic given 
the nature of differences in methodology and design. It was, however, clear 
that when studies included positive symptoms or incipient psychosis in their 
definitions of "prodromes" (Subotnik & Nuechterlein, 1988; Birchwood et al., 
1989; Tamer et al., 1991; Jorgensen, 1998), this inclusion increased the 
sensitivity of "prodromes" to relapse. This finding questions the very basis of 
the concept of the prodrome itself. Prodromes are viewed as dichotomous 
phenomena; that is events, which occur before a relapse. The inclusion of low 
level positive psychotic symptoms, such as ideas of reference or thought 
control, changes the concept of relapse to a more continuous model, where the 
appearance of increased dysphoric symptoms represent an individual's 
response to the re-emergence of psychotic symptoms. Such a continuous 
model of relapse therefore sees apparent prodromal signs, as evidence of early 
stages of relapse. The consistency of the findings on specificity, which are 
reported across these studies (64 to 93%), is supportive of this proposal. That 
is, when non-psychotic symptoms increase they are almost always, but not 
inevitably followed by a relapse in positive psychotic symptoms. 
Chapter 3 examined the possible psychological factors, which may account for 
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the idiosyncratic nature of dysphoric responses during early relapse. For 
example, Birchwood (1995) pointed out that the individual variations in the 
nature and timing of early signs will act to reduce their apparent amplitude in 
group studies. Group studies fail to capture the qualitative and quantitative 
differences between individuals in their early signs. Therefore it may be more 
appropriate to think of early signs as an individualised configuration of 
symptoms which Birchwood refers to as a `relapse signature'. Birchwood 
(1995) accounts for this variation in the nature and timing of early signs by 
integrating individual's own idiosyncratic response to emerging relapse. This 
cognitive explanation for the variation in early signs suggests that dysphoric 
symptoms such as anxiety, tension, withdrawal, depressed mood, 
suspiciousness, and sleeplessness arise from the way in which individuals 
explain and interpret internal and external events. Birchwood (1995) proposes 
that the attributions made by individuals to account for and explain the 
emergence of disturbing symptoms can serve to either accelerate or retard the 
process of relapse. In this model, dysphoria is seen as a response to the fear of 
impending relapse (perhaps for those with previous experience of relapse) or a 
failure to explain symptoms and experiences (perhaps for those with less 
experience of relapse). This model might therefore predict that those 
individuals with extensive prior experience of relapse and its associated 
negative repercussions would respond with high levels of fear and perhaps 
helplessness leading to depression and withdrawal. On the other hand, those 
with less experience may respond with puzzlement, confusion and perplexity. 
The model may also help explain the speed at which relapse proceeds by 
specifying the cognitive mechanisms and associated emotional consequences 
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responsible for acceleration. In Chapter 3, I proposed that the definitions, 
which are currently used to capture sensitivity of early signs could well benefit 
from definitions more closely allied to how individuals' appraise their 
experience of psychosis rather than relying on a more closely delineated set of 
individual signs and symptoms alone. For example, for an individual a 
combination of signs and symptoms such as increased sleep disturbance, 
reduced attention and concentration and increased agitation may trigger 
negative beliefs concerning the control of (e. g. "I can't control my illness"), or 
consequences of relapse (e. g. "I'll let everyone down", "I'm a failure"). If the 
clinician pays sole attention to the occurrence of specific signs and symptoms, 
they risk failing to capture the central meanings experienced by the individual. 
Therefore, configurations of early signs which are more closely allied to the 
schematic meanings activated during early relapse may increase sensitivity, 
and reduce the apparent variance in the nature and timing of experiences 
signaling future relapse. Second, the activation of negative beliefs concerning 
psychosis results in a range of negative automatic thoughts, distressing 
emotions, and safety behaviours, which may lead to the acceleration of 
relapse. Therefore the activation of negative beliefs about self, and self in 
relation to psychosis constitute the central engine responsible for relapse 
acceleration. Interventions targeted on these beliefs during the early relapse 
phase may therefore be effective in preventing or ameliorating relapse. In 
Chapter 5, I provided some preliminary evidence that negative appraisals of 
self and entrapment in illness were predictive of relapse, and that negative 
appraisals of self were predictive of duration to relapse. These findings were 
interpreted as evidence of a role for these cognitive factors in conferring a 
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vulnerability to relapse. 
However, negative appraisals of self and psychosis have also been found to be 
associated with the development of Post Psychotic Depression (PPD; 
Birchwood et al., 2000; Igbal et al., 2000). Birchwood et al., (2000) found that 
in a sample of 105 individuals with schizophrenia, 36% (n = 28) developed 
PPD without concomitant changes in positive and negative symptoms. Igbal et 
al., (2000) have proposed that, in line with Gilbert (1992) certain life 
situations are likely to be depressogenic, particularly if they encapsulate 
feelings of loss, humiliation and entrapment. In line with their proposal, 
psychosis is seen as a life event whose appraisal may involve these elements. 
Participants who developed PPD were more likely than their non-PPD 
counterparts to attribute the cause of psychosis to themselves, perceive greater 
loss of autonomy and valued role, and perceive themselves to be entrapped 
and humiliated by their illness. In the same study, Igbal et al., (2000) did not 
find that individuals who relapsed (n = 11,10.5%) during the study, differed 
from non-relapsers without PPD (n = 31,29.5%) in their appraisal of 
psychosis (loss, humiliation and entrapment), insight, self-esteem, 
sociotrophy, self-efficacy or self-criticism. Iqbal and colleagues concluded 
that "there were no cognitive vulnerability factors for psychotic relapse, in 
stark contrast to PPD: different processes would seem to be in operation" (p 
526). However differences between these groups on appraisals of shame and 
attribution of blame for illness are not reported. How can these disparate 
findings be reconciled? Birchwood and colleagues propose that according to 
the social ranking theory of depression (Gilbert, 1992): 
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"The effect of powerful and oppressive experiences (or shattering life 
events, such as psychotic illness).... Initiates an internal defensive 
mechanism that forces the individual to 'down-rank' and yield to 
others, particularly if escape is blocked (entrapment). This mechanism 
may be accompanied by cognitions that are `self-attacking' leading to 
feelings of inferiority and self-blame. " (p. 526) 
If Birchwood and colleagues' proposal is correct then (1) relapse will be 
associated with the development of psychological co-morbidity and, (2) 
relapse itself will be associated with increasing negative appraisals concerning 
psychosis. 
Abramson et al., (1978) have proposed that individuals who are vulnerable to 
depression tend to explain negative events in terms of being caused by 
themselves (internal to self), unlikely to change over time (stable) and likely to 
pervade all areas of their lives (global). This theory was later developed to 
suggest that a stable and global attributional style for negative events 
represents a cognitive vulnerability to depression that in the context of 
stressful life events generates hopelessness and helplessness (Abramson et al. 
1989). The Temple-Wisconsin Cognitive Vulnerability to Depression project 
found that non-depressed, euthymic individuals who have such a pessimistic 
attributional style combined with dysfunctional attitudes towards self 
evaluation are at high risk of developing depression at a later date (Alloy et al., 
1999). 
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The findings in Chapter 5, suggest that individuals who go on to relapse 
already have greater feelings of inferiority and self-criticism (Rosenberg Self 
Esteem Scale) and perceive themselves as unable to control by their psychosis 
(entrapment). Therefore with their perception of escape from psychosis 
blocked it is hypothesised that individuals will react to the reemergence of 
psychosis with increased self-blaming attributions, a sense shame and 
humiliation, and an increased perception of loss of autonomy and social role. 
Through these appraisals of their psychosis, relapse will therefore be 
associated with the emergence of psychological comorbidity. 
8.2 Method 
Methodology, case identification, and criteria for relapse are described in 
Chapter 5. To summarise briefly, 144 individuals with a diagnosis of a 
schizophrenia spectrum disorder, who were outpatients, receiving 
antipsychotic medication, and considered relapse prone, were entered into a 
pragmatic clinical trial of Cognitive Behavioural Therapy for relapse. 
Participants were randomly allocated to receive treatment as usual (TAU 
alone) or TAU plus Cognitive Behavioural Therapy (CBT + TAU). Relapse 
was identified prospectively, and assessments were carried out at four time 
points: at entry, 12 weeks, 26 weeks, and 52 weeks. A total of 133 participants 
completed the study (66 CBT + TAU and 67 TAU). Amongst this completers 
group 34 relapses were identified over 12-months; 10 (14.9%) in CBT + TAU 
and 24 (35.8%) from TAU alone. 
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8.2.1 Hypotheses 
First, relapsing participants will show increasing negative appraisals of 
psychosis over time, in comparison to non-relapsing participants. 
Second, relapsing participants will show increasing negative appraisals of self 
over time, in comparison to non-relapsing participants. 
Third, relapsing participants will show higher levels of psychological co- 
morbidity at 12-months, in comparison to non-relapsing participants. 
8.2.2 Measures 
8.2.2.1 Negative appraisals of psychosis 
Cognitive vulnerability to relapse was assessed using two measures. First, 
participants' appraisal of their illness was evaluated using the Personal Beliefs 
about Illness Questionnaire (PBIQ; Birchwood et al., 1993; Appendix C). The 
PBIQ is comprised of 16-items rated on a four-point scale and assesses 
individuals' beliefs in five domains: loss, humiliation, shame, attribution of 
behaviour to self or to illness, and entrapment in psychosis. The scale has been 
demonstrated to have good reliability and validity with schizophrenia. 
8.2.2.2 Negative appraisals of self 
Negative beliefs concerning participants' worth and value were assessed using 
the Rosenberg Self-Esteem Scale (RSES; Rosenberg, 1965; Appendix D). The 
RSES is a ten-item self-report measure of self-esteem. The scale was 
originally developed as a measure to assess self-esteem in adolescents but has 
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been widely used in adult populations. Rosenberg (1965) proposed a complex 
scoring system, which was simplified by Corcoran & Fischer, (1987). Items 
are in statement form, and respondents are asked to rate their agreement on a 
four point Guttman Scale (strongly agree to strongly disagree). The RSES 
gives a score range of 4 to 40, with higher scores indicating lower self-esteem. 
8.2.2.3 Psychological co-morbidity 
Psychological distress was measured using the Brief Symptom Inventory 
(BSI; Derogatis & Melisaratos, 1983; Appendix B). This self-rated instrument 
gives measures across nine symptom dimensions: somatisation, obsessive - 
compulsive symptoms, interpersonal sensitivity, depression, anxiety, hostility, 
phobic anxiety, paranoid ideation, and psychoticism. The BSI gives three 
global indices of distress: the Positive Symptom Total (PST), the Positive 
Symptom Distress Index (PSDI) and the Global Severity Index (GSI). The 
PST is simply a count of the symptoms which individuals report experiencing 
to any degree. The PSDI is an intensity of distress measure, corrected for the 
number of symptoms positively endorsed. According to Derogatis & 
Melisaratos (1983) PSDI functions as a measure of response style, 
communicating whether an individual is `augmenting' or `attenuating' distress 
in their manner of reporting. According to the authors, the GSI is the single 
best indicator of current distress levels. The GSI combines information on the 
numbers of symptoms reported, and the intensity of perceived distress 
associated with those symptoms. 
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8.2.3 Data Analysis 
Participants who were in the CBT + TAU group were excluded from the 
analysis because the therapy, which entailed interventions before and during 
the early relapse phase included interventions targeted at reducing negative 
appraisals of self and psychosis, and psychological distress, could have altered 
the relationships between the variables. Indeed the CBT deliberately 
manipulated many of the variables considered in the analysis described below. 
Therefore, a longitudinal analysis was conducted on participants in the TAU 
alone group. Comparison of baseline characteristics of relapsers (n = 24, 
35.8%) and non-relapsers (n = 43,64.2%) was made using Multivariate 
ANOVA. Changes over time in negative appraisals of self and psychosis 
between relapsers and non-relapsers were examined using Repeated Measures 
ANOVA. Psychological distress was examined using Multivariate ANOVA 
controlling for any pre-treatment differences in baseline measures. 
8.2.4 Baseline Characteristics 
Table 8.1 below summarises the baseline ratings on the PANSS and the BSI of 
the study sample of participants in TAU. There were no significant differences 
between the two groups. Table 7.1 also summarises the baseline ratings of the 
PBIQ and RSES. There were no significant differences between relapsers and 
non-relapsers on subscales of the PBIQ. Relapsers had significantly higher 
baseline scores on the Rosenberg Self Esteem Scale indicating higher negative 
appraisals of self (F (1,59) = 4.6, p=0.036). 
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Table 8.1 Baseline characteristics (PANSS & BSI) of relapsers versus non- 
relapsers in TAU 
Relapsers 
N=20 
Mean (s. d. ) 
Positive and Negative Syndrome 
Scale 
Positive symptoms 
Negative symptoms 
Global Psychopathology 
Brief Symptom Inventory (BSI) 
Somatisation 
Obsessive compulsive 
Interpersonal sensitivity 
Depression 
Anxiety 
Hostility 
Phobic anxiety 
Paranoid ideation 
Psychoticism 
Global severity index (GSI) 
Positive symptom total (PST) 
Positive symptom distress index 
(PSDI) 
Personal beliefs about Illness 
Questionnaire (PBIQ) 
Self versus illness 
Entrapment 
Shame 
Humiliation 
Loss 
Rosenberg Self Esteem Scale 
*p <. 05 
Non-relapsers F Sig 
n=40 1,59 p 
Mean (s. d. ) 
10.90 (2.71) 
12.75 (6.34) 
29.00 (7.09) 
10.15 (2.61) 
12.18 (4.48) 
29.00 (6.43) 
1.1 0.305 
0.2 0.686 
0.0 1.000 
0.65 (0.69) 2.2 0.140 
1.16 (0.78) 3.6 0.063 
1.16 (1.14) 0.2 0.661 
1.11 (0.86) 1.7 0.199 
1.07 (0.87) 1.6 0.209 
0.49 (0.47) 2.6 0.111 
1.01 (1.05) 1.7 0.192 
0.81(0.82) 3.2 0.080 
0.86 (0.71) 3.4 0.070 
0.93 (0.56) 3.1 0.082 
25.25 (12.76) 1.7 0.200 
1.78 (0.71) 1.0 0.330 
0.98 (0.99) 
1.62 (1.08) 
1.30 (1.08) 
1.45 (1.15) 
1.41 (1.14) 
0.75 (0.77) 
1.42 (1.32) 
1.24 (0.97) 
1.27 (1.01) 
1.26 (0.91) 
29.90 (13.71) 
1.98 (0.74) 
8.65 (2.90) 0.3 0.583 
9.78 (3.02) 1.1 0.303 
6.90 (0.30) 0.2 0.627 
4.45 (0.17) 1.5 0.233 
7.35 (0.39) 0.1 0.826 
21.60 (0.83) 4.6 0.036* 
9.1 (3.13) 
10.60 (2.64) 
7.15 (0.42) 
4.80 (0.24) 
7.20 (0.55) 
24.70 (1.18) 
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8.3 Results 
8.3.4 Do relapsing participants show increasing negative appraisals of 
psychosis? 
The findings from the repeated measures analysis of variance on negative 
appraisals of psychosis (PBIQ) are summarised in Table 8.2 below. There 
were no significant time effects for any of the PBIQ subscales. There were 
significant group effects for self versus illness (F (1,52) = 5.8, p=0.020), and 
entrapment (F (1,52) = 6.1, p=0.017), with relapsers having significantly 
higher ratings of self-blame for illness (Figure 8.1), (t (58) = -2.6, p=0.012) 
and higher levels of perceived entrapment (Figure 8.2), (t (58) = -2.1, p= 
0.04). Simple effects F- tests revealed those differences in appraisal of self- 
blame emerged at 12-weeks (F (1,52) = 4.5, p=0.038) and were maintained 
through 26-weeks (F (1,52) = 12.6, p=0.001) to 52-weeks (F (1,52) = 6.2, p= 
0.016). Simple effects F- tests revealed those differences in appraisal of 
entrapment emerged at 26-weeks (F (1,52) = 8.8, p=0.004) and were 
maintained at 52-weeks (F (1,52) = 4.7, p=0.035). 
There were significant time by group effects found for self versus illness (F 
(3,156) = 2.9, p=0.038), shame (F (3,156) = 4.0, p=0.009), and loss (F 
(3,156) = 2.8, p=0.041). Simple effects F- tests revealed that differences in 
the appraisal of shame (Figure 8.3) emerged at 26-weeks (F (1,52) = 13.8, p= 
0.001). No significant group differences were observed for appraisals of loss 
or humiliation. 
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Table 8.2 Analysis of variance and Simple Effects on PBIO for relapsers and 
non-relapsers 
df FP Comparison 
Entrapment 
Factor A (time of assessment) 3,156 1.6 0.211 t (58) = -2.105, p=0.04 
Factor B (treatment group) 1,52 6.1 0.017* 1>2 
Interaction (A X B) 3,156 2.4 0.127 
Simple effects (SS, Factor A) 
Entry 1,52 0.7 0.422 
12-weeks 1,52 3.8 0.058 
26-weeks 1,52 8.8 0.004** 
52-weeks 1,52 4.7 0.035* 
Shame 
Factor A (time of assessment) 3,156 0.4 0.769 t (58) = -1.529, p=0.132 
Factor B (treatment group) 1,52 3.8 0.058 
Interaction (A X B) 3,156 4.0 0.009** 
Simple effects (SS, Factor A) 
Entry 1,52 0.0 0.913 
12-weeks 1,52 1.5 0.234 
26-weeks 1,52 13.8 0.001** 
52-weeks 1,52 1.5 0.219 
Humiliation 
Factor A (time of assessment) 3,156 1.1 0.366 
Factor B (treatment group) 1,52 0.8 0.365 
Interaction (A X B) 3,156 0.5 0.655 
Simple effects (SS, Factor A) 
Entry 1,52 0.8 0.387 
12-weeks 1,52 0.0 0.928 
26-weeks 1,52 0.2 0.696 
52-weeks 1,52 1.8 0.187 
Self versus Illness 
Factor A (time of assessment) 3,156 0.3 0.837 t (58) = -2.597, p=0.012 
Factor B (treatment group) 1,52 5.8 0.020* 1>2 
Interaction (A X B) 3,156 2.9 0.038* 
Simple effects (SS, Factor A) 
Entry 1,52 0.2 0.649 
12-weeks 1,52 4.5 0.038* 
26-weeks 1,52 12.6 0.001** 
52-weeks 1,52 6.2 0.016* 
Loss 
Factor A (time of assessment) 3,156 1.2 0.308 t (58) = -1.594, p=0.116 
Factor B (treatment group) 1,52 0.1 0.822 
Interaction (A X B) 3,156 2.8 0.041 * 
Simple effects (SS, Factor A) 
Entry 1,52 0.5 0.474 
12-weeks 1,52 0.1 0.712 
26-weeks 1,52 0.8 0.370 
52-weeks 1,52 1.3 0.264 
*p < 0.05, ** p<0.01, *** p<0.001. 
1= Relapsers, 2= Non-relapsers 
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Figure 8.1 Appraisals of Self versus Illness (Relapsers versus Non- 
relapsers) 
S elf versus Illness over time 
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Figure 8.2 Appraisals of entrapment of illness (Relapsers versus Non- 
relapsers) 
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Figure 8.3 Appraisals of Shame about illness (Relapsers versus Non- 
relapsers) 
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8.3.5 Do relapsing participants show increasing negative appraisals of self? 
The findings from the repeated measures analysis of variance on negative 
appraisals of self (RSES) are summarised in Table 8.3 below. There were no 
significant time, group, or time by group effects observed. Simple effects F- 
tests revealed that there were differences at 26-weeks (F (1,52) = 4.5, p= 
0.039), with relapsers having higher negative appraisals of self (Figure 8.4). 
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Table 8.3 Analysis of variance and Simple Effects on RSES for relapsers 
and non-relapsers 
df FP Comparison 
Rosenberg Self-Esteem Scale 
Factor A (time of assessment) 3,156 0.4 0.724 
Factor B (treatment group) 1,52 3.9 0.054 
Interaction (A X B) 3,156 0.3 0.820 
Simple effects (SS, Factor A) 
Entry 1,52 1.5 0.232 
12-weeks 1,52 3.3 0.077 
26-weeks 1,52 4.5 0.039* 
52-weeks 1,52 2.4 0.125 
*p < 0.05 
1= Relapsers, 2= Non-relapsers 
Figure 8.4 Negative appraisals of self (Relapsers versus Non-relapsers) 
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8.3.3 Do relapsing participants show higher levels of psychological co- 
morbidity at 12-months? 
Significant differences were observed between relapsers and non-relapsers on 
the Rosenberg Self Esteem Scale at baseline, with relapsers having 
significantly higher baseline scores on the Rosenberg Self Esteem Scale 
indicating higher negative appraisals of self (F (1,59) = 4.6, p=0.036). 
Therefore analysis of psychological co-morbidity at 12-months was conducted 
using Multivariate Analysis of Covariance (MANCOVA) with baseline scores 
for Rosenberg Self-Esteem Scale entered as the covariate. Tables 8.4 a and b 
show that significant covariate effects were observed for the following BSI 
subscales; Interpersonal Sensitivity (F (1,54) = 15.0, p<0.001), Depression 
(F (1,54) = 12.6, p=0.001), Phobic anxiety (F (1,54) = 5.2, p=0.026), 
Psychoticism (F (1,54) = 5.9, p=0.018), and Global Severity Index (F (1,54) 
= 5.5, p=0.023). 
After adjusting for baseline Rosenberg Self Esteem scores, relapsers had 
significantly higher levels of Somatisation (F (2,54) = 7.3, p=0.002), 
Obsessive Compulsive symptoms (F (2,54) = 4.8, p=0.012), Interpersonal 
Sensitivity (F (2,54) = 11.6, p<0.001), Depression (F (2,54) = 10.2, p< 
0.001), Anxiety (F (2,54) = 3.6, p=0.034), Phobic anxiety (F (2,54) = 4.8, p 
= 0.012), Psychoticism (F (2,54) = 5.4, p=0.007), Global Severity (F (2,54) 
= 6.7, p=0.006). 
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Table 8.4 a Psychological morbidity at 12-months (Relapsers versus Non- 
rela sers 
Relapsers Non- 
Brief Symptom 
Inventory (BSI) 
Somatisation 
Obsessive compulsive 
Interpersonal sensitivity 
Depression 
Anxiety 
Hostility 
Phobic anxiety 
Paranoid ideation 
Psychoticism 
F 
N=20 relapsers Error df = 54 
n=38 
Mean (s. d. ) Mean (s. d. ) 
Sig 
P- 
1.24(l. 01) 0.53 (0.54) Covariate (1) = 2.3 0.139 
Main effect (1) = 9.4 0.003** 
Interaction (2) = 7.3 0.002** 
1.82 (1.86) 1.03 (0.99) Covariate (1) = 2.3 0.138 
Main effect (1) = 5.3 0.026* 
Interaction (2) = 4.8 0.012* 
1.71 (1.24) 0.92 (1.05) Covariate (1) = 15.0 0.000*** 
Main effect (1) = 3.5 0.065 
Interaction (2) 11.6 0.000*** 
1.47 (1.05) 0.84 (0.81) Covariate (1) = 12.6 0.001** 
Main effect (1) = 3.6 0.065 
Interaction (2) = 10.2 0.000*** 
1.42 (1.15) 0.90 (0.87) Covariate (1) = 3.3 0.073 
Main effect (1) = 2.2 0.144 
Interaction (2) = 3.6 0.034* 
0.84 (1.07) 0.42 (0.52) Covariate (1) = 0.5 0.487 
Main effect (1) = 4.5 0.038* 
Interaction (2) = 2.3 0.112 
1.49 (1.26) 0.88 (1.00) Covariate (1) = 5.2 0.026* 
Main effect (1) = 2.3 0.138 
Interaction (2) = 4.8 0.012* 
1.25 (1.25) 0.90 (0.99) Covariate (1) = 0.7 0.423 
Main effect (1) = 0.9 0.348 
Interaction (2) =1.0 0.372 
1.24 (1.21) 0.69 (0.77) Covariate (1) = 5.9 0.018* 
Main effect (1) = 2.5 0.124 
Interaction (2) = 5.4 0.007** 
*p <. 05, **p <. 01, ***p < 0.001 
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Table 8.4 b Psychological morbidity at 12-months (Relapsers versus Non- 
rela sers 
Relapsers 
N=20 
Non- F Sig 
relapsers Error df = 54 p= 
n=38 
Mean (s. d. ) Mean (s. d. ) 
Brief Symptom 
Inventory (BSI) 
Global severity index 1.36 (0.98) 
(GSI) 
0.78 (0.64) Covariate (1) = 5.5 0.023* 
Main effect (1) = 4.8 0.033* 
Interaction (2) = 6.7 0.003** 
Positive symptom total 27.25 
(PST) 
(16.30) 
Positive symptom distress 2.03 (0.86) 
index (PSDI) 
22.16 Covariate (1) = 1.6 0.207 
(14.21) Main effect (1) = 0.8 0.367 
Interaction (2) = 1.6 0.214 
1.65 (0.74) Covariate (1) = 1.9 0.174 
Main effect (1) = 2.0 0.168 
Interaction (2) = 2.5 0.091 
*p <. 05, **p <. 01, ***p < 0.001 
8.4 Discussion 
It has already been demonstrated that CBT was associated with significant 
reductions in relapse and admission rates (Chapter 5), and improvements in 
remission and social functioning (Chapter 6). This Chapter has sought to 
investigate the links between the theory proposed in Chapters 3 and 4 and the 
outcome of relapsers versus non-relapsers. To summarise briefly, the 
conceptualisation of relapse proposed that negative beliefs concerning self and 
self in relation to psychosis represent a cognitive vulnerability to relapse 
(Birchwood, 1995; Gumley et al., 1999; Chapter 3). These beliefs are 
proposed to have their origins in the early episodes of psychosis (e. g. Iqbal et 
al, 2000) and result from a process of a search for meaning and integration 
with pre-morbid beliefs about self, world and future (Fowler et al., 2000; 
Jackson & Iqbal, 2000). 
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Therefore this study sought to examine the stability of negative appraisals of 
self and psychosis amongst relapsers and non-relapsers over a one-year period. 
Negative appraisals of self and entrapment appeared to show remarkable 
stability over time amongst relapsers. In Chapter 5 negative beliefs about self 
and entrapment were found to be predictive of relapse, whilst negative beliefs 
about self were predictive of duration to relapse. These findings were 
interpreted as evidence of a cognitive vulnerability to relapse in psychosis. 
The relative stability of these appraisals over time amongst relapsers and non- 
relapsers is consistent with this proposal. 
Consistent with the predictions made by Birchwood (1995) and Gumley et al., 
(1999) the results from this study suggest that relapse is associated with 
increasing negative appraisals of psychosis. Specifically, increasing negative 
appraisals of self versus illness and shame about illness were associated with 
relapsers, whilst there appeared to be relative stability in these appraisals 
amongst non-relapsers. Within the relapsers group, appraisals of self versus 
illness increased between entry and 12-weeks, whilst appraisals of shame 
increased between 12-weeks and 26-weeks. Given that the mean duration to 
relapse amongst this group was 158 days (22.6 weeks) these findings strongly 
indicate that increasing negative appraisals of psychosis are associated with 
the experience of relapse. This pattern of results are suggestive that increasing 
self-blame (Self versus Illness) may precede the onset of relapse, whilst 
increasing appraisals of shame may occur later in the relapse trajectory either 
as a consequence of increasing self blame, or of relapse itself. Central to this 
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interpretation of these findings is the proposal that these negative appraisals of 
psychosis are contextually cued by the experience of signs and symptoms 
suggestive or confirmatory of a forthcoming relapse. 
In line with this interpretation of the findings of the present study, Zoellner et 
al., (1996) found that individuals with Panic Disorder gave more credence to 
their catastrophic cognitions in the midst of panic than at other times. 
Furthermore, Zoellner and her colleagues (2001) also found evidence that 
memories for the emotional intensity of a traumatic event amongst individuals 
with Post-traumatic Stress Disorder (PTSD) were not fixed. Memories for 
emotional intensity of the traumatic event fluctuated over time, and fluctuated 
as PTSD symptoms changed. Amongst individuals with acute PTSD as 
symptoms decreased, reported emotional intensity decreased. However in her 
chronic PTSD group, Zoellner et al., (2001) found that as symptoms 
decreased, memory for emotional intensity increased. These investigators 
argued that this increasing emotional intensity associated with improvements 
in an imaginal exposure treatment was consistent with the activation of trauma 
memories and their subsequent emotional processing. Indeed Foa et al., (1995) 
found that imaginal exposure was associated with an increase in the vividness 
of the thoughts and feelings contained in trauma narratives. Given these 
findings, the results found in the present study could be interpreted as 
providing some evidence that (1) relapse is associated with a strengthening of 
negative beliefs and attributions concerning self-blame and shame and (2) that 
this may indicate a process of emotional re-experiencing of previously (and 
possibly traumatic) episodes of psychosis. Indeed the strengthening of such 
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negative self-related beliefs and attributions are likely to drive the 
development of relapse itself. 
Bentall & Kaney (In submission) have proposed an attribution - self- 
representation cycle model to explain attributional lability in depression and 
paranoia. The model proposes that dysphoric mood is a consequence of 
negative self-representations, especially when such representations are in 
conflict with long-held standards of self-evaluation or dysfunctional attitudes 
(Alloy et al., 1999). The model assumes that a cognitive search process, which 
terminates when an appropriate explanatory construct is found, generates 
attributions for events. This search begins with current self-representations; if 
these include attributes that match the event (for example, when an individual 
begins to experience a relapse who already sees themselves as a failure) an 
internal attribution will be generated. In line with this, Flett et al., (1995) 
found that individuals with low self-esteem tend to generate internal 
attributions for failure experiences, and Bentall et al., (1999) found that 
depressed and paranoid participants take less time to generate internal 
attributions for negative events. A central assumption of Bentall's attribution - 
self-representation cycle model is that attributions are (1) unstable, (2) derived 
from self-representations, and (3) reinforce individuals self-representations. 
The findings in the present study are in line with this proposal. Individuals 
who are prone to relapse have more negative representations of themselves 
and in the context of relapse show increasing negative appraisals of self-blame 
and shame concerning psychosis. Furthermore, the experience of relapse was 
found to be associated with increased psychological co-morbidity. 
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Specifically, the present study found that relapse was associated with 
increased psychological morbidity across a number of domains including 
somatisation, obsessive-compulsive symptoms, interpersonal sensitivity, 
depression, anxiety, phobic anxiety and psychoticism. The findings of this 
study point towards a relationship between relapse and negative appraisals of 
psychosis and the evolution of psychological morbidity. Indeed negative 
appraisals of psychosis may have a mediating role in the evolution of both 
relapse and psychological morbidity. 
The study has a number of limitations. First, the relationship between negative 
appraisals of psychosis and the evolution of relapse requires further 
investigation. The study design did not allow for repeated measurements of 
negative appraisals of self and psychosis before, during and following relapse. 
Such a design would have allowed for a much more detailed view of the role 
of these factors in the evolution of relapse. Second, it was not possible to 
establish whether the psychological morbidity observed at 52-weeks was a 
feature of the relapse process itself, or whether, as in Birchwood and 
colleagues (2000) study it was part of a de novo psychological disorder such 
as Post Psychotic Depression. These limitations could be addressed through 
further prospective research employing detailed repeated measures of 
psychological factors associated with the predisposition to, evolution of, and 
reactions to relapse over the short, medium and longer term. The present study 
provides evidence of possible candidate psychological factors associated with 
the development of relapse that are worthy of further investigation. In 
addition, experimental research could be employed to examine the nature and 
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stability of attributional style and negative appraisals of psychosis. Such 
research could compare individuals who are at high risk of relapse with 
individuals who are at low risk. This combination of further prospective and 
experimental research may yield further insights into the nature of relapse and 
the evolution of psychological morbidity. 
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Integrating theory and therapy on relapse: current status and future directions 
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9.1 Introduction 
This thesis began with the proposal that understanding the personal meanings 
attached to the experience of psychosis is critical to the development and 
evolution of problem and disorder relevant, psychological approaches to the 
both conceptualisation and treatment of relapse and the control of illness 
experience in psychosis. Indeed the DNA of this thesis is contained in the 
conjecture that theory and therapy in the area of cognitive therapy for 
psychosis are mutually enhancing (Garety et al., 2001). Therapy provides a 
context for theoretical developments and the empirical investigation of 
cognitive models. In turn this process should clarify the appropriate targets of 
psychological treatment, enable the refinement of its techniques, and thereby 
enhance its efficacy. 
9.2 Summary of Findings 
Chapter 5 described a 12-month exploratory randomised-controlled trial 
comparing cognitive behavioural therapy and treatment as usual (CBT + 
TAU) with TAU alone in the prevention of relapse. CBT was delivered during 
the early signs of relapse and focused on (1) the development of an 
individualised case formulation of psychological factors associated with 
relapse acceleration, (2) the modification of negative beliefs concerning 
illness, and (3) the development and implementation of cognitive or 
behavioural coping strategies within and between sessions. This study found 
that receipt of CBT + TAU was associated with a significant reduction in 
relapse rate (10 / 66; 14.9%) in comparison to TAU alone (24 / 67; 35.8%). 
CBT + TAU was also associated with a significant reduction in admission rate 
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(8 / 66; 11.8%) compared to TAU alone (18 / 67; 26.9%). However, the study 
did not find that CBT + TAU was associated with reduced duration to relapse, 
or reduced severity of relapse itself. Chapter 6 described the clinical 
significance of reducing relapse rate associated with CBT + TAU. CBT + 
TAU was associated with increased remission rates (41 / 66; 62.1%) in 
comparison to TAU alone (26/ 67; 38.8%) at 12-months. In addition, receipt 
of CBT + TAU was associated with increased rates of clinically significant 
improvements in prosocial functioning (39 / 66; 59.1%) in comparison to TAU 
alone (25 / 67; 38.5%). Chapter 7 investigated the effect of CBT + TAU on 
reducing psychological distress, and negative appraisals of self and psychosis. 
That study did not find that receipt of CBT was associated with improvements 
in psychological distress, negative appraisals of psychosis, and negative 
appraisals of self. 
This was an unexpected finding given that the CBT protocol explicitly focused 
on the identification and modification of negative appraisals of self and 
psychosis during the targeted CBT phase. The CBT targeted negative 
appraisals of self and psychosis in the specific context of early signs of 
relapse. It was therefore proposed that it may be possible that the beliefs 
targeted amongst those participants who received targeted CBT were specific 
to that context, and that any changes in those beliefs during that phase were 
not elaborated to corresponding or associated mental representations. If this 
was the case then future experimental research could investigate biases in 
cognitive processes amongst individuals who are at high risk of relapse versus 
those who are low risk of relapse, or amongst individuals during remission and 
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during early relapse. In particular experimental research could investigate 
cognitive processes involved in integrative and elaborative processing. Graf 
and Mandler (1984) have proposed that the integration of stimulus information 
is an automatic process that strengthens the internal structure of a stimulus 
representation, thus making that representation more accessible in the sense 
that activation of any part will serve to activate the whole. In consequence, 
stimuli corresponding to representations that are in a high state of integration 
will tend to `pop out' of the stimulus array, and hence will tend to be 
selectively encoded. Therefore, according to Graf and Mandler's (1984) model 
of stimulus integration, individuals at high risk of relapse (e. g. those 
experiencing early signs) would, like patients with anxiety, show selective 
processing of threat-related stimuli and a biased implicit recall of threat- 
related information (e. g. relapse or hospital-related words). In contrast, Graf & 
Mandler propose that elaborative processing is a strategic process that serves 
to establish and strengthen associative connections between a mental 
representation and other existing representations in memory. A highly 
elaborated representation will be disproportionately easy to retrieve on 
intentional memory tasks, such as recall and recognition. If the treatment 
effects of targeted CBT were specific to the context of relapse, and therefore 
changes in negative appraisals of psychosis and self did not generalise, one 
would not expect individuals at high risk of relapse to show biased intentional 
memory for threat-related information in comparison to those at low-risk of 
relapse. Therefore, future experimental research could examine the nature of 
cognitive biases associated with increased risk of relapse in psychosis. 
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9.3 CBT for schizophrenia: context and refinement 
Chapter 3 provided a review of treatment outcome trials of CBT for 
schizophrenia with a particular emphasis on the outcome results for relapse 
and psychological distress. The rationale for this focus was based on the 
findings of numerous investigators (e. g. Subotnik & Neuchterlein, 1988; 
Birchwood et al. 1989; Gaebel et al. 1993; Jolley et al. 1990; Jorgensen, 1998; 
Marder et al. 1991; Marder et al. 1994; Tarrier et al. 1991) that relapse tends to 
be preceded by a period of increased psychological distress characterised by 
increased fear, confusion, perplexity and depression. It was concluded that 
there was encouraging evidence that CBT was associated with maintenance of 
treatment gains at follow-up (e. g. Kuipers et al., 1997; Sensky et al., 2000), 
but that the evidence concerning the efficacy of CBT for prevention of relapse 
(Kuipers et al., 1997; Tamer et al., 2000) and reduced psychological co- 
morbidity was lacking (Kuipers et al., 1997, Tarrier et al., 2001). How can the 
results of the present study be understood in context of these previous trials of 
CBT for schizophrenia? 
The key to developing proposals which can contribute to shedding light on this 
question lie in the interface between theory and therapy. With regards to 
relapse the treatment protocol described in Chapter 4 proposed that what is 
critical during relapse is the interaction between the individuals' pre-existing 
beliefs concerning themselves, the world and future, the occurrence of 
psychosis as a critical incident, and the individuals' attempt to assimilate or 
accommodate their experience. Therefore the treatment protocol specified that 
the targeting of negative beliefs concerning self, and self in relation to illness 
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would result in the deceleration and the prevention of relapse. As described in 
Section 9.2 above there was no evidence from the treatment outcome data that 
CBT resulted in reduced negative appraisals of self and illness, or reduced 
psychological distress. 
The evidence, on which targeting these negative beliefs were based, was 
drawn from the literature concerning cognitive factors in the development of 
psychological distress and co-morbidity. Igbal et al., (2000) have proposed 
that, in line with Gilbert (1992) certain life situations are likely to be 
depressogenic, particularly if they encapsulate feelings of loss, humiliation 
and entrapment. In line with their proposal, psychosis is seen as a life event 
whose appraisal may involve these elements. Birchwood et al., (1993) and 
Iqbal et al., (2000) have provided strong evidence that secondary depression is 
related to negative beliefs concerning entrapment, shame and humiliation 
arising from illness experience. 
The results of the present study do attest to the possibility that CBT could be 
refined to reduce relapse risk and improve psychological co-morbidity. In the 
present study CBT was targeted on the relapse process. The cognitive factors 
hypothesised to increase relapse risk described in Chapter 3, and the 
techniques described in Chapter 4 could be delivered in a different way. The 
targeting of these cognitive factors using the techniques specified could be 
provided in a more conventional format. In the future CBT treatments which 
delineate techniques focused on the transformation of beliefs and assumptions 
regarding self worth and appraisal of psychosis could result in improved 
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outcomes in relation to psychological co-morbidity and the reduction of 
medium to long-term relapse risk. The utilisation of a model of psychosis, 
which sees the psychosis itself as a critical incident and the individual's 
psychological response to the experience of psychosis as attempts to assimilate 
and accommodate their experience into pre-existing beliefs, may provide a 
framework to such an enterprise. 
9.4 A Psychological Model of Relapse 
Chapter 7 concluded that relapse could be understood as the outcome of an 
interaction between stable vulnerability factors and mediating factors which 
act to accelerate the process of relapse. Findings providing evidence for a 
cognitive vulnerability to relapse were described in Chapter 5. First, a logistic 
regression analysis revealed that negative appraisals of self and negative 
appraisals of entrapment in psychosis were significant predictors of relapse. 
Second, a Cox proportional hazards regression analysis found that increased 
negative appraisals of self were associated with reduced duration to relapse. 
Furthermore, in Chapter 7 it was observed that amongst relapsers, these 
appraisals showed remarkable stability over time. 
In terms of mediating cognitive factors, there was evidence that relapse was 
associated with increasing negative appraisals of self-blame for psychosis and 
shame concerning psychosis. The timing of these changes in appraisal of 
psychosis suggested that increased self-blame might precede the advent of 
relapse, whereas increased appraisals of shame appeared to occur later in the 
relapse trajectory. These findings were interpreted as evidence for a role for 
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the cognitive factors in mediating the development of relapse. 
Such an approach to the conceptualisation of relapse is illustrated in Figure 9.1 
below. This model integrates existing perspectives developed through 
attribution theory (Abramson et al., 1978,1989; Bentall & Kaney, In 
submission). Attribution theory proposes that dysphoric mood is a 
consequence of negative self-representations which predispose individuals to 
making internal, stable and global attributions for negative events. This 
attributional style results in increased hopelessness and helplessness. 
According to Alloy et al., (1999) this is especially the case when such negative 
self-representations are in conflict with long-held standards of self-evaluation 
or dysfunctional attitudes. Furthermore, this model assumes that a search for 
meaning (Birchwood, 1995) terminates when an appropriate explanatory 
construct is found, and generates attributions for events. This search begins 
with current self-representations; if these include attributes that match the 
event (for example, when an individual begins to experience a relapse who 
already sees themselves as a failure) an internal attribution will be generated. 
According to this model, negative appraisals of self and a perception of 
entrapment in psychosis confer a cognitive vulnerability to relapse. Therefore 
when a vulnerable individual, who sees themselves as a disappointment and 
failure, is confronted by internal or external stressors which are indicative of 
an impending relapse, that individual perceives their escape from psychosis as 
blocked. Faced with the inevitability of relapse, they attribute blame for 
relapse to themselves, resulting in increased demoralisation and shame. It is 
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proposed that such a dysphoric response results in the acceleration of relapse. 
Evidence for the role of dysphoria and increased psychological distress prior 
to relapse has already been reported by a number of investigators (e. g. 
Subotnik & Neuchterlein, 1988; Birchwood et al. 1989; Gaebel et al. 1993; 
Jolley et al. 1990; Jorgensen, 1998; Marder et al. 1991; Marder et al. 1994; 
Tamer et al. 1991). These investigators have found that relapse tends to be 
preceded by a period of increased psychological distress characterised by 
increased fear, confusion, perplexity and depression. Indeed, the predictive 
validity of increased psychological distress to relapse has been shown to be 
improved by the inclusion of low-level psychotic symptoms such as delusional 
thoughts, ideas of reference, voices and anomalous experiences (e. g. 
Birchwood et al., 1989; Jorgensen, 1998; Tamer et al., 1991). Indeed the 
occurrence of low-level psychotic symptoms in combination with subtle 
changes in attention (e. g. Neuchterlein & Dawson, 1984), perception (e. g. 
McGhie & Chapman, 1961) and body state (Tarrier & Turpin, 1992) are 
likely to represent internal stressors which trigger an attributional search for 
meaning. 
This model is also in line with the evidence concerning the development of 
psychological comorbidity (Birchwood et al, 1993; Iqbal et al., 2000). Iqbal et 
al., (2000) have proposed that, in line with Gilbert (1992) certain life 
situations are likely to be depressogenic, particularly if they encapsulate 
feelings of loss, humiliation and entrapment. In line with their proposal, 
psychosis is seen as a life event whose appraisal may involve these elements. 
Birchwood et al., (1993) and Iqbal et al., (2000) provided strong evidence that 
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post psychotic depression is related to negative beliefs concerning entrapment, 
shame and humiliation arising from illness experience. In line with their 
findings this study found that relapse was associated with the increasing 
negative appraisals of psychosis, and that relapse itself was associated with 
increased psychological co-morbidity at 52-weeks. 
Figure 9.1 An Attributional Model of Relapse in Psychosis 
Negative appraisals of self 
Negative appraisals of 
entrapment 
Body State 
Information processing 
Voices 
Feelings of reference 
Delusional thoughts 
Anomalous experiences 
Self blame for illness 
Shame regarding illness 
Anxiety 
Depression 
Delusions 
Hallucinations 
9.5 Attributional Theory and Persecutory Delusions 
The study outlined in Chapter 7 found that negative appraisals of self-blame 
for psychosis and shame associated with psychosis were associated with 
274 
Integrating theory and therapy on relapse: current status and future directions 
relapse. These findings were interpreted as evidence that these cognitive 
factors might mediate the development of relapse itself through the evolution 
of self-blaming attributions, which could drive the development of dysphoria 
and withdrawal during the early stages of relapse. It was argued that these 
findings are consistent with the findings derived from tests of attribution 
theory (Abramson et al., 1978; Alloy et al., 1989) and indeed consistent with 
the findings derived from research on the instability of cognitive factors in 
other disorders such as PTSD (e. g. Zoellner et al., 2001). However, the role of 
self-blaming attributions in the evolution of relapse would appear to be 
inconsistent with the evidence concerning the role of attributions in the 
development and maintenance of paranoid (persecutory) delusions. A number 
of studies have shown that individuals with persecutory delusions appear to 
have an externalizing or other-blaming attributional style for negative events 
in comparison to both depressed and normal controls (Kaney & Bentall, 1989; 
Candido & Romney, 1990; Kaney & Bentall, 1992; Fear et al., 1996; 
Kinderman & Bentall, 1997). Kinderman and Bentall (1997) found that 
paranoia was associated with a relative tendency to use external-personal 
(other-blaming) attributions rather than situational attributions for negative 
events. 
Therefore in (apparent) contrast to the findings described in Section 8.3 above, 
the results of attributional studies of paranoid delusions have been interpreted 
as evidence that the external attributional biases serve a function of 
maintaining self-esteem. Bentall and colleagues (1994) have proposed that 
individuals with persecutory beliefs have implicit negative self-schemas and 
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externalizing attributions triggered following activation of these schemas 
function to reduce discrepancies between the self-concept and ideals at the 
expense of holding beliefs about negative opinions that others hold about the 
self. However, Freeman et al., (1998) have criticized this view of persecutory 
delusions. They found that self-esteem was not spared in individuals with 
paranoid delusions compared to individuals with schizophrenia not suffering 
from paranoid delusions. Freeman et al. used Robson's (1989) measure of 
self-esteem, which includes items concerning beliefs about others' negative 
opinions about the self, and Kinderman & Bentall (1996) found that 
individuals with persecutory paranoia had few discrepancies between their 
actual and ideal selves, but believed that others held negative opinions about 
them. Lyon et al. (1994) gave deluded, depressed and normal participants the 
Pragmatic Inference Test (PIT), a non-obvious or implicit attributional 
measure. On this measure individuals with persecutory paranoia made 
excessively internal (self-blaming) attributions for negative events and 
external attributions for positive events, in contrast to the same participants 
showing an external (other blaming) attributional bias for negative events on 
an explicit measure of attributional style. Krstev et al., (1999) investigated 
implicit and explicit attributional style in first episode psychosis. Rather than 
measuring the presence or absence of persecutory delusions, these 
investigators examined the severity of suspiciousness. Krstev et als' (1999) 
findings were broadly in line with Bentall and coworkers' findings for the 
relationship between explicit attributional style, suspiciousness and 
depression, with higher suspiciousness being associated with a more 
externalizing attributional style for negative events and higher depression 
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being associated with a more internalizing attributional style for negative 
events. Krstev et al did not replicate the findings of Lyon et al., (1994) for 
implicit attributional style. Krstev et als. ' sample was younger (mean age = 
21.6 years) than Lyon et als. ' sample (mean age = 35.6 years). In addition, the 
attributional biases found in both the implicit and explicit measures were less 
pronounced than those observed by Lyon et al., (1994). Krstev et al., 
concluded that it could be the case that in older individuals with more chronic 
illness the threat to self might be more pronounced resulting in an individual's 
need to maintain a positive explicit self concept or that an externalizing 
attributional style is only present in a subgroup of young persons with a first 
episode of psychosis. Therefore the apparent discrepancies between studies 
concerning attributional style, self-esteem and persecutory delusions may be 
due to differences in measurement of self-esteem (e. g. Freeman et al., 1998), 
or differences between participant samples (e. g. Krstev et al., 1999). 
It is also possible that external-personal attributional biases associated with 
persecutory delusions may be related to the ability of individuals to represent 
other peoples' perceptions of events (theory of mind). External-personal 
attributions are associated with poor theory of mind skill in normal 
participants (Kinderman et al., 1998). The theory of mind deficit has been 
reported in paranoid participants (Corcoran, et al., 1995; Frith & Corcoran, 
1996). Whilst there is evidence that the theory of mind deficit is associated 
with having psychosis, there is no evidence that these deficits are specific to 
paranoid symptoms (Garety & Freeman, 1999). According to Bentall et al., 
(1998) the presence of the theory of mind deficit results in individuals with 
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paranoid delusions being prone to making external-personal (as opposed to 
external-situational) attributions. Gilbert et al., (1988) found that under 
pressure, normal participants make fewer situational attributions and more 
external-personal attributions compared to normal conditions. Therefore under 
stress, individuals with persecutory paranoia will make more external-personal 
attributions which will in turn less readily prime negative self-representations, 
but should reinforce the paranoid world-view (Bentall et al., 1998). Such a 
proposal would be consistent with the findings of Krstev and colleagues 
(1999) as over time repeated regeneration of external-personal attributions 
would result in strengthening of a paranoid world-view and under stress the 
accessibility of negative beliefs about others. In addition, Bentall et als. ' 
(1998) theory would not be incompatible with the model of relapse described 
in Section 8.3 above. It is possible that cognitive processes could evolve in 
parallel where the experience of relapse results in increasingly negative self- 
representations of self in relation to psychosis, and given the experience of 
such a stressful event, the generation of negative other-representations and 
external-personal attributions resulting in the development of paranoia. This 
would account for the co-incidence of persecutory paranoid beliefs and low 
self esteem (e. g. Freeman et al., 1998). 
Future research could investigate (de)synchrony in attributional processes and 
self-representations amongst individuals with psychosis, in particular 
qualitative research could examine whether self-blaming attributions for 
psychosis co-exist with other-blaming attributions for negative events in 
general. Experimental or longitudinal research could examine whether 
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negative beliefs about self in relation to psychosis affect or mediate the 
evolution of external-personal attributions. For example, Bentall & Kaney (In 
submission) examined attributional lability in depressed, paranoid and 
"normal" participants. Attributional measures were administered before and 
after a contrived failure experience. Prior to task administration, the 
performance of depressed and paranoid participants was consistent with that 
predicted by previous research prior to the failure experience. Depressed and 
paranoid participants made excessively stable and global attributions in 
comparison to normal participants. However, paranoid patients made 
excessively external attributions for negative events and depressed patients 
made excessively internal attributions. In comparison to "normals", both 
paranoid and depressed participants' scores for internality increased, even 
after controlling for self-reported depression. There were no changes in 
stability and globality after test administration. Following the task participants 
were asked to estimate their degree of control over the outcome of the task. 
Paranoid participants rating of their control were significantly higher than the 
"normal" and depressed participants were. Therefore, this study demonstrated 
that (1) attributional style is unstable and (2) paranoid participants with an 
externalising attributional style, in comparison to depressed and "normal" 
participants, failure experiences increase their ratings of internality (or self- 
blame) for an event that they assume some measure of control over. In relation 
to relapse, one could hypothesise that individuals at high-risk of relapse, in 
comparison to individuals at low-risk, would show greater shifts towards self- 
blame (or internality) in their attributional style following a contrived failure 
experience. 
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9.6 Long term outcome and prognosis in schizophrenia 
Chapter 1 reviewed the development of the clinical concept of schizophrenia. 
The evolution of diagnostic systems since Bleuler's (1911) description and 
classification of schizophrenia have improved in the reliability of diagnosis 
(Tsuang et al., 2000). However, questions still remain regarding the validity of 
the diagnosis. For a diagnostic category to have validity it provides 
information on the aetiology and prognosis of the disorder. As was pointed 
out, diagnostic systems such as DSM and ICD have become divorced from 
conceptualisations of the aetiology of schizophrenia. At the same time they 
emphasise the presence of positive psychotic symptoms and impact on day-to- 
day functioning. However, Bell and colleagues (1998) showed that the 
duration of illness and the absence of affective symptoms correctly classified 
97% of individuals with first episode psychosis as having DSM-III-R 
schizophrenia, and also correctly identified 97% of those who did not have 
schizophrenia. Inclusion of DSM-III-R's psychosis criteria did not improve 
prediction. Serretti et al., (1996) found that the psychopathology of 
participants with schizophrenia and bipolar disorder overlapped on the 
disorganisation factor. Crow (1990,1991,1998b) proposed that schizophrenia, 
schizoaffective disorder, and affective illnesses exist along the same 
continuum, rejecting the concept of distinct disease entities. Indeed a variety 
of evidence demonstrates that psychosis is not specific to schizophrenia, that 
Schneiderian symptoms occur in other disorders (Peralta & Cuesta, 1998), and 
indeed measures of psychosis do not differentiate schizophrenia from other 
disorders. Furthermore, Chapter 1 found that, notwithstanding the 
methodological shortcomings and variations in diagnostic criteria employed, 
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the outcome of schizophrenia is heterogeneous (e. g. Carpenter and Strauss, 
1991; Thara et al., 1994; Eaton et al., 1995; Harrison et al., 1996; Mason et al., 
1996). Poor outcome is however associated with longer duration of untreated 
illness, poor pre-morbid adjustment, and higher levels of social isolation. 
Indeed longer duration of untreated illness is associated with poorer outcome 
and increased risk of relapse for pharmacological treatments (e. g. Crow et al., 
1986; Robinson et al., 1999). This means that the diagnosis of schizophrenia 
in itself is not predictive of long-term outcome. However, some investigators 
have proposed that a disorder of insidious onset, in individuals with poor pre- 
morbid social networks and poor pre-morbid social adjustment is indicative of 
biological vulnerability and an underlying neurodevelopmental disorder 
preceding the evolution of psychosis (Tsuang et al., 1999). However only one 
study (Leiberman et al., 1989) has found evidence that abnormal brain 
pathology is associated with poor long-term outcome. Indeed it may be that 
neurodevelopmental abnormalities result from early social adversity. For 
instance, recent research has shown that repeated practice of complex memory 
tasks results in change in brain size. Maguire et al., (2000) studied brain scans 
of London taxi drivers, who have to learn enormous amounts of information, 
and found enlargement of certain brain structures. Indeed in a review of the 
literature concerning the biological basis of schizophrenia, Chua & McKenna 
(1995) concluded that `although the concept of schizophrenia has been in 
existence for nearly a century.... there has been no identification of any causal 
pathology'. Furthermore, Bremner (1995) has shown that traumatic life 
experiences, which result in Post traumatic stress disorder, are associated with 
structural changes in the hippocampus. 
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Therefore poor pre-morbid social isolation and long duration of untreated 
psychosis are likely to be experiences, which are psychologically toxic. 
Evidence of psychological vulnerability to the development of psychosis has 
been described by Van Os (2000) who found a role for negative schemas in 
the development of psychosis. In a large epidemiological study over 7000 
people were screened for symptoms and psychiatric status and followed up for 
three years. Those who subsequently developed psychosis were found to be 
more likely to have low self-esteem and depressive schemata. In addition, 
Birchwood et al., (2000) found that childhood experiences of social adversity 
lead to the development of negative schemata involving social humiliation and 
subordination, which in turn fuel voices and paranoia. Indeed in terms of the 
prediction of developing psychosis Albers et al. (1998) found that subjective 
experience of basic cognitive symptoms was predictive of developing 
psychosis. They examined individuals who showed definite evidence of the 
basic symptoms (as described by Chapman, 1966) at an index examination but 
did not show any evidence of psychosis, in order to determine whether the 
presence and type of basic symptoms can predict the development of 
schizophrenia. Of the 78 patients who showed definite evidence of basic 
symptoms, 56 (72%) underwent transition to psychosis during the intervening 
8-year follow-up period. None of the 18 patients without evidence of basic 
symptoms at index examination were found to have developed psychosis in 
the intervening period. The analysis was able to predict the presence or 
absence of transition to schizophrenia accurately in 77% of individuals. 
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These findings suggest that an interaction between the appearance of subtle 
changes in information processing, perhaps reflecting underlying 
neurodevelopmental processes, and the experience of social adversity, poor 
parental bonding, social isolation and a long period of illness experience 
without help or assistance produce a toxic biological, psychological and social 
outcome for such individuals. Indeed, as described in Chapter 2 living in 
adverse social environments is a robust predictor of outcome in terms of 
relapse and social functioning (Kavanagh, 1992) and that adverse 
environments arise from relatives' beliefs and attributions arising from their 
family member's behaviour (Brewin et al., 1991; Barrowclough et al., 1994). 
Indeed, the experience of psychosis is traumatic (McGorry et al., 1991) and 
the lifetime prevalence of trauma amongst individuals with psychosis is 
extremely high (Meuser et al., 1998). 
Given the possible role of psychological factors early in the experience of 
psychosis, particularly around transition to psychosis, psychological models of 
relapse may assist the development of psychological models of transition to 
psychosis itself. Such an enterprise could hold out the possibility that 
psychological therapies may be designed to assist individuals who are at high- 
risk of developing psychosis. This will be discussed below. 
9.7 Transition to Psychosis 
Gumley et al., (1999) described a model of relapse, which was based on the 
Interacting Cognitive Subsystems (ICS) framework developed by Teasdale 
and Barnard (1993). A simplified version of this model was described in 
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Chapters 3 and 4. However, Gumley et als. ' (1999) adoption of the ICS 
conceptualisation was based on the limitations of single level psychological 
approaches. For example, schema theory developed by Beck and colleagues 
(e. g. Beck et al., 1979) has been a powerful model, which has lead to the 
development of a range of treatments for a range of psychological disorders. 
Indeed, as described above schema theory offers a potentially powerful means 
of understanding the nature and processes of outcome in psychosis. Schema 
theory emphasised the cognitive content of beliefs, for example "I am bad" but 
does not provide a detailed analysis of how cognitive processes or levels of 
cognition such as attention and memory lead to the evolution and maintenance 
of emotional disorders (for example Wells, 2000). For this reason ICS was 
adopted as a guiding conceptualisation. In this model qualitatively distinct 
types of information are distinguished: sensory information codes, which 
includes basic visual, acoustic and proprioceptive stimuli, intermediate 
information codes representing recurring patterns of visual, acoustic and 
proprioceptive information, a propositional information code representing 
specific meanings, and a holistic implicational code representing generic 
meanings. In ICS implicational meaning is responsible for the generation of 
emotion. In terms of relapse, Gumley and colleagues proposed that subtle and 
recurring patterns of internal and external stimuli, which were reminiscent of 
previous episodes of psychosis, activated implicational meaning. The 
activation of implicational meaning triggered a range of emotional and 
cognitive changes observed during early relapse and therefore implicational 
meaning was proposed to be responsible for the activation and acceleration of 
relapse. Clinically the model enabled the binding of subjective experience 
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during early relapse and the role of personal meaning in the development of 
relapse. However, from an empirical viewpoint, the model has a number of 
limitations outlined by Wells (2000). First, it is unclear in ICS how automatic 
processes such as attention interact with self-knowledge (propositional and 
implicational meaning). ICS does not provide an account of attentional 
processes and their relationship to psychological disorder. Second, ICS 
specifies that implicational meaning governs individuals' emotional reactions 
to internal or external events. However, implicational meaning is non-verbal 
and therefore difficult to measure or demonstrate empirically. Third, given that 
implicational meaning is apparent by the presence of adverse emotional 
reactions such as depression, implicational meaning can therefore only be 
identified because it elicits an emotional response. Thus the theory produces 
circularity in its predictions. 
Wells & Matthews (1994) and Wells (2000) provide a metacognitive account 
of the development of psychological distress. Metacognition refers to any 
knowledge or cognitive process that is involved in the appraisal, monitoring or 
control of cognition. Metacognitive knowledge is information that an 
individual has about their own cognition and task factors or learning that affect 
it. Metacognitive regulation refers to a range of executive functions, such as 
the allocation of attention, monitoring, checking, planning and detection of 
errors in performance. According to Wells and Matthews (1994) there are 
three types of intrusion into cognitive awareness; these are external stimulus 
information, cognitive state information and body state information. Clearly 
given the evidence from the subjective experience literature reviewed in 
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Chapter 3, intrusions across these domains are likely to be relevant to the 
relapse process. Indeed, Hemsley (1993) suggests that the `intrusion of 
unexpected/ unintended material from long-term memory' is a cognitive 
abnormality associated with schizophrenia. 
There is growing evidence, some of which was discussed in Chapter 3, that 
metacognitive knowledge and regulation are involved in the development and 
maintenance of symptoms of psychosis. In terms of metacognitive knowledge, 
increased negative beliefs concerning the controllability of thoughts, the 
acceptability of thoughts, and the negative consequences of lack of control of 
thoughts were associated individuals diagnosed with schizophrenia who 
experienced auditory hallucinations compared to controls with schizophrenia 
who did not experience auditory hallucinations (Morrison & Baker, 2000). In 
addition, positive beliefs concerning unusual perceptual experiences were the 
best predictor of predisposition to auditory and visual hallucinations occurring 
in normal participants (Morrison, Wells, & Nothard, 2000). In addition, 
negative beliefs concerning the controllability of thoughts and responsibility 
for intrusive thoughts were found to be the best predictor of hallucinatory 
predisposition in normal subjects (Gray & Gumley, in submission). Freeman 
& Garety (1999) found that the majority of a sample of individuals with 
persecutory delusions experienced meta-worry concerning the control of 
delusion-relevant thoughts. In terms of metacognitive regulation attentional 
biases to threat related information have been found by a number of 
investigators (e. g. Bentall & Kaney, 1989) investigating persecutory delusions. 
In addition, paranoia has been found to be associated with increased self- 
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consciousness (Smari, Stefansson, & Thorgilsson, 1994), as have auditory 
hallucinations (Morrison & Haddock, 1997). 
A measure of metacognition was not included in the present study. Future 
research into relapse and transition to psychosis could benefit from the 
inclusion of measures of metacognitive knowledge and regulation. This would 
be especially relevant given the evidence for the disruption of information 
processing during the early stages of psychosis and the intrusion of unusual 
cognitive, perceptual and body-state experiences during this phase. 
9.8 Future research 
There are a number of implications for future research and therapy concerning 
relapse in psychosis. First, the relationship between relative's attributions for 
their family member's behaviour, and the individual's own attributions are a 
potentially important focus of investigation. One would predict that 
attributions associated with increased hostility and blame will be associated 
with individual attributions of self-blame, shame, and humiliation associated 
with illness. On the other hand, attributions responsible for the development of 
emotional overinvolvement will be associated with individual attributions of 
helplessness and powerlessness to control illness. Whilst both of these 
communicative styles are associated with increased risk of relapse, it may be 
that increased relapse risk is via the individual's own beliefs developed from 
their familial experience. The findings of the present study concerning the 
relationship between appraisal of illness and relapse, and appraisal of illness 
and withdrawal are supportive of this line of investigation. 
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Future studies of psychological interventions could pay special attention to the 
inclusion of measurements of cognitive processes associated with the 
evolution of illness chronicity and relapse. Indeed potential candidate 
measures would include assessments of self-concept, secondary appraisal of 
illness, attributional style, and metacognitive beliefs and processes. This study 
included a simple measure of self-esteem, but future studies could employ 
more sophisticated measures, which provide an assessment of multiple 
dimensions of self-concept and self-discrepancies. This study did not include 
any metacognitive measures. There is a need to examine in more detail the 
interaction of schematic beliefs concerning self and self-related beliefs 
concerning appraisal of thinking, and the regulation and control of cognitive 
processes. 
In addition there is a need to develop experimental investigations into the 
nature of cognitive processes such as attention, memory, and attributional style 
in the development of increased risk of relapse. The model outline in Section 
9.4 above may provide a guide to such endeavours. Furthermore, given that 
there is growing evidence that psychological vulnerability precedes the 
development of psychosis itself, research involving individuals at high-risk 
could incorporate these measures into their design. The inclusion of measures 
of schematic beliefs and appraisals of cognitive-perceptual experience would 
provide a detailed view of the emergence of psychosis and the development of 
the social disabilities, which predate the first episode. 
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Finally, the cognitive behavioural intervention examined during this study 
could be improved in terms of its format and mode of delivery. The integration 
of cognitive behavioural techniques targeted on the transformation of 
meanings related to self and illness offer a potentially useful approach to the 
treatment of psychological co-morbidity, the facilitation of remission, the 
improvement of social functioning, and the reduction of medium-term and 
perhaps long-term relapse risk. In terms of mode of delivery, such strategies 
could be easily integrated into existing cognitive behavioural interventions 
delivered to individuals recovering from an acute episode of psychosis or who 
continue to experience symptoms which are not responsive to pharmacological 
treatment. 
As such the mutual relationship between theory and therapy offers a 
scientifically viable approach to the evolution of models of psychosis which 
specify in detail the cognitive behavioural factors responsible for the 
development of illness chronicity and social disability. Thereby such an 
approach to treatment offers real hope and optimism to individuals and their 
families who have long experienced psychosis as an uncontrollable and 
traumatic event, which results in social marginalisation and stigmatisation. 
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Appendix A 
Positive and Negative Syndrome Scale 
356 
Date of Assessment: ..................................... Observation Period:................................ 
POSITIVE AND NEGATIVE SYNDROME SCALE 
Circle the appropriate rating for each dimension following the specified clinical interview. Refer to the 
rating manual for item definitions, description of anchoring points, and scoring procedure. 
POSITIVE SCALE 
Abs Min Mild Mod M/S Sev X 
Delusions 1234567 
Conceptual Disorganisation 1234567 
Hallucinatory Behaviour 1234567 
Excitement 1234567 
Grandiosity 1234567 
Suspiciousness/ persecution 1234567 
Hostility 1234567 
NEGATIVE SCALE 
Blunted Affect 1234567 
Emotional Withdrawal 1234567 
Poor Rapport 1234567 
Passivity/ apathy 1234567 
Abstract Thinking 1234567 
Lack of Spontaneity 1234567 
Stereotyped thinking 1234567 
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GENERAL PSYCHOPATHOLOGY SCALE 
Somatic Concern 1234567 
Anxiety 1234567 
Guilt feelings 1234567 
Tension 1234567 
Mannerisms and posturing 1234567 
Depression 1234567 
Motor retardation 1234567 
Uncooperativeness 1234567 
Unusual thought content 1234567 
Disorientation 1234567 
Poor Attention 1234567 
Lack of judgement and insight 1234567 
Disturbance of volition 1234567 
Poor impulse control 1234567 
Preoccupation 1234567 
Active social avoidance 1234567 
SCALE TOTAL 
Positive 
Negative 
Composite 
General Psychopathology 
Investigators Signature :................................................................................................ 
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PANSS RATING CRITERIA 
Positive Scale (P) 
P 1. Delusions. Beliefs which are unfounded, unrealistic, and 
idiosyncratic. Basis for rating: thought content expressed in the 
interview and its influence on social relations and behaviour. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Presence of one or two delusions which are value, 
uncrystallized, and not tenaciously held. Delusions do not interfere 
with thinking, social relations, or behaviour. 
4. Moderate - Presence of either a kaleidoscopic array of poorly 
formed, unstable delusions or of a few well-formed delusions that 
occasionally interfere with thinking, social relations, or behaviour. 
5. Moderate severe - Presence of numerous well-formed 
delusions that are tenaciously held and occasionally interfere with 
thinking, social relations, or behaviour. 
6. Severe - Presence of a stable set of delusions which are 
crystallized, possibly systematized, tenaciously held, and clearly 
interfere with thinking, social relations, and behaviour. 
7. Extreme - Presence of a stable set of delusions which are either 
highly systematized or very numerous, and which dominate major 
facets of the patient's life. This frequently results in inappropriate and 
irresponsible action, which may even jeopardize the safety of the 
patient or others. 
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P2. Conceptual disorganization. Disorganized process of thinking 
characterized by disruption of a goal-directed sequencing, e. g., 
circumstantiality, targentiality, loose associations, non sequiturs, gross 
illogicality, or thought block. Basis for rating: cognitive-verbal 
processes observed during the course of interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Thinking is circumstantial, tangential, or paralogical. 
There is some difficulty in directing thoughts towards a goal, and some 
loosening of associations may be evidenced under pressure. 
4. Moderate - Able to focus thoughts when communications are 
brief and structured, but become loose or irrelevant when dealing with 
more complex communications or when under minimal pressure. 
5. Moderate severe - Generally has difficulty in organizing 
thoughts, as evidenced by frequent irrelevancies, disconnectedness, or 
loosening of associations even when not under pressure. 
6. Severe - Thinking is seriously derailed and internally 
inconsistent, resulting in gross irrelevancies and disruption of thought 
processes, which occur almost constantly. 
7. Extreme - Thoughts are disrupted to the point where the patient 
is incoherent. There is marked loosening of associations, which results 
in total failure of communication, e. g. "word salad" or mutism. 
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P3. Hallucinatory behaviour. Verbal report or behaviour indicating 
perceptions which are not generated by external stimuli. These may 
occur in the auditory, visual, olfactory, or somatic realms. Basis for 
ratin : Verbal report and physical manifestations during the course of 
interview as well as reports of behaviour by primary care workers or 
family. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - One or two clearly formed but infrequent hallucinations, 
or else a number of vague abnormal perceptions which doe not result in 
distortions of thinking or behaviour. 
4. Moderate - Hallucinations occur frequently but nor 
continuously, and the patient's thinking and behaviour are affected only 
to a minor extent. 
5. Moderate severe - Hallucinations are frequent, may involve 
more than one sensory modality, and tend to distort thinking and/or 
disrupt behaviour. Patient may have a delusional interpretation of these 
experiences and respond to them emotionally and, on occasion, verbally 
as well. 
6. Severe - Hallucinations are present almost continuously, 
causing major disruption of thinking and behaviour. Patient treats these 
as real perceptions, and functioning is impeded by frequent emotional 
and verbal responses to them. 
7. Extreme - Patient is almost totally preoccupied with 
hallucinations, which virtually dominate thinking and behaviour. 
Hallucinations are provided a rigid delusional interpretation and 
provoke verbal and behavioural responses, including obedience to 
command hallucinations. 
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P4. Excitement - Hyperactivity as reflected in accelerated motor 
behaviour, heightened responsivity to stimuli, hypervigilance, or 
excessive mood lability. Basis for rating: Behavioural manifestations 
during the course of interview as well as reports of behaviour by 
primary care workers or family. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Tends to be slightly agitated, hypervigilant, or mildly 
overaroused throughout the interview, but without distinct episodes of 
excitement or marked mood lability. Speech may be slightly pressured. 
4. Moderate - Agitation or overarousal is clearly evident 
throughout the interview, affecting speech and general mobility, or 
episodic outbursts occur sporadically. 
5. Moderate severe - Significant hyperactivity or frequent 
outbursts of motor activity are observed, making it difficult for the 
patient to sit still for longer than several minutes at any given time. 
6. Severe - Marked excitement dominates the interview, delimits 
attention, and to some extent affects personal functions such as eating 
and sleeping. 
7. Extreme - Marked excitement seriously interferes in eating and 
sleeping and makes interpersonal interactions virtually impossible. 
Acceleration of speech and motor activity may result in incoherence 
and exhaustion. 
362 
PANNS Rating Manual 
P5. Grandiosity. Exaggerated self-opinion and unrealistic 
convictions of superiority, including delusions of extraordinary 
abilities, wealth, knowledge, fame, power, and moral righteousness. 
Basis for rating: thought content expressed in the interview and its 
influence on behaviour. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Some expansiveness or boastfulness is evident, but 
without clear-cut grandiose delusions. 
4. Moderate - Feels distinctly and unrealistically superior to 
others. Some poorly formed delusions about special status or abilities 
may be present but are not acted upon. 
5. Moderate severe - Clear-cut delusions concerning remarkable 
abilities, status, or power are expressed and influence attitude but not 
behaviour. 
6. Severe - Clear-cut delusions of remarkable superiority 
involving more than one parameter (wealth, knowledge, fame, etc. ) are 
expressed, notably influence interactions, and may be acted upon. 
7. Extreme - Thinking, interactions, and behaviour are dominated 
by multiple delusions of amazing ability, wealth, knowledge, fame, 
power, and/or moral stature, which may take on a bizarre quality. 
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P6. Suspiciousness/persecution. Unrealistic or exaggerated ideas 
of persecution, as reflected in guardedness, a distrustful attitude, 
suspicious hypervigilance, or frank delusions that others mean one 
harm. Basis for rating: thought content expressed in the interview and 
its influence on behaviour. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Presents a guarded or even openly distrustful attitude, 
but thoughts, interactions, and behaviour are minimally affected. 
4. Moderate - Distrustfulness is clearly evident and intrudes on 
the interview and/or behaviour, but there is no evidence of persecutory 
delusions. Alternatively, there may be indication of loosely formed 
persecutory delusions, but these do not seem to affect the patient's 
attitude or interpersonal relations. 
5. Moderate severe - Patient shows marked distrustfulness, 
leading to major disruption of interpersonal relations, or else there are 
clear-cut persecutory delusions that have limited impact on 
interpersonal relations and behaviour. 
6. Severe - Clear-cut pervasive delusions of persecution which 
may be systematized and significantly interfere in interpersonal 
relations. 
7. Extreme -A network of systematized persecutory delusions 
dominates the patient's thinking, social relations, and behaviour. 
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P7. Hostility - Verbal and nonverbal expressions of anger and 
resentment, including sarcasm, passive-aggressive behaviour, verbal 
abuse, and assaultiveness. Basis for rating: interpersonal behaviour 
observed during the interview and reports by primary care workers or 
family. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Indirect or restrained communication of anger, such as 
sarcasm, disrespect, hostile expressions, and occasional irritability. 
4. Moderate - Presents an overtly hostile attitude, showing 
frequent irritability and direct expressions of anger or resentment. 
5. Moderate severe. Patient is highly irritable and occasionally 
verbally abusive or threatening. 
6. Severe - Unco-operativeness and verbal abuse or threats notably 
influence the interview and seriously impact upon social relations. 
Patient may be violent and destructive but is not physically assaultive 
towards others. 
7. Extreme - Marked anger results in extreme unco-operativeness, 
precluding other interactions, or in episode(s) of physical assault toward 
others. 
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PANSS RATING CRITERIA 
Negative Scale (N) 
N l. Blunted affect. Diminished emotional responsiveness as 
characterized by a reduction in facial expression, modulation of 
feelings, and communicative gestures. Basis for rating: observation of 
physical manifestations of affective tone and emotional responsiveness 
during the course of interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Changes in facial expression and communicative 
gestures seem to be stilted, forced, artificial, or lacking in modulation. 
4. Moderate - Reduced range of facial expression and few 
expressive gestures result in a dull appearance. 
5. Moderate severe - Affect is generally "flat", with only 
occasional changes in facial expression and a paucity of communicative 
gestures. 
6. Severe - Marked flatness and deficiency of emotions exhibited 
most of the time. There may be unmodulated extreme affective 
discharges, such as excitement, rage or inappropriate uncontrolled 
laughter. 
7. Extreme - Changes in facial expression and evidence of 
communicative gestures are virtually absent. Patient seems constantly 
to show a barren or "wooden" expression. 
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N2. Emotional withdrawal - Lack of interest in, involvement with, 
and affective commitment to life's events. Basis for rating: reports of 
functioning from primary care workers or family and observation of 
interpersonal behaviour during the course of interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Usually lacks initiative and occasionally may show 
deficient interest in surrounding events. 
4. Moderate - Patient is generally distanced emotionally from the 
milieu and its challenges but, with encouragement, can be engaged. 
5. Moderate severe - Patient is clearly detached emotionally from 
persons and events in the milieu, resisting all efforts at engagement. 
Patient appears distant, docile, and purposeless but can be involved in 
communication at least briefly and tends to personal needs, sometimes 
with assistance. 
6. Severe - Marked deficiency of interest and emotional 
commitment results in limited conversation with others and frequent 
neglect of personal functions, for which the patient requires 
supervision. 
7. Extreme - Patient is almost totally withdrawn, 
uncommunicative, and neglectful of personal needs as a result of 
profound lack of interest and emotional commitment. 
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N3 Poor rapport. Lack of interpersonal empathy, openness in 
conversation, and sense of closeness, interest, or involvement with the 
interviewer. This is evidenced by interpersonal distancing and reduced 
verbal and nonverbal communication. Basis for rating: interpersonal 
behaviour during the course of interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Conversation is characterized by a stilted, strained, or 
artificial tone. It may lack emotional depth or tend to remain on an 
impersonal, intellectual plane. 
4. Moderate - Patient typically is aloof, with interpersonal 
distance quite evident. Patient may answer questions mechanically, act 
bored, or express disinterest. 
5. Moderate severe - Disinvolvement is obvious and clearly 
impedes the productivity of the interview. Patient may tend to avoid 
eye or face contact. 
6. Severe - Patient is highly indifferent, with marked interpersonal 
distance. Answers are perfunctory, and there is little nonverbal 
evidence of involvement. Eye and face contact are frequently avoided. 
7. Extreme - Patient is totally uninvolved with the interviewer. 
Patient appears to be completely indifferent and consistently avoids 
verbal and nonverbal interactions during the interview. 
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N4. Passive/apathetic social withdrawal Diminished interest and 
initiative in social interactions due to passivity, apathy, anergy, or 
avolition. This leads to reduced interpersonal involvements and neglect 
of activities of daily living. Basis for rating: reports on social 
behaviour from primary care workers or family. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Shows occasional interest in social activities but poor 
initiative. Usually engages with others only when approached first by 
them. 
4. Moderate - Passively does along with most social activities but 
in a disinterested or mechanical way. Tends to recede into the 
background. 
5. Moderate severe - Passively participates in only a minority of 
activities and shows virtually no interest or initiative. Generally spends 
little time with others. 
6. Severe - Tends to be apathetic and isolated, participating very 
rarely in social activities and occasionally neglecting personal needs. 
Has very few spontaneous social contacts. 
7. Extreme - Profoundly apathetic, socially isolated, and 
personally neglectful. 
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N5. Difficulty in abstract thinking. Impairment in the use of the 
abstract-symbolic mode of thinking, as evidenced by difficulty in 
classification, forming generalizations, and proceeding beyond concrete 
or egocentric thinking in problem-solving tasks. Basis for rating: 
responses to questions on similarities and proverb interpretation, and 
use of concrete vs. abstract mode during the course of the interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Tends to give literal or personalized interpretations to the 
more difficult proverbs and may have some problems with concepts 
that are fairly abstract or remotely related. 
4. Moderate - Often utilizes a concrete mode. Has difficulty with 
most proverbs and some categories. Tends to be distracted by 
functional aspects and salient features. 
5. Moderately severe - Deals primarily in a concrete mode, 
exhibiting difficulty with most proverbs and many categories. 
6. Severe - Unable to grasp the abstract meaning of any proverbs 
or figurative expressions and can formulate classifications for only the 
most simple of similarities. Thinking is either vacuous or locked into 
functional aspects, salient features, and idiosyncratic interpretations. 
7. Extreme - Can use only concrete modes of thinking. Shows no 
comprehension of proverbs, common metaphors or similes, and simple 
categories. Even salient and functional attributes do not serve as a basis 
for classification. This rating may apply to those who cannot interact 
even minimally with the examiner due to marked cognitive impairment. 
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N6 Lack of spontaneity and flow of conversation. Reduction in 
the normal flow of communication associated with apathy, avolition, 
defensiveness, or cognitive deficit. This is manifested by diminished 
fluidity and productivity of the verbal-interactional process. Basis for 
ratin : cognitive-verbal processes observed during the course of 
interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Conversation shows little initiative. Patient's answers 
tend to be brief and unembellished, requiring direct and leading 
questions by the interviewer. 
4. Moderate - Conversation lacks free flow and appears uneven or 
halting. Leading questions are frequently needed to elicit adequate 
responses and proceed with conversation. 
5. Moderate severe - Patient shows a marked lack of spontaneity 
and openness, replying to the interview's questions with only one or 
two brief sentences. 
6. Severe - Patient's responses are limited mainly to a few words 
or short phrases intended to avoid or curtail communication. (E. g., !I 
don't know", "I'm not at liberty to say". ) Conversation is seriously 
impaired as a result, and the interview is highly unproductive. 
7. Extreme - Verbal output is restricted to, at most, an occasional 
utterance, making conversation not possible. 
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N7. Stereotype thinking. Decreased fluidity, spontaneity, and 
flexibility of thinking, as evidenced in rigid, repetitious, or barren 
thought content. Basis for rating: cognitive-verbal processes observed 
during the interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Some rigidity shown in attitudes or beliefs. Patient may 
refuse to consider alternative positions or have difficulty in shifting 
from one idea to another. 
4. Moderate - Conversation revolves around a recurrent theme, 
resulting in difficulty in shifting to a new topic. 
5. Moderate severe - Thinking is rigid and repetitious to the point 
that, despite the interviewer's efforts, conversation is limited to only 
two or three dominating topics. 
6. Severe - Uncontrolled repetition of demands, statements, ideas, 
or questions which severely impairs conversation. 
7. Extreme - Thinking, behaviour, and conversation are 
dominated by constant repetition of fixed ideas or limited phrases, 
leading to gross rigidity, inappropriateness, and restrictiveness of 
patient's communication. 
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PANNS RATING CRITERIA 
General Psychopathology Scale (G) 
GI. Somatic concern. Physical complaints or beliefs about bodily 
illness or malfunctions. This may range from a vague sense of ill being 
to clear-cut delusions of catastrophic physical disease. Basis for rating: 
thought content expressed in the interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Distinctly concerned about health or somatic issues, as 
evidenced by occasional questions and desire for reassurance. 
4. Moderate - Complains about poor health or bodily malfunction, 
but there is no delusional conviction, and overconcern can be allayed by 
reassurance. 
5. Moderate severe - Patient expresses numerous or frequent 
complaints about physical illness or bodily malfunction, or else patient 
reveals one or two clear-cut delusions involving these themes but is not 
preoccupied by them. 
6. Severe - Patient is preoccupied by one or a few clear-cut 
delusions about physical disease or organic malfunction, but affect is 
not fully immersed in these themes, and thoughts can be diverted by the 
interviewer with some effort. 
7. Extreme - Numerous and frequently reported somatic 
delusions, or only a few somatic delusions of a catastrophic nature, 
which totally dominate the patient's affect and thinking. 
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G2. Anxiety - Subjective experience of nervousness, worry, 
apprehension, or restlessness, ranging from excessive concern about the 
present or future to feelings of panic. Basis for rating: verbal report 
during the course of interview and corresponding physical 
manifestations. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Expresses some worry, overconcern, or subjective 
restlessness, but no somatic and behavioural consequences are reported 
or evidence. 
4. Moderate - Patient reports distinct symptoms of nervousness, 
which are reflected in mild physical manifestations such as fine hand 
tremor and excessive perspiration. 
5. Moderate severe - Patient reports serious problems of anxiety 
which have significant physical and behavioural consequences, such as 
marked tension, poor concentration, palpitations, or impaired sleep. 
6. Severe - Subjective state of almost constant fear associated with 
phobias, marked restlessness, or numerous somatic manifestations. 
7. Extreme - Patient's life is seriously disrupted by anxiety, which 
is present almost constantly and at times reaches panic proportion or is 
manifested in actual panic attacks. 
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G3. Guilt feelings. Sense of remorse or self-blame for real or 
imagined misdeeds in the past. Basis for rating: verbal report of guilt 
feelings during the course of interview and the influence on attitudes 
and thoughts. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Questioning elicits a vague sense of guilt or selfblame 
for a minor incident, but the patient clearly is not overly concerned. 
4. Moderate - Patient expresses distinct concern over his 
responsibility for a real incident in his life but is not pre-occupied with 
it, and attitude and behaviour are essentially unaffected. 
5. Moderate severe - Patient expresses a strong sense of guilt 
associated with self-depreciation or the belief that he deserves 
punishment. The guilt feelings may have a delusional basis, may be 
volunteered spontaneously, may be a source of preoccupation and/or 
depressed mood, and cannot be allayed readily by the interviewer. 
6. Severe - Strong ideas of guilt take on a delusional quality and 
lead to an attitude of hopelessness or worthlessness. The patient 
believes he should receive harsh sanctions for the misdeeds and may 
even regard his current life situation such punishment. 
7. Extreme - Patient's life is dominated by unshakeable delusions 
of guilt, for which he feels deserving of drastic punishment, such as life 
imprisonment, torture, or death. There may be associated suicidal 
thoughts or attribution of others' problems to one's own past misdeeds. 
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G4. Tension. Overt physical manifestations of fear, anxiety and 
agitation, such as stiffness, tremor, profuse sweating and restlessness. 
Basis for rating: verbal report attesting to anxiety and, thereupon, the 
severity of physical manifestations of tension observed during the 
interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Posture and movements indicate slight apprehensiveness, 
such as minor rigidity, occasional restlessness, shifting of position, or 
fine rapid hand tremor. 
4. Moderate -A clearly nervous appearance emerges from various 
manifestations, such as fidgety behaviour, obvious hand tremor, 
excessive perspiration, or nervous mannerisms. 
5. Moderate severe - Pronounced tension is evidenced by 
numerous manifestations, such as nervous shaking, profuse sweating, 
and restlessness, but conduct in the interview is not significantly 
affected. 
6. Severe - Pronounced tension to the point that interpersonal 
interactions are disrupted. The patient, for example, may be constantly 
fidgeting, unable to sit still for long, or show hyperventilation. 
7. Extreme - Marked tension is manifested by signs of panic or 
gross motor acceleration, such as rapid restless pacing and inability to 
remain seated for longer than a minute, which makes sustained 
conversation not possible. 
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G5. Mannerisms and Posturing. Unnatural movements or posture 
as characterised by an awkward, stilted, disorganised, or bizarre 
appearance. Basis for rating: observation of physical manifestations 
during the course of interview as well as reports from primary care 
workers or family. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Slight awkwardness in movements or minor rigidity of 
posture. 
4. Moderate - Movements are notably awkward or disjointed, or 
an unnatural posture is maintained for brief periods. 
5. Moderate severe - Occasional bizarre rituals or contorted 
posture are observed, or an abnormal position is sustained for extended 
periods. 
6. Severe - Frequent repetition of bizarre rituals, mannerisms, or 
stereotyped movements, or a contorted posture is sustained for extended 
periods. 
7. Extreme - Functioning is seriously impaired by virtually 
constant involvement in ritualistic, manneristic, or stereotyped 
movements or by an unnatural fixed posture which is sustained most of 
the time. 
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G6. Depression. Feelings of sadness, discouragement, helplessness, 
and pessimism. Basis for rating: verbal report of depressed mood 
during the course of interview and its observed influence on attitude 
and behaviour. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Expresses some sadness or discouragement only on 
questioning, but there is no evidence of depression in general attitude or 
demeanour. 
4. Moderate - Distinct feelings of sadness or hopelessness, which 
may be spontaneously divulged, but depressed mood has no major 
impact on behaviour or social functioning, and the patient usually can 
be cheered up. 
5. Moderate severe - Distinctly depressed mood is associated 
with obvious sadness, pessimism, loss of social interest, psychomotor 
retardation, and some interference in appetite and sleep. The patient 
cannot be easily cheered up. 
6. Severe - Markedly depressed mood is associated with sustained 
feelings of misery, occasional crying, hopelessness, and worthlessness. 
In addition, there is major interference in appetite and/or sleep as well 
as in normal motor and social functions, with possible signs of self- 
neglect. 
7. Extreme - Depressive feelings seriously interfere in most major 
functions. The manifestations include frequent crying, pronounced 
somatic symptoms, impaired concentration, psychomotor retardation, 
social disinterest, self-neglect, possible depressive or nihilistic 
delusions, and/or possible suicidal thoughts or action. 
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G7. Motor retardation - Reduction in motor activity as reflected in 
slowing or lessening of movements and speech, diminished 
responsiveness to stimuli, and reduced body tone. Basis for rating: 
manifestations during the course of interview as well as reports by 
primary care workers or family. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Slight but noticeable diminution in rate of movements 
and speech. Patient may be somewhat underproductive in conversation 
and gestures. 
4. Moderate - Patient is clearly slow in movements, and speech 
may be characterized by poor productivity, including long response 
latency, extended pauses, or slow pace. 
5. Moderate severe -A marked reduction motor activity renders 
communications highly unproductive or delimits functioning in social 
and occupational situations. Patient can usually be found sitting or 
lying down. 
6. Severe - Movements are extremely slow, resulting in a 
minimum of activity and speech. Essentially the day is spent sitting 
idly or lying down. 
7. Extreme - Patient is almost completely immobile and virtually 
unresponsive to external stimuli. 
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G8. Unco-operativeness. Active refusal to comply with the will of 
significant others, including the interviewer, hospital staff, or family, 
which may be associated with distrust, defensiveness, stubbornness, 
negativism, rejection of authority, hostility, or belligerence. Basis for 
ratin : interpersonal behaviour observed during the course of 
interview as well as reports by primary care workers or family. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Complies with an attitude of resentment, impatience, or 
sarcasm. May inoffensively object to sensitive probing during the 
interview. 
4. Moderate - Occasional outright refusal to comply with normal 
social demands, such as making own bed, attending scheduled 
programs, etc. The patient may project a hostile, defensive or negative 
attitude but usually can be worked with. 
5. Moderate severe - Patient frequently is incompliant with the 
demands of his milieu and may be characterized by others as an 
"outcast" or having "a serious attitude problem. " Unco-operativeness is 
reflected inn obvious defensiveness or irritability with the interviewer 
and possible unwillingness to address many questions. 
6. Severe - Patient is highly unco-operative, negativistic, and 
possibly also belligerent. Refuses to comply with most social demands 
and may be unwilling to initiate or conclude the full interview. 
7. Extreme - Active resistance seriously impact on virtually all 
major areas of functioning. Patient may refuse to join in any social 
activities, tend to personal hygiene, converse with family or staff, and 
participate even briefly in an interview. 
380 
PANSS Rating Manual 
G9. Unusual thought content - Thinking characterized by strange, 
fantastic, or bizarre ideas, ranging from those which are remote or 
atypical to those which are distorted, illogical, and patently absurd. 
Basis for rating: thought content expressed during the course of 
interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Thought content is somewhat peculiar or idiosyncratic, 
or familiar ideas are framed in an odd context. 
4. Moderate - Ideas are frequently distorted and occasionally 
seem quite bizarre. 
5. Moderate severe - Patient expresses many strange and fantastic 
thoughts (e. g. being the adopted son of a king, being an escapee from 
death row) or some which are patently absurd (e. g. having hundreds of 
children, receiving radio messages from outer space through a tooth 
filling). 
6. Severe - Patient expresses many illogical or absurd ideas or 
some which have a distinctly bizarre quality (e. g. having three heads, 
being a visitor from another planet). 
7. Extreme - Thinking is replete with absurd, bizarre, and 
grotesque ideas. 
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G 10. Disorientation. Lack of awareness of one's relationship to the 
milieu, including persons, place, and time, which may be due to 
confusion or withdrawal. Basis for rating: responses to interview 
questions or orientation. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - General orientation is adequate but there is some 
difficulty with specifics. For example, patient knows his location but 
not the street address, knows hospital staff names but not their 
functions, knows the month but confuses the day of week with an 
adjacent day, or errs in the date by more than two days. There may be 
narrowing of interest evidenced by familiarity with the immediate but 
not extended milieu, such as ability to identify staff but nor the Mayor, 
Governor, or President. 
4. Moderate - Only partial success in recognizing persons, places, 
and time. For example, patient knows he is in a hospital but not its 
name, knows the name of his city but not the burrough or district, 
knows the name of his primary therapist but not many other direct care 
workers, knows the year and season but not sure of the month. 
5. Moderate severe - Considerable failure in recognizing persons, 
place, and time. Patient has only a vague notion of where he is and 
seems unfamiliar with most people in his milieu. He may identify the 
year correctly or nearly so but not know the current month, day of week 
or even the season. 
6. Severe - Marked failure in recognizing persons, place, and time. 
For example, patient has now knowledge of his whereabouts, confuses 
the date by more than one year, can name only one or two individuals in 
his current life. 
7. Extreme - Patient appears completely disoriented with regard to 
persons, place and time. There is gross confusion or total ignorance 
about one's location, the current year, and even the most familiar 
people, such as parents, spouse, friends and primary therapist. 
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G 11. Poor attention. Failure in focused alertness manifested by 
poor concentration, distractibility from internal and external stimuli, 
and difficulty in harnessing, sustaining, or shifting focus to new stimuli. 
Basis for rating: manifestations during the course of interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Limited concentration evidenced by occasional 
vulnerability to distraction or faltering attention toward the end of the 
interview. 
4. Moderate - Conversation is affected by the tendency to be 
easily distracted, difficulty in long sustaining concentration on a given 
topic, or problems in shifting attention to new topics. 
5. Moderate severe - Conversation is seriously hampered by poor 
concentration, distractibility, and difficulty in shifting focus 
appropriately. 
6. Severe - Patient's attention can be harnessed for only brief 
moments or with great effort, due to marked distraction by internal or 
external stimuli. 
7. Extreme - Attention is so disrupted that even brief conversation 
is not possible. 
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G12. Lack of iudgement and insight. Impaired awareness or 
understanding of one's own psychiatric condition and life situation. 
This is evidenced by failure to recognize past or present psychiatric 
illness or symptoms, denial of need for psychiatric hospitalisation or 
treatment, decisions characterized by poor anticipation of 
consequences, and unrealistic short-term and long-range planning. 
Basis for rating: thought content expressed during the interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Recognizes having a psychiatric disorder but clearly 
underestimates it seriousness, the implications for treatment, or the 
importance of taking measures to avoid relapse. Future planning may 
be poorly conceived. 
4. Moderate - Patient shows only a vague or shallow recognition 
of illness. There may be fluctuations in acknowledgement of being ill 
or little awareness of major symptoms which are present, such as 
delusions, disorganized thinking, suspiciousness, and social withdrawal. 
the patient may rationalize the need for treatment in terms of its 
relieving lesser symptoms, such as anxiety, tension, and sleep difficulty. 
5. Moderate severe - Acknowledges past but not present 
psychiatric disorder. If challenged, the patient may concede the 
presence of some unrelated or insignificant symptoms, which tend to be 
explained away by gross misinterpretation or delusional thinking. The 
need for psychiatric treatment similarly goes unrecognised. 
6. Severe - Patient denies ever having had a psychiatric disorder. 
He disavows the presence of any psychiatric symptoms in the past or 
present and, though complaint, denies the need for treatment and 
hsopialization. 
7. Extreme - Emphatic denial of past and present psychiatric 
illness. Current hospitalization and treatment are given a delusional 
interpretation (e. g. as punishment for misdeeds, as persecution by 
tormentors, etc. ) and the patient may thus refuse to co-operate with 
therapists, medication or other aspects of treatment. 
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G13. Disturbance of volition. Disturbance in the wilful initiation, 
sustenance, and control of one's thoughts, behaviour, movements, and 
speech. Basis for rating: thought content and behaviour manifested in 
the course of interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - There is evidence of some indecisiveness in conversation 
and thinking, which may impede verbal and cognitive processes to a 
minor extent. 
4. Moderate - Patient is often ambilivent and shows clear 
difficulty in reaching decisions. Conversation may be marred by 
alternation in thinking, and in consequence verbal and cognitive 
functioning are clearly impaired. 
5. Moderate severe - Disturbance of volition interferes in thinking 
as well as behaviour. Patient shows pronounced indecision that 
impedes the initiation and continuation of social and motor activities, 
which also may be evidenced in halting speech. 
6. Severe - Disturbance of volition interferes in the execution of 
simple, automatic motor functions, such as dressing and grooming, and 
markedly affects speech. 
7. Extreme - Almost complete failure of volition is manifested by 
gross inhibition of movement and speech, resulting in immobility 
and/or mutism. 
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G14. Poor impulse control. Disordered regulation and contröl of 
action on inner urges, resulting in sudden, unmodulated arbitrary, or 
misdirected discharge of tension and emotions without concern about 
consequences. Basis for rating: behaviour during the course of 
interview and reported by primary care workers or family. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Patient tends to be easily angered and frustrated when 
facing stress or denied gratification but rarely acts on impulse. 
4. Moderate - Patient gets angered and verbally abusive with 
minimal provocation. May be occasionally threatening, destructive, or 
have one or two episodes involving physical confrontation or a minor 
brawl. 
5. Moderate severe - Patient exhibits repeated impulsive episodes 
involving verbal abuse, destruction of property, or physical threats. 
There may be one or two episodes involving serious assault, for which 
the patient requires isolation, physical restraint, or p. r. n. sedation. 
6. Severe - Patient frequently is impulsively aggressive, 
threatening, demanding, and destructive, without any apparent 
consideration of consequences. Shows assaultive behaviour and may 
also be sexually offensive and possibly respond behaviourally to 
hallucinatory commands. 
7. Extreme - Patient exhibits homicidal attacks, sexual assaults, 
repeated brutality, or self-destructive behaviour. Requires constant 
direct supervision or external constraints because of inability to control 
dangerous impulses. 
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G15. Preoccupation. Absorption with internally generated thoughts 
and feelings and with autistic experiences to the detriment of reality 
orientation and adaptive behaviour. Basis for rating: interpersonal 
behaviour observed during the course of interview. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Excessive involvement with personal needs or problems, 
such that conversation veers back to egocentric themes and there is 
diminished concern exhibited towards others. 
4. Moderate - Patient occasionally appears self-absorbed, as if 
daydreaming or involved with internal experiences, which interferes 
with communication to a minor extent. 
5. Moderate severe - Patient often appears to be engaged in 
autistic experiences, as evidenced by behaviours that significantly 
intrude on social and communicational functions, such as the presence 
of a vacant stare, muttering or talking to oneself, or involvement with 
stereotyped motor patterns. 
6. Severe - Marked preoccupation with autistic experiences, which 
seriously delimits concentration, ability to converse, and orientation to 
the milieu. The patient frequently may be observed smiling, laughing, 
muttering, talking, or shouting to himself. 
7. Extreme - Gross absorption with autistic experiences, which 
profoundly affects all major realms of behaviour. The patient 
constantly may be responding verbally and behaviourally to 
hallucinations and show little awareness of other people or the external 
milieu. 
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G16. Active social avoidance. Diminished social involvement 
associated with unwarranted fear, hostility, or distrust. Basis for 
ratin : reports of social functioning by primary care workers or family. 
1. Absent - Definition does not apply. 
2. Minimal - Questionable pathology; may be at the upper 
extreme of normal limits. 
3. Mild - Patient seems ill at ease in the presence of others and 
prefers to spend time alone, although he participates in social functions 
when required. 
4. Moderate - Patient begrudgingly attends all or most social 
activities but may need to be persuaded or may terminate prematurely 
on account of anxiety, suspiciousness, or hostility. 
5. Moderate severe - Patient fearfully or angrily keeps away from 
many social interactions despite others' efforts to engage him. Tends to 
spend unstructured time along. 
6. Severe - Patient participates in very few social activities 
because of fear, hostility, or distrust. When approached, the patient 
shows a strong tendency to break off interactions, and generally he 
tends to isolate himself from others. 
7. Extreme - Patient cannot be engaged in social activities 
because of pronounced fears, hostility, or persecutory delusions. To the 
extent possible, he avoids all interactions and remains isolated from 
others. 
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Prototypic Questions for the PANSS Interview in Pursuing Major Areas of 
Psychopathology 
1. Judgement and Insight 
What brought you to the hospital (clinic, etc. )? 
Are you in need of treatment? Medicine? Hospitalisation? 
Is your hospitalisation a mistake? A punishment? Part of a scheme or plot? 
Do you have a psychiatric disorder? Have you had one in the past? 
What are the symptoms of your illness? 
(If receiving chemotherapy: ) Why are you taking medicine? 
Are you ready to be discharged from the hospital (clinic, etc. )? 
2. Hallucinations 
Do you ever have strange experiences? Hear strange noises? 
Do you sometimes hear things that others don't hear? 
Do you sometimes receive personal communications from the radio or 
television? From God? 
Can you sometimes hear your thoughts aloud inside your head? Do they 
sound like voices? 
Do you sometimes hear voices inside your head? When How often? How 
clear are they? How loud are they? 
Whose voices do you hear inside your head? How many are there? Do they 
speak to you, comment about you, or speak to each other? 
What do the voices say? Are they good or bad voices? Are you afraid of 
them? 
Do the voices tell you what to do? Give you direct orders? 
Do you obey the voices' commands? Must you? 
Do ordinary things ever appear strange or distorted? 
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Hallucinations (cont'd) 
Do ordinary things ever appear strange or distorted? 
Do you ever have "visions" or see things that others don't? How often? How 
clear are these visions? 
Do the visions occur together with the voices or separately? 
Do you ever smell things that other don't? 
Do you get strange sensations from within your body or feel something 
strange inside you? 
What do you make of these voices (visions, etc. )? How did they come about? 
Are they a problem for you? 
3. Delusions (general) 
When you are by yourself, what do you think about? 
What are your convictions or beliefs about life? 
Do you have a particular philosophy that you follow? 
4. Ideas of suspicion and persecution 
How do you get along with others? 
Do you like people? Dislike people? Are you annoyed with people? Afraid 
of people? Why? 
Do you prefer to be alone? Why? 
Do you trust most people that you know? Are there some whom you distrust? 
Who? Why? 
Do people sometimes talk about you behind your back? What do they say? 
Why? 
Do some people harbour ill will toward you? Spy on you? Plot against you? 
Attempt to harm you? Attempt to kill you? 
What is the evidence of this? Who is behind all this? Why does this happen? 
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5. Grandiosity 
How do you compare to the average person? Better or worse? 
Are you special in some ways? 
Do you have talents or abilities that most people don't have? 
Do you have ESP? Can you read another person's mind? 
Do you have special or unusual powers? 
Do you consider yourself wealthy? Famous? Have you ever appeared on 
television, radio, movies, or stage? Made records? 
Do you rate higher than others in terms of your moral standards? Does this 
make you special in some respect? 
Do you have a special mission in life? How did this come about? 
Are you a religious person? What is your relationship with God? Are you 
closer to God than others are? Are you one of God's angels (children, 
emissaries, etc. )? 
6. Guilt feelings 
Do you feel less worthwhile than the average person? 
Do you consider yourself a bad person in some ways? 
Do you feel guilty about something you may have done in the past? 
Have you done something to deserve punishment? What kind of punishment 
do you deserve? 
Is your present situation (hospitalisation, illness, etc. ) some kind of 
punishment? How do you know this? 
Have you had thoughts of harming yourself as one kind of punishment? Have 
you ever acted on those thoughts? 
7. Somatic concern 
How have you been feeling? 
Is there any problem with your physical health? With the way your body has 
been functioning? 
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Somatic concern (cont'd) 
Do you have some medical illness or disease? If so, how serious is it? 
How is your head? How is your heart? 
Any trouble with your lungs? Arms? Legs? With any other part of your 
body? 
Does your head or body ever feel strange? 
Has your head or body changed in shape or size? 
What is causing these problems? 
8. Depression 
What is your typical mood like? 
Are you mostly happy? Sad? Why? 
How unhappy have you been feeling? 
When do you feel the saddest? How long do these feelings last? 
Do you sometimes cry? How often? 
Has your mood affected your appetite? Your sleep? Your ability to work? 
Have you had any thoughts of harming yourself or ending your life? Have 
you attempted suicide? 
9. Anxiet 
Is anything worrying you? 
Have you been feeling nervous? Tense? 
Would you please hold your hands out straight (to inspect for tremor) 
Now may I see your palms (to inspect for perspiration)? 
Are you afraid of something? Of someone? 
How anxious have you been feeling? 
Do you ever get into a state of panic? 
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Have your worries or nervousness affected your appetite? Your sleep? Your 
ability to work? 
10. Orientation 
What day of the week is it? What is today's date (day, month, year)? What 
season are we in? 
Where are we now located (city, state, district/burrough, and street address)? 
What is the name of this hospital (clinic, etc. )? What ward (service, division 
etc. ) are we on? 
What are the names of the other hospital (clinic, etc. ) staff members? What 
are the names of your friends at home? 
Do you know the name of our Mayor (Town Supervisor, etc. )? Our 
Governor? Our President? 
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Brief Symptom Inventory 
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Appendix C 
Personal Beliefs about Illness Questionnaire 
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Personal Beliefs About Illness Questionnaire (PBIQ) 
Initials .......... ID code ............... 
Date 
.......................... 
I will always need to be cared for by professional medical staff 
My illness frightens me ................................................... 
I am embarrassed by my illness ........................................ 
I am capable of very little as a result of my illness .......... 
Because of my illness I have to rely on psychiatric services. 
There must always have been something wrong with me to have caused 
my illness .................................................... 
I find it difficult to cope with my current symptoms ...... 
My illness is too delicate/brittle for me to work or keep a job 
.................................................................................. 
I know when I'm relapsing but I can't do anything about 
it 
........................................................................................ 
My illness is a judgement on me ..................................... 
I am powerless to influence or control my illness .............. 
I am fundamentally normal, my illness is like any other ... 
Society needs to keep people with my illness apart from everyone 
else ....................................................................... 
There must be something about my personality that causes me to be 
what I am .............................................................. 
I can talk to most people about my illness ......................... 
There is something strange about me that causes my illness. 
Strongly 
Disagree Disagree Agree 
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Strongly 
Agree 
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Rosenberg Self Esteem Inventory 
Initials .............. ID code .................... Date ........................ 
This is a short questionnaire to measure thoughts about yourself. Please indicate 
whether you strongly agree, agree, disagree, or strongly disagree with each statement 
by ticking the appropriate box. 
Strongly Strongly 
Agree Agree Disagree Disagree 
On the whole I am satisfied 
with myself. 
At times I think I am no 
good at all. 
I feel I have a number of 
good qualities. 
I am able to do things as 
well as most other people. 
I feel I do not have much to 
be proud of. 
I certainly feel useless at 
times. 
I feel I am a person of 
worth, at least equal to 
others. 
I wish I could have more 
respect for myself. 
All in all, I am inclined 
to feel I am a failure. 
I take a positive attitude 
towards myself. 
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SOCIAL FUNCTIONING SCALE (SFS) 
Guidelines for use 
The SFS is a reliable measure designed to assess the social functioning of individuals 
with Schizophrenia. The questionnaire should be completed with the person to whom 
it applies, and/or a relative or some one in everyday contact with that person. 
Preferably this should be separate to ensure privacy and unprompted replies. The 
administrator should be present to go through the items to ensure questions are 
understood and perhaps clarify any misunderstood items. 
Name: ............................................................ 
Subject No:.............................. 
SECTION RAW SCORE SCALED SCORE 
Withdrawal/ social 
engagement 
Interpersonal 
communication 
Independence 
(performance) 
Independence 
(competence) 
Recreation 
Prosocial 
Employment/ 
occupation 
Investigators Signature: ................................................ Date:............................. 
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This questionnaire helps us learn how you have been getting on since you became ill. 
This questionnaire takes about 20 minutes to complete - before starting could you 
please answer the following: 
1. Where do you live? 
Answer: .............................................................................................................. 
2. Who do you live with? 
Answer: .............................................................................................................. 
SOCIAL ENGAGEMENT/ WITHDRAWAL 
1. What time do you get up each day? 
Average weekday: .................... 
Average weekend: ................... 
2. How many hours do you spend alone? 
e. g. alone in a room 
walking out alone 
listening to radio or watching T. V. alone etc. 
0-3 Very little time spent alone 3 
3-6 Some of the time 2 
6-9 Quite alot of the time 1 
9-12 A great deal of time 0 
12 Practically all the time 
3. How often do you start a conversation at home? 
Before gam -3 
9-11 am -2 
11-Ipm -1 
after I pm -0 
0 
Almost never Rarely Sometimes Often 
0123 
4. How often do you leave the house (for any reason)? 
Almost never Rarely Sometimes Often 
0123 
5. How do you react to the presence of strangers? 
Avoid them Feel nervous Accept them Like them 
012 3 
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INTERPERSONAL COMMUNICATION 
1. How many friends do you have at the moment? 
(people you see regularly, do activities with etc. ) 
2. Do you have a boyfriend/ girlfriend? (if not married) Yes/ No 
30 
Total of 1 and 2 0=0 
1=1 
2=2 
3+=3 
3. How often are you able to carry out a sensible or rational conversation? 
Almost never Rarely Sometimes Often 
0123 
4. How easy or difficult do you find it talking to people at the moment? 
Very easy Quite easy Average Quite difficult Very difficult 
33210 
INDEPENDENCE- PERFORMANCE 
please tick against each item to show how often you have done the following over the 
last three months. 
ACTIVITY NEVER RARELY SOMETIMES OFTEN 
0 1 2 3 
Buying items from 
shops (without help) 
Washing pots, 
tidying up etc. 
Regular washing, 
bathin etc. 
Washing own 
clothes 
Looking for a job 
(if unemployed) 
Doing the food 
shopping 
Prepare and cook 
a meal 
403 
Independence- performance continued 
ACTIVITY NEVER RARELY SOMETIMES OFTEN 
0 1 2 3 
Leaving the house 
alone 
Using buses, 
trains etc 
Using money 
Budgeting 
Choosing and buying 
clothes for self 
Take care of 
personal appearance 
RECREATION 
Please tick the appropriate column to indicate how often you have done any of the 
following activities over the last three months. 
ACTIVITY NEVER 
0 
RARELY 
1 
SOMETIMES 
2 
OFTEN 
3 
Playing musical 
instruments 
Sewing, knitting 
Gardening 
Reading 
Watching T. V. 
Listening to record 
radio 
Cooking 
DIY activities 
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ACTIVITY NEVER 
0 
RARELY 
1 
SOMETIMES 
2 
OFTEN 
3 
Fixing things (car, 
bike etc. ) 
Walking/ rambling 
Driving/ cycling 
(as a recreation) 
Swimming 
Hobby (eg. 
collecting things) 
Shopping 
Artistic activity 
(painting, crafts etc) 
PROSOCIAL 
Please tick the appropriate column to show how often you have participated in any of 
the following activities over the last three months. 
ACTIVITY NEVER 
0 
RARELY 
1 
SOMETIMES 
2 
OFTEN 
3 
Cinema 
Theatre/ concert 
Watching indoor 
sport 
Watching outdoor 
sport 
Art gallery/ 
museum 
Exhibition 
Visiting places of 
interest 
Meetings, talks etc 
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Prosocial continued 
ACTIVITY NEVER 
0 
RARELY 
1 
SOMETIMES 
2 
OFTEN 
3 
Evening class 
Visiting relatives 
in their homes 
Being visited by 
relatives 
Visiting friends 
(including boy/ 
girlfriend) 
Parties 
Formal occasions 
Discos etc. 
Night-club/ social 
club 
Playing indoor 
sport 
Playing outdoor 
sport 
Club/ society 
Pub 
Eating out 
Church activity 
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INDEPENDENCE- COMPETENCE 
Please tick against each item how able you are at doing or using the following. 
ACTIVITY ADEQUATELY 
3 
NEEDS HELP 
2 
UNABLE 
1 
DK 
0 
Public transport 
Handling money 
Budgeting 
Cooking for self 
Weekly shopping 
Looking for a job 
Washing own 
clothes 
Personal hygiene 
Washing, tidying 
Purchasing from 
shops 
Leaving house 
alone 
Choosing/ buying 
clothes 
Caring for personal 
appearance 
407 
OCCUPATION / EMPLOYMENT 
Are you in regular employment? YES/ NO 
(This includes industrial therapy, rehabilitation, or retraining courses) 
1. IF YES What sort of job? ............................................................ 
How many hours each week? .......................................... 
How long have you had this job? ..................................... 
2. IF NO When were you last in employment? ................................ 
3. 
What sort of job was this? ............................................... 
How many hours per week? ............................................ 
Are you registered disabled YES/ NO 
4. Do you attend a hospital as a day patient? YES/ NO 
5. 
0 
Definitely Yes Would have difficulty Definitely no 
3 
6. 
Score 10- 
Score 9- 
Score 8- 
Score 7- 
123 
Full-time gainful earnings or full time student 
Part-time gainful earnings or housewife/ mother 
Employed until recently e. g. in last six months, and pursuing work 
Industrial therapy and /or rehabilitation 
If none of the above add together scales for scores on items 5 an 6. 
Do you think you are capable of some sort of employment? 
20 
How often do you make attempts to find a new job? 
(e. g. go to job centre, look in newspaper) 
Almost never Rarely Sometimes Often 
408 
